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Background: Writing therapy to improve physical or mental health can take many forms. The most
researched model of therapeutic writing (TW) is unfacilitated, individual expressive writing (written
emotional disclosure). Facilitated writing activities are less widely researched.
Data sources: Databases, including MEDLINE, EMBASE, PsycINFO, Linguistics and Language Behaviour
Abstracts, Allied and Complementary Medicine Database and Cumulative Index to Nursing and Allied
Health Literature, were searched from inception to March 2013 (updated January 2015).
Review methods: Four TW practitioners provided expert advice. Study procedures were conducted by
one reviewer and checked by a second. Randomised controlled trials (RCTs) and non-randomised
comparative studies were included. Quality was appraised using the Cochrane risk-of-bias tool.
Unfacilitated and facilitated TW studies were analysed separately under International Classification of
Diseases, Tenth Revision chapter headings. Meta-analyses were performed where possible using RevMan
version 5.2.6 (RevMan 2012, The Cochrane Collaboration, The Nordic Cochrane Centre, Copenhagen,
Denmark). Costs were estimated from a UK NHS perspective and three cost–consequence case studies
were prepared. Realist synthesis followed Realist and Meta-narrative Evidence Synthesis: Evolving
Standards guidelines.
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Objectives: To review the clinical effectiveness and cost-effectiveness of TW for people with long-term
conditions (LTCs) compared with no writing, or other controls, reporting any relevant clinical outcomes.
To conduct a realist synthesis to understand how TW might work, and for whom.
Results: From 14,658 unique citations, 284 full-text papers were reviewed and 64 studies (59 RCTs) were
included in the final effectiveness reviews. Five studies examined facilitated TW; these were extremely
heterogeneous with unclear or high risk of bias but suggested that facilitated TW interventions may be
beneficial in individual LTCs. Unfacilitated expressive writing was examined in 59 studies of variable or
unreported quality. Overall, there was very little or no evidence of any benefit reported in the following
conditions (number of studies): human immunodeficiency virus (six); breast cancer (eight); gynaecological
and genitourinary cancers (five); mental health (five); asthma (four); psoriasis (three); and chronic pain
(four). In inflammatory arthropathies (six) there was a reduction in disease severity [n= 191, standardised
mean difference (SMD) –0.61, 95% confidence interval (CI) –0.96 to –0.26] in the short term on
meta-analysis of four studies. For all other LTCs there were either no data, or sparse data with no or
inconsistent, evidence of benefit. Meta-analyses conducted across all of the LTCs provided no evidence
that unfacilitated emotional writing had any effect on depression at short- (n= 1563, SMD –0.06, 95% CI
–0.29 to 0.17, substantial heterogeneity) or long-term (n= 778, SMD –0.04 95% CI –0.18 to 0.10, little
heterogeneity) follow-up, or on anxiety, physiological or biomarker-based outcomes. One study reported
costs, no studies reported cost-effectiveness and 12 studies reported resource use; and meta-analysis
suggested reduced medication use but no impact on health centre visits. Estimated costs of intervention
were low, but there was insufficient evidence to judge cost-effectiveness. Realist synthesis findings
suggested that facilitated TW is a complex intervention and group interaction contributes to the perception
of benefit. It was unclear from the available data who might benefit most from facilitated TW.
Limitation: Difficulties with developing realist synthesis programme theory meant that mechanisms
operating during TW remain obscure.
Conclusions: Overall, there is little evidence to support the therapeutic effectiveness or cost-effectiveness
of unfacilitated expressive writing interventions in people with LTCs. Further research focused on facilitated
TW in people with LTCs could be informative.
Study registration: This study is registered as PROSPERO CRD42012003343.
Funding: The National Institute for Health Research Health Technology Assessment programme.
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Glossary
Technical terms, abbreviations and/or acronyms are used throughout this report with definitionsprovided. In some cases, usage may differ in the literature, but the term has a constant meaning
throughout this review.
Context In realist synthesis, context refers to the backdrop of programmes and research. As these
conditions change over time, the context may reflect aspects of those changes while the programme is
implemented. Context can be broadly understood as any condition that triggers and/or modifies the
behaviour of a mechanism.
Facilitated therapeutic writing Writing activities involving a facilitator, such as a trained writing
practitioner or a psychologist. It may be a group activity or one to one, and can be delivered face to face
or remotely, for example over the web.
Mechanism In realist synthesis, mechanisms are underlying entities, processes or structures, which
operate in particular contexts to generate outcomes of interest. Mechanisms (1) are usually hidden;
(2) are sensitive to variations in context; and (3) generate outcomes.
Positive writing Involves writing about positive experiences such as events that stimulated happiness or
joy and it may be facilitated or unfacilitated.
Programme theory In realist synthesis, the term programme theory refers to an abstracted description
and/or diagram that lays out what a programme (or family of programmes or interventions) comprises and
how it is expected to work.
Unfacilitated emotional writing Also known as unfacilitated expressive writing or written emotional
disclosure, a type of unfacilitated therapeutic writing, as described by Pennebaker and Beall (Pennebaker JW,
Beall SK. Confronting a traumatic event: towards an understanding of inhibition and disease. J Abnorm
Psychol 1986;95:274–81) or a variant thereof.
The trauma–emotion subjects were asked to write about a personally upsetting experience and to
describe the feelings they had about the experience. It was emphasized that they were to write only
about their feelings, with no mention of what actually happened.
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Plain English summary
Long-term health conditions (chronic illness) can reduce the quality of people’s daily lives and can becostly to the health service. It has been suggested that when patients write about their experiences, this
can have positive effects on patients’ lives and the health service. We refer to this type of writing as writing
therapy. The aim of this study was to see if people with long-term health conditions benefit from
writing therapy.
We undertook a thorough search for scientific studies that tested writing therapy in people diagnosed with
any long-term condition (LTC). We looked at whether or not writing therapy helped the individuals in the
study, if the study was conducted properly, how the writing therapy might produce benefits and if it could
lower health service costs.
We found that most of the available evidence looked at writing done by individuals on their own and
focused on writing about distressing events. Overall, there was very little evidence that this type of writing
therapy had benefits for people with LTCs. A few studies looked at another type of writing therapy,
which was done mainly in groups, was led by a leader and which we called facilitated writing. People with
LTCs appeared to get some benefits from this type of writing, but much more research needs to be done
to see how useful it is. Overall, studies were unclear on how writing therapy might work to produce health
benefits or if it reduced health-care spending.
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Scientific summary
Background
Long-term conditions (LTCs) may cause reduced health-related quality of life (HRQoL) and considerable
health service expenditure. Alternative and complementary therapies, other than the usual medical
treatments, are increasingly being introduced within clinical practice. Therapeutic writing (TW) has been
widely reported in psychology textbooks and scientific journals as having the potential to improve physical
and mental health but its effectiveness in people with LTCs is not clear.
Objectives
To establish the clinical effectiveness and cost-effectiveness of TW in LTCs, through systematic reviews
and economic evaluation, and to evaluate context and mechanisms by which it might work, through
realist synthesis.
Methods
A protocol was lodged with PROSPERO – CRD42012003343. A group of practitioner experts informed
and validated all review phases in regular meetings and compared research findings with their UK
clinical experience.
Data sources
Systematic reviews
Electronic searches were conducted for primary studies in the following databases: MEDLINE, EMBASE,
PsycINFO, CAB Abstracts, Physiotherapy Evidence Database, Published International Literature on Traumatic
Stress, The British Library’s Electronic Table of Contents, Science Citation Index (SCI), Social Sciences
Citation Index, Linguistics and Language Behavior Abstracts, Periodicals Index Online, Applied Social
Sciences Index and Abstracts, Education Resources Information Center, Allied and Complementary
Medicine Database, Cumulative Index to Nursing and Allied Health Literature (CINAHL), Cochrane Central
Register of Controlled Trials and Database of Abstracts of Reviews of Effects from inception to March 2013.
Additional searches to January 2015 were made in those databases yielding all of the previous primary
studies (MEDLINE, EMBASE, PsycINFO, CINAHL, The Cochrane Library and SCI). Additional hand-searches
and cross-referencing were implemented for both sets of searches. For the realist synthesis, searches were
conducted from the database created from the 2013 searches. After initial screening, further purposive and
iterative searches linked to the included studies in the effectiveness review were performed: related papers
and relevant papers cited in the reference lists were used.
Study selection (inclusion criteria)
One reviewer carried out first and second screenings, and 10% of studies were screened by a second
reviewer working independently.
Systematic reviews
We included any type of comparative study of TW compared with no writing, waiting list controls,
attention controls or placebo writing, in patients with any diagnosed LTCs. Studies had to report at least
one of the following: relevant clinical outcomes; quality of life (QoL); health service use; psychological,
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behavioural or social functioning; adherence; or adverse events related to the TW intervention. For the
resource-use systematic review, those studies included in the effectiveness systematic review reporting
any resource-use outcomes were included.
Realist synthesis
Any type of study design assessing TW in people with LTCs was of interest.
Data extraction
Systematic review
One reviewer performed data extraction in full. All numerical results and each study quality assessment
were checked by a second reviewer working independently. Authors of primary studies were contacted for
unreported, or inadequately reported, numerical data. Study quality was assessed with the Cochrane
risk-of-bias tool [for randomised controlled trials (RCTs) and non-RCTs] or the Newcastle–Ottawa Scale
(for cohort and case–control studies). Studies were categorised by facilitated TW/unfacilitated emotional
writing (EW) and then by ICD-10 (International Classification of Diseases, Tenth Edition) code.
Realist synthesis
One reviewer selected relevant sections on context, mechanisms and outcomes from the included studies,
process evaluations and discussion papers to refine the programme theory. Included studies were
rescrutinised to search for data that were relevant to the revised theory. Publications were selected if they
were relevant, and quality assessment used the concept of rigour.
Data synthesis
Systematic review
Narrative and tabular synthesis was used. Meta-analysis was conducted when three or more studies
reported the same outcome, using RevMan version 5.2.6 (RevMan 2012, The Cochrane Collaboration,
The Nordic Cochrane Centre, Copenhagen, Denmark).
Economic considerations
Resource use was systematically reviewed using the same methods as outlined above. Costs and resource
use were estimated given de novo economic modelling was not possible owing to lack of information.
Realist synthesis
Realist and Meta-review Evidence Synthesis: Evolving Standards methodological standards were followed.
Programme theory was developed with extensive input from TW practitioners. Data extracted were used to
develop and refine programme theory. This was presented diagrammatically, detailing how and why
inferred mechanisms and key contextual influences potentially influence intermediate and final outcomes.
Results
Systematic reviews
From 14,658 unique citations, 284 full-text papers were reviewed and 64 studies (59 RCTs, one non-
randomised controlled study, three controlled cohort studies and one matched case–control study) were
included in the effectiveness reviews. Thirty-nine studies were conducted in the USA. The largest study had
507 participants, but half of the studies included fewer than 50 participants in each arm. Five studies were
in facilitated TW, and examined positive writing, enhanced meaning writing, song, poetry and internet
chat forums. Fifty-nine studies were of unfacilitated TW and used either standard EW or an adapted
version. Studies reported mainly psychological, physical and QoL outcomes, with 172 instruments used and
more than 300 different outcome measures reported. Follow-up was mostly at between 1 and 3 months.
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Five studies from different countries were included. Studies used very different TW intervention methods
and different instruments or subscales to report relevant outcomes, which included physical and
psychological assessments. Data to inform quality assessment were scarcely reported, and all five studies
were at unclear risk of detection bias. The studies could not be meta-analysed because of a lack of
consistency in measurement and heterogeneity in participants’ LTCs and the interventions. However, all
studies reported significant improvement in all but one outcomes in favour of the TW group.
Unfacilitated emotional writing
A total of 59 studies assessed an unfacilitated EW intervention. Twenty-seven ICD-10 codes were used to
categorise over 30 LTCs in the included studies. The most frequently investigated were breast cancer
(eight studies) and human immunodeficiency virus (HIV) (six studies). Only one study was reported on each
of the following ICD-10 categories: type 2 diabetes mellitus, sickle cell disease, cystic fibrosis, dementia,
bulimia nervosa, amyotrophic lateral sclerosis, tension and migraine headaches, and chronic obstructive
pulmonary disease.
Overall there was no, or very little, evidence of any benefit reported in the following conditions: HIV
(six studies, overall unclear risk of bias); breast cancer (eight studies, overall low or unclear risk of bias);
gynaecological and genitourinary cancers (five studies, variable risk of bias); asthma (four studies, low or
unclear risk of bias); psoriasis (three studies, unclear or high risk of bias); inflammatory arthropathies
(six studies, high or unclear risk of bias); and chronic pain (four studies, low or unclear risk of bias). There
were five small studies of heterogeneous populations with mental health problems (low or unclear risk of
bias) for which no clear patterns emerged. For all other LTCs there were either no data, or sparse data
with no or inconsistent evidence of benefit.
Meta-analyses by International Classification of Diseases, Tenth Edition code
Few meta-analyses could be performed because of heterogeneity. The analyses included different
outcomes measured at different follow-ups in the following chronic conditions: HIV (depression at short
term in 249 participants); breast cancer (depression in 562 participants, positive and negative mood at
short term in 618 participants each); asthma (lung function at short term in 177 participants); mental and
psychiatric disorders (anxiety at short term in 127 participants); inflammatory arthropathies (disease activity
at both immediate and short term in 146 participants); and fibromyalgia and chronic pain (pain severity at
two different short-term assessments in 216 participants).
Differences between EW and control groups were not significant in almost all of the outcome measures
meta-analysed, except for disease severity in people with inflammatory arthropathy, for which significant
differences in favour of the EW group – at short-term follow-up only – were found [n= 216, standardised
mean difference (SMD) –0.61, 95% confidence interval (CI) –0.96 to –0.26, with a random-effects model
and with non-significant heterogeneity, I2= 1%].
Consideration of outcomes across long-term medical conditions
Twenty-four studies among 12 different LTCs reported either physiological or biomarker outcomes.
The EW intervention groups did not show better results than controls in any of the physiological and/or
biomarker outcomes reported, except for diastolic blood pressure (but not systolic blood pressure) in
Willmott et al. (Willmott L, Harris P, Gellaitry G, Cooper V, Horne R. The effects of expressive writing
following first myocardial infarction: a randomized controlled trial. Health Psychol 2011;30:642–50), which
was significantly better in the EW group at the final follow-up (21 weeks).
The most frequently measured outcomes across the LTCs were depression and anxiety. Meta-analyses of
depression showed no statistical significance at any duration of follow-up. For example, at 4–17 weeks’
follow-up (17 studies) the SMD was –0.09 (95% CI –0.31 to 0.14) with substantial heterogeneity (I2= 71%).
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Eleven studies assessed anxiety in 527 participants at immediate (197 participants) and short-term
(330 participants) follow-up. Differences in anxiety between EW and control groups were not significant
in either case.
Economic considerations
No full economic evaluations were found. One study reported cost of EW at US$130 per patient. Twelve
studies reported on resource use, covering a wide range of disease areas and populations. Meta-analysis of
health centre visits (seven studies) showed no statistical differences between EW groups and control
subjects. Meta-analysis of medication use from three studies showed fewer medications with unfacilitated
EW (SMD –0.28, 95% CI –0.54 to –0.02) than controls. Cost–consequence analysis suggested that there
might possibly be a favourable balance of participant benefits to UK NHS costs for selected interventions in
selected LTC groups. There is insufficient evidence to judge cost-effectiveness.
Realist synthesis
The realist synthesis included 59 studies from the systematic review, a further single related paper
describing additional aspects of one study, 13 studies excluded from the systematic review, and one
additional paper. They provided information on qualitative research, process evaluation, and theoretical or
methodological discussions, for the realist synthesis.
Two distinct TW programme theories were developed:
1. For unfacilitated (individual) EW, the main mechanisms and contexts were difficult to clarify as relevant
explanatory data were not explored and/or reported within the studies – unfacilitated EW appeared to
have been treated like a black box. It was unclear why participants would have wanted to undertake
EW or what they would hope to gain from it.
2. For the facilitated (group) TW, there were multiple potential mechanisms that interacted in a complex
way with each other and context to generate (intermediate) outcomes. In brief, mechanisms related to
the forming of relationships and the group acting as a safe environment and an audience for TW.
Unfacilitated TW was pragmatic in that it did not assume that TW was necessarily appropriate for all
people with LTCs but instead provided opportunities for participants to try to see if it helped.
Conclusions and implications for health care
Most interventions evaluated were unfacilitated and did not mirror those currently used by professional TW
practitioners in clinical practice in the UK. There is insufficient clinically relevant evidence on facilitated
TW to know whether or not it is beneficial. Unfacilitated EW was not effective for most outcomes in most
LTCs, although data were very sparse in many areas. The effectiveness of unfacilitated EW in LTCs is not
as immediately obvious, as might have been expected from research about this intervention in general
populations reported in textbooks.
Recommendations for research
Further research that evaluates facilitated TW interventions currently used in clinical settings is needed,
using feasibility or pilot studies and progressing to cluster RCTs or stepped-wedge designs, evaluating
patients with chronic physical and mental health conditions. The comparators could be standard practice
without TW and also other comparable therapeutic interventions, such as relaxation CDs or reading
bibliotherapy. Useful outcomes would be the standard clinical outcome measures or instruments for the
patients’ medical conditions, patient satisfaction, HRQoL and costs. The study sample sizes would need to
be large enough to find a potentially modest effect.
SCIENTIFIC SUMMARY
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Study registration
This study is registered as PROSPERO CRD42012003343.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research.
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Chapter 1 Background
Therapeutic writing
Writing as a form of therapy to improve physical or mental health has a long history1 and is widely
reported in psychology textbooks as being of therapeutic value.2–5 It can take many formats including those
from a psychotherapeutic background, such as therapeutic letter writing,6 specific controlled interventions,
such as emotional disclosure/expressive writing,7 to more recent approaches, such as developmental
creative writing8 and other epistolary approaches, such as blogging.8 With the development of UK
organisations such as Lapidus (Association for Literary Arts in Personal Development), dedicated to the
promotion of therapeutic writing (TW) based on the premise that it has health benefits, and an increased
interest in the potential of non-pharmacological adjunctive therapies, it is important to evaluate the
effectiveness of a variety of different approaches within this field. These include two main categories:
written emotional disclosure [or emotional writing (EW)]9 and creative writing, such as poetry.7 Other forms
of creative writing include alpha writes/poems (a poetic device in which each successive line of the poem
starts with the next letter of the alphabet, or a predetermined word or phrase written vertically down the
page);10 writing from published poems/narratives; acrostics; and haiku poems (traditionally a haiku contains
three lines of five, seven and then five syllables, making a total of 17 syllables; the tradition is modified so
that no more than 17 syllables are arranged in no more than three lines, but the shorter the better);11
autobiographical writing (such as reflective diaries, journaling); descriptive writing; genre writing
(e.g. fairy tales); free writing; short stories; drama or fictional narratives; unsent letters; diary/journaling;
collaborative writing (workshops); writing accompanying other art forms; life writing or memoirs (such as
reminiscence, life review); list writing; redrafting or sentence stems writing; scribing for others; writing
from visual/sound stimuli (e.g. writing from mindfulness); writing from the senses; and writing in form
and writing from music (as part of a music therapy).10,12 Newer forms of writing include blogging or
participating in web-based forums.13,14
Dimensions of therapeutic writing
Within each type of TW there may be significant process variability, for example in the flexibility and
number of topics; the dose (frequency and duration); group or individual delivery; computerised compared
with handwritten exercises; participant recruitment; and financial compensation. However, a major
distinction lies in whether the writing is facilitated or unfacilitated.
Facilitated therapeutic writing
Facilitated TW interventions, when a facilitator is present at some stage before or during the writing, might
be delivered in many different ways and contexts: in a health-care centre, as part of a programme in a
rehabilitation clinic or within a group of people with common or different chronic conditions, face to face
or via the internet. People using these therapeutic tools may receive feedback from someone else, a
health-care professional, a group of persons or not receive feedback at all.10
Furthermore, the topic of the writing can be varied, from positive to negative expression of emotions
through neutral topics (e.g. childhood/birth, life aims and goals, places, relationships).10 TW can also be
used in children, adolescents or adults and among different clients, such as the chronically ill (e.g. cancer,
mental health problems, chronic infections) or healthy individuals, and assessed from different angles such
as community carers, doctors and nurses, peer training, patient’s family and/or friends or the participant
him/herself – the most usual perspective.10
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The writing event should not be considered as solely an isolated exercise but as a sequence of exercises,
not necessarily all of which encompass a written component. As such, a common practice is that writing
starts with (visual) stimuli12 or with mindfulness meditation in order to inspire people and to act as a form
of distraction from reality.15 The following examples of the work of facilitated writing practitioners in the
UK exemplify the variety of this type of TW (Box 1).
Perhaps the last thing to add is that clinicians at Freedom from Torture continue to send more clients than
can be coped with, which is some vindication of the practice. As a bridge between intense therapy and the
outside world, giving clients a skill they can take with them and a means of self-discovery, self-healing and
personal growth, it seems, as the Hippocratic Oath puts it, to do no harm, and a great deal of good.
Unfacilitated emotional writing
Unfacilitated EW means writing, completed without any assistance, feedback, comment or any other form
of support. Therefore, in the current review, an unfacilitated writing intervention has been defined as
when a facilitator was simply not present in person during the writing exercise, as opposed to facilitated
writing (described above). Typically, in unfacilitated writing interventions, participants are instructed to
write for 15–30 minutes on 3 to 4 consecutive days (or at weekly intervals). Instructions on these
unfacilitated writing assignments can be delivered in writing via leaflets, verbally over the telephone or
even via video or the internet. Participants are asked to do their writing unassisted and alone at home or
on their own in a given clinic or laboratory setting. In the most commonly evaluated form of unfacilitated
EW, there is a single writing topic that can be chosen (usually disease or treatment focused), for which
participants are directed to write emotionally and disclose about their deepest thoughts and feelings or
about a self-selected trauma. Thereafter, either the writings may be collected by the practitioner without
any feedback or the participant can simply decide what to do with the writing. Sometimes, practitioners
provide participants the option to make telephone calls during the writing exercise should any concerns
emerge; however, this action has not been considered as facilitation in this review.
BOX 1 Examples of facilitated therapeutic writing
Therapeutic writing practice with mental health inpatients: Carol Ross
Writing practitioner Carol Ross (CR) facilitates weekly TW groups for inpatients in mental health units in a UK
NHS Foundation Trust. CR has developed her own practice, influenced by a number of published research
studies, e.g. on positive writing; and by established therapies such as mindfulness-based cognitive therapy and
narrative therapy.
A typical session lasts 60 minutes, attended by one to seven self-referred inpatients, and comprising 25 minutes
of writing interventions (duration 5–15 minutes each) and 25 minutes of reading aloud and group discussion,
with the remaining time being taken up with introductions, explanations and evaluation forms. Flexible writing
interventions are used to allow tailoring of interventions for individuals and give patients some freedom to
choose what they write. The writing practitioner writes and reads aloud what they have written with the group.
Many of the writing interventions CR uses in acute mental health settings, e.g. mindful writing, are aimed at
calming the individual, decreasing anxiety, increasing mental focus and lifting mood. With some writing
interventions, another effect is intended, e.g. broadening of cognitive focus, reframing, insight, improved
self-expression.
BACKGROUND
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CR’s TW toolbox includes mindful writing with either an external or internal focus; positive writing about the
past, present and future; perspective shift writing, including unsent letters; and responding to published poems.
The broadest range of TW is used in the general adult ward. In the older people’s assessment unit, some
interventions are designed to trigger positive/neutral memories in a low pressure way (see Appendix 1,
Table 75, illustrating the types of TW interventions used by CR).
In the PICU, the sessions are typically one to one or one to two, with individuals experiencing acute symptoms,
e.g. of psychosis or mania. The PICU writing group is held in an open area so that patients who decline to do
any writing, or even sit at the table, still sometimes take part in a brief conversation with the practitioner or
other patients, and look at whatever prompt materials are on display, e.g. photographs or objects. Data from
an internal audit suggest that the writing group contributes to a reduction in violent incidents in the PICU.
It will be seen that the practice described differs markedly from the unfacilitated EW method described by
Pennebaker and Beall1 (see section below on EW), e.g. writing interventions are facilitated and take place in a
group. Patients are also never directed to write about trauma.
Poetry therapy for people with mild mental health problems: Victoria Field
Poetry therapy practitioner Victoria Field (VF) facilitates a weekly Words for Wellbeing group in the Beaney House
of Art and Knowledge in Canterbury (part of Kent Library Service), aimed at people with mild mental health
problems, often as a result of LTCs. She ran a similar group for some years at Falmouth Health Centre, with
referrals from GPs. VF qualified in 2005 as a Certified Poetry Therapist, with the NFBPT, which works with the
therapeutic potential of both the receptive (reading and listening) and expressive (writing and sharing) aspects of
writing. The practice can be adapted for individuals and non-writers but is always interactive for reasons
outlined.16 She is now approved as a Provisional Mentor–Supervisor for the NFBPT, training others in these
techniques. The aims of the group are closely aligned with the NHS Wellbeing agenda.17 A typical session lasts
2 hours, including a break, attended by anything from 2 to 18 people. An ideal group size is around 10, fewer
when participants are more unwell or distressed. The group follows a set format, and this predictability is valued
by attendees:
1. Reflective writing This is the activity closest to a written emotional disclosure type of intervention as
described by Pennebaker and Beall.1 However, it is firmly contained. Participants are invited to write for
6 minutes or so from a given prompt. This might be as simple as ‘I can see’ or ‘Here now’, or more
elaborated, such as a list of statements, ‘Then I was, now I am’ or working with a metaphor, e.g. a colour
or weather ‘Today I am’ or ‘Red is . . .’ This initial writing is intended to be private, although participants are
invited to talk about what might have come up, and sometimes some wish to read.
2. The reading aloud of a poem Not necessarily literary, which VF has chosen for that week, followed by
discussion of what it suggests.
3. Writing in response to the poem Again for a short period of 6/7 minutes, typically from a choice of prompts.
The writing that emerges is often fully formed, powerful, satisfying to the writer and helpful for the listeners.
Writing and reading in this way offers a container for complex emotions, catharsis, pleasure, connection,
validation, self-expression and mastery that may improve mood, decrease anxiety, allow reframing, insight
and encourage a more nuanced approach to life. The group dynamic is also a powerful therapeutic tool
(see Appendix 1, outlining VF’s professional perspective).
BOX 1 Examples of facilitated therapeutic writing (continued)
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Write to life at Freedom from Torture: Sheila Hayman
Sheila Hayman is a member of Lapidus, and has run creative and therapeutic workshops for elderly day-care
patients, detention centre visitors, children and the general public. However, her main work for the past
11 years has been with Write to Life, a unique therapeutic creative writing programme based at, and funded
by, Freedom from Torture, the UK’s only national charity dedicated to the support and rehabilitation of torture
survivors from around the world.
In 12 years, the group has grown to about 20 members, of whom a dozen regularly attend bi-weekly group
workshops and individual one-to-one sessions. Members are referred, while still in clinical treatment,
by the clinical key worker, and while they remain in treatment the group works closely with the clinician.
However, as the group is open-ended, clients can stay as long as they like, and there are members who have
been with the group for 6 years or more. This enables them to make huge strides in what they can achieve.
When they arrive, many are still very traumatised, unable to trust others or communicate freely, unable to talk
about their past or present experiences or make friends. Over time, they make friends inside and outside the
group, begin to enjoy not just writing but performing their work, and are enabled to address large gatherings of all
sorts about the effects of torture, asylum and other aspects of their situation, as well as perform in public in plays
and other events. They report improved sleep, reduced headaches and other sorts of pain, and most of all the
reduction or even elimination of the flashbacks, nightmares and other symptoms of their post-traumatic condition.
The writing falls into two parts: the first is the public setting of the group, which is run by a group of volunteers
who are professional writers rather than clinicians. This group writing sometimes focuses on matters of interest to
the client base, such as journeys, poverty, or trust, but equally could be an exercise in literary criticism, or an
invitation to reflect on living in London. It usually takes the form of a short exercise and discussion, followed by a
longer piece of writing which members are invited to read out. Everybody has to write, but not everybody has to
read out, as sometimes they find that the subject has unearthed things they prefer to keep private.
It is noticeable that the framework, often quite unguided as to the form of writing, enables group members to
dig as deeply into their feelings, including bad ones, as they wish. Some people will always find a way of
writing about the source of their pain, no matter how the exercise is framed. And that is how it should be.
Others may want to be more structured, or literary, or metaphorical.
The strong feelings, and the personal exploration and laying of ghosts, are dealt with in the one-to-one
element of the work. Usually, on the same day as the workshop, and purely for practicality, each group
member is offered one-to-one sessions with one of the six writer/mentors. This is an opportunity to write about
whatever they choose, and to dig as deeply as they wish into their past or present trauma. This writing may
remain private, or be published, as they choose. Leaving the level of introspection up to them gives much more
sense of control and safety, as reported by more than one group member, compared with their clinical therapy
sessions, which may leave them distressed when they need to be okay for a meeting, or may make them jump
with unexpected reactions.
Sometimes the writing seems to gloss over, or miss out, a crucial painful moment or event, and on these occasions
the mentor, in consultation with the writer, may guide them to look again at that portion of the writing and fill in
the missing emotion. This is why it’s important to collaborate with a clinician, at least in the early stages when
clients are still raw and vulnerable. But in practice, our work, and, by their own account, that of our clinical
colleagues, is often guided as much by instinct, common sense and experience, as any theory or training.
GP, general practitioner; LTC, long-term condition; NFBPT, National Federation for Biblio/Poetry;
PICU, psychiatric intensive care unit.
BOX 1 Examples of facilitated therapeutic writing (continued)
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The Pennebaker writing paradigm: expressive writing or written
emotional disclosure
This is the most common form of unfacilitated EW. It is a technique whereby people are encouraged to write
(or talk into a tape recorder) in private about a traumatic, stressful or upsetting event, usually from their
recent or distant past. They write for 15–30 minutes typically for 3 or 4 days within a relatively short period
of time, such as on consecutive days or within 2 weeks. The format has been relatively consistent since the
earliest randomised controlled trials (RCTs),1,18 but more recent studies have varied the duration, number of
sessions and topic of writing, including positive events and thoughts and feelings about illnesses.19 RCTs
of expressive/emotional writing have been conducted in a wide variety of participants, including healthy
students, people undergoing psychological stressors, such as bereavement or being in a caregiving role, or in
people with long-term physical conditions, such as rheumatoid arthritis (RA) and asthma. Variants of the
technique include disclosure in front of a listener, who can be a confederate, a researcher or a doctor. For
the purposes of this project, these activities are not considered to be EW and lie outside the scope of this
review. The presence of a listener is likely to affect outcomes, as it potentially adds a counselling dimension.
Positive writing
Positive writing can be delivered either as part of a facilitated TW or unfacilitated EW intervention. The
exercise involves writing about positive topics only, including positive emotions, typically for 20–30 minutes,
three or four times per week if delivered as an unfacilitated EW intervention. Otherwise, the duration and
length of the positive writing can be very varied when facilitated (see Appendix 1). Pennebaker et al.19 found
in a review published in 1997 that the description of positive emotions could predict improvements in health
outcomes. Since then, researchers have studied the positive effects of the positive emotional disclosure,
advocating that participants writing about the positive aspects of past traumas (benefit finding by describing
any positive outcomes of the disease experience or treatment in detail) or simply about positive life events,
could achieve comparable health improvements as those writing about past traumas.20
Bibliotherapy
Although the above require the individual to write as part of therapy, other forms of therapy use existing
texts. The most commonly encountered type of bibliotherapy, Reading Bibliotherapy, involves reading
material specifically selected for its therapeutic potential for that person.21 In the UK, Books on Prescription
Schemes have been running in primary care for several years, and in 2013 a national scheme was launched
in England by the Society of Chief Librarians and the Reading Agency.22 Such reading bibliotherapy is not
covered by this review.
In contrast, interactive bibliotherapy has been defined as the use of literature to bring about a therapeutic
interaction between participant and facilitator.21 The triad of participant, literature and therapist is viewed
as critical. In fact, interactive bibliotherapy does not restrict itself to the written word: it can include the
spoken word, for example in film or theatre but it must involve the coherent use of language. When
interactive bibliotherapy uses poetry, it is synonymous with poetry therapy and they are both encompassed
by the term biblio/poetry therapy.21 Sometimes the literature involved in biblio/poetry therapy is new
writing generated by the participants themselves. This type of creative writing biblio/poetry therapy is the
principal form of facilitated TW included in this review and it is the form of TW used by the practitioner
experts collaborating in the current systematic reviews (see Box 1, in which the TW expert practitioners
describe their different facilitated biblio/poetry therapy practices).
Nonetheless, little has been published around all the different types of facilitated TW, and literature
shows that the most evaluated form of TW is the EW intervention, described by Pennebaker and Beall1
Comprehensive research around the writing paradigm18,23–27 and narrative analysis within the health-care
setting28–31 has been performed through the last decades.
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Long-term conditions
The prevalence of long-term conditions (LTCs) increases with ageing populations. In 2002, the leading
chronic diseases [cardiovascular disease (CVD), cancer, chronic respiratory disease and diabetes] were
responsible for 29 million deaths worldwide.32 According to the UK Department of Health (DH),33 more
than 15 million people in England (including half of all those aged > 60 years) are living with at least one
LTC, and the risk of death is particularly high in those with three or more conditions occurring
concurrently.34 LTCs also result in a huge burden on UK NHS resources. Although some are preventable,
for most LTCs the only realistic management strategy is continuing care, as biological and psychosocial
mechanisms regulating disease progression are not yet fully understood. As LTCs are difficult to improve,
especially for elderly populations, health-care programmes, such as self-management support and patient
education, often combined with structured clinical follow-up, have been suggested as a way to improve
the quality of life (QoL) of such patients.35 New therapeutic approaches, such as TW, have the potential to
improve the QoL in people with LTCs.
Possible pathways linking memory, emotions and
physical health
There are several potential ways that writing might impact on physical health. For example, cognitive
restructuring or behavioural mechanisms (e.g. reflection on health behaviours) may lead to improvement in
outcomes. However, many of the types of TW described above engage emotions and memories (both
positive or negative) and there are physiological pathways linking memory, emotions, chronic stress and
physical health.
Two interdependent memory systems are thought to be associated with remembering events in humans.36
Episodic memory is linked to the hippocampus and this structure is vital for processing events that
eventually become long-term memories.37 Emotional memory is linked to the amygdala, part of the limbic
system involved with emotions, in particular fear-related responses and general pleasant and unpleasant
emotional processing.38 Although the episodic and emotional memory systems are independent,
they affect each other in a variety of ways.36 Emotion enhances perception of, and attention to, the
memory-provoking stimulus, as well as the long-term storage of the memory.36 Episodic memory also
influences emotional memory by, for example, causing the autonomic effects of emotional arousal
(e.g. the sweaty palms and dry mouth) when remembering a past situation.36
The limbic system has links with the cerebral cortex, the brainstem and the pituitary gland (part of the
hypothalamic–pituitary–adrenal axis). Parts of the cerebral cortex have a role in cognitive appraisal and
the conscious awareness of emotional states, and can regulate amygdalar activity.38 Through the
brainstem, areas in the limbic system can control many internal conditions of the body, for example
cardiovascular regulation. The hypothalamic–pituitary–adrenal axis is both responsive to psychological
inputs and has significant influences on the immune system, which, in turn, influences physical health.39
This pathway may be one of the ways chronic stress is linked to poor health.39–42 It is therefore possible
that a psychological intervention might improve aspects of physical health, and if modification of such
pathways had even a small effect then this could have profound public health significance.
BACKGROUND
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Realist synthesis
In this review, a conventional systematic review of the effectiveness of unfacilitated EW and facilitated TW
was conducted, but, in addition, the findings of a realist synthesis are reported. Realist synthesis is a
theory-driven interpretive approach to evidence synthesis. Rather than producing a judgement on whether
(or not) an intervention works, realist syntheses attempt to explain outcome patterns in data using theory
(or theories). It is particularly useful when interventions are complex and evidence is mixed or conflicting
and provides little or no clues as to why the intervention worked or did not work when used in different
contexts, by different stakeholders or when used for different purposes.43
In brief, realist syntheses ask what works for whom in what circumstances, how and why? To do so,
realist syntheses use a particular logic of analysis that deliberately breaks down how an outcome has
arisen. An outcome is considered to have occurred because it is caused to do so by a causal process
known as a mechanism. In addition, the contexts in which an outcome has occurred are also considered to
be important as they cause mechanisms to be activated. This logic of analysis thus provides an approach
for understanding how and why it is that context can influence outcomes. In summary, the realist logic of
analysis used in a realist synthesis considers the interaction between context, mechanism and outcome
(sometimes abbreviated as CMO). That is how particular contexts have triggered (or, conversely, interfered
with) mechanisms to generate the observed outcomes.43
To elaborate further, in order to understand how outcomes are generated, the roles of both external reality
and human understanding and response need to be incorporated. Realism does this through the concept of
mechanisms, whose precise definition is contested but for which a working definition is ‘. . . underlying
entities, processes, or structures which operate in particular contexts to generate outcomes of interest.’44
Different contexts interact with different mechanisms to make particular outcomes more or less likely –
hence, in general, a realist synthesis produces recommendations of the general format ‘In situations [X],
complex intervention [Y], modified in this way and taking account of these contingencies, may be
appropriate’. This approach, when done well, is widely recognised as a robust set of methods, which is
particularly appropriate when seeking to explore the interaction between CMO in a complex intervention
[e.g. see Berwick’s editorial explaining why experimental (RCT/meta-analysis) designs may need to be
supplemented (or perhaps in some circumstances replaced) by realist studies aimed at elucidating CMOs].45
The philosophical basis underpinning a realist synthesis is realism. Realism assumes the existence of an
external reality (a real world) but one that is filtered (i.e. perceived, interpreted and responded to) through
human senses, volitions, language and culture. Such human processing initiates a constant process of
self-generated change in all social institutions, a vital process that has to be accommodated in evaluating
social programmes. In other words, the way individuals interpret and respond (or not) to the world around
them has the potential to cause changes to this world around them. Such changes may then cause
additional responses from individuals, potentially leading to a series of feedback loops. Within a realist
synthesis, where possible, attempts are made to understand these feedback loops.
A realist approach is particularly useful for this project because TW is a complex intervention that could be
useful in a variety of patient groups, and currently it is unclear whether it is effective for all or some, and
how and why it might be effective.
Realist syntheses often use input from content experts to help develop the programme theories needed to
explain how complex interventions work. In this project, input from practitioner experts was deliberately
sought. During the second programme theory-building meeting with practitioner experts, they were asked
for their feedback on what their views were on how TW was meant to work, for whom and why (see
Chapter 5, Methods, for more details). Two practitioner experts [Carole Ross (CR) and Victoria Field (VF)]
provided written responses (see Appendix 1, Tables 76 and 77, respectively) and have been included in this
report as they provide an insight into how facilitated TW is used in the NHS and voluntary sector.
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Previous systematic reviews on therapeutic writing in
long-term conditions
There have been a number of systematic reviews on expressive writing,18,23,46,47 published in psychology
journals, that have conducted meta-analyses according to normal practice in psychology, combining different
types of participants and outcomes across different conditions, and using Cohen’s d or Hedges’ g statistics.
Their results are difficult to interpret because effect sizes for specific populations and interventions are unclear.
There have been three recent systematic reviews on TW in LTCs. One concerned post-traumatic stress disorder
(PTSD) only and included five studies.27 One of the included studies is on cognitive–behavioural therapy (CBT)
rather than TW,48 and another49 is a very small, non-randomised study with students. A second, unpublished
systematic review was accessed via the internet.26 This assessed TW for psychological morbidity in people with
long-term physical conditions. The review included 14 RCTs and searches were conducted up to May 2011.
It is unclear why this review did not include a number of potentially includable studies including Abel et al.50
[human immunodeficiency virus (HIV)], Graham et al.51 (chronic pain), Halpert et al.52 [inflammatory bowel
syndrome (irritable bowel syndrome, IBS)], Henry et al.53 (breast cancer), Hughes54 (breast cancer), Kraaij et al.55
(HIV), Petrie et al.56 (HIV), Stark57 [fibromyalgia (FM)] and Theadom et al.58 (asthma), as all of these studies
measure psychological morbidity and were published before the search end date. It may be that they
did not include some of these because of their definition of long-term physical conditions, as there is no
uniform definition as yet. It is unclear how the results might have differed if some of these studies had
been included. The third systematic review evaluated the impact of support on the effectiveness of written
cognitive–behavioural self-help59 and thus was not really focused on TW per se. It included 38 studies, none of
which are included in this project.
Hypotheses tested in the review (research questions)
Overall aims and objectives of this review
1. What are the different types of TW that have been evaluated in comparative studies? What are their
defining characteristics? How are they delivered? What underlying theories have been proposed for
their effect(s)?
2. What is the clinical effectiveness of the different types of TW for LTCs compared with no writing or
other suitable comparators?
3. How is heterogeneity in results of empirical studies accounted for in terms of patient and/or contextual
factors, and what are the potential mechanisms responsible for the success, failure or partial success
of interventions (i.e. what works for whom in what circumstances and why)?
4. What is the cost-effectiveness or cost–consequences of one or more types of TW, in one or more
representative LTCs, when there is sufficient information on the intervention, comparator and outcomes
to conduct an economic evaluation?
BACKGROUND
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Chapter 2 Systematic effectiveness review
methods
Expert advisory group
We invited practitioner experts in the area of the TW who approached us following our contact with
Lapidus and/or publicity following the awarding of the grant to contribute to the project. On invitation
to join the project we were unaware of the techniques of TW that they were employing. Although they
were all working in different fields, and with slightly different techniques and approaches, they were all
practitioners of facilitated TW. Indeed, we were unable to identify any UK-based practitioners of
clinically-based unfacilitated TW to invite to join us as advisors. However, one of our authors, CM, had
previously conducted a trial of unfacilitated TW.60 The practitioner experts were invited to collaborate
during all phases of this project in the role of advisors, in order to inform our understanding of the range
of TW interventions and to help reach consensus within the Steering Group Committee (SGC).
Search strategy
All electronic and hand-searches were conducted up to March 2013 by the lead researcher (OPN) in
collaboration with a librarian (JB). A mapping search was performed in order to determine the extent of
relevant literature (looking for both qualitative and quantitative studies). From the list of studies,
appropriately includable studies for the systematic review were selected according to the selection criteria.
A single electronic search was performed for both the mapping search and the systematic reviews of
effectiveness and economic studies. A further search was conducted by CM in January 2015 to cover the
2 years since the previous search.
Search engines
Studies were systematically identified by searching a total of 22 electronic medical and psychological
electronic databases: MEDLINE, EMBASE, PsycINFO, CAB Abstracts, Physiotherapy Evidence Database
(PEDro), Published International Literature on Traumatic Stress (PILOTS), The British Library’s Electronic
Table of Contents (Zetoc), Science Citation Index (SCI), Social Sciences Citation Index (SSCI), Linguistics and
Language Behaviour Abstracts, Periodicals Index Online, Applied Social Sciences Index and Abstracts
(ASSIA), Education Resources Information Center (ERIC), Allied and Complementary Medicine Database
(AMED), Cumulative Index to Nursing and Allied Health Literature (CINAHL), Cochrane Central Register of
Controlled Trials (CENTRAL) and Database of Abstracts of Reviews of Effects (DARE) for primary studies,
and NHS Economic Evaluation Database (NHS EED) for economic studies. Grey literature was searched
because of the possibility that effect size estimates might have been overestimated owing to selective
reporting bias and unpublished studies are known to be less likely to have statistically significant results
compared with published studies.61 Information on studies in progress and unpublished research or
research reported in the grey literature was also sought by searching relevant databases including the
Inside Conferences, Open System for Information on Grey Literature in Europe, Dissertation Abstracts,
Current Controlled Trials database and ClinicalTrials.gov, Cochrane Database of Systematic Reviews
(CDSR), Health Technology Assessment (HTA) Database, and The Campbell Library was searched for
systematic reviews and economic evaluations. In addition, internet searches were also carried out using
a specialist search gateway (OMNI), general search engine (Google) and a meta-search engine
(ReadCube).The search was first conducted in Ovid for MEDLINE and MEDLINE In-Process & Other
Non-Indexed Citations and then translated into the other databases. Similarly, the search in The Cochrane
Library retrieved papers from the CDSR, Cochrane DARE and NHS EED.
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The update searches (January 2015) included only the databases that had found all of the relevant
citations in the previous search (i.e. MEDLINE, EMBASE, PsycINFO, Web of Science and Social SSCI, CINAHL
and The Cochrane Library databases).
Additional searches and cross-referencing
Reference lists of included studies and previous reviews of emotional disclosure were screened. Experts in
the area were contacted to identify additional unpublished literature. All studies previously included in
former systematic reviews were searched for, screened against the inclusion criteria and considered for
inclusion in current systematic review.
Search terms
Medical subject headings together with key words and controlled vocabulary were combined to capture
two components of the review question: the populations and the interventions of interest. The search was
limited to humans and there were no restrictions regarding the study design. The search terms used
for each of the databases are listed in Appendix 3. In the update searches (January 2015) sensitive
searches using very wide search terms (writing, writ*, etc.) were used in order to find all relevant studies
that had been recently published.
The population of interest: long-term conditions
No definite list of LTCs was pre-established, as the potential range of diseases of interest was both
extensive and diverse and made it difficult to create an exhaustive list. For the purposes of the search
strategy and subsequent steps of the review, the UK DH definition of a LTC was adopted.33 The definition
states: ‘Long term conditions are those conditions that cannot, at present, be cured, but can be controlled
by medication and other therapies. They include diabetes, asthma, and chronic obstructive pulmonary
disease’. Where it was unclear whether or not a condition met criteria discussion was held with the SGC
and consensus reached (Table 1, column 1).
For inclusion, populations had to have received a clinical diagnosis of the condition. In some studies
participants had symptoms of LTCs (e.g. student populations) but no formal evidence of a clinical diagnosis
and study participants did not report having been diagnosed with these conditions. For such studies the
full text was scrutinised before making a decision regarding inclusion. The chronic conditions in these
studies included anxiety, chronic stress, closed head injury, depression (usually stated as symptoms of
depression), insomnia or poor sleep, migraine or tension headache, and suicidality.
The authors also discussed whether to consider some diagnosed conditions as LTCs, for example newly
diagnosed cancer, or whether congenital conditions might be seen by some to reflect a continuum of
normality (e.g. congenital deafness). It was decided to include these conditions but to analyse them
separately. These are listed below (see Table 1, column 3).
It was decided to include all other cancer studies because patients may receive palliative care for prolonged
periods, and terminally ill patients in hospices may still be receiving active treatment. Thus the distinction
between active treatment and palliation might be difficult to distinguish and, furthermore, disease
trajectories are not always predictable. There is a debate around whether or not obesity in the absence of
any comorbidity is a disease;62 therefore, studies in people with uncomplicated overweight and obesity
were excluded. Studies of addictive conditions (alcohol, smoking, illegal drugs, legal drugs) and learning
disability were also included because the results could be useful to the NHS, although these might not
meet the current definition of LTC. The following conditions were excluded:
l personality traits, such as alexithymia, body dissatisfaction
l people who had undergone stressful life events, such as bereavement, domestic violence, child sex
abuse (unless PTSD diagnosed)
l people found to be at increased risk of developing a LTC.
SYSTEMATIC EFFECTIVENESS REVIEW METHODS
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The intervention of interest: therapeutic writing
Prior to the drafting of the definitive list of search terms used to develop the search strategy, consensus
within the SGC was reached on the relevant and appropriate terms related to TW interventions. The terms
under debate had been identified as part of the mapping search. The aim was to capture the published
literature related to the different types of TW interventions; therefore the main key terms referring to TW
were defined, discussed, agreed and validated with the expert advice (Table 2, column 1).
Some terms were not considered because:
l they had been already identified with a more common synonym thought to be equivalent
(e.g. writing for healing/writing to cure vs. wellness writing)
l the focus of the writing was thought not to be therapeutic (e.g. written divulgation, written exposé or
written material/information).
TABLE 1 Long-term conditions discussed and considered for the review
Included LTCs after executive
decision Excluded LTCs after executive decision
Included LTCs but analysed in
separate groupa
Acquired brain injury Acute stress Addictive conditions (such as
drug, alcohol dependence)
Anorexia Alexythimia Aphasia/agraphia
Body dysmorphia Benign prostate enlargement/hypertrophy Asperger’s syndrome
Bulimia Bereavement Bladder papilloma resection
(low-grade non-invasive cancer)
Chronic pain (at least 3 months) Body dissatisfaction Cancers including those newly
diagnosed
Cystic fibrosis Child sex abuse Learning disabilities
Deafness/blindness Chronic dieters
Eating disorders Domestic violence
High BP EBV
HIV Lesbian/gay-related stress
IBS Mild traumatic brain injury
Infertility Obesity
MI Overweight
Serious traumatic brain injury People found to be at increased risk of
developing a LTC
Personality traits
Smoking
Unresolved grief
BP, blood pressure; EBV, Epstein–Barr virus; MI, myocardial infarction.
a These LTCs were included in the review after discussion. It was decided to group them separately because of their
special relevance to the NHS.
A clinical and reliable diagnosis of the LTC had to be performed in order to include the study. Any studies of populations
screened for instance for symptoms of a disease using a self-report questionnaire or any non-clinical population (students
recruited from a university) not clinically diagnosed with a condition that is not using a validated diagnostic tool
were discarded.
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TABLE 2 Therapeutic writing key words and variants discussed for the search strategy
Terms considered Terms not considered
Blogging Bibliotherapy
Catharsis Emotional announcement
Creative writing Emotional perspective
Descriptive writing Emotional revelation, revealment
Diary e-therapy
EW Internet writing
Epistolary writing Moral disclosure
Experimental disclosure Patient-reported outcomes writing
Expressive writing Therapeutic (or therapy) disclosure
Forum Truth disclosure
Handwriting Wellness writing
Health status writing Writing (or written) exercise
Journal, journaling Written confession
Letter writing Written divulgation
Life reminiscence Written exposé
Life review Written information
Life writing Written material
Memoirs Written/emotional betrayal
Narratives Written/emotional declaration
Poetry, poem, poetic
Reactive writing
Reflective writing
Sensitive writing
Story writing
Typing, keying
Writing (as such)
Writing as self-concealment
Writing as self-disclosure
Writing as self-help or self-management
Writing for healing
Writing therapy
Writing to cure
Writing workshop
Written (Pennebaker) paradigm
Written emotion
written emotional disclosure
written expression
SYSTEMATIC EFFECTIVENESS REVIEW METHODS
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Selection of papers
Results from the electronic searches (titles and abstracts where available) were transferred into a
spreadsheet using Microsoft Excel® 2010 (Microsoft Corporation, Redmond, WA, USA) following automatic
de-duplication within the citation manager EndNote X 4.02 (Thomson Reuters, CA, USA) and the manual
removal of other duplicates.
Peer-reviewed articles and non-peer-reviewed papers (e.g. conference abstracts and dissertations) were
then selected for potential inclusion in a two-stage process by one reviewer (OPN), with a random 10%
selection of citations independently checked by a second reviewer (LB and CM). The two reviewers
independently selected studies that met the predefined inclusion criteria. Disagreements were resolved by
discussion and/or arbitration involving a third reviewer or by the full team, depending on the complexity of
the issues. When it was not possible to determine the study eligibility by title and abstract alone the full
text was retrieved for assessment. Authors of conference abstracts were contacted for full articles.
During the selection of studies, the Preferred Reporting Items for Systematic reviews and Meta-Analyses
(PRISMA) approach was used.63 A diagram was developed to show the numbers of studies in the different
categories and the reasons for exclusion of full-text studies. Additionally, an expert in the field of TW was
shown the list of included studies to check whether or not they believed that all relevant papers had
been identified.
Inclusion criteria
Studies meeting the following inclusion criteria were included in the systematic review:
l Studies assessing participants with at least one LTC as per DH definition.33
l Studies assessing any form of TW including emotional disclosure/expressive writing, poetry, diaries, etc.,
with inactive comparators or comparison groups thought to be inactive:
¢ For example, if participants in the control arm were directed to write in a non-emotional way by
using, for instance, neutral topics or by describing facts or how they managed their time. When the
control group wrote about topics related to their illness or treatment, or when arousal of emotions
might occur, these were not considered to be inactive controls and these studies were excluded.
However, if descriptions of the comparators used were not provided, the paper was not be
excluded on this basis alone.
l Studies reporting any relevant clinical outcomes including both disease-specific outcomes and
generic outcomes.
¢ Outcomes related to physical (including physiological, haematological/immunological outcomes,
pain, or disability), psychological, social and behavioural health. Performance, health-related quality
of life (HRQoL), as well as participant mental status, satisfaction and both intervention safety and
compliance to treatment for the LTC, were of interest. Resource-use or cost data were also
collected for economic consideration. Outcomes could be self-reported or evaluated by a clinician
or a carer.
¢ If the study could report relevant outcomes without reporting any usable numerical data. In this
particular case, the authors were contacted for unpublished data.
l Full versions of prospective randomised or non-randomised trials or observational studies having any
form of comparison group including, for instance, RCTs/non-RCTs, cohort, case–control studies and
economic evaluations.
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Exclusion criteria
The following were excluded:
l Studies including participants with acute conditions, stress, bereavement or any acute event.
l Studies assessing any form of psychotherapy, counselling, talking to a listener, talking into a tape
recorder, mobile phone or similar, where this was the primary mode of delivering the intervention,
expressive drama, dance or film-making.
¢ Any study that evaluated other people’s writing.
¢ Any study that evaluated any type of writing as a diagnostic tool instead of as a therapeutic tool in
the course of a disease treatment (e.g. patients with agraphia).
l A comparative study with any active or probably active control including any form of TW or talking into
a tape recorder or mobile telephone.
l Studies assessing only intermediate physiological outcomes such as salivary cortisol, immune
parameters not routinely measured in the management of LTCs or studies not reporting relevant
numerical and usable data and/or where unpublished data could not be obtained.
l Inappropriate study design for this review: single case reports, case series (as both have no comparator
arm) and studies where results for intervention and control groups were not presented separately. Studies
only available in brief abstract form.
Data collection
The forms used for the data extraction are shown in Appendix 4.
Data extraction methods
Study findings were extracted and entered into a spreadsheet by one reviewer (OPN) and checked by a
second reviewer (CM, ST, AH, LS and LB) working independently. A purpose-built data extraction form
(Excel) was developed and piloted prior to data collection. Any disagreements were resolved by consensus
and/or arbitration involving a third reviewer. Missing information was obtained from investigators if it was
crucial to subsequent analysis (this was not possible for the five studies identified in the updated search
to January 2015). The software GetData Graph Digitizer version 2.26.0.20 (GETDATA Graph Digitizer,
Moscow, Russia) was used when numerical data had to be derived from graphs. To avoid introducing bias,
unpublished information was coded in the same fashion as published information.
Quality assessment methods
Quality of studies was assessed based on accepted contemporary standards including the Newcastle–Ottawa
Scale for case–control studies.64 The Cochrane risk-of-bias tool65 was used for RCTs and quasi-randomised
trials. Risk of bias was qualified as high, low or unclear. The first assessment was performed by one reviewer
(OPN) on all studies, with a second reviewer (CM, LB, LS, SJCT) independently checking each study.
SYSTEMATIC EFFECTIVENESS REVIEW METHODS
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Data analysis
Synthesis of data
In order to collate, combine and summarise the information from the included studies, narrative and
quantitative (meta-analysis) approaches were undertaken. After all included studies were identified, the
SGC discussed organisation of the data for analysis. It became clear that the studies fell into two distinct
categories: those that were facilitated (such as interactive biblio/poetry therapy) and those that were not
(such as unfacilitated TW models and its various elaborations). Discussion with our expert practitioners
and consideration of the literature revealed that facilitated and unfacilitated writing interventions are
fundamentally different. As explained by the practitioner experts, facilitated TW interventions consist of
one or more interactive activities (including TW) between the group facilitator and participant, which
allows a live, in-person communication and an element of quality control and tailoring. Usually, the
facilitator is in the same room as the participant, and may help with any unexpected concern and/or guide
the participant in the usual process of the intervention. For unfacilitated writing, studies were categorised
by ICD-10 (International Classification of Diseases, Tenth Edition) code according to the LTC assessed
(see Chapter 3).
Analysis of studies
The numerical results from each of the included studies were checked to identify possible data entry
problems. For each study, for continuous measures, either the mean and standard deviation (SD) at the
various follow-ups, or any other statistic that could be used to calculate SD, such as the standard error (SE),
were extracted for further analysis. For categorical measures, dichotomous or binary data, or counts and
rates calculated from the number of events that each individual experienced, were collected.
Meta-analyses
Pooled-effect estimations were conducted using the standard software package Review Manager 5.2.6
(RevMan 2012, The Cochrane Collaboration, The Nordic Cochrane Centre, Copenhagen, Denmark).
Analyses were stratified according to the type of outcome measured. A comparison was performed when
at least three studies used the same (or a similar) instrument to assess the same (or similar) aspects of a
given outcome and when sufficient numerical data were reported. In the case of different follow-up
periods, results were combined using threshold intervals of ‘immediate’, ‘short term’, ‘medium term’ and
‘long term’, as shown in Table 3.
In cases where two studies reported short-term follow-up, and one study reported an immediate follow-up
assessment, the studies were meta-analysed and combined into a short-term follow-up comparison. For
continuous outcomes, standardised mean differences (SMDs) were used when outcomes were measured
with different instruments. Random-effects models were used because of clinical heterogeneity. Statistical
heterogeneity of results between studies was assessed using the I2-value. Conclusions regarding the
estimates of effect sizes were interpreted cautiously if there was significant heterogeneity.
TABLE 3 Thresholds intervals for follow-up combinations in meta-analysis
Follow-up thresholdsa for meta-analysis, months Equivalence, weeks
Immediate < 1 < 4
Short term ≥ 1 and < 4 ≥ 4 and < 17
Medium term ≥ 4 and < 8 ≥ 17 and < 34
Long term ≥ 8 ≥ 34
a These thresholds were decided by consensus during a SGC meeting.
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Unit of analysis issues
Only comparative studies were included. Participants were usually randomised to one group of two
groups; however, some studies could compare one experimental TW intervention group against both a
standard intervention (such as standard care) and one with placebo writing. Alternatively, two or more
experimental interventions could be tested against a standard intervention (or with both a standard
intervention and with placebo writing), giving a four-arm trial. There could be also trials with the same
outcome assessed at different time points or just measured after the writing session or at the end of the
treatment period.
For the systematic review, the interest lay only in the direct comparison between a TW intervention
arm and an inactive comparator. If a trial had two intervention groups and two control groups, for
meta-analysis the trial was treated as two separate trials one comparing, for instance, a more brief TW
intervention against inactive comparator and one comparing a longer TW intervention against inactive
comparator. Where there were two intervention groups and one control group, the TW intervention
most widely used (i.e. the unfacilitated EW with the standard instructions was the one included in the
meta-analysis).
Results across LTCs
Four analyses were performed:
1. physiological, disease-related and biomarker outcomes (results tabulated)
2. positive writing across LTCs (results tabulated)
3. depression (results tabulated and meta-analysed where possible)
4. anxiety (results tabulated and meta-analysed where possible).
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Chapter 3 Systematic review results
Study selection
A total of 18,235 citations were initially retrieved from the searches in the different electronic databases.
After removal of duplicates, 14,658 citations were initially screened. Based on the review of their
corresponding titles and abstracts 14,374 records were excluded, while 284 full papers were marked for
retrieval, either because they were potentially relevant or because insufficient information was reported in
the title and abstract to make a final decision regarding inclusion in the systematic review. After screening
the full papers, 64 publications relating to 64 unique studies were finally included in the systematic
review: 58 from database searches and six from hand-searches. The duplicate checking of 10% of the
titles and abstracts revealed no studies missed and excellent agreement on excluded studies. Therefore,
no further checking was indicated.
All included studies were comparative studies evaluating a TW intervention in patients with different LTCs.
A description of the process followed for the identification and selection of studies, and the number of
studies identified through each step, is presented in the PRISMA diagram (Figure 1).
Records identified through 
other sources 
(n = 6)
Records excluded 
(n = 14,374)
Full-text articles assessed 
for eligibility 
(n = 284)
References excluded, with reasons (n = 220)
• Duplicates, n = 28
• Not TW, n = 34
• Not LTC, n = 51
• Not a comparative study, n = 43
• Not the comparator of interest, n = 29
• No outcome of interest, n = 1
• No useable numerical data reported, n = 9a
• Abstracts only, n = 20b
• Ongoing studies, n = 31b
• Could not be retrieved, n = 2
Included in the narrative
synthesis
 (n = 64)
Included in the quantitative
synthesis (meta-analysis)
 (n = 35)
Duplicates removed 
(n = 3583)
Records identified through
database searching 
(n = 18,235)
Records screened after
duplicates removed 
(n = 14,658)
FIGURE 1 Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) diagram. a, Final number
of studies with no numerical results (after correspondence with authors); b, authors of the abstracts and ongoing
studies were contacted to obtain a full-text version if available.
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Included studies
Details on the study design, participants’ chronic conditions, intervention types and processes, outcome
measures, as well as the quality assessment of the included studies, are reported in Appendix 5. The
number of studies categorised by ICD-10 code according to the LTC evaluated, together with the names of
the studies in each category, are shown in Table 4. The number of studies published by year is shown in
Figure 2, and the frequency of outcomes evaluated across the included studies is shown in Figure 3.
TABLE 4 Table of full list of LTCs included, with their ICD-10 codes
Condition ICD-10 code
Number of
unfacilitated
EW studies
(facilitated TW) Authors
HIV B24 6 Abel 2004,50 Ironson 2013,71 Kraaij 2010,55
Mann 2001,72 Petrie 2004,56 Wagner 201073
Breast cancer C50 8 Craft 2013,74 Gellaitry 2010,75 Henry 2010,53
Hughes 2007,54 Jensen-Johansen 2013,76
Mosher 2012,77 Park 2012,78 Walker 199979
Gynaecological and
genitourinary cancers
C57, C61,
C62, C64
5 (1) Arden-Close 2013,80 Milbury 2014,81 Pauley 2011,82
(Rickett 201166), Rosenberg 2002,83 Zakowski 200484
Other cancers C80 2 Cepeda 2008,85 Rini 201486
Sickle cell disease D57 1 McElligott 200687
Type 2 diabetes mellitus E11 1 Dennick 201488
Cystic fibrosis E84 1 Taylor 200389
Dementia F03 (1) (Hong 201167)
SUD F14/F19 3 Grasing 2010,90 Meshberg-Cohen 2010,91
Van Dam 201392
Psychiatric disorders F41–60 5 (1) Bernard 2006,93 Canna 2006,94 (Golkaramnay 200768),
Graf 2008,95 Krpan 2013,96 Richards 200097
PTSD F43 2 (2) Gidron 1996,98 (Lange 200369), (Sloan 201270),
Smyth 20089
BN F50 1 Robinson 200899
Amyotrophic lateral
sclerosis
G12 1 Averill 2013100
Migraines and tension
headaches
G43/G44 1 D’Souza 2008101
CVD I51 3 Bartasiuniene 2011,102 Hevey 2012,103 Willmott 2011104
COPD and IPF J44, J84 1 Sharifabad 2010105
Asthmaa J45 4 Harris 2005,106 aSmyth 1999,107 Theadom 2010,58
Warner 2006108
IBS K58 2 Halpert 2010,52 Wallander 2011109
Psoriasis L40 3 Paradisi 2010,110 Tabolli 2012,111 Vedhara 2007112
Inflammatory
arthropathiesa
M06/M45 6 Broderick 2004,113 Hamilton-West 2007,114
Lumley 2011,115 Lumley 2014,116 aSmyth 1999,107
Wetherell 2005117
FM and chronic pain M79 4 Broderick 2005,118 Gillis 2006,119 Graham 2008,51
Stark 201057
BN, bulimia nervosa; COPD, chronic obstructive pulmonary disease; IPF, idiopathic pulmonary fibrosis; SUD, substance
use disorder.
a Note that Smyth et al.107 was reported twice separately under both M06/M45 and J45, ICD-10 categories, hence the
total count of studies by condition is 65 (instead of the 64 included studies).
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FIGURE 3 Frequency of outcomes evaluated across the included studies.
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Regarding interventions, five used a facilitated type of TW66–70 and 59 studies71–119 used an unfacilitated
type of EW therapy. Participants in the control groups were usually instructed to neutral writing;
time-management writing; factual writing; non-writing; or waiting list. Most of the studies were published
in the USA and, since 2008, the year with most studies published (n= 11) was 2010. Breast cancer and
HIV were the most frequently evaluated conditions, followed by PTSD and rheumatoid arthritis (RA). The
outcomes most frequently evaluated were, in descending order, psychological, physiological and HRQoL.
Of the 64 included studies,9,51–58,66–119 599,51,54–58,66–68,71–77,79–86,88,89,91,93–119 were RCTs, and four52,78,87,92 were
non-randomised studies. The remaining study53 was a matched case–control study. Among the
64 studies,9,51–58,66–119 one was written not in the English language but in Korean.78 Smyth et al.107 and
D’Souza120 evaluated the effect of TW in two groups of patients with different conditions and reported
relevant outcomes independently. Data were extracted on the most recent paper, or the most complete
piece of information in the case of duplicates of an abstract and when the corresponding published article
of a PhD thesis was retrieved. Fifty papers required correspondence with authors in order to get relevant
unpublished information (or adequate data for meta-analysis purposes): 32 authors could be contacted
and 14 provided the sought information. All 64 studies9,51–58,66–119 provided information (numerical data)
relating to the efficacy and/or effectiveness of TW. Among those, numerical results were derived from
graphs in nine studies.51,53,56,70,85,103,110,114,121 Several studies under-reported the numerical data (e.g.
reporting the mean with no measure of variability, such as the SD) or used different statistics [such as the
median, together with confidence intervals (CIs) and/or ranges or the mean together with the SE] to report
the results. All 64 studies9,51–58,66–119 were considered for the quantitative analysis and 35 were finally
included in the meta-analyses.
Excluded studies
Abstracts and ongoing studies were excluded from the systematic review and have been listed separately
with details of all excluded papers, with their reasons for exclusion (see Appendix 6, List of excluded
studies with reasons for exclusion).
Nine studies evaluated TW but reported no numerical results for any of the outcomes measured and were
therefore excluded from the systematic review, as they could not contribute to estimation of efficacy or
effectiveness (see Appendix 6, List of excluded studies with reasons for exclusion).
Results of the different therapeutic writing interventions
This section is organised as follows:
l facilitated writing (in one or more arms of the study)
l unfacilitated writing (standard type) categorisated by ICD-10 code122
l positive unfacilitated writing
l summaries across different LTCs for:
¢ physiological, disease-related and biomarker outcomes
¢ depression
¢ anxiety.
Most of the current published research focuses usually on unfacilitated EW for disease intervention types
encompassing many variants. When a study had two groups of patients with different conditions, for
example asthma and RA, results for each condition were reported under the separate ICD-10 codes where
possible.
SYSTEMATIC REVIEW RESULTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
20
Facilitated therapeutic writing
Overview
There were five studies66–70 evaluating facilitated TW. A summary of their main characteristics is presented
in Table 5.
All studies66–70 evaluated one facilitated intervention group against one control group. All studies66–70 were
conducted in a different country. Two studies69,70 concerned PTSD and involved writing on trauma-related
topics, but the remaining studies examined different conditions [dementia,67 mental health problems68
and serious physical illness66 (primarily cancer)]. Although grouped together here as facilitated TW, the
interventions studied were all very different and the type and amount of level of facilitation (and indeed
actual writing) varied greatly.
The studies conducted by Golkaramnay et al.68 and Lange et al.69 were internet based. Golkaramnay
et al.68 studied a chat room through which groups of participants recently discharged from psychiatric
hospital communicated with each other in writing during weekly 90-minute sessions, guided by
experienced group therapists who knew all of the participants beforehand. The intervention in Lange
et al.69 (Interapy) involved psychoeducation and 10 structured writing assignments over 5 weeks, delivered
one to one via a website, with seven lots of feedback on the writing assignments from a therapist. Hong
and Choi67 studied weekly group songwriting sessions in care home residents with dementia, but it is not
clear how much actual writing was involved. Rickett et al.66 examined the impact of eight weekly 2-hour
facilitated poetry-writing workshops. The intervention in Sloan et al.70 involved five 30-minute writing
exercises with the first session preceded by some scripted psychoeducation delivered over 1 hour.
The facilitation was limited to reading verbatim writing instructions at the start of the session and
answering questions at the end.
The duration of the therapy sessions ranged from 45 minutes in Lange et al.69 to 210 minutes in Sloan
et al.70 The duration of the intervention varied from five sessions in Sloan et al.70 up to 16 weeks in Hong
and Choi.67
The outcomes evaluated in the studies with a facilitated intervention are reported in Table 6.
Physical symptoms were evaluated in two studies67,68 using the SCL-90-R (Symptom Checklist-90-Revised)
although different subscales. The remaining studies66,69,70 evaluated different outcomes, although three
TABLE 5 Characteristics of the studies in facilitated TW
First author,
year Country Study design LTC Intervention group Control group
Golkaramnay
200768
Germany Matched case–control
study
Mental health disorders Group therapy through
internet chat
No interventiona
Hong 201167 Korea RCT Dementia (Alzheimer’s
disease/vascular
dementia/Parkinson’s
disease)
Songwriting Waiting list
Lange 200369 The Netherlands Non-randomised trial PTSD Interapy Waiting list
Rickett 201166 Australia Non-randomised trial Primarily cancer Poetry writing
programme/workshop
Waiting list
Sloan 201270 USA RCT PTSD Written exposure
therapy
Waiting list
a Usual care was assumed.
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studies assessed aspects of the participant’s emotional distress using different instruments [Kessler
Psychological Distress Scale (K-10), Self-Assessment Manikin (SAM) and Outcome Questionnaire (OQ-45.2)]
with different scales and scoring systems.
Quality of the included studies
A summary of the quality of the studies of facilitated TW is shown in Figures 4 and 5.
Golkaramnay et al.68 was a matched case–control study; therefore, without allocation concealment (as it
was not an RCT, it is not included in the risk-of-bias table). Participants and personnel were not blinded to
the intervention performance. Blinding of the outcome assessment was unclear. The information related
to the participation rates was unclear, thus the study was likely to introduce attrition bias. Similarity of
groups at baseline was unclear. Selection was adequate, as the case definition and comparators were
representative and comparable controls were selected from hospital records.
Two studies had allocation concealment. Hong and Choi67 may have introduced selection bias given the
sequence generation was not concealed, whereas in Sloan et al.70 randomisation was computerised and with
allocation concealment. Selection bias was unclear in the remaining two studies. Participants and/or personnel
masking was not performed in Hong and Choi,67 as opposed to Lange et al.,69 in which masking was
maintained at the intervention performance level. In the remaining studies, the information related to blinding
was unclear. Rickett et al.66 was the only study with a high risk of attrition bias. However, reporting bias was
absent in all studies66,68–70 but Hong and Choi,67 in which it was assessed as unclear.
Numerical results
The numerical results reported in each of the five studies66–70 are summarised in Table 7.
The follow-up assessment ranged from 5 weeks in Lange et al.69 to 52 weeks in Golkaramnay et al.92
In Sloan et al.,70 data are available to only 18 weeks. Total sample sizes varied on each of the outcomes
measured in Golkaramnay et al.,68 in which initial total sample sizes were of 228 participants with a
dropout rate of 10–15%. The remaining trials used intention-to-treat (ITT) analyses. All of the studies66–69
reported final mean scores together with corresponding SDs, except Sloan et al.,70 in which SEs were
reported in a graph. All studies66–70 reported improvement in favour of the intervention group across all
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outcomes and follow-ups (except on health-care use outcomes in Golkaramnay et al.68). It must be noted
that three of the studies66,67,70 were very small. None of the studies evaluating facilitated TW interventions
could be meta-analysed owing to lack of consistency in measurement and heterogeneity in interventions
and participants.
Unfacilitated emotional writing by International Classification of Diseases,
Tenth Edition code
B24: human immunodeficiency virus
Overview
There were six studies50,55,56,71–73 evaluating unfacilitated EW in patients with HIV. A summary of main
characteristics is presented in Table 8. All participants were diagnosed with HIV and were receiving active
treatment at the time of the study. Some participants in Ironson et al.71 also had PTSD (n= 85 men,
n= 47 women).
Four studies were conducted in the USA,50,71–73 with Kraaij et al.55 and Petrie et al.56 conducted in the
Netherlands and New Zealand, respectively. All studies50,56,71–73 except Kraaij et al.55 had two groups and
evaluated one EW intervention compared with one control. Kraaij et al.55 also compared EW with a
cognitive–behavioural self-help programme but this is not considered further here. Mann72 asked
participants to write about a positive future with their HIV, in which they had to take only one tablet
per day, and the remaining studies all explicitly involved standard EW writing. The studies by Abel et al.50
and Kraaij et al.55 used a disease-focus topic in the intervention arm, and the latter study was web based.
The remaining studies56,71–73 used self-selected worst trauma for participants to write about. The length of
the interventions varied across studies. In the studies by Abel et al.,50 Petrie et al.56 and Ironson et al.,71
EW was conducted over 3 or 4 consecutive days, whereas in the remaining studies55,72,73 the writing
exercises were distributed over 4 weeks (once or twice a week). Participants in the studies by Kraaij et al.,55
Petrie et al.56 and Wagner et al.73 used computers or tablets to write, as opposed to the other studies in
which EW was handwritten. Participants in the studies by Abel et al.,50 Mann72 and Wagner et al.73 were
financially compensated for participation in the study.
The outcomes evaluated across the HIV studies of unfacilitated EW are reported in Table 9.
TABLE 8 Characteristics of the unfacilitated EW studies in HIV
First author, year Study design Intervention group Control group
Abel 200450 RCT Unfacilitated EW Factual writing
Ironson 201371 RCT Unfacilitated EW Factual writing
Kraaij 201055 RCT Computerised, structured,
unfacilitated EW
Waiting list
Mann 200172 RCT Unfacilitated EW (positive writing) Non-writing
Petrie 200456 RCT Unfacilitated EW Time-management writing
Wagner 201073 RCT Unfacilitated EW Factual and time-management writing
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Psychological outcomes (e.g. depression or mood) were the most commonly evaluated outcomes, together
with physiological (e.g. HIV symptoms) and biological outcomes [e.g. viral load (VL) and cluster of
differentiation antigen 4-positive lymphocyte cell count (CD4+ count)].
Quality assessment
A summary of the quality of the studies in HIV is shown in Figures 6 and 7. Two studies56,73 reported methods
of randomisation. Allocation concealment was reported in only one study,56 and blinding was preserved in
one other study.50 The methods used were scarcely reported in almost all of the studies.
Numerical results
The numerical results reported in the HIV studies are summarised in Table 10. Follow-up assessments ranged
from 2 weeks in Petrie et al.56 to 52 weeks in Ironson et al.71 Total sample sizes ranged from 11 participants
in Abel et al.50 to 212 participants in Ironson et al.71 Petrie et al.56 reported medians and SEs rather than
means and SDs as in the other studies. Statistical significance of the follow-up results differences were
not reported in the studies by Abel et al.,50 Ironson et al.,71 Mann,72 Petrie et al.56 or Wagner et al.73 The
group-by-time interaction analysis in the Ironson et al.71 and Kraaij et al.55 studies was non-significant for the
following outcomes: biomarkers, such as VL at long term only and CD4+ count at short, medium and long
term, as well as depression [Hamilton Depression Scale (HAM-D)] or social distress [The Davidson PTSD scale
(PTSDTOT)]. However, in the Petrie et al.56 study, the CD4+ count increased significantly in the EW group
compared with control subjects when assessed at 26 weeks only.
In the Mann study,72 the writing intervention was stated as a promising technique to increase medication
adherence and decrease symptoms of distress in pessimistic individuals. However, these differences
between the two groups at follow-up were not further reported. The studies by Petrie et al.56 and
Wagner et al.73 did not report any association or interaction between groups in the outcomes evaluated
[i.e. VL in Petrie et al.;56 Positive and Negative Affect Schedule, positive subscale (PANAS-PA), Positive and
Negative Affect Schedule, negative subscale (PANAS-NA), Perceived Stress Scale (PSS), HIV-Specific
Optimism Scale (HIV-OS), Sense of Coherence Scale (SOC) and Short Form questionnaire-36 items (SF-36)
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in Wagner et al.73]. In the Ironson et al. study,71 among the women, only the EW was associated with a
significant reduction in PTSD symptoms, depression and physical symptoms, and this finding was more
pronounced in the group with elevated PTSD symptom scores at baseline. Men, however, reported greater
decrease in depression among control subjects than in the EW group.
Meta-analysis
The outcome depression was meta-analysed (Figure 8).
Depression at short-term Three studies50,55,71 used different instruments each [Centre for Epidemiological
Studies Depression Scale (CES-D), HAM-D and Hospital Anxiety and Depression Scale, depression subscale
(HADS-D)] to measure similar aspects of depression.
l Clinical differences between studies In Ironson et al.,71 participants were diagnosed with both HIV
falling into a CD4 range of 100–600. Additionally, some were also diagnosed with PTSD. In
Abel et al.,50 participants were taking antiretroviral therapy (ART) and reported their last VL
< 80,000–100,000 copies/ml. All participants in all three studies were self-reportedly free of major
psychiatric problems. There were no substantial clinical differences between the three studies50,51,55
regarding HIV diagnosis.
l Follow-up length All three studies50,55,71 assessed depression at a short term, that is, at 4 weeks or at
4.5 weeks.
l Forest plot A total of 249 participants were meta-analysed (124 in the EW group and 125 in the
control group). The SMD was –0.08 [95% confidence interval (CI) –0.33 to 0.17] with a random-effects
model and with no significant heterogeneity (I2= 0%). The overall analysis suggests that there is no
significant difference in depression for the EW group compared with the control group.
C50: breast cancer
Overview
There were eight studies53,54,74–79 evaluating unfacilitated EW in patients with breast cancer, including one
very large study (507 participants) by Jensen-Johansen et al.76 A summary of main characteristics is
presented in Table 11.
Most of the participants were women with breast cancer at stage 0–III, who were mainly receiving curative
radiation therapy, but the patients in Mosher et al.77 had stage IV breast cancer and presented with
significant distress. The patients in Jensen-Johansen et al.76 had recently completed treatment with surgery,
radiotherapy or chemotherapy. Participants in Craft et al.,74 Gellaitry et al.,75 Hughes54 and Walker et al.79
included patients with stage I–III breast cancer. Participants were reported to have completed definitive
treatment,74 were receiving the last radiotherapy appointment75 or were still receiving curative radiotherapy.54,59
In the remaining studies, participants in Henry et al.53 had stage 0–III breast cancer and had completed
radiation, and in Park and Yi78 they had stage II and III breast cancer and had undergone surgery, radiotherapy
and hormone therapy. Participants in Henry53 were urban and rural women with breast cancer who were
still attending radiation oncology clinics, whereas patients in Park and Yi,78 had been recruited from
self-help groups.
Almost all studies were conducted in the USA except for Park and Yi,78 which was conducted in Korea
and published in the Korean language (which was translated into English), and Jensen-Johansen et al.,76
which was conducted in Denmark and published in English.
One study had four groups (two experimental and two control groups) and one other study evaluated
three groups (two experimental and one control). The remaining studies evaluated one intervention group
each against one control (see Table 11).
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In six of the breast cancer studies, only unfacilitated EW was evaluated. Topics across all studies included
disease-focused writing exercises. Participants were asked to write about their deepest thoughts and feelings
about their cancer and treatment–related emotions during 20–30 minutes over 3/4 days at different
intervals. Craft et al.74 assessed two additional types of unfacilitated EW interventions in which topics
changed: participants had to write about a self-selected trauma in one group and about facts of treatment
and daily events related to breast cancer in the other group. One other study79 evaluated a modified version
of the unfacilitated EW intervention using the same topic but feelings and emotions had to be expressed in
a positive way. On the other hand, Gellaitry et al.75 used a different form of EW, combining in 4 days the
standard unfacilitated EW (first 2 days) and a positive writing type of EW (the remaining 2 days). Patients
were instructed to change the topic throughout the writing sessions starting with an emotional disclosure
exercise and cognitive appraisal related to their condition and moving to the benefit finding of it, looking
into the future where they wrote about their experience being shared with others. Four studies delivered the
intervention on 1,53 354,79 or 474,75 consecutive days. Three other studies delivered three or four sessions at
weekly intervals.76–78 Henry et al.53 used one single session. Four studies53,54,70,74 used SMC as the control arm,
two studies used a non-emotional factual writing,69,72 one study71 used a time-management writing as
control, and in the remaining two studies the control group either did not write69 or did not receive an
intervention73 at all. Patients were financially compensated in Mosher et al.77 and Henry et al.53
The outcomes evaluated in the breast cancer studies are reported in Table 12. QoL was assessed in
four studies;54,74,75,77 two studies74,75 used the same instrument [Functional Assessment of Cancer Therapy,
Breast Cancer Version (FACT-B)], which contains 10 specific breast cancer items (in addition to the
27 general items) addressing physical and psychological concerns related to breast cancer. The study by
Mosher et al.77 used the meaning/peace subscale of FACIT [Functional Assessment of Chronic Illness
Therapy meaning/peace subscale (FACI-Sp)], an instrument tailored to measure the spiritual well-being of
patients. Six studies53,54,75–77,79 evaluated affect (mood states). Two studies77,78 assessed anxiety with the same
instrument (HADS). Depression was evaluated in four studies53,76–78 using three different instruments each
[CES-D, Beck Depression Inventory-Short Form (BDI-SF) and HADS-D].
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Quality assessment
A summary of the quality of the studies in breast cancer is shown in Figures 9 and 10.
Almost all studies, except that of Park and Yi,78 were reported as RCTs. However, in the Walker et al.
study,79 the method of randomisation was not provided. In the Craft et al. study,74 authors reported
that randomisation was performed using sequential numbering, which remained unclear as a method of
randomisation. The Hughes study54 was truly randomised, but allocation of the sequence generation was
not concealed and there was no blinding. Among the remaining studies, almost all did not report on the
allocation and blinding methods, except Jensen-Johansen et al.,76 in which allocation was concealed,
and blinding was conducted at both the performance and outcome assessment stages.
One study74 was more likely to have introduced attrition bias. Two other studies54,75 reported selectively on
specific outcomes and the Henry et al. study53 reported outcomes but with insufficient detail for the data
to be included in the meta-analysis. No measure of variability could be derived from the graphs.
Numerical results
The numerical results reported in the breast cancer studies are summarised in Table 13.
The broadest range of outcomes measures were collected in Hughes54 on several occasions between 1
and 52 weeks’ follow-up. Almost all studies followed the patients for between 6 and 12 months, except
those of Park and Yi78 and Mosher et al.,77 for which follow-up after the writing intervention was
performed at 1 and 2 months, respectively. The total sample sizes ranged from 56 in Craft et al.74 to
435 participants in Jensen-Johansen et al.76
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Overall, there were significant improvements at short-term follow-up mainly (from 4 to 13 weeks) in favour of
the EW groups compared with control subjects regarding QoL [Functional Assessment of Cancer Therapy,
Breast Cancer Version (FACT-B) at 4 weeks only, Cancer Quality of Life (C-QoL)], physical symptoms
[Pennebaker Inventory of Limbic Languidness (PILL)] particularly regarding nervousness, distress, and
unhappiness and mood [Profile of Mood States (POMS) at 13 weeks]. No significant group-by-time interaction
differences were reported in the following outcomes when evaluated at both shorter and longer follow-ups
(up to 39 weeks): QoL, as measured by FACIT-sp at 8 weeks, FACT-B at 26 weeks in both Craft et al.74 and
Gellaitry et al.75, mood (POMS at 13 and 39 weeks), immediate mood [PANAS-PA, PANAS-NA and Passive
Positive Mood Scale (PPMS) at 11 and 39 weeks, respectively], depression (HADS-D, CES-D, BDI-SF at 4, 8, 13
and 39 weeks), sleep quality [Pittsburgh Sleep Quality Index (PSQI) at 8 weeks], fatigue [Functional Assessment
of Chronic Illness Therapy, fatigue subscale (FACIT-F) at 8 weeks], anxiety [Hospital Anxiety and Depression
Scale, anxiety subscale (HADS-A) at 4 and 8 weeks], physical symptoms including distress [Distress Thermometer
(DT)] or measures of intrusions and avoidance [intrusion subscale of the Impact of Event Scale (IES; IES-I),
avoidance subscale of the IES (IES-Av)]. The studies by Park and Yi78 and Mosher et al.77 evaluated outcomes at
shorter follow-ups (4 and 8 weeks, respectively) than in the remaining studies. For instance, Mosher et al.77
evaluated the impact of the EW intervention on QoL, depression and general well-being at 8 weeks only.
In Mosher et al.,77 participants in the intervention group reported greater use of mental health services
during the study period than did those in the control group (24/44 vs. 11/42, respectively), and differences
between groups were statistically significant [odds ratio (OR)= 3.40, 95% CI 1.05 to 11.08]. In the largest
study, by Jensen-Johansen et al.,76 no significant differences were found in the group-by-time interaction
analysis on any of the outcomes evaluated (depression, mood, and symptoms such as intrusions
or avoidance).
In Gellaitry et al.,75 adverse events were assessed but not reported by group; however, four women of the
total sample indicated that writing was difficult, not helpful and of no benefit to them personally. They
also reported feeling negatively on completion of writing, but these negative feelings were not prolonged.
In addition, separate studies reported significant differences [statistically significant (SS)] for the following
outcomes: FACT-B at 4 weeks, Significant Others Scale (SOS) at 26 weeks, and PILL and QoL at 4 weeks,
as shown in Table 13.
Meta-analysis
The outcomes positive and negative mood (Figures 11 and 12) and depression (Figure 13) were
meta-analysed. In addition, three studies76–78 assessed general mood but the Henry et al. study53 did not
report any numerical data on the POMS outcome, so meta-analysis was not performed for this outcome.
Positive mood at short-term follow-up Three studies54,76,79 assessed positive mood using different
instruments (PANAS-PA and PPMS).
l Clinical differences between studies Jensen-Johansen et al.76 included newly diagnosed patients with
stage I or stage II breast cancer, who had been treated surgically within 3 weeks of their diagnosis
(mastectomy or lumpectomy) and/or recently completed radiotherapy or chemotherapy. The patients in
the other two studies were attending or completing radiation therapy.
l Intervention differences Walker et al.79 had two intervention groups. In one arm unfacilitated EW1 was
administered as a single episode whereas in the other unfacilitated EW2 was administered in three
episodes. Unfacilitated EW2 (three episodes) was selected as the closest intervention to the standard
type of EW intervention and was therefore included in the meta-analysis. This also applies to the
meta-analysis of the negative mood outcome comparison.
l Duration of follow-up length All studies reported short-term outcome measures at 13, 17 and 16 weeks.
l Forest plot A total of 621 participants were meta-analysed (301 in the EW group and 320 in the
control group). The SMD was 0.10 (95% CI –0.15 to 0.36) with a random-effects model and with
non-significant but substantial heterogeneity (I2= 47%). It suggests that there is no statistically
significant difference in positive mood at short term for the EW group compared with the control group.
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Negative mood at short-term follow-up The same three studies54,76,79 assessed negative mood using
different instruments (PANAS-NA and Profile of Mood States – negative affect).
l Forest plot A total of 621 participants were meta-analysed (301 in the EW group and 320 in the
control group). The SMD was –0.04 (95% CI –0.20 to 0.12) with a random-effects model and with
non-significant heterogeneity (I2= 0%). This result suggests that there is no significant difference in
negative mood at short term for the TW group compared with the control group.
Depression at short-term follow-up Four studies53,76–78 assessed depression using different instruments
(CES-D, BDI-SF and HADS-D).
l Clinical and intervention group differences described above apply also in this section.
l Follow-up All studies reported short-term outcome measures at 4, 8 and 13 weeks.
l Study by Henry et al.53 The mean value for depression was derived from a graph but data regarding
variability could not be collected. Therefore, the individual effect size for this study could not
be estimated.
l Forest plot A total of 562 participants were meta-analysed (270 in the EW group and 292 in the
control group). The SMD was –0.08 (95% CI –0.25 to 0.08) with a random-effects model and with
non-significant, unimportant heterogeneity (I2= 0%). This result suggests that there is no significant
difference in depression at short term for the TW group compared with the control group.
C57, C61 and C62: gynaecological and genitourinary cancers
There were five studies80–84 included in this section with different ICD-10 codes; however, all were of
gynaecological or genitourinary cancers:
l C57: ovarian cancer – two studies80,84
l C61: prostate cancer – two studies83,84
l C62: testicular cancer – one study82
l C64: renal cell carcinoma – one study.81
Overview
All five studies80–84 evaluated unfacilitated EW. A summary of their main characteristics is presented in
Table 14. In all except one of the studies, participants had undergone between 4 and 5 years of treatment.
In the Rosenberg et al.83 study, patients all had adenocarcinoma of the prostate (staging not given) and
were being followed up after definitive local treatment (prostatectomy or radiotherapy) within the last
4 years. In Zakowski et al.84 all patients were diagnosed with prostate or gynaecological cancer (no further
details supplied) and had completed treatment within the last 5 years. No further details were available for
Arden-Close et al.80 and Pauley et al.82 In Milbury et al.81 participants were patients with newly diagnosed
TABLE 14 Characteristics of the unfacilitated EW gynaecological/urinary cancer studies
First author, year Study design Intervention group 1 Intervention group 2 Control group 1
Arden-Close 201380 RCT Unfacilitated EW – Time-management writinga
Milbury 201481 RCT Unfacilitated EW – Neutral topics
Pauley 201182 RCT Unfacilitated EW Positive writing Factual writing
Rosenberg 200283 RCT Unfacilitated EW – Non-writing
Zakowski 200484 RCT Unfacilitated EW – Factual writing
a Control group participants were asked to write about other daily activities for the previous day, which has been
categorised here as time-management writing.
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renal cell carcinoma (RCC), with stage I–IV disease and with a Zubrod performance status of < 2 points
(i.e. either fully active and unrestricted by their disease, or only restricted in performing physically
strenuous activities).
Arden-Close et al.80 was conducted in the UK, and the remaining studies were in the USA.
Four studies80,81,83,84 assessed one intervention group against one control but Pauley et al.82 had two
different intervention groups. All studies80–84 assessed the impact of the standard expressive writing
intervention whereby participants were instructed to write about their experience with cancer and its
treatment compared with a time-management or factual writing control group.
Additionally, Pauley et al.82 also assessed the effect of a positive EW intervention, whereby participants were
asked to write about any aspect of their cancer characterised as positive. In Rosenberg et al.83 and Zakowski
et al.,84 all participants wrote for 20–30 minutes for 3 or 4 consecutive days. In Arden-Close et al.80 and
Pauley et al.,82 participants had to write at 1-week intervals over a 3-week period, and in Milbury et al.81
participants had to complete the four writing assignments within 10 days. Participants in Pauley et al.82 were
recruited online, received EW instructions and submitted their writing via the internet. In the studies by
Pauley et al.82 and Milbury et al.,81 participants were financially compensated for their participation in the
study. Participants in the other studies82–84 did not receive financial compensation.
The outcomes evaluated in each of the studies on gynaecological/urinary cancer patients are reported in
Table 15. Psychological symptoms, coping with cancer and QoL were the most frequently assessed
outcomes. In the Milbury et al. study,81 intrusions and avoidance, as well as specific cancer physical
symptoms, were evaluated using two different instruments. Sleep disturbance was also evaluated in
addition to general HRQoL.
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Quality assessment
A summary of the quality of the studies in gynaecological and genitourinary cancers is shown in Figures 14
and 15.
In Arden-Close et al.,80 Milbury et al.81 and Pauley et al.,82 the method of randomisation was adequately
reported (Milbury et al.81 used minimisation). Allocation concealment was not specified in Pauley et al.,82
Milbury et al.81 or Zakowski et al.,84 as opposed to Arden-Close et al.80 and Rosenberg et al.,83 for which
concealment of sequence generation was adequate. Blinding was not preserved at the performance
level in Arden-Close et al.,80 and was unclear in the rest of the studies. ITT analysis was performed in
Arden-Close et al.,80 Milbury et al.81 and Zakowski et al.,84 but not in the remaining studies. Almost all
studies,81–84 except that of Arden-Close et al.,80 were likely to introduce selective reporting as data for the
outcomes assessed were under-reported or the information was unclear. In Milbury et al.,81 there was
substantial attrition and non-compliance in both arms at 10-month follow-up (approximately 50% of
baseline cohort).
Numerical results
The numerical results reported in the gynaecological and genitourinary cancers studies are summarised in
Table 16.
Follow-up assessments ranged from 5 weeks in Pauley et al.,82 to 34 weeks in Zakowski et al.84 Total
sample sizes ranged from 30 participants in Rosenberg et al.83 up to 277 participants in Milbury et al.81
In Milbury et al.81 the total sample size varied throughout the study. There were 173 participants evaluated
at 4 weeks, 168 participants evaluated at 17 weeks and 148 participants evaluated at 43 weeks.
Pauley et al.82 and Rosenberg et al.83 did show statistically significant differences between the two groups
for the General Health Questionnaire (GHQ-12) and Brief Pain Inventory (BPI) outcomes, respectively.
In Pauley et al.,82 participants in the positive expression writing group scored higher in mental health than
participants in the negative expression writing group or than those in the control group. However, no
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significant effects were reported regarding the QoL and sexual performance outcomes. In Milbury et al.,81
there were significant group differences for the expressive writing group compared with the neutral
writing group at the 10 months’ follow-up assessment for the following outcomes measures:
the MD Anderson Symptom Inventory (MDASI), the Brief Fatigue Inventory (BFI) and the Short Form
questionnaire-36 items physical composite score (SF-36 PCS).
Regarding the other outcomes assessed across the remaining studies, either no significant group-by-time
interaction was reported or differences between groups were not addressed as in Pauley et al.82 or
Rosenberg et al.83
Quality of life was assessed in four studies,80–82,84 in which instruments were sufficiently similar to pool in a
meta-analysis. However, in Rosenberg et al.,83 numerical data regarding the Functional Assessment of
Cancer Therapy (FACT) or the Medical Outcomes Short-Form Health Survey (MOS-SF-36) were not
reported, and the results for the other studies80–82,84 were at two different follow-up time periods and so
no meta-analysis was performed for this outcome.
C80 and C96: other non-specified cancers
Overview
Three studies66,85,86 evaluated EW in participants with various types of cancer. The study by Rickett et al.66 is
reported in the Facilitated TW section. Here, the studies by Cepeda et al.85 and Rini et al.86 are described.
A summary of main characteristics is presented in Table 17.
Cepeda et al.85 included participants with any type of cancer reporting average pain intensity levels of
at least 5 on a 0–10 scale. Participants scored > 50% in the Karnofsky performance scale (ranging from
having no evidence of their disease to requiring occasional assistance but able to care for most of their
personal needs). The study was conducted in Colombia and published in English. The authors evaluated
one intervention group against two control groups. However, only the group receiving standard medical
care (SMC) was considered in the analysis, as the other group was an active control involving
an educational intervention. The unfacilitated EW group (narrative group) had to write about a
disease-focused topic during 20 minutes over 3 non-consecutive days (at 1-week intervals). Participants
were not financially compensated.
Rini et al.86 included participants who had had a stem cell transplant for any form of haematological cancer
within the previous 9 months to 3 years and not in current relapse. The study was conducted in the USA.
Participants were randomised to three intervention groups or one neutral writing control (factual writing
about their experience). The three intervention groups were standard unfacilitated EW, peer helping and
unfacilitated EW with peer helping. As the peer-helping component is not part of this systematic review,
it is not discussed further. The unfacilitated EW group had to write about their deepest emotions and
thoughts about the time before, during and after the transplant. Writing took place at the participants’
homes: one 20-minute episode of writing per week for 4 weeks. A researcher telephoned the participant
before and after each writing episode. Participants were financially compensated.
TABLE 17 Characteristics of the unfacilitated EW studies in other cancers
First author, year Study design Intervention group Control group
Cepeda 200885 RCT Unfacilitated EW SMC
Rini 201486 RCT Unfacilitated EW Non-EW
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The outcomes evaluated in the studies are reported in Table 18. For almost all of the outcomes in the
Rini et al. study,86 the results were split into subgroups of high and low survivorship problems rather than
whole scores for the groups.
Quality assessment
A summary of the study quality is shown in Figure 16.
Both studies85,86 had the method of randomisation described. In Cepeda et al.,85 allocation concealment was
performed using opaque envelopes, and in Rini et al.86 it was by sequentially numbered computer files. The
personnel (evaluators) were blinded in both studies though participants were not. However, it was likely
that selective reporting was introduced for the QoL outcome in Cepeda et al.85 Therefore, the quality item
referring to selection bias was rated as low risk in this study. ITT analysis was used in both studies.85,86
Numerical results
The numerical results are reported in Table 19.
In Cepeda et al.,85 follow-up assessments were performed at 2, 4, 6 and 8 weeks post writing, whereas in
Rini et al.86 they were at carried out at 13 weeks only. The total sample size in Cepeda et al.85 was
157 participants, and in Rini et al.86 it was 151 participants in the unfacilitated EW and control groups.
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FIGURE 16 Risk-of-bias summary in the cancer studies.
TABLE 18 Outcomes collected by the unfacilitated EW studies in other cancers
First author, year Pain intensity Well-being/QoL Physical symptoms Resource use
Cepeda 200885 Verbal numerical rating scale 7-point Likert scale – –
Rini 201486 – FACT, BSI/GSI Deaths, Inventory
of physical symptoms
–
BSI, Brief Symptom Inventory; GSI, Global severity Index.
Italic text shows outcomes for which no data were reported.
A description of all acronyms is listed in Appendix 5, Table 106.
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In Cepeda et al.,85 no significant differences in pain intensity or QoL were reported between the groups
throughout the study. The authors used a single question with a Likert scale to measure HRQoL, as they
reported it was minimally burdensome, but no numerical data were reported for this outcome. However,
authors reported that those disclosing a high degree of emotion had better well-being and pain intensity
level outcomes.
In Rini et al.,86 there was one relapse and one death in the unfacilitated EW group, and two relapses and
two deaths in the control group.
D57: sickle cell disease
Overview
There was one non-randomised study evaluating unfacilitated EW in participants with sickle cell disease. The
participants in McElligott87 were adolescents, with an average age of 14.9 years (SD 2.3 years). The study87
was conducted in the USA. The authors evaluated an EW intervention for which participants had to write
about their deepest thoughts and feelings related to their illness. The control group had to write about details
of the previous day (factual writing). The written exercise ran over 3 weeks, with one session per week.
Participants were financially compensated. The outcomes evaluated in McElligott87 are reported in Table 20.
Quality assessment
A summary of the quality of the study by McElligott87 is shown in Figure 17. The study87 was very likely to
introduce various biases. All risk-of-bias items were unclear except for lack of blinding among outcome
assessors and no evidence of selective reporting.
TABLE 20 Outcomes collected in the unfacilitated EW study in sickle cell disease
First author,
year
Physical
symptoms Self-esteem Depression
Behavioural
problems Anxiety QoL Resource use
McElligott
200687
PSC, PSC-Y ADSEI CDI ADSEI RCMAS Well-being Number of
patients
hospitalised,
number of visits
to clinician
ADSEI, Adult version of the Coopersmith Self-Esteem Inventory; CDI, Children Depression Inventory; PSC, Paediatric
Symptom Checklist; PSC-Y, Paediatric Symptom Checklist Youth Report; RCMAS, Revised Children’s Manifest Anxiety Scale.
A description of all acronyms is listed in Appendix 5, Table 106.
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FIGURE 17 Risk-of-bias summary in the sickle cell disease study.
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Numerical results
The numerical results are reported in Table 21. The follow-up assessment in McElligott87 was performed at
2 weeks post writing. The total sample size was 36 participants.
Authors reported there were no significant differences between groups for any of the outcomes evaluated.
E11: diabetes mellitus
Overview
There was one RCT88 evaluating unfacilitated EW in participants who had been diagnosed with type 2
diabetes mellitus. The main characteristics are summarised in Table 22. Participants were adults attending a
general practitioner (GP) practice in the UK. Unfacilitated EW for 20 minutes on 3 days was compared with
the same amount of writing about the previous day’s activities (factual writing). Both groups wrote at
home in private and then returned their writing to the researcher. They were not financially compensated.
The outcomes evaluated in Dennick et al.88 are reported in Table 22.
TABLE 21 Numerical results in the unfacilitated EW study in sickle cell disease
First
author,
year
Outcome
measures
Follow-up
(weeks)
Intervention group Control group
Author’s reported
statistical significance
(group-by-time
interaction)n totala
Final
mean
score SD n totala
Final
mean
score SD
McElligott
200687
ADSEI 2 19 74 36.8 17 100 0 NS
SEI 2 19 84.6 9.4 17 64.4 19.8 NS
RCMAS 2 19 8 5.9 17 9.5 5.7 NS
CDI 2 19 5.9 5.6 17 7.2 6.1 NS
PSC-Y 2 19 14.5 9.1 17 20 9.7 NS
PSC 2 19 12.8 12.6 17 16.8 6.8 NS
Well-being 2 19 NR NR 17 NR NR NS
Number of
visits to
clinician
2 19 0 0 17 0.38 0.65 NS
Number
of days
hospitalised
2 19 0.17 0.71 17 0.12 1.1 NS
ADSEI, Adult version of the Coopersmith Self-Esteem Inventory; CDI, Children Depression Inventory; NR, not reported;
NS, not statistically significant (p> 0.05); PP, per protocol; PSC, Paediatric Symptom Checklist; PSC-Y, Paediatric Symptom
Checklist Youth Report; RCMAS, Revised Children’s Manifest Anxiety Scale; SEI, Coopersmith Self-Esteem Inventory.
a Sample size analysed (ITT or PP).
A description of all acronyms is listed in Appendix 5, Table 106.
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Quality assessment
A summary of the study88 quality is shown in Figure 18. Randomisation was using random numbers in
sealed envelopes, stratified by recruitment approach and with random block sizes of four, six and eight per
block. GPs were blinded to the group allocation. ITT was used. It was noticeable that of 1715 individuals
who were given information about the study, only 41 consented to join the study88 and 32 completed the
follow-up.
Numerical results
The numerical results are reported in Table 23. Follow-up assessment was performed at 3 months. The
total sample size where all completed all writing and the follow-up was 27 participants. The study found
that EW resulted in worse depression at follow-up for the intervention group. There were no significant
differences in the other outcomes measured.
E84: cystic fibrosis
Overview
There was one RCT89 evaluating unfacilitated EW in participants that had been medically diagnosed with
cystic fibrosis. Participants in Taylor et al.89 were adolescents of at least 15 years of age. The study89 was
conducted in the USA. A written self-disclosure intervention compared with usual care was assessed.
Participants had to write about their deepest thoughts and feelings about the most distressing experience
of their entire life and were encouraged to connect the topic to their relationships with others. They had
to write for 20 minutes, three times over a 5-day period. The control was SMC. Participants were not
financially compensated. The outcomes evaluated in Taylor et al.89 are reported in Table 24.
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FIGURE 18 Risk-of-bias summary for the diabetes mellitus study.
TABLE 22 Outcomes collected in the unfacilitated EW study in diabetes mellitus
First author, year
Physical
symptoms Depression
Behavioural
problems QoL Resource use
Dennick 201488 PAID CES-D SDSCA EQ-5D –
EQ-5D, European Quality of Life-5 Dimensions; PAID, Problem Areas in Diabetes scale; SDSCA, Summary of Diabetes
Self-Care Activities scale.
A description of all acronyms is listed in Appendix 5, Table 106.
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Quality assessment
A summary of the study quality is shown in Figure 19.
Taylor et al.89 was reported as randomised. However, selection, performance and detection biases were
possible as the information related to the method of randomisation, allocation concealment of the
sequence generation or any statement regarding masking were unclear. The quality item selective reporting
was rated as low risk [although data for the Visit Specific Satisfaction Questionnaire (VSQ) were not
reported this was intended as a measure of the acceptability of the intervention]. ITT analysis was used.
TABLE 23 Numerical results in the unfacilitated EW study in diabetes mellitus
First
author,
year
Outcome
measures
Follow-up
(weeks)
Intervention group Control group
Author’s reported
statistical significance
(group-by-time
interaction)n totala
Final
mean
score SD n totala
Final
mean
score SD
Dennick
201488
CES-D 13 23 9.9 5.3 18 5.1 5.1 0.006
EQ-5D utility 13 23 0.92 0.1 18 0.87 0.1 0.907
EQ-5D VAS 13 23 77.4 13.4 18 82.1 12.7 0.268
PAID 13 23 35.3 6.7 18 34.4 6.8 0.658
SDSCA
(general diet)
13 23 5.8 1.2 18 5.8 1.1 0.826
SDSCA
(specific diet)
13 23 4.5 0.9 18 5.1 0.9 0.057
SDSCA
(exercise)
13 23 3.5 1.3 18 4.0 1.3 0.245
SDSCA blood
glucose testing)
13 23 2.5 1.9 18 2.5 2.0 0.922
SDSCA (foot
care)
13 23 3.2 1.2 18 3.0 1.1 0.755
EQ-5D, European Quality of Life-5 Dimensions; PAID, Problem areas in Diabetes scale; PP, per protocol; SDSCA, Summary
of Diabetes Self-Care Activities scale; VAS, visual analogue scale.
a Sample size analysed (ITT and PP).
A description of all acronyms is listed in Appendix 5, Table 106.
TABLE 24 Outcomes collected by the unfacilitated EW study in cystic fibrosis
First author, year
Physical health
status Psychological health status
Patient’s
satisfaction QoL Resource use
Taylor 200389 FEV1, BMI PHQ, Somatization Scale, SLESQ VSQ
a SF-12 Outpatient use,
inpatient use
BMI, body mass index; FEV1, forced expiratory volume in 1 second; PHQ, Patient Health Questionnaire; SF-12; Short Form
questionnaire-12 items; SLESQ, Stressful Life Events Screening Questionnaire; VSQ, Visit Specific Satisfaction Questionnaire.
a Participants in the unfacilitated EW intervention only rated for example, satisfaction with the length of the writing
sessions, convenience of the packets, level of comfort while writing, technical skills of the research team, integration of
the intervention into the clinic, value of the writing sessions on patient’s mental, physical, and overall health.
A description of all acronyms is listed in Appendix 5, Table 106.
DOI: 10.3310/hta20270 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 27
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Nyssen et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
61
Numerical results
The numerical results are reported in Table 25. Follow-up assessment was performed at 13 weeks post
writing. The total sample size was 39 participants. The authors reported that participants in the written
self-disclosure group had a significantly reduced number of inpatient days over a 3-month period after
the intervention compared with before the intervention, which was not the case in the control group.
However, the overall number of participants was small and the intervention group had a higher mean
number of inpatient days than the control group at baseline. The physical or psychological health status
remained unchanged over the study period and no changes were reported regarding QoL.
F03: dementia
In the systematic review, one study67 evaluated participants diagnosed with dementia. However, it assessed
a facilitated type of TW intervention and the study67 has been summarised in the facilitated TW section.
F14 and F19: substance use disorder
Overview
There were three studies90–92 (Meshberg-Cohen91 was a doctoral thesis) evaluating unfacilitated EW on
patients with drug dependence (cocaine dependence, ICD-10 code – F14) or substance use disorder (SUD).
A summary of their main characteristics is presented in Table 26.
Two studies90,91 were conducted in the USA and one study92 in the Netherlands. All three studies90–92
recruited individuals from residential drug treatment programmes. In a small, non-randomised, feasibility
study by Grasing et al.,90 participants (all military veterans and only one female) met DSM-IV (Diagnostic and
Statistical Manual of Mental Disorders-Fourth Edition) criteria for cocaine dependence at the time of
admission or fulfilled criteria for a SUD following the structured clinical interview for DSM-IV-TR (Diagnostic
and Statistical Manual of Mental Disorders-Fourth Edition, Text Revision): Alcohol and Substance Use
Disorders Module [Structured Clinical Interview for DSM Disorders (SCID)]. Meshberg-Cohen91 recruited
women who fulfilled the DSM-IV criteria for a SUD with the SCID; 80% had cocaine as their primary drug of
dependence and 57% were dependent on more than one drug. Van Dam et al.92 recruited men and women
who were addicted to a variety of substances including alcohol, cocaine and cannabis.
All three studies90–92 assessed an EW intervention for which participants had to write about a self-selected
trauma. In Grasing et al.,90 participants had to complete the exercise on 17 non-consecutive days, a
longer period than in Meshberg-Cohen,91 when participants completed the task in 4 consecutive days.
In Van Dam et al.92 they wrote for 10 sessions, for unspecified amount of time that was < 45 minutes.
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FIGURE 19 Risk-of-bias summary in the cystic fibrosis study.
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TABLE 25 Numerical results in the unfacilitated EW study in cystic fibrosis
First
author,
year
Outcome
measures
Follow-up
(weeks)
Intervention group Control group
Author’s reported
statistical significance
(group-by-time
interaction)n totala
Final
mean
scoreb SD n totala
Final
mean
score SD
Taylor
200389
FEV1 13 18 48.50 21.2 21 50.40 20.1 NS
BMI 13 18 19.30 3 21 19.00 2.1 NS
Somatisation
scale
13 18 3.90 3.4 21 7.00 3.8 NS
SLESQ 13 18 14.80 6.9 21 14.30 3.1 NS
SF-12 MCS 13 18 53.70 7.5 21 49.50 9.1 NS
SF-12 PCS 13 18 43.80 10.3 21 43.30 10 NS
VSQ-
modified
13 18 All good
to very
good, but
one fair
NR 21 NR NR NR
PHQ –
depression
13 18 12.40 4.1 21 13.90 4.2 NS
PHQ –
anxiety
13 18 15.30 1.4 21 16.10 3.1 NS
Outpatients
use
13 18 1.20 1 21 2.00 2.4 NS
Inpatients
use
13 18 5.60 7 21 8.40 9.6 SS
BMI, body mass index; FEV1, forced expiratory volume in 1 second; NR, not reported; NS, not statistically significant;
PHQ, Patient Health Questionnaire; PP, per protocol analysis; SF-12 MCS, Short form questionnaire-12 items mental
composite score; SF-12 PCS, Short form questionnaire-12 items physical composite score; SLESQ, Stressful Life Events
Screening Questionnaire; SS, statistically significant; VSQ-modified, Visit Specific Satisfaction Questionnaire modified.
a Sample size analysed (ITT or PP).
b Unless otherwise reported.
A description of all acronyms is listed in Appendix 5, Table 106.
TABLE 26 Characteristics of the unfacilitated EW studies in SUD
First author, year Study design Intervention group Control group
Grasing 201090 RCT Unfacilitated EW Time-management writing
Meshberg-Cohen 201091 RCT Unfacilitated EW Factual writing
Van Dam 201392 RCT Unfacilitated EW Treatment as usual
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The control group tasks emphasised objective, neutral and factual topics with no emotional component in
Grasing et al.90 and Meshberg-Cohen.91 For Van Dam et al.,92 the control was treatment as usual.
Participants were financially compensated in Grasing90 and Meshberg-Cohen,92 but not in Van Dam et al.93
The outcomes assessed in the studies on SUD are reported in Table 27. Drug craving, distress and general
mood were the outcomes most frequently assessed in the studies.90–92
Quality assessment
A summary of the quality of the studies on SUD is shown in Figures 20 and 21. The study by
Meshberg-Cohen91 was truly randomised; however, there was no information related to the concealment
of the sequence generation or the masking. Therefore, this study91 was likely to introduce selection and
performance biases. In addition, data were not reported or were under-reported, introducing high risk of
reporting bias. The study by Grasing et al.90 was evaluated in the same way for all of the quality items,
except that the method of randomisation was not provided. In the Van Dam et al. study,92 the method of
randomisation was by assignments in closed envelopes. These were opened at the start so that there
was no allocation concealment. Blinding was not mentioned. The studies by Meshberg-Cohen91 and
Van Dam et al.92 used an ITT analysis, whereas in the Grasing et al. study90 this information was unclear.
Grasing 201090
Meshberg-Cohen 201091
Van Dam 201392
+
+
–
–
––
––
– ?
??
?
?
?
?
?
?
?
–
+
Ra
nd
om
 se
qu
en
ce
 g
en
er
at
io
n 
(se
lec
tio
n 
bi
as
)
Al
lo
ca
tio
n 
co
nc
ea
lm
en
t (
se
lec
tio
n 
bi
as
)
Bl
in
di
ng
 o
f p
ar
tic
ip
an
ts 
an
d 
pe
rso
nn
el 
(p
er
fo
rm
an
ce
 b
ias
)
Bl
in
di
ng
 o
f o
ut
co
m
e a
sse
ssm
en
t (
de
te
cti
on
 b
ias
)
In
co
m
pl
et
e o
ut
co
m
e d
at
a (
at
tri
tio
n 
bi
as
)
Se
lec
tiv
e r
ep
or
tin
g 
(re
po
rti
ng
 b
ias
)
Ot
he
r b
ias
?
+
–
Low risk of bias
Unclear risk of bias
High risk of bias
FIGURE 20 Risk-of-bias summary in the SUD studies.
TABLE 27 Outcomes collected by the unfacilitated EW studies in SUD
First author, year
Objective
markers
Drug
craving
Symptom
severity Distress Mood Depression Resource use
Grasing 201090 BP, heart rate BSCS – PSS, BSI POMS – Self-report
use of cocaine
Meshberg-Cohen
201091
– BSCS PDS, PILL BSI/GSI PANAS-X CES-D –
Van Dam 201392 – TLFB
abstinence
PDS – – – –
BP, blood pressure; BSCS, Brief Substance Craving Scale; BSI, Brief Symptom Inventory; GSI, Global Severity Index;
PANAS-X, Positive and Negative Affect Schedule–Expanded Form; PDS, Posttraumatic Stress Diagnostic Scale; TLFB, Timeline
Followback Method.
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Numerical results
The numerical results reported in the studies on SUD are shown in Table 28. The follow-up assessment
ranged from 4 weeks in Meshberg-Cohen91 to 13 weeks in Grasing et al.90 The total sample size was
42 participants in Grasing et al.90 and 141 participants in Meshberg-Cohen.91 In Grasing et al.,90 expressive
writing participants reported a higher final average number of visits to the clinician than in the control
group; however, it was not reported whether or not this difference was significant. Authors mentioned
cocaine use differences based on self-reports but there were a very small number of participants assessed
and a considerable attrition. There were no usable data reported for the remaining outcomes assessed in
this study (results are shown in graphs only and the numbers of participants providing results are unclear).
In Meshberg-Cohen,91 the EW group showed significantly greater reductions than control subjects only in
post-traumatic symptom severity and anxiety scores at 2 weeks’ follow-up, but not at 1 month, when
there was no difference in any measure between the two groups. No adjustments for multiple testing
were made. At 1 month, there were significant improvements for both groups over the course of
residential treatment, suggesting that there was little scope to detect any additional benefit from the
intervention. In addition, the EW participants showed increased negative affect immediately after each
writing session, but there were no differences in pre-writing negative affect scores between groups the
following day.
Van Dam et al.92 was a very small study, with a large number of rather unclear and complicated statistical tests
reported. It is likely that no significant differences were seen at follow-up for the two outcome measures.
F40, F59 and F99: psychiatric disorders
Overview
There were five studies93–97 evaluating unfacilitated EW with patients with mental and/or psychiatric
disorders. A summary of main characteristics is presented in Table 29. (Golkaramnay et al.68 also assessed
TW in patients with mental disorders but used facilitated EW so is reported in the Facilitated TW section.)
All studies93–97 were described as RCTs. Study participants were very heterogeneous. The patients in Bernard
et al.93 had a first episode of psychosis conforming to broad ICD-10 categories (F20, F22, F23, F25) but,
for ethical reasons, patients were not suicidal or acutely psychotic; rather they were in the recovery phase of
their illness. The participants in Graf et al.95 were recruited from a university-based outpatient psychiatric
clinic and student counselling centre, and all participants were also undergoing psychotherapy. In Richards
et al.97 and Canna94 (a doctoral thesis), participants had an axis I anxiety or mood disorder primary diagnosis
or were diagnosed with at least one mental disorder as classified by the [Diagnostic and Statistical Manual
of Mental Disorders-Third Edition, Revised (DSM-III-R)]. In Krpan et al.,96 all participants had major depressive
disorder. In Richards et al.,97 all participants were male psychiatric maximum security prison inmates
(47% sex offenders).
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Bernard et al.93 had two groups: one standard EW intervention and one non-EW control in which
participants had to write about facts of the day, describe the room they were in and their plans for the
next week. Canna94 examined four groups: CBT with TW, CBT alone, CBT with inexpressive writing
(activities of the day) and a waiting list control group. The CBT with TW compared with CBT with
inexpressive writing was used in this systematic review, as both arms had CBT: its effect in each would be
cancelled out when the two groups were compared. In Richards et al.,97 one intervention group and two
control groups were evaluated: trivial writing and no writing. For the systematic review, EW was compared
with trivial writing. The remaining study95 assessed one intervention group compared with one control
group. Intervention topics were disease-focused EW or participants were asked to write about their worst
trauma. Participants in Krpan et al.96 and Richards et al.97 were financially compensated, whereas participants
in the remaining studies were not. In Graf et al.,95 the EW intervention lasted 14 non-consecutive days,
whereas in the other four studies93,94,96,97 the intervention was delivered on 3 consecutive days. Follow-up
assessments ranged from just after the writing exercise in Graf et al.,95 up to 24 weeks after in Canna.94
The results of the outcomes evaluated across the studies are given in Table 30.
TABLE 29 Characteristics of the unfacilitated EW studies in mental and psychiatric disorders
First author, year
Study
design
Intervention
group 1
Intervention
group 2 Control group 1
Control
group 2
Bernard 200693 RCT Unfacilitated EW – Factual and time-management
writing
–
Canna 200694 RCT Unfacilitated EW – Time-management writing –
Graf 200895 RCT Unfacilitated EW – Time-management writing SMC
Krpan 201396 RCT Unfacilitated EW – Time-management writing –
Richards 200097 RCT Unfacilitated EW
plus CBTa
CBTb Factual writing plus CBTc Waiting list
a In this intervention arm, CBT was identical to comparator and only EW was evaluated.
b The intervention group 2 (CBT) was not relevant for the analysis.
c In this control arm, CBT was identical to comparator and only factual writing was evaluated.
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Quality assessment
A summary of the quality of the psychiatric disorders studies93–97 is shown in Figures 22 and 23. All
studies93–97 were reported as randomised but Canna,94 Krpan et al.96 and Richards et al.97 did not provide
information regarding the method of randomisation used. All studies93–97 were very likely to introduce
performance and detection biases. All studies except Graf et al.95 adequately addressed items related to
the selection of participants. Krpan et al.96 and Richards et al.97 were the most likely to introduce biases
that could affect outcomes, as randomisation and information related to masking, as well as assessment of
outcomes, was under-reported. Participation rates were reported in Bernard et al.93 and Graf et al.95 but
unclear information regarding withdrawals was provided in the other three studies.94,96,97 Only Graf et al.95
clearly used an ITT analysis.
Numerical results
The numerical results reported in the studies evaluating mental disorders are summarised in Table 31. Total
sample sizes ranged from 22 participants in Bernard et al.93 to 65 participants in Richards et al.97 Bernard
et al.93 reported significant differences between group-by-time interaction in the total IES score in favour of
the intervention group (a reduction in PTSD – symptoms associated with the diagnosis of psychosis); no
other differences between groups were seen. Canna94 and Graf et al.95 reported significant improvements
post treatment in a variety of measures of psychological distress in favour of the experimental condition. In
the Canna study94 (a doctoral thesis), improvement was reported in a variety of measured of psychological
distress, such as the Beck Anxiety Inventory (BAI); the revised Beck Depression Inventory (BDI-II), Brief
Symptom Inventory (BSI)/Global Severity Index (GSI) and the Penn State Worry Questionnaire (PSWQ) at the
final follow-up assessment (24 weeks), but the author stated that these improvements could not be
attributed specifically to the writing intervention. Graf et al.95 reported significant reductions in anxiety,
depression and stress symptoms, as well as greater overall progress in psychotherapy, in the experimental
group compared with the writing control group immediately after the third writing session (longer follow-up
was not reported). However, in Richards et al.,97 the written emotional disclosure participants reported
significantly more physical symptoms and less anxiety at 6 weeks after the intervention than those in the
control arm, with no other differences between groups.
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FIGURE 22 Risk-of-bias summary in the mental and psychiatric disorders studies.
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Three studies93,94,97 evaluated positive affect and four studies93–96 assessed depression and three could be
meta-analysed. With respect to the positive affect outcomes, Canna94 and Richards et al.97 reported
absolute scores but Bernard et al.93 used change scores, and different instruments were used, so the
meta-analysis could not be performed. Four studies93–95,97 reported information on physical symptoms
and anxiety. The PILL and IES were not meta-analysed because the SGC considered that they were
measuring different things. In total, three93,94,97 of the five studies93–97 assessed anxiety at short term and
this outcome was meta-analysed.
Meta-analysis
The outcomes of anxiety and depression were meta-analysed separately (Figures 24 and 25).
Four studies93–95,97 assessed anxiety: three of them at short term93,94,97 and the remaining one95 at
immediate term. Canna94 also assessed anxiety at a medium term (16 weeks), but the 8-week assessment
was chosen for consistency and proximity with the other two study follow-up times (5 and 6 weeks in the
studies by Bernard et al.93 and Richards et al.,97 respectively). Bernard et al.93 used the anxiety subscale of
the Hospital Anxiety and Depression Scale (HADS-A) and Richards et al.97 used the total score of the
Cognitive–Somatic Anxiety Questionnaire (CSAQ). Canna94 used two instruments to assess anxiety: the BAI
and the STAI – both are self-reported questionnaires. The BAI measures the severity of anxiety and
provides a total score and the STAI, which has two subscales, measures state and trait anxiety. Thus, the
BAI was chosen for inclusion in the meta-analysis.
l Forest plot A total of 127 participants were meta-analysed (70 in the EW group and 57 in the control
group) (see Figure 24). The SMD was –0.07 (95% CI –0.42 to 0.29) with a random-effects model,
and with unimportant, non-significant heterogeneity, I2= 2%. This result suggests that there is no
significant difference in anxiety at short term for the EW group compared with the control group.
There was considerable clinical heterogeneity as follows:
l Clinical differences between studies Participants in Bernard et al.93 were first episode psychosis patients,
those in Canna94 were diagnosed with Axis I anxiety or mood disorder, and those in Richards et al.97
had at least one diagnosis of mental disorder and were different from the other study participants as
they were psychiatric maximum-security prison inmates. They were reported to have had a higher use
of health-care services than non-incarcerated men.
l Intervention differences Bernard et al.93 and Canna94 instructed their participants to write about a
disease- and treatment-related topic, whereas the prison inmates in Richards et al.97 had to write about
their deepest thoughts and feelings, regarding an experience that had not been previously shared with
others at all, or in very little detail. In addition, Richards et al.97 evaluated two control groups, whereas
one control group was evaluated in the other two studies.93,94 The prison inmates were financially
compensated, whereas participants in the other two studies were not.
Four studies measured depression:93,94,96,97 one study97 immediately after writing and three studies93,94,96 at
short-term follow-up, which could be meta-analysed. Bernard et al.93 measured the HADS-D at 5 weeks,
and Canna94 measured the BDI-II at 8, 16 and 24 weeks so the 8-week value was used, and Krpan et al.96
measured the Beck Depression Inventory (BDI) at 4 weeks. Krpan et al.96 also measured depression with
the Patient Health Questionnaire 9-item subscale (PHQ-9) but the BDI was used for the meta-analysis
because it was similar to the BDI used by Canna.94
l Forest plot In the meta-analysis a total of 97 participants were included (54 in the EW groups and 43 in
the control groups). The SMD was –0.35 (95% CI –0.76 to 0.06), suggesting that there is no significant
difference in depression at short term for the EW group compared with the control group.
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F43: post-traumatic stress disorder
Overview
There were two small studies evaluating unfacilitated EW on PTSD.98,121 A summary of their main
characteristics is presented in Table 32. Two other studies97,98 also evaluated patients with PTSD; however,
they used facilitated TW and are reported in the facilitated TW section.
One study121 was conducted in the USA and the other one98 in Israel. In Gidron et al.,98 10 out of the
14 participants had PTSD following a motor vehicle accident (MVA), and the 25 participants in Smyth and
Arigo121 were recruited from a veterans hospital and a community rape and trauma centre. In both
studies,98,121 patients had been diagnosed with PTSD as defined by the DSM-IV.
The outcomes evaluated in each of the studies on PTSD patients are reported in Table 33.
The main outcomes assessed were related to the physical symptoms and to psychological factors,
mostly depression.
TABLE 32 Characteristics of the unfacilitated EW studies in PTSD
First author, year Study design Intervention group Control group
Gidron 199698 RCT Unfacilitated EW Factual writing
Smyth 2008121 RCT Unfacilitated EW Time-management writing
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Quality assessment
A summary of the quality of the studies on PTSD is shown in Figure 26. Both studies were randomised but
the method of randomisation was not indicated in either study.
Gidron et al.98 was likely to introduce both detection and attrition biases. The study by Smyth and Arigo121
was more likely to introduce attrition and selection biases. The remaining items in these two studies98,121
were unclear or not reported. Overall, the quality of the methods used in each of the studies was
under-reported. Only participants in Gidron et al.98 were analysed by ITT analysis.
Numerical results
The numerical results reported in the PTSD studies are summarised in Table 34. The follow-up periods
were 5 weeks in Gidron et al.98 and 13 weeks in Smyth and Arigo.121 The final sample size was
14 participants in Gidron et al.96 and 21 participants in Smyth and Arigo.121
Overall, a significant effect of group-by-time interaction in mood outcomes was reported in both
studies.98,121 In Smyth and Arigo,121 there was a significant improvement in mood in the TW group
compared with control subjects, as opposed to Gidron et al.,98 in which participants in the experimental
group increased significantly the negative affect compared with control subjects.
F50: bulimia nervosa
Overview
There was one RCT99 on bulimia nervosa (BN), binge-eating disorder (BED) and other eating disorders
evaluating unfacilitated EW. Participants in Robinson and Serfaly99 were UK university students and staff,
recruited via e-mail, and diagnosed with the Questionnaire for Eating Disorders Diagnosis (QEDD) using
DSM-IV.123 Two interventions were assessed. One intervention was e-mail bulimia therapy (eBT), which did not
involve TW, and is not considered further here. In the other active intervention, unsupported self-directed
writing (SDW) participants were sent an e-mail and were asked to write about their self-selected difficulties at
least twice a week and send it back to the authors. The duration of the intervention was not specified.
Participants in the control group were placed in a waiting list for 3 months, after which they were offered eBT
or SDW by random allocation. The outcomes evaluated in the studies on BN are reported in Table 35.
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Quality assessment
A summary of the study quality is shown in Figure 27. Robinson et al.99 was truly randomised; however,
the sequence generation was not concealed. Masking of participants was performed but information
related to masking of outcome assessment was unclear. The study99 was likely to introduce high risk of
selection bias and unclear risk of detection bias and high risk of attrition bias. Authors reported that they
used an ITT analysis.
Numerical results
The numerical results reported in Robinson et al.99 are summarised in Table 36. The follow-up assessments
were performed at 13 weeks post writing. The total sample size in the study arms relevant to this
review was 51 participants.
Authors reported that overall severity scores were reduced within the intervention group but differences
were not significant. However, the number of participants fulfilling DSM-IV eating disorder criteria tended
to be lower (but was not significantly different) in the EW group than in the control group.
G12: amyotrophic lateral sclerosis/motor neurone disease
Overview
There was one RCT100 evaluating unfacilitated EW on patients who had been diagnosed with amyotrophic
lateral sclerosis (ALS) (also known as motor neurone disease). Participants in the Averill et al. study100 were
diagnosed with definite or probable ALS using El Escorial World Federation of Neurology criteria at least
6 months prior to study entry124 (World Federation of Neurology Research Group on Neuromuscular
Diseases, 1994). The study100 was conducted in the USA. One intervention group was compared with
one control group. Intervention group participants had to disclose, by handwriting (or orally), about a
disease-focused topic during 20 minutes over 3 non-consecutive days. The control group did no writing
TABLE 35 Outcomes collected by the unfacilitated EW study in BN
First author, year Diagnosis of eating disorder Desired weight Bulimia test Depression Resource use
Robinson 200899 QEDD BMIa BITE BDI –
BITE, Bulimia Investigatory Test Edinburgh; BMI, body mass index.
a BMI was collected as the participant-desired weight and was a secondary outcome.
A description of all acronyms is listed in Appendix 5, Table 106.
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and had to complete study outcome measures only. Participants were not financially compensated. The
outcomes evaluated in Averill et al.100 are reported in Table 37. Psychological outcomes were the most
extensively assessed, together with QoL.
Quality assessment
A summary of the quality of the study in ALS is shown in Figure 28.
Averill et al.100 was truly randomised but information relating to the allocation concealment of the
sequence generation was unclear. There was no information reported regarding the masking of
participants and/or personnel. Therefore, there was a possibility of selection and performance biases.
Numerical outcome data were supplied for only the QoL measure; none of the remaining outcomes was
reported. The authors did not perform ITT analysis.
Numerical results
The numerical results reported in Averill et al.100 are summarised in Table 38.
Follow-up assessments were performed at 13 and 26 weeks. The total sample size was 48 participants at
both time points. At 13 weeks, there was a small but significant improvement in well-being measures in the
intervention group compared with baseline, and a significant reduction in well-being (QoL) in the control
group; both these differences had disappeared at 26 weeks. The authors pointed out that ALS is a
progressive condition and it may be that the physical and emotional challenges faced by those with the
condition at 6 months might be very different from those faced by them at baseline and it could be
that booster sessions of EW are required in conditions such as this. Ambivalence Emotional Expression
(or Ambivalence over Emotional Expression; AEE) appeared to moderate psychological well-being. Authors
reported that those participants who were more ambivalent about expressing emotion appeared to benefit
particularly from emotional disclosure at 13 weeks.
TABLE 37 Outcomes collected by the unfacilitated EW study in ALS
First author, year Affect Coping Depression Various others QoL Resource use
Averill 2013100 ABS Likert scale GDS AEE, SCS McGill QOL –
ABS, Affects Balance Scale; AEE, Ambivalence Emotional Expression; GDS, Geriatric Depression Scale; McGill QOL, McGill
Quality Of Life; SCS, Social Constraints Scale.
Italic text shows outcomes for which no data were reported.
A description of all acronyms is listed in Appendix 5, Table 106.
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FIGURE 28 Risk-of-bias summary in the ALS study.
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G43 and G44: migraine and tension headache
Overview
There was one RCT101 evaluating unfacilitated EW on patients diagnosed with migraine or tension
headache, using the International Headache Society criteria. D’Souza et al.101 was conducted in the USA on
psychology students, who reported either tension or migraine headaches on screening. The majority
(86.5%) of participants were female. Unfacilitated EW was compared with time-management writing;
intervention participants were asked to write about their most significant trauma, upheaval or stressful
experience for 20 minutes on four occasions over 2 weeks. A third arm (not reported further here)
examined the effect of relaxation training. Control subjects had a time-management writing task.
Participants received financial compensation for participating in the study. The outcomes evaluated in
D’Souza et al.101 are reported in Table 39. Physical symptoms were the main outcomes assessed.
Quality assessment
A summary of the study quality is shown in Figure 29. D’Souza et al.101 was truly randomised. Allocation
concealment was performed, and blinding was preserved at the performance level. Withdrawals were
adequately reported and outcomes were fully reported. This study101 was not likely to introduce any bias
other than detection bias. ITT analyses were performed. However, numbers involved in the study101 were
very small and no sample size calculation was reported.
Numerical results
The numerical results are summarised in Table 40. Follow-up assessment was performed at 12 weeks post
writing for all outcomes but for the Positive and Negative Affect Schedule (PANAS), which was evaluated
just after writing as a manipulation check to verify that the conditions operated as expected. The total
TABLE 39 Outcomes collected by the unfacilitated EW study in migraine and tension headache
First author,
year Physical symptoms
Positive
mood
Negative
mood
Behavioural disability
from headache
Resource
use
D’Souza
2008101
Headache frequency, disability
and severity, SCL-90-R
PANAS-PA PANAS-NA MIDAS –
MIDAS, Migraine Disability Assessment Scale; SCL-90-R, Symptom Checklist-90-Revised.
A description of all acronyms is listed in Appendix 5, Table 106.
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FIGURE 29 Risk-of-bias summary in the migraine and tension headache study.
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sample size was 62 participants. The results were reported separately for the two types of headache. If
12-week outcome data were missing then 4-week data were used. The intervention group had increased
negative mood immediately after administration compared with control subjects but whether or not
differences between groups were statistically significant was not reported.
No difference in any outcome was seen between intervention and control subjects for either type of
headache at 4 or 12 weeks (only 12-week data were provided in full).
I51: cardiovascular disease
Overview
There were three studies102–104 evaluating unfacilitated EW on patients with CVD. A summary of their
main characteristics is presented in Table 41. Participants in Willmott et al.104 were patients with a first
myocardial infarction (MI) receiving treatment at one of two acute hospital clinics. Participants in Hevey
et al.103 were patients with a confirmed MI, who had received treatment at a large teaching hospital.
Bartasiuniene et al.102 included rehabilitation hospital patients with CVD. Bartasiuniene et al.102 was
conducted in Lithuania, Hevey et al.103 was conducted in Ireland and Willmott et al.104 was conducted in
the UK.
All studies102–104 assessed an expressive writing intervention in which the topic was disease focused.
Additionally, participants in Willmott et al.104 had to express both positive and negative disease-related
feelings, whereas in the remaining studies only negative thoughts were to be expressed. Factual writing
was the control intervention in all three studies. Bartasiuniene et al.102 also included a second, non-writing
control group, in which participants received what the authors described as usual care. However, this
latter control group was not included in current analyses, as the usual care consisted of aromatherapy and
other activities that were considered active, in that participants would have been getting more attention
than those receiving only usual care. Hevey et al.103 and Willmott et al.104 both implemented writing for
20 minutes over 3 consecutive days, whereas intervention group participants in Bartasiuniene et al.102
wrote for 30 minutes on 4 consecutive days.
The outcomes evaluated in the studies102–104 are reported in Table 42. Negative affect and QoL were the
most frequent outcomes measured.
TABLE 41 Characteristics of the unfacilitated EW studies in CVD
First author, year Study design Intervention group Control group
Bartasiuniene 2011102 RCT Unfacilitated EW Factual writing
Hevey 2012103 RCT Unfacilitated EW Factual writing
Willmott 2011104 RCT Unfacilitated EW Factual writing
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Quality assessment
A summary of the quality of the CVD studies102–104 is shown in Figures 30 and 31.
All three studies102–104 were randomised. However, Bartasiuniene et al.102 and Hevey et al.103 did not report
the method of randomisation used or whether or not the sequence of the random generation was
concealed. Willmott et al.,104 however, reported adequately on all quality items except for the outcome
assessment, which was unclear. In the remaining studies,102,103 selection, performance and detection biases
were possible. Additionally, in Hevey et al.,103 numerical data were reported for only QoL, and these data
were derived from graphs so no measure of variability could be computed. Similarly, Bartasiuniene et al.102
under-reported outcomes; it was also unclear whether or not the authors performed an ITT analysis, as
they reported that only 48 out of 60 participants completed the study, and they did not report further on
the 12 dropouts. The remaining studies103,104 reported on only those who continued to participate in
the study.
Numerical results
The numerical results of the CVD studies are reported in Table 43. Follow-up assessments were performed
from just after writing up to 21 weeks later. Total study sizes ranged from 30 participants in the
Bartasiuniene et al. study102 to 128 participants in the Willmot et al. study.104
Differences between groups by time interaction were reported as statistically significant for the following
outcomes measures: PANAS-PA/PANAS-NA; QoL; number of prescribed medication/month; diastolic blood
pressure (DBP) and Short Form questionnaire-36 items mental composite score (SF-36 MCS). No other
significant effect of group-by-time interaction was reported across the studies in CVD. Additionally,
Willmott et al.104 stated that the intervention group had significantly fewer symptoms than those in the
control group (p< 0.001). Likewise, DBP in the control group was reported as significantly higher than in
the experimental group at the 5-month follow-up (p< 0.008).
Bartasiuniene 2011102 ? ?–
Hevey 2012103 ? +
+
+++
–
–Wilmott 2011104
?
?
?
+
?
?
?
Ra
nd
om
 se
qu
en
ce
 g
en
er
at
io
n 
(se
lec
tio
n 
bi
as
)
Al
lo
ca
tio
n 
co
nc
ea
lm
en
t (
se
lec
tio
n 
bi
as
)
Bl
in
di
ng
 o
f p
ar
tic
ip
an
ts 
an
d 
pe
rso
nn
el 
(p
er
fo
rm
an
ce
 b
ias
)
Bl
in
di
ng
 o
f o
ut
co
m
e a
sse
ssm
en
t (
de
te
cti
on
 b
ias
)
In
co
m
pl
et
e o
ut
co
m
e d
at
a (
at
tri
tio
n 
bi
as
)
Se
lec
tiv
e r
ep
or
tin
g 
(re
po
rti
ng
 b
ias
)
?
+
–
Low risk of bias
Unclear risk of bias
High risk of bias
FIGURE 30 Risk-of-bias summary in the CVD studies.
DOI: 10.3310/hta20270 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 27
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Nyssen et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
91
Lo
w
 r
is
k 
o
f 
b
ia
s
U
n
cl
ea
r 
ri
sk
 o
f 
b
ia
s
H
ig
h
 r
is
k 
o
f 
b
ia
s
0%
25
%
50
%
75
%
10
0%
R
an
d
o
m
 s
eq
u
en
ce
 g
en
er
at
io
n
 (
se
le
ct
io
n
 b
ia
s)
A
llo
ca
ti
o
n
 c
o
n
ce
al
m
en
t 
(s
el
ec
ti
o
n
 b
ia
s)
B
lin
d
in
g
 o
f 
p
ar
ti
ci
p
an
ts
 a
n
d
 p
er
so
n
n
el
 (
p
er
fo
rm
an
ce
 b
ia
s)
B
lin
d
in
g
 o
f 
o
u
tc
o
m
e 
as
se
ss
m
en
t 
(d
et
ec
ti
o
n
 b
ia
s)
In
co
m
p
le
te
 o
u
tc
o
m
e 
d
at
a 
(a
tt
ri
ti
o
n
 b
ia
s)
Se
le
ct
iv
e 
re
p
o
rt
in
g
 (
re
p
o
rt
in
g
 b
ia
s)
FI
G
U
R
E
31
R
is
k-
o
f-
b
ia
s
g
ra
p
h
in
th
e
C
V
D
st
u
d
ie
s.
SYSTEMATIC REVIEW RESULTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
92
TA
B
LE
43
N
u
m
er
ic
al
re
su
lt
s
in
th
e
u
n
fa
ci
lit
at
ed
EW
st
u
d
ie
s
in
C
V
D
Fi
rs
t
au
th
o
r,
ye
ar
O
u
tc
o
m
e
m
ea
su
re
s
Fo
llo
w
-u
p
(w
ee
ks
)
In
te
rv
en
ti
o
n
g
ro
u
p
C
o
n
tr
o
l
g
ro
u
p
A
u
th
o
r’
s
re
p
o
rt
ed
st
at
is
ti
ca
l
si
g
n
if
ic
an
ce
(g
ro
u
p
-b
y-
ti
m
e
in
te
ra
ct
io
n
)
n
to
ta
la
Fi
n
al
m
ea
n
sc
o
re
SD
n
to
ta
la
Fi
n
al
m
ea
n
sc
o
re
SD
Ba
rt
as
iu
ni
en
e
20
11
10
2
PA
N
A
S-
PA
D
ay
4
15
28
.5
3
N
R
15
28
.0
6
N
R
SS
b
PA
N
A
S-
N
A
D
ay
4
15
15
.9
3
N
R
15
18
.7
3
N
R
SS
b
H
ev
ey
20
12
10
3
Q
oL
Ju
st
af
te
r
w
rit
in
g
43
4.
97
N
R
46
4.
84
N
R
N
R
13
43
5.
65
N
R
46
5.
08
N
R
SS
H
A
D
S-
D
Ju
st
af
te
r
w
rit
in
g
43
N
R
N
R
46
N
R
N
R
N
S
13
43
N
R
N
R
46
N
R
N
R
N
S
H
A
D
S-
A
Ju
st
af
te
r
w
rit
in
g
43
N
R
N
R
46
N
R
N
R
N
S
13
43
N
R
N
R
46
N
R
N
R
N
S
Ty
pe
D
ne
ga
tiv
e
af
fe
ct
iv
ity
Ju
st
af
te
r
w
rit
in
g
43
N
R
N
R
46
N
R
N
R
N
S
13
43
N
R
N
R
46
N
R
N
R
N
S
Ty
pe
D
so
ci
al
in
hi
bi
tio
n
Ju
st
af
te
r
w
rit
in
g
43
N
R
N
R
46
N
R
N
R
N
S
13
43
N
R
N
R
46
N
R
N
R
N
S
Br
ie
f
C
O
PE
-a
d
Ju
st
af
te
r
w
rit
in
g
43
N
R
N
R
46
N
R
N
R
N
S
13
43
N
R
N
R
46
N
R
N
R
N
S
Br
ie
f
C
O
PE
-m
Ju
st
af
te
r
w
rit
in
g
43
N
R
N
R
46
N
R
N
R
N
S
13
43
N
R
N
R
46
N
R
N
R
N
S
co
nt
in
ue
d
DOI: 10.3310/hta20270 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 27
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Nyssen et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
93
TA
B
LE
43
N
u
m
er
ic
al
re
su
lt
s
in
th
e
u
n
fa
ci
lit
at
ed
EW
st
u
d
ie
s
in
C
V
D
(c
o
n
ti
n
u
ed
)
Fi
rs
t
au
th
o
r,
ye
ar
O
u
tc
o
m
e
m
ea
su
re
s
Fo
llo
w
-u
p
(w
ee
ks
)
In
te
rv
en
ti
o
n
g
ro
u
p
C
o
n
tr
o
l
g
ro
u
p
A
u
th
o
r’
s
re
p
o
rt
ed
st
at
is
ti
ca
l
si
g
n
if
ic
an
ce
(g
ro
u
p
-b
y-
ti
m
e
in
te
ra
ct
io
n
)
n
to
ta
la
Fi
n
al
m
ea
n
sc
o
re
SD
n
to
ta
la
Fi
n
al
m
ea
n
sc
o
re
SD
W
ill
m
ot
t
20
11
10
4
n
of
vi
si
ts
cl
in
ic
ia
n
21
68
8.
60
3.
70
60
10
.3
0
5.
00
N
S
n
of
pr
es
cr
ib
ed
pa
in
m
ed
ic
at
io
n/
m
on
th
4
68
5.
00
1.
60
60
5.
00
1.
60
N
R
8
68
4.
90
1.
70
60
5.
20
1.
70
N
R
21
68
4.
80
1.
70
60
5.
30
1.
70
SS
n
of
ca
rd
ia
c
sy
m
pt
om
s
4
68
0.
62
0.
70
60
0.
96
0.
90
N
R
8
68
0.
73
1.
00
60
1.
10
0.
90
N
R
21
68
0.
63
0.
80
60
1.
10
0.
90
N
S
D
BP
4
68
73
.7
0
9.
00
60
73
.1
0
8.
80
N
R
8
68
71
.8
0
8.
40
60
74
.2
0
8.
80
N
R
21
68
71
.0
0
9.
00
60
75
.0
0
9.
80
SS
SB
P
4
68
12
6.
50
16
.2
0
60
12
6.
50
17
.0
0
N
R
8
68
12
5.
20
17
.3
0
60
12
9.
90
16
.4
0
N
R
21
68
12
7.
60
17
.0
0
60
13
3.
90
18
.3
0
N
S
SF
-3
6
PC
S
4
68
44
.0
0
14
.8
0
60
40
.5
0
15
.8
0
N
R
8
68
65
.5
0
21
.6
0
60
60
.3
0
22
.0
0
N
R
21
68
68
.1
0
22
.5
0
60
63
.6
0
16
.3
0
N
S
SF
-3
6
M
C
S
4
68
48
.3
0
16
.2
0
60
47
.8
0
16
.0
0
N
R
8
68
66
.8
0
21
.6
0
60
64
.8
0
21
.6
0
N
R
21
68
71
.4
0
20
.2
0
60
62
.9
0
22
.4
0
SS
b
Br
ie
f
C
O
PE
-a
d,
Br
ie
f
C
op
in
g
In
ve
nt
or
y,
ad
ap
tiv
e;
Br
ie
f
C
O
PE
-m
,
Br
ie
f
C
op
in
g
In
ve
nt
or
y,
m
al
ad
ap
tiv
e;
D
BP
,
di
as
to
lic
bl
oo
d
pr
es
su
re
;
N
R,
no
t
re
po
rt
ed
;
N
S,
no
t
st
at
is
tic
al
ly
si
gn
ifi
ca
nt
(p
>
0.
05
);
PP
,
pe
r
pr
ot
oc
ol
;
SB
P,
sy
st
ol
ic
bl
oo
d
pr
es
su
re
;
SF
-3
6
M
C
S,
Sh
or
t
Fo
rm
qu
es
tio
nn
ai
re
-3
6
ite
m
s
m
en
ta
lc
om
po
si
te
sc
or
e;
SF
-3
6
PC
S,
Sh
or
t
Fo
rm
qu
es
tio
nn
ai
re
-3
6
ite
m
s
ph
ys
ic
al
co
m
po
si
te
sc
or
e;
SS
,
st
at
is
tic
al
ly
si
gn
ifi
ca
nt
(p
<
0.
05
).
a
Sa
m
pl
e
si
ze
an
al
ys
ed
(IT
T
or
PP
).
b
Si
gn
ifi
ca
nt
st
at
is
tic
al
as
so
ci
at
io
n
be
tw
ee
n
ex
pr
es
si
ve
w
rit
in
g
an
d
ne
ut
ra
lg
ro
up
s
on
ly
in
Ba
rt
as
iu
ni
en
e
et
al
.1
02
A
de
sc
rip
tio
n
of
al
la
cr
on
ym
s
is
lis
te
d
in
A
pp
en
di
x
5,
Ta
bl
e
10
6.
SYSTEMATIC REVIEW RESULTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
94
J44 and J84: chronic obstructive pulmonary disease and idiopathic
pulmonary fibrosis
Overview
There was one RCT105 evaluating unfacilitated EW on patients medically diagnosed with chronic obstructive
pulmonary disease (COPD) or idiopathic pulmonary fibrosis (IPF), who were recruited while participating
in an 8-week pulmonary rehabilitation programme. Sharifabad et al.105 was conducted in the USA. A
written emotional disclosure intervention was evaluated, for which participants had to write about their
most traumatic or upsetting life experiences for 20 minutes once a week for 3 consecutive weeks, whereas
control participants had to write in detail about an assigned neutral topic (a specific event or an object)
without referring to their emotions. The outcomes evaluated by Sharifabad et al.105 are reported in
Table 44. They include physical function, symptom and QoL.
Quality assessment
A summary of the quality of the COPD/ IPF studies is shown in Figure 32. Sharifabad et al.105 was described
as randomised but authors did not report the method of randomisation. They stated, ‘The pulmonary
rehabilitation program had two morning sessions and one evening session. For one cycle of patients, those
in the morning sessions were enrolled in the WDT group [i.e. intervention] and patients in the evening
group were enrolled in the control group. Then, for the following cycle of patients the enrolment switched
. . .’ Thus, it is not clear whether or not this study105 was truly randomised. The quality items assessed
showed that this study105 was likely to introduce selection, performance, detection and attrition biases.
TABLE 44 Outcomes collected by unfacilitated EW study in COPD/IPF
First author, year Physical function Physical symptoms QoL Resource use
Sharifabad 2010105 6MWD, FEV1, FVC MMRC dyspnoea scale CRQ, SGRQ –
6MWD, 6 Minutes’ Walk Distance; CRQ, Chronic Respiratory Disease Questionnaire; FEV1, forced expiratory volume in
1 second; FVC, forced vital capacity; MMRC, Modified Medical Research Council dyspnoea scale; SGRQ, St George’s
Respiratory Questionnaire.
A description of all acronyms is listed in Appendix 5, Table 106.
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FIGURE 32 Risk-of-bias summary in the COPD/IPF study.
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Numerical results
The numerical results of this study are reported in Table 45. Follow-up assessments were performed at 8 and
26 weeks. The total sample size was 66 participants (no power calculation was provided). At 6 months,
and adjusting for baseline differences, authors reported significant improvement between groups favouring
the control group in the emotion domain of the Chronic Respiratory Disease Questionnaire, emotion
subscale (CRQ-e). The remaining outcomes had non-significant differences in scores between groups.
TABLE 45 Numerical results in the unfacilitated EW study in COPD/IPF
First
author,
year
Outcome
measures
Follow-up
(weeks)
Intervention group Control group Author’s
reported
statistical
significance
(group-by-time
interaction)n totala
Final
mean
score SD n totala
Final
mean
score SD
Sharifabad
2010105
Modified
MRC
dyspnoea
8 29 1.61 1.14 37 1.79 1.00 NS
Modified
MRC
dyspnoea
26 29 1.94 0.98 37 1.83 0.95 NS
SGRQ 8 29 39.46 16.80 37 42.21 14.76 NS
SGRQ 26 29 40.06 17.06 37 42.78 16.15 NS
CRQ-d 8 29 4.39 1.37 37 4.17 1.45 NS
CRQ-d 26 29 3.98 1.86 37 4.22 1.60 NS
CRQ-m 8 29 5.42 1.03 37 5.39 1.18 NS
CRQ-m 26 29 5.46 1.21 37 5.44 1.33 NS
CRQ-f 8 29 4.67 1.16 37 4.54 1.03 NS
CRQ-f 26 29 4.78 1.20 37 4.50 1.06 NS
CRQ-e 8 29 5.20 1.06 37 5.26 0.99 SS
CRQ-e 26 29 5.00 1.17 37 5.11 1.22 SS
6MWD 8 29 314.60 99.70 37 314.20 122.50 NS
6MWD 26 29 263.70 110.40 37 278.40 118.90 NS
FEV1 8 29 0.97 0.48 37 1.09 0.65 NS
FEV1 26 29 1.00 0.51 37 1.10 0.61 NS
FVC 8 29 1.72 0.68 37 1.93 0.80 NS
FVC 26 29 1.70 0.72 37 2.01 0.69 NS
6MWD, 6 Minute’s Walk Distance; CRQ, Chronic Respiratory Disease Questionnaire; CRQ-d, Chronic Respiratory Disease
Questionnaire, dyspnoea subscale; CRQ-e, Chronic Respiratory Disease Questionnaire, emotion subscale; CRQ-f, Chronic
Respiratory Disease Questionnaire, fatigue subscale; CRQ-m, Chronic Respiratory Disease Questionnaire, mastery subscale;
FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; MRC, Medical Research Council; NS, not statistically
significant; PP, per protocol; SGRQ, St George’s Respiratory Questionnaire; SS, statistically significant (p<0.05).
a Sample size analysed (ITT or PP).
A description of all acronyms is listed in Appendix 5, Table 106.
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J45: asthma
Overview
There were four studies58,106–108 evaluating unfacilitated EW on patients with asthma (Table 46). A summary
of main characteristics is presented in Table 46. Participants were diagnosed through a clinical history of
asthma and confirmed by a physician. In all studies,58,106–108 patients were reported to be on regular inhaled
medication to treat persistent symptoms. Three studies106–108 were conducted in the USA and Theadom
et al.58 was conducted in the UK.
Three studies58,107,108 evaluated one intervention group compared with one control group but Harris et al.106
assessed two intervention arms: in one group, participants had to write about stressful traumatic
experiences, whereas in the other active group participants had to write about positive experiences such
as events that stimulated feelings of happiness or joy. In the remaining studies58,107,108 the topic of the
intervention arm was focused on a self-selected trauma/emotional issue or worst experience. Therefore,
because of similarity to the other active interventions, only the intervention group which wrote about
negative experiences in Harris et al.,106 was used for meta-analysis. All control groups were focused on
descriptions of neutral topics/events of previous day or on the management of time. Three studies58,107,108
delivered the intervention over 3 consecutive days except for Harris et al.,106 which delivered the
intervention once per week for 3 weeks. Patients in Smyth et al.,107 Warner et al.108 and Harris et al.106
were financially compensated.
The outcomes assessed within the studies58,106–108 on asthma are reported in Table 47. Lung function was
evaluated through spirometry in three studies.106–108 The remaining outcomes were mostly evaluated
once across studies.
TABLE 46 Characteristics in the unfacilitated EW studies in asthma
First author, year Study design Intervention group 1 Intervention group 2 Control group 1
Harris 2005106 RCT Unfacilitated EW Positive writing Factual writing
Smyth 1999107 RCT Unfacilitated EW – Time-management writing
Theadom 201058 RCT Unfacilitated EW – Factual writing
Warner 2006108 RCT Unfacilitated EW – Time-management writing
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Quality assessment
A summary of the quality of the studies in asthma is shown in Figures 33 and 34. All studies58,106–108 were
randomised; however, in Theadom et al.58 the method of randomisation was not reported. Two
studies106,107 reported having protected the allocation sequence before and until assignment. The other
two studies58,108 were unclear on this item. Additionally, information related to masking was not reported
in any of the studies or the information given was scarce, making more likely to introduce certain risk
of bias and to affect outcomes. Warner et al.108 was contacted in order to get numerical data related to
the outcome collected ‘five moods’, which were not reported in the published article. The information was
supplied, and therefore the selective reporting item was rated as low risk of bias. All studies performed ITT
analysis, but Harris et al.106 did not reflect this clearly.
Numerical results
The numerical results reported in the asthma studies58,106–108 are summarised in Table 48. Follow-up
assessments ranged from 2 weeks in Smyth et al.107 to 28 weeks in Warner et al.108 Total sample sizes
ranged from 77 patients in Harris et al.106 to 28 patients in Theadom et al.58 The most frequent outcome
evaluated was lung function through spirometry. The follow-up assessments for forced expiratory volume
in 1 second (FEV1)/forced vital capacity (FCV) were performed immediately after the writing and at short
term. Warner et al.108 reported a statistically significant group-by-time interaction between the two groups
for the positive affect subscale of the Positive and Negative Affect Schedule for Children (PANAS-PA) and
on the Child Behavior Checklist (CBCL), in favour of the EW group. However, no differences between
groups were found for lung function, the negative affect subscale of the Positive and Negative Affect
Schedule for Children (PANAS-NA) or mood changes. In Warner et al.,108 participants rated their mood
and physical symptoms immediately before and after each day’s writing and change scores (after writing –
before writing) were computed for all ratings, but were not reported. There were significant group main
effects for two variables: the disclosure group participants rated themselves as significantly less calm
and angrier after writing than did control group participants. A marginal group effect was also found for
the physical symptom ratings, with the disclosure group reporting slightly higher levels of physical
symptoms after writing compared with control subjects, who reported a slight decrease in physical
symptoms following the writing. Finally, there was one significant early effect. Participants in both groups
reported a greater increase in sadness after writing on the third day relative to the first and second days.
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FIGURE 33 Risk-of-bias summary in the asthma studies.
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The remaining studies did not report on any association between the groups across time for the
outcomes assessed.
Meta-analysis
The percentage of predicted forced expiratory volume in 1 second (FEV1% pred) was the outcome
meta-analysed (Figure 35). Three studies106–108 assessed lung function by means of spirometry.
l Clinical differences between studies Participants in Warner et al.108 were adolescents aged 12–17 years,
whereas the other two studies106,107 included adults. In addition, all participants in Warner et al.108
reported never having smoked, as opposed to the participants in the other studies,106,107 which had a
proportion of non-smokers, ex-smokers and current smokers.
l Follow-up length All studies included in the meta-analysis evaluated the impact of TW at 8 and
13 weeks (short-term follow-up). In addition, Smyth et al.107 assessed FEV1% pred at 2 weeks
(immediate follow-up).
l Forest plot A total of 167 participants were meta-analysed (95 in the EW group and 72 in the
control group). The SMD was 0.24 (95% CI –0.07 to 0.56) with a random-effects model and with
no heterogeneity (I2= 0%). This result suggests that there is no statistically significant difference in
mean percentage of FEV1 at short term for the TW groups compared with the control groups.
K58: irritable bowel syndrome
Overview
There were two studies evaluating unfacilitated EW. A summary of main characteristics is presented in
Table 49. Halpert et al.52 evaluated young participants who were diagnosed with IBS using the Rome III
Criteria for IBS. This study52 was conducted entirely online with participants recruited via adverts at
IBS-related websites and the intervention writing submitted online. Wallander et al.109 evaluated young
participants who were diagnosed with gastrointestinal (GI) recurrent abdominal pain (RAP) meeting the
Apley’s criteria for functional RAP. Both studies52,109 were conducted in the USA.
Halpert et al.52 was conducted entirely online and only young participants were recruited. The separation
of writing group compared with non-writing group was formed post hoc after completing the four
writing exercises. Thus, participants completing all four writing assignments became the writing group
(intervention group) and those who initially intended to write but did not write became the non-writing
group (control group). For the purposes of the systematic review, this comparator group was considered as
a suitable comparator, even though it seems that the researchers were not planning to have a comparator
group and assumed that some participants did not write happened at random. The Wallander et al.
study109 used a written standard disclosure intervention, whereby each young participant was taken to a
private room in the clinic to perform the first session and then was sent home to complete the remaining
two assignments. The control group received usual care.
The outcomes evaluated in the studies52,109 on IBS/GI RAP are reported in Table 50. QoL was evaluated in
both studies.52,109 The remaining outcomes were assessed once in each study.
Quality assessment
A summary of the quality of the studies in IBS/GI RAP is shown in Figure 36. Halpert et al.52 was described
as an exploratory study, and was not randomised. It is likely to be at very high risk of selection bias
because the intervention group included only those who completed the entire 4-day writing exercise
(and those who did not were excluded as dropouts). On the other hand, the comparison group comprised
participants recruited to the intervention but who did not even start it (the non-writers group). Wallander
et al.,109 which was a randomised trial, was at high risk of bias across some domains such as selection,
detection and attrition biases. Neither study involved ITT analysis.
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TABLE 50 Outcomes collected by the unfacilitated EW studies in IBS/GI RAP
First
author,
year
Pain
frequency
Pain
severity
Somatisation
severity
Cognition
concerning
their IBS
Catastrophising/
coping QoL Resource use
Halpert
201052
– IBSSS – CG-FBD CT3 IBS-QoL –
Wallander
2011109
The abdominal
pain frequency
rating
– CSI – – PedsQL Number of
visits to clinician
CG-FBD, Functional Bowel Disease-related Cognition; CSI, Children’s Somatisation Inventory; CT3, catastrophising
(maladaptive coping); IBS-QoL, Irritable Bowel Syndrome Quality of Life; IBSSS, Irritable Bowel Syndrome Severity Scale;
PedsQL, Paediatric Quality of Life.
A description of all acronyms is listed in Appendix 5, Table 106.
TABLE 49 Characteristics of the unfacilitated EW studies in IBS/GI RAP
First author, year Study design Intervention group Control group
Halpert 201052 Non-RCT Unfacilitated EW (via internet) Non-writing
Wallander 2011109 RCT Unfacilitated EW SMC
Halpert 201052 ? +
++
––––
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FIGURE 36 Risk-of-bias summary in the IBS/GI RAP studies.
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Numerical results
The numerical results reported in the IBS/GI RAP studies52,109 are summarised in Table 51. Follow-up
assessments were 4 weeks in Halpert et al.52 and 26 weeks in Wallander et al.109 Total sample sizes were
103 and 56 participants in Halpert et al.52 and Wallander et al.,109 respectively.
In Halpert et al.,52 there were statistically significant differences at 4 weeks for the following outcomes:
the functional bowel disease-related cognition [Functional Bowel Disease-related Cognition questionnaire
31 (CG-FBD Q31)] and IBS severity [Irritable Bowel Syndrome Severity Scale (IBSSS)], where improvements
were made in favour of the writing. Likewise, at 13 weeks differences between groups were significant for
the following outcomes: the functional bowel disease-related cognition [Functional Bowel Disease-related
Cognition (CG-FBD) and CG-FBD Q31]; IBS severity (IBSSS); and psychosocial QoL, where improvements
were made in favour of the writing group. In addition, between-group differences were reported at
26 weeks as well for the abdominal pain frequency rating and number of visits to the clinician in favour of
the writing group.
Physical symptoms and resource use were reported to be significantly reduced at short time points
assessments in both studies. Wallander et al.109 reported a significant reduction in pain and frequency of
clinician visits in the intervention group at 26 weeks also, but no improvement in QoL at this time point.
However, QoL was reported as not showing any between group difference when measured at 4 and
13 weeks in Halpert et al.52 and at 26 weeks in Wallander et al.109
L40: psoriasis
Overview
There were three studies110–112 evaluating unfacilitated EW in patients with psoriasis. A summary of their
main characteristics is presented in Table 52. Paradisi et al.110 and Tabolli et al.111 were conducted in Italy,
and Vedhara et al.112 was conducted in New Zealand. In Vedhara et al.112 and Tabolli et al.111 a minority of
patients were diagnosed with psoriatic arthritis (22% and 19%, respectively). In the latter study,111 psoriatic
arthritis was significantly more prevalent in the control group than in the EW group. In Vedhara et al.,112
patients had plaque-type psoriasis involving > 10% of the body area. In Paradisi et al.,110 all participants
were undergoing phototherapy for their psoriasis.
The main intervention assessed across studies110–112 was disease-focused writing, including worst
experience/trauma/stressful life events. All interventions were delivered on 3–4 consecutive days for
20 minutes each day and by handwriting. Patients were not financially compensated over the study period.
One study110 also assessed one other active intervention based on an emotional positive writing technique
focused on the best possible future self and achieving life-goals: ‘Think about your life in the future.
Imagine that every-thing has gone as well as it possibly could, and the desires related to the psoriasis have
been realised’.
The outcomes assessed within the studies110–112 on psoriasis are reported in Table 53. The most frequent
outcome evaluated was disease severity from both the clinicians’ [Psoriasis Area and Severity Index (PASI)]
and patients’ [Self-Administered Psoriasis Area and Severity Index (SAPASI)] perspectives. QoL was also
measured in all three studies110–112 by either general or disease-specific instruments [SF-36, Dermatology
Life Quality Index (DLQI) and Skindex-29].
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Quality assessment
All three studies110–112 were randomised, but allocation concealment was unclear in Vedhara et al.112
Paradisi et al.110 did not blind study personnel; the remaining studies111,112 were unclear about masking.
All three studies110–112 were likely to introduce both performance and detection bias mainly (Figures 37
and 38). Paradisi et al.110 under-reported data for PASI and data regarding SAPASI had to be derived
from a graph, with no measure of variability reported. Vedhara et al.112 performed ITT analysis, whereas
per-protocol analyses were used in the other two studies.110,111
TABLE 52 Characteristics of the unfacilitated EW studies in psoriasis
First author, year Study design Intervention group 1 Intervention group 2 Control group 1
Paradisi 2010110 RCT Unfacilitated EW Positive writing Non-EW
Tabolli 2012111 RCT Unfacilitated EW – Non-writing
Vedhara 2007112 RCT Unfacilitated EW – Factual writing
TABLE 53 Outcomes collected by the unfacilitated EW studies in psoriasis
First
author,
year
Psoriasis
severity
Physical
global
health Mood
Psychological
distress
Depression
and anxiety QoL
Resource
use
Paradisi
2010110
PASI,
SAPASI
– – GHQ-12 – Skindex-29 Symptoms,
Emotions and
Functioning subscales
–
Tabolli
2012111
PASI,
SAPASI
PGA,
PtGA, BMI
– GHQ-12 – SF-36, Skindex-29
Symptoms, Emotions and
Functioning subscales
–
Vedhara
2007112
PASI – POMS – HADS-A,
HADS-D
DLQI –
BMI, body mass index; DLQI, Dermatology Life Quality Index; PASI, Psoriasis Area and Severity Index; PGA, physician global
assessment; PtGA, patient global assessment; SAPASI, Self-Administered Psoriasis Area and Severity Index.
Italic text shows outcomes for which no data were reported.
A description of all acronyms is listed in Appendix 5, Table 106.
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FIGURE 37 Risk-of-bias summary in the psoriasis studies.
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Numerical results
The numerical results reported in the studies on psoriasis are summarised in Table 54. Follow-up
assessments were performed from 2 weeks in Vedhara et al.112 up to 52 weeks in Tabolli et al.111 Total
samples were 78 participants randomised in Paradisi et al.110 (taking into account both intervention
groups), 67 participants in Tabolli et al.111 and 59 participants in Vedhara et al.112
Few statistical differences between groups were reported in the three studies,110–112 although typically both
control and intervention groups improved over time. Significant effects in favour of the written emotional
disclosure groups compared with control subjects were reported on the following outcomes: PASI scores at
8 weeks, SAPASI scores at 17 weeks and SF-36 PCS. No effect between groups by time interaction was
reported for the remaining outcome measures.
All three studies110–112 assessed psoriasis severity at short term (at 4 and 8 weeks) using PASI and SAPASI
questionnaires. However, in Paradisi et al.,110 data on the PASI (the clinician-rated version as opposite to
the SAPASI, the participant self-rated index) were not reported and therefore a meta-analysis could not
be performed.
M06 and M45: inflammatory arthropathies
Overview
There were six studies107,113–117 evaluating unfacilitated EW in inflammatory arthropathy patients. A
summary of main characteristics is presented in Table 55. Hamilton-West and Quine114 assessed patients
with ankylosing spondylitis (AS). The remaining studies involved patients diagnosed with RA. Four
studies107,113,115,116 were conducted in the USA but Wetherell et al.117 and Hamilton-West and Quine114 were
conducted in the UK. All of the included studies107,113–117 examined the effect of unfacilitated EW about a
stressful or traumatic event/s in an emotional way for 20 minutes on 3 or 4 consecutive days. Broderick
et al.113 included a second intervention group to assess the impact of EW about the meaning of the
trauma. Lumley et al.116 had four groups: two coping skills training (one EW intervention and one control)
and two with arthritis education (one EW intervention and one control). These were combined in the
publication to provide scores for the unfacilitated EW and control groups.
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In all studies except Lumley et al.,116 the control group carried out time-management writing, writing
in an unemotional way about their plans or activities on specific days (e.g. the next day, next week).
Lumley et al.115 used a second control arm, in which participants were asked to write about positive
emotional events in their lives in an emotional way. Results for these two control groups were combined
together in the paper but are presented separately here. This positive writing intervention is analysed
separately in a later section of this systematic review. The effect of having an active intervention as a
control is likely to have reduced the ability of this study to demonstrate an effect of EW, so we have
presented results for the two different control interventions separately and have omitted the results for
the combined control. It should be noted that Lumley et al.115 was powered to compare the intervention
against the two control interventions combined. (Neither Brodericks et al.’s113 nor Lumleys et al.’s115
alternative writing interventions are included in meta-analyses here.) Lumley et al.115 also examined a
spoken emotional disclosure intervention, which was compared with spoken control groups; however,
these results are not discussed further here, as it appeared that the speaking intervention was not
specifically designed for those who were unable write.
In Wetherell et al.,117 participants were contacted at home by telephone at a prearranged time and told of
the topic on which they would be writing on for the next 20 minutes. However, it is important to note
that the facilitator (the term used in the paper to define the researcher delivering the intervention) was
available only by telephone should the need arise.
The outcomes assessed within the studies on inflammatory arthropathies are reported in Table 56.
TABLE 55 Characteristics of the unfacilitated EW studies in inflammatory arthropathies
First author, year
Study
design Intervention group 1 Intervention group 2 Control groups
Broderick 2004113 RCT Unfacilitated EW EW with meaning
writing
Time-management writing
Hamilton-West 2007114 RCT Unfacilitated EW – Time-management writing
Lumley 2011115 RCT Unfacilitated EW Positive writing Time-management writing
Lumley 2014116 RCT Unfacilitated EW with
coping skills training
Unfacilitated EW with
arthritis education
1. Time-management writing
with coping skills training
2. Time-management writing
with arthritis education
Smyth 1999107 RCT Unfacilitated EW – Time-management writing
Wetherell 2005117 RCT Unfacilitated EW – Time-management writing
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Quality assessment
A summary of the quality of the studies in inflammatory arthropathy is shown in Figures 39 and 40. All studies
were described as randomised but Broderick et al.113 did not provide the method of randomisation. Blinding of
participants and personnel was performed only in Broderick et al.113 and Smyth et al.107 Almost all studies
(except Lumley et al.115) introduced reporting bias in several ways: either by omission of the outcomes, by
providing subscales of a full measurement scale without providing the total score, or by under-reporting the
data, that is not giving enough detail for the data to be included in the meta-analysis. For instance, in
Hamilton-West and Quine,114 results regarding disease activity [Bath Ankylosing Spondylitis Disease Functional
Index (BASFI)] were not adequately reported. Mean values were derived from a graph without no information
regarding variability and no other data were provided among the outcomes a priori evaluated.
Numerical results
The numerical results reported in the studies on inflammatory arthropathies are summarised in Table 57.
The shorter follow-up assessments was performed just after writing in Lumley et al.115 when assessing
immediate mood. Otherwise, the follow-up length varied from 1 week in Wetherell et al.117 to 26 weeks
in Broderick et al.113 and Lumley et al.115 The total sample sizes ranged from 34 participants in Wetherell
et al.117 to 218 participants in Broderick et al.113
Differences between groups by time interaction were reported for the following outcomes – BASFI, PANAS,
Disease Activity Score (DAS) and the Profile of Mood States Short Form (POMS-SF) – in Hamilton-West
and Quine,114 Lumley et al.,115 Smyth et al.107 and Wetherell et al.,117 respectively (see Table 57). In
Hamilton-West and Quine114 the functional status (measured using BASFI) was reported as statistically
greater at 3-month follow-up in the EW group than with the control subjects. However, the clinical
improvement was not apparent in the previous measurement at 4 weeks. On the other hand, Lumley et al.115
assessed also the functional status [measured using the Arthritis Impact Measurement Scale-2 (AIMS2) pain
subscale (AIMS2-ps)] at the same time points as Hamilton-West and Quine.114 No significant differences
were reported between intervention and any control group (positive writing, time-management writing or
combined – results not shown in this review) within this study at any of the time points.
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Regarding mood outcomes in Lumley et al.,115 in the writing sample, compared with combined control
subjects, disclosure led to significantly larger increases in the anger, sadness and guilt subscales of PANAS,
but not fear, during the sessions. The authors stated that these differences were probably due to
differences between the disclosure and positive control groups, but not the neutral control group.
However, Wetherell et al.117 reported that measures of total mood disturbance (POMS-SF) did increase in
the disclosure group at 1 month compared with control subjects.
Disease activity measures were reported in all studies. This outcome is meta-analysed in the
corresponding heading.
Meta-analysis
Outcomes related to the disease activity and inflammation were meta-analysed (Figures 41–43).
Disease activity immediately after writing Six studies107,113–117 used different scales to measure similar
aspects of the disease activity and severity. All of the studies, except Hamilton-West and Quine,114 reported
complete numerical data regarding disease activity, but in Lumley et al.116 some of the scores are minus
numbers, which means they cannot be meta-analysed, as they may be change scores.
l Clinical differences between studies All of the patients included in these studies had been diagnosed
with RA and were free of other major illnesses. In Smyth et al.,107 the sample consisted of volunteers
recruited from local communities, whereas in the remaining studies113–117 patients were recruited from
rheumatological clinics.
l Follow-up length Disease activity was measured immediately after the writing and at short term.
The effect of the TW intervention on disease activity/severity was evaluated in Smyth et al.,107
Hamilton-West and Quine,114 Wetherell et al.117 and Lumley et al.115 almost immediately after the writing
exercise at 1, 2, 4 and 4 weeks.
l Forest plot A total of 202 participants were meta-analysed (131 in the EW group and 71 in the
control group). The SMD was –0.02 (95% CI –0.37 to 0.32) with a random-effects model and with
non-significant heterogeneity (I2= 0%). This result suggests that there is no statistically significant
difference in disease activity when measured immediately after the writing exercise for the TW group
compared with the control group (Figure 43).
The same studies evaluated the short-term effect of the TW intervention at 8, 10 and 13 weeks.
l Forest plot A total of 191 participants were meta-analysed (123 in the EW group and 68 in the
control group). The SMD was –0.61 (95% CI –0.96 to –0.26) with a random-effects model and with
non-significant heterogeneity (I2= 1%). The result suggests that there are significant differences in
disease activity in favour of the TW group at short-term follow-up (Figure 44).
Inflammation The effect of inflammation [erythrocyte sedimentation rate (ESR) or C-reactive protein
(CRP)] was evaluated in Lumley et al.115,116 and Wetherell et al.117 at short-term follow-up
(4, 4 and 6 weeks, respectively).
l Clinical differences between studies All patients included in these studies had been diagnosed with RA
and were free of other major illnesses. In Lumley et al.116 the sample consisted of volunteers recruited
from local communities as well as from a rheumatology clinic, whereas in the remaining studies
patients were recruited only from rheumatological clinics.
l Forest plot A total of 362 participants were meta-analysed (198 intervention, 164 control). The SMD
was –0.10 (95% CI –0.34 to 0.53) with a random-effects model and with significant heterogeneity
(I2= 62%). The result suggests that there are no significant differences in disease activity in favour of
the TW group at short-term follow-up. Wetherell et al.117 measured ESR and CRP and both made no
significant difference to the meta-analysis result (Figure 45).
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M79 and RSI: fibromyalgia and chronic pain and facial pain
Overview
There were two studies evaluating unfacilitated EW in fibromyalgia (FM)118,119 and two studies in chronic
pain.51,57 A summary of the main characteristics is presented in Table 58. All studies51,57,118,119 were
conducted in the USA. Stark57 included facial pain patients (ICD-10 code: R51). Broderick et al.118 and Gillis
et al.119 used a standard written emotional expression intervention. Stark57 combined a trauma writing
exercise with a Change Theory-based positive writing technique. Graham et al.51 was unique in the current
systematic review in using a written anger expression exercise through a letter-writing format. This
technique was based on Rusting and Nolen-Hoeksema’s type of EW125 and consisted of completing a
pre-writing short exercise, where intervention group patients had to focus their attention on existing anger
related to their pain experience. In this brief questionnaire, participants were asked to consider if they
currently or recently felt anger towards a health-care provider, themselves, or someone or something else
and, if so, to remember and/or focus on it. Participants were given a writing tablet and instructions to write
a letter to the person at whom, or thing at which, they were most angry. They were instructed to focus on
their anger rather than other emotions. Gillis et al.119 and Stark57 delivered the intervention in three and four
20-minute consecutive sessions, respectively, whereas in Broderick et al.118 and Graham et al.51 the
interventions were delivered at 1-week (three sessions) and 2.5-week (two sessions) intervals. All patients
were financially compensated except for those in Gillis et al.119
The outcomes assessed within the different studies are reported in Table 59. Pain severity, depression and
resource use were the outcomes that were most frequently evaluated.
TABLE 58 Characteristics of the unfacilitated EW studies in FM/chronic pain
First author, year
Study
design Intervention group Control group 1 Control group 2
Broderick 2005118 RCT Unfacilitated EW Time-management writing SMCa
Gillis 2006119 RCT Unfacilitated EW Time-management writing –
Graham 200851 RCT Questionnaire plus unfacilitated EW Factual goal writing –
Stark 201057 RCT Unfacilitated EW (mixed writing) Non-writing –
a The SMC group results were combined and reported with those of the time-management writing group.
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Quality assessment
A summary of the quality of the studies is shown in Figures 44 and 45. All studies51,57,118,119 were truly
randomised and three studies51,118,119 out of four reported concealment of the allocation of the sequence
generation. In one study,51 the outcome assessment was masked. In one other study,119 the blinding was
preserved at the performance level. The remaining studies51,57,118 were likely to introduce both performance
and detection bias, and one study51 was unclear regarding the reporting of pain severity, with data derived
from a graph.
Numerical results
The numerical results reported in the FM/chronic pain studies are summarised in Table 60. Follow-up
assessments ranged between 4 weeks in Gillis et al.119 and Graham et al.51 up to 17 weeks in Broderick
et al.118 Total sample sizes ranged from 42 patients in Stark57 to 102 patients in Graham et al.51 Studies
reported a statistical significant association of group-by-time interaction for the following outcomes:
depression, control over pain in Graham et al.,51 global impact, physical disability, poor sleep, health-care
use in Gillis et al.,119 and pain severity, fatigue and well-being in Broderick et al.118
Meta-analysis
It was decided not to combine data related to depression, as numerical outcomes could not be pooled
together: studies were reporting change scores, median and SE and means and SD using different
instruments each and at different follow-up times. The outcomes related to pain severity were
meta-analysed (Figures 46 and 47).
Pain severity Four studies51,57,118,119 used different scales [McGill Pain Questionnaire, impact (MPQ-i),
AIMS2-ps and Multidimensional Pain Inventory (MPI)] to measure pain intensity. All of the studies except
Broderick et al.118 (reporting change scores only)51,57,119 reported data that could be pooled.
l Clinical differences between studies In Gillis et al.,119 patients had been diagnosed with FM for a mean
of 5.9 years (range 1–20 years) before entering the study. In the other two studies, patients were
diagnosed with chronic pain. For instance, in Graham et al.,51 patients had chronic pain from diverse
sources such as arthritis (22.4%), injury (57.2%), complex regional pain syndrome (9.7%), and other
(27.5%), such as myofascial pain, pancreatitis and migraine; locations included back (65.5%),
shoulder/arms (41.8%), neck (14.5), hips/pelvis (11.5%), hands/feet (12.7%), head (9.2%) and all
over (6.9%). In Stark,57 patient’s condition was mainly related to muscle pain.
l Follow-up length All three studies51,57,119 assessed pain intensity at short term, that is between 4 and
5 weeks up to 13 weeks. Although these measurements were in the same short-term follow-up
category defined in Table 2, it was decided that two meta-analyses should be performed, one for
outcomes at 4 or 5 weeks and one for outcomes between 9 and 13 weeks.
Short term, at 4/5 weeks:
l Forest plot A total of 216 participants were meta-analysed (110 in the EW group and 106 in the
control group). The SMD was –0.04 (95% CI –0.23 to 0.30) with a random-effects model and with no
significant heterogeneity (I2= 0%). This result suggests that there is no statistically significant difference
in pain severity when measured at 4/5 weeks after the writing exercise for the TW group compared
with the control group (Figure 48).
Short term, at 9, 10 and 13 weeks:
l Forest plot A total of 216 participants were meta-analysed (110 in the EW group and 106 in the
control group). The SMD was 0.18 (95% CI –0.09 to 0.44) with a random-effects model and with no
significant heterogeneity (I2= 0%). This result suggests that there is no statistically significant difference
in pain severity when measured at 9/10 weeks to 13 weeks after the writing exercise for the EW group
compared with the control group (Figure 49).
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Positive therapeutic writing
Overview
Previously, Chapter 3 summarised the effect of the standard forms of unfacilitated EW and used those in
meta-analyses where possible. In addition to these forms of writing, which were usually disease/treatment,
or trauma-focused, seven of the included studies53,57,72,82,106,110,115 used a form of positive writing.
As mentioned in Chapter 1, positive writing is a form of expressive/emotional writing and is a more usual
form of writing used among facilitated types of TW, although it can be used as part of an unfacilitated EW
as evaluated here.
These seven studies53,57,72,82,106,110,115 have been already described in corresponding ICD-10 sections; however,
Table 61 outlines the interventions evaluated. Four82,106,110,115 of the seven studies used positive writing as a
second intervention group in addition to the unfacilitated EW. Two studies53,72 used positive writing only
and the doctoral thesis by Stark57 used a combined form of expressive writing mixing both a form of
emotional disclosure and positive writing. In this study, participants in the positive writing group had to
write about a self-selected worst experience from a positive perspective. This intervention is unusual and
was compared against a non-writing control group.
As shown in Table 62, the outcomes evaluated in all seven studies were very varied, although two
studies110,117 evaluated mental health using the GHQ-12 and were among patients with psoriasis110 and
testicular cancer.77 In the remaining studies, three studies53,57,115 evaluated affect and mood states;
two studies82,110 assessed QoL; two studies110,115 assessed disease severity; and three studies53,106,115
evaluated biomarkers.
Numerical results
The numerical results on positive writing and controls are reported in Table 63. All studies on positive
writing were of small sample sizes, with follow-ups conducted up to 26 weeks. All studies evaluated
different LTC populations.
Harris et al.106 did not show significant differences between positive writing and control groups on lung
function (similar results to the EW group compared with control subjects).
In Henry et al.,53 there was a significant improvement in POMS scores for the writing group compared with
the matched control subjects at 13 weeks but not at 39 weeks. No other outcomes measured showed
significant differences.
TABLE 61 Characteristics of the studies of unfacilitated positive writing
First author, year LTC Intervention group 1 Intervention group 2 Control group
Harris 2005106 Asthma Unfacilitated EW Positive writing Factual writing
Henry 201053 Breast cancer Positive writing – Usual care
Lumley 2011115 RA Unfacilitated EW Positive writing Time-management
writing
Pauley 201182 Testicular cancer Unfacilitated EW Positive writing Factual writing
Paradisi 2010110 Psoriasis Unfacilitated EW Positive writing Non-EW
Mann 200172 HIV Positive writing – Non-writing
Stark 201057 FM and facial pain Unfacilitated EW (mixed
writing including positive
writing)
– Non-writing
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In Pauley et al.,82 as in the EW group, significant differences were found in mental health in favour of the
positive writing group compared with control subjects.
In Paradisi et al.,110 intragroup analyses show increases in SAPASI scores between the end of intervention
and the final assessment in the positive writing group and control subjects, whereas no differences were
found in the EW group participants. In addition, significant differences in Skindex-29 values between
positive writing and the control group were reported (similarly to the EW group compared with control
subjects) at final follow-up. Participants allocated to the EW group had a longer period of remission after
phototherapy; this was not seen in the positive writing group participants.
Mann72 measured optimism and pessimism but differences between groups in the time-by-group
interaction analysis were not reported.
Given the heterogeneity in conditions, outcomes measured and results, no meta-analysis could be
performed for this subgroup of participants for whom positive writing was evaluated.
Outcomes measured across long-term conditions
As described in previous chapters, authors of included studies have used a wide range of instruments and
outcome measures to illustrate how TW interventions may have affected the different LTCs assessed. The
purpose of this section is to describe whether among the included studies with any LTC, TW improved
people’s depression, anxiety and disease-based outcomes (Table 64).
Therapeutic writing effect on disease-based outcomes
From all of the included studies on LTCs, only 25 measured disease-specific outcomes (see Table 64).
Of these – the TW intervention – only two had a significant effect on outcomes: the DBP of patients
following first MI in Willmott et al.104 and PASI in Paradisi et al.110 The effects were in favour of
participants receiving unfacilitated EW compared with control subjects. None of the other outcomes
showed statistical differences between groups, apart from when subsets of questionnaire measures were
reported separately, such as in Broderick et al.118
Therapeutic writing effect on depression
Overview of studies
Overall, 26 studies50,51,53,55–57,76–78,81,87–96,99,100,103,106,107,112,114,115,118 out of 64 included studies9,51–58,66–119
evaluated depression. These 26 studies evaluated participants with different chronic conditions:
three studies50,55,56 evaluated HIV patients; four studies53,76–78 evaluated patients with breast cancer; one
study81 evaluated renal cell carcinoma patients; one study87 evaluated sickle cell disease; one study88
evaluated type 2 diabetes mellitus; one study92 evaluated patients with SUD; three studies94–96 evaluated
patients with psychiatric disorders; three studies93,98,107 evaluated PTSD patients; one study99 evaluated BN;
one study100 evaluated amyotrophic lateral sclerosis; one study103 in patients with a first myocardial arrest;
one study112 evaluated patients with psoriasis; two studies114,115 evaluated patients with inflammatory
arthropathy; and three other studies51,57,118 evaluated patients with FM and chronic pain. Fourteen different
conditions were included in the overall analysis of depression. Almost all of the studies evaluated an EW
intervention whereby instructions to write about the most upsetting event related to their life or disease
were given. But, in one study,57 participants were instructed to change the topic throughout the writing
intervention to write in the same emotional way about the positive life/disease-related events. Instruments
used varied across studies and included following: HAM-D, CES-D, HADS-D, BDI (including both the
revised and short form versions), CDI, Depression Anxiety Stress Scales, depression subscale (DASS-D),
POMS-d and Geriatric Depression Scale (GDS).
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TABLE 64 Physiological, disease-related and biomarker outcomes collected across LTCs
Disease area (total
number of studies)
Number of studies
reporting
physiological and
biomarker outcomes
(listed)
Total number of
patients (maximum
number)
Whether EW showed
statistically significant
improvement, no
difference or
worsening Comments
HIV (6) 3a (VL, CD4+ count) Abel50 (208) Abel50 – NS
Ironson71 (207) Ironson71 – NS
Petrie56 (37) Petrie56 – NS at 2 and
13 weeks, improvement
at 26 weeks
Breast cancer (8) 0 NA NA
Gynaecological
and genitourinary
cancers (6)
1 (PSA levels, peripheral
blood T-cell proliferation,
serum cytokine levels of
TNF-α, IL-4 and IL-10)
Rosenberg83 (30) Rosenberg83 – NS
Cancer from various
sources (2)
0 NA NA
Sickle cell disease (1) 0 NA NA
Type 2 diabetes
mellitus (1)
0 NA NA
Cystic fibrosis (1) 1 (FEV1, BMI) Taylor
89 (34) Taylor89 – NS
Dementia (1) 0 NA NA
SUD (2) 1 (BP, heart rate) Grasing90 (42) Grasing90 – NS
Psychiatric
disorders (6)
0 NA NA
PTSD (4) 0 NA NA
BN (1) 1 (BMI) Robinson99 (61) Robinson99 – NR BMI was used
as baseline
moderator
ALS (1) 0 NA NA
Migraine and tension
headache (1)
1 (headache frequency
and headache severity)
D’Souza120 –
migraine headache
sample (62)
D’Souza120 – migraine
headache – NS
D’Souza120 – tension
headache sample
(34)
D’Souza120 – tension
headache – NS
CVD (3) 1 (BP, cardiac symptoms) Willmott104 (128) Willmott104 – cardiac
symptoms – NS
Willmott104 – DBP – SS
Willmott104 – SBP – NS
COPD (1) 1 (6MWD, FEV1, FVC) Sharifabad
105 (66) Sharifabad105 – 6MWD –
NR
Sharifabad105 – FEV1 – NS
Sharifabad105 – FVC – NS
continued
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TABLE 64 Physiological, disease-related and biomarker outcomes collected across LTCs (continued )
Disease area (total
number of studies)
Number of studies
reporting
physiological and
biomarker outcomes
(listed)
Total number of
patients (maximum
number)
Whether EW showed
statistically significant
improvement, no
difference or
worsening Comments
Asthma (4) 4 (FEV1% predicted,
FVC)
Harris106 (77)b Harris106 – NS
Smyth107 (58) Smyth107 – NS
Theadom58 (114) Theadom58 – NR
Warner108 (32) Warner108 – NS
IBS (2) 0 NA NA
Psoriasis (3) 3 (psoriasis severity) Paradisi110 (50) Paradisi110 – SS/NR Paradisi100 – SS
first follow-up
onlyTabolii
111 (67) Tabolli111 – NS
Vedhara112 (59) Vedhara112 – NS
Rheumatoid
arthropathies (6)
4 (swollen joint count,
walking speed, grip
strength, ESR)
Lumley115 (64)a Lumley115 – NS
Lumley116 (264) Lumley116 – NS
Smyth107 (49) Smyth107 – NS
Wetherell117 (34) Wetherell117 – NS
FM and chronic
pain (4)
4 (chronic pain) Broderick118 (83) Broderick118 – NS/SS Broderick118 – SS
for some
subsets of
questionnaire
only
Gillis119 (72) Gillis119 – NS
Graham51 (102) Graham51 – NR
Stark57 (42) Stark57 – NR
6MWD, 6 Minutes’ Walk Distance; BMI, body mass index; BP, blood pressure; IL-4, interleukin 4; IL-10, interleukin 10;
NA, not applicable; NS, not statistically significant; NR, not reported; PSA, prostate-specific antigen; SBP, systolic blood
pressure; SS, statistically significant; TNF-α, tumour necrosis factor alpha.
a Total sample size counting the intervention group 1 and the control group.
Shaded cell shows statistically significant results.
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Numerical results
The numerical results reported in the included studies evaluating depression are summarised in Table 65.
Meta-analysis
Depression was assessed at immediate-, short-, medium- and long-term follow-up across studies
(Figures 48–51).
l Immediate follow-up A total of 440 participants were meta-analysed (229 in the EW group and 211 in
the control group). The SMD was –0.01 (95% CI –0.20 to 0.18) with no significant heterogeneity
(I2= 0%). This result suggests that there is no statistically significant difference in depressive symptoms
up to 4 weeks after writing exercise in the TW group compared with the control group.
l Short-term follow-up A total of 1563 participants were meta-analysed (791 in the EW group and 772
in the control group). The SMD was –0.06 (95% CI –0.29 to 0.17) with substantial, significant
heterogeneity (I2= 74%). This result suggests that there is no statistically significant difference in
depressive symptoms between 4 and 17 weeks after the writing exercise in the TW group compared
with the control group.
l Medium-term follow-up A total of 393 participants were meta-analysed (197 in the EW group
and 196 in the control group). The SMD was –0.06 (95% CI –0.31 to 0.18) with a significant
heterogeneity (I2= 28%). This result suggests that there is no statistically significant difference in
depressive symptoms between 17 and 34 weeks after the writing exercise in the TW group compared
with the control group.
l Long-term follow-up A total of 778 participants were meta-analysed (375 in the EW group and 403 in
the control group). The SMD was –0.04 (95% CI –0.18 to 0.10) with no significant heterogeneity
(I2= 0%). This result suggests that there is no statistically significant difference in depressive symptoms
34 weeks after the writing exercise in the TW group compared with the control group.
The overall analysis of the effect of TW on depression showed no significant differences between the TW
group and the control subjects at any of the time points.
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Therapeutic writing effect on anxiety
Overview of studies
Overall, 977,78,87,93–95,97,112,118 studies out of 59 evaluated anxiety across the included LTCs. These 9 studies
evaluated participants with different chronic conditions: two studies77,78 evaluated patients with breast
cancer; one study87 evaluated patients diagnosed with sickle cell disease; four93–95,97 evaluated participants
with mental and psychiatric disorders; one study112 evaluated patients with psoriasis; and the remaining
study118 assessed patients with fibromyalgia. Five different conditions were accounted in the overall analysis
of anxiety. All studies evaluated an unfacilitated EW intervention. In one study,97 participants were
instructed to write about the deepest thoughts and feelings, regarding an experience that had not been
previously shared with others at all or in very little detail. Instruments used varied across studies and
included the following: HADS-A, Revised Children’s Manifest Anxiety Scale (RCMAS), BAI, Depression
Anxiety Stress Scales, anxiety subscale (DASS-A) and CSAQ.
Numerical results
The numerical results reported in the included studies evaluating anxiety are summarised in Table 66.
Meta-analysis
Anxiety was assessed with different instruments at immediate, short and medium term only (Figures 52
and 53). Only one study94 assessed anxiety in the medium term, so no meta-analysis was required.
l Immediate follow-up Four studies78,87,95,112 assessed anxiety at immediate follow-up, just after the
writing exercise.
¢ A total of 197 participants were meta-analysed (101 in the EW group and 96 in the control group).
The SMD was –0.16 (95% CI –0.44 to 0.12) and with no significant heterogeneity, I2= 0%. This
result suggests that there is no statistically significant difference in anxiety at immediate follow-up in
the EW group compared with the control group.
l Short-term follow-up Six studies77,78,93,94,97,112 assessed anxiety at short-term follow-up. Broderick et al.,113
however, was not included in the meta-analysis, as only change scores were reported. Canna94 reported
anxiety at 8 and 16 weeks. Likewise, Vedhara et al.112 reported anxiety at 8 and 12 weeks. For
consistency among the studies included in the meta-analysis, the 8-week assessments were chosen.
¢ A total of 330 participants were meta-analysed (174 in the EW group and 156 in the control group).
The SMD was –0.15 (95% CI –0.37 to 0.07) with no significant heterogeneity (I2= 0%). This result
suggests that there is no statistically significant difference in anxiety at short-term follow-up for the
EW group compared with the control group.
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Chapter 4 Economic considerations
Introduction
In a health-care system such as the NHS it is important to consider not just the benefits and potential
harms of interventions for the recipients, but also the impact that interventions may have on the use of
limited health-care resources. In the previous chapter the available evidence on the effects of TW on health
outcomes for people with a variety of LTCs is summarised. Here the evidence on the economic impacts of
TW in these populations from a NHS perspective is reviewed. NHS provision of TW interventions would
incur direct costs; the cost for staff training and time to deliver the intervention, or of payments to external
experts; administrative costs; and costs for the use of a room and, possibly, some materials. There may also
be some indirect costs or savings for the NHS if TW encouraged patients to increase or decrease their use
of other health services. For example, patients might feel better able to manage their condition and
consult their GP or hospital specialist less often or, conversely, TW might lead patients to recognise a need
to make more use of available health services. The net effect on NHS expenditure might therefore be
positive or negative.
In addition to financial costs and savings, a full economic evaluation would account for the intrinsic value
of any impacts on patients’ health and well-being. For example, health gains or losses attributable to the
intervention could be quantified in terms of quality-adjusted life-years (QALYs), where one QALY is defined
as 1 year lived in perfect health for one person. The cost-effectiveness of the intervention could then be
summarised as the additional cost per QALY gained, in relation to some appropriate comparator. For such
a calculation, the magnitude and persistence of any effects of TW on HRQoL would need to be estimated.
This calculation of QALYs from the studies in this review is problematic because although some of the
studies reviewed in the preceding chapter reported on general HRQoL (23 out of 64 studies), only one
study88 used a measure suitable for QALY estimation, such as the EQ-5D, and none used the Short Form
questionnaire-6 Dimensions (SF-6D).
From the early stages of the project, the need for flexibility in the approach to the consideration of the
economic evidence was apparent. Given the limitations of the evidence base, it was concluded that it was
not possible to directly estimate QALY impacts of TW across the range of populations with LTCs.
Consideration was given to the possibility of using a decision-analytic model to estimate the effects of the
intervention on intermediate indicators of disease progression, and then to link to the effects of disease
progression on health-care costs and outcomes. However, the lack of convincing or consistent evidence of
such effects led us to conclude that such modelling exercises would not be appropriate or feasible. Instead,
a more pragmatic approach was taken, making the most of the evidence available.
The economics section is in three parts:
1. a systematic review of TW studies reporting on economic outcomes (resource use, costs and/or
cost-effectiveness)
2. an estimation of the cost of providing a range of TW interventions in a NHS context
3. case studies presenting balance sheets of available economic and clinical evidence for three conditions:
PTSD, RA and breast cancer.
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Systematic review of therapeutic writing studies with
resource-use outcomes
Methods
A review across LTCs of the available literature on comparative studies of TW for patients with LTCs
reporting economic outcomes was conducted. This resource-use systematic review was nested within the
overall systematic review described in the previous chapter and the realist synthesis presented in the
following chapter. The full search strategy is given in Appendix 3.
The inclusion criteria used for the economic systematic review are shown in Table 67.
Titles and abstracts were checked by two reviewers to find relevant studies, data extraction was
undertaken by one reviewer and checked by a second. If there were disagreements, a third senior
systematic reviewer or health economist was consulted to make a decision. All of the studies in the
economic review were also included in the effectiveness review, and critically appraised as part of that
review (see Appendices 4 and 5). Quality assessment using a critical appraisal checklist for economic
evaluations was planned if any economic evaluations were identified.
Where three or more studies presented outcomes in the same category (e.g. health centre visits,
medications used), meta-analysis was conducted using the same methods as for the effectiveness
systematic review.
TABLE 67 Inclusion criteria for resource-use systematic review
Inclusion criteria Details
Patients Any patients with at least one LTC
Intervention Any form of TW
Comparator Any inactive comparator
Outcomes Resource use, costs or cost-effectiveness
Study design Any fully published comparative study (PhD dissertations were not used)
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Results of economic review (resource use)
No full economic evaluations (cost-effectiveness, cost–benefit or cost–utility studies) were identified. One
study89 estimated that the cost of a writing intervention was US$130 per patient, based on a psychologist’s
fee and some administration time. This study89 found a reduction in inpatient use for the EW intervention
compared with SMC and estimated that this represented a cost saving of US$25,878 per patient per year.
Another study113 estimated that the cost of delivering videotaped instructions for an EW intervention
was approximately US$5 per patient. The basis for this estimate was unclear but it seems to be reasonable.
Twelve studies57,68,75,77,83,89,90,97,98,104,109,119 that reported on some element of health-care resource use were
identified. One study reported on the cost of the TW intervention89 and none on monetary estimates of
costs or savings relating to differences in health-care use between the study groups. Consequently, no
additional economic quality assessment was conducted.
Study details
Details of the studies57,68,75,77,83,89,90,97,98,104,109,119 are outlined in Table 68. The publication dates ranged
from 1996 to 2012: six studies57,75,77,90,104,109 were published after 2009. The majority of the
studies57,77,83,89,90,97,109,119 were from the USA. Two studies75,104 were conducted in the UK. All patients were
recruited via flyers distributed at disease-specific clinics or approached by health-care professionals during
their treatment cycle. The disease areas varied, but can be broadly grouped into three categories: cancer
(n= 3),75,77,83 chronic pain or FM (n= 3),57,109,119 or PTSD, mental health disorders or drug dependency
(n= 4).68,90,97,98 The remaining studies related to MI104 and cystic fibrosis.89 One study68 was a case–control
study and tested a facilitated form of TW – an internet discussion. The other studies57,75,77,83,89,90,97,98,104,109,119
were RCTs and tested unfacilitated EW.1 The control interventions varied: seven studies68,75,83,89,97,98,109
included a normal care or non-writing control arm. Six studies57,77,89,90,104,119 used a non-emotional form
of writing.
Numerical results of resource-use studies
Numerical results are shown in Table 69. The quality and detail of studies reporting on health-care
resource use varied widely across studies. The types of use recorded were broadly similar: almost all
reported on contacts with health-care services, consultations with clinicians or inpatient stays (n= 11).
Four papers57,68,83,104 also reported on use of medication. Willmott et al.104 also reported the number of
weeks’ absence from work as an outcome, which is an important indicator for the personal and broader
economic impact of an intervention.
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TABLE 68 Details of studies reporting resource use
First author,
year Country
Patient
LTC n total Intervention Comparator Resource-use outcomes
Gellaitry
201075
UK Breast
cancer
80 Unfacilitated
EW
Normal care Use of health-care facilities
(6 months following
completion of treatment)
Gidron
199698
Israel PTSD 14 Unfacilitated
EW
Normal care Number of health-care visits
at 5 weeks
Gillis 2006119 USA FM 155 Unfacilitated
EW
Time-
management
writing
Number of visits to health-
care specialist at 1 and
3 months
Golkaramnay
200768
Germany Mental
disorders
228 Internet chat
(facilitated)
Normal care Proportion accessing
psychotherapeutic care
during 12-month follow-up
Proportion receiving
medication
Grasing
201090
USA Drug
dependency
42 Unfacilitated
EW
Time-
management
writing
Outpatient follow-up visits
12 weeks after discharge
Mosher
201277
USA Breast
cancer
87 Unfacilitated
EW
Factual writing Proportion using mental
health services at 8 weeks’
follow-up
Richards
200097
USA Mental
disorders
98 Unfacilitated
EW
Trivial writing
Normal care
Infirmary visits at 6 weeks
Rosenberg
200283
USA Prostate
cancer
30 Unfacilitated
EW
Non-writing Number of health-care
contacts at 3 months
Medication use
Stark 201057 USA FM 43 Unfacilitated
EW
Time-
management
writing
Medication use at 5 and
10 weeks
Taylor 200389 USA Cystic
fibrosis
39 Unfacilitated
EW
Normal care Number of days in hospital
Outpatient clinic visits over
3 months’ follow-up
Wallander
2011109
USA RAP 63 Unfacilitated
EW
Normal care Number of health-care
contacts during 6 months’
follow-up
Willmott
2011104
UK MI 156 Unfacilitated
EW
Inexpressive
writing
GP and hospital visits during
5 months’ follow-up
Medication use
Attendance at cardiac
rehabilitation sessions
Return to work
ECONOMIC CONSIDERATIONS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
156
TABLE 69 Resource use results
First author,
year Resource use reported
Intervention:
mean (SD) or
percentages
Control:
mean (SD) or
percentages Comments
Gellaitry
201075
Number of medical visits
in the 6 months following
baseline
NR NR Authors report a significant time effect,
i.e. health-care use decreasing in the
6 months following completion of
treatment [F(3,213)= 5.43; p< 0.01].
Authors report no difference between
groups in terms of resource usage.
No numerical data are provided
Gidron
199698
Number of health-care
visits
3.1 (2)
(n= 8)
0.7 (1.6)
(n= 6)
Authors report a significant increase in
health-care visits among patients in the
intervention group (from 1.6 to 3.1)
compared with a significant decrease
among patients in the control group
(from 1.3 to 0.7)
Gillis 2006119 Number of health-care
visits in the 3 months
after baseline
1.13 (1.07)
(n= 38)
1.80 (2.21)
(n= 34)
Authors report a significant decrease in
health service use for the intervention
group at 3 months (p= 0.05) but not at
1 month (p= 0.16)
Golkaramnay
200768
Proportion accessing
psychotherapeutic care
53.6% (52/97) 62.8%
(59/94)
Original sample was 114 in each group.
NS
Proportion receiving
medication
55.9% (57/97) 60.4%
(57/94)
NS
Grasing
201090
Number of outpatient
mental health clinic visits
7 (15.3)
(n= 23)
2.36 (2.8)
(n= 19)
Although resource use was higher
among patients in the intervention
group in all three categories, none of
these differences were statistically
significant. SEs were given in paper,
converted here to SDs
Number of clinical
support visits
9.68 (12.2) 10.27 (23.9)
Number of study
follow-up visits
2.05 (1.9) 1.57 (1.7)
Mosher
201277
Proportion of patients
accessing mental health
services
NR NR Intervention and control group numbers
given combined only – 27/86
Richards
200097
Infirmary visits NR NR Mean (SD) infirmary visit results given
split by sex offender status only.
No complete group results available
Rosenberg
200283
Number of health-care
contacts 6 months after
baseline
4.4 (3.12)
(n= 16)
7.6 (8.33)
(n= 14)
Authors report a trend towards lower
health-care utilisation and reduced use
of medications based on these findings;
however, the paper does not report on
statistical significanceNumber of medicines
being used 6 months
after baseline
4.94 (2.66) 6.05 (4.7)
Stark 201057 Number of pain
medications taken per
month
144.5 (110.44)
(n= 21)
169.9
(128.99)
(n= 21)
Number of psychotropic
medications taken per
month
44.9 (47.48) 60.20 (60.36)
Taylor 201389 Number of days in
hospital
5.6 (NR)
(n= 18)
8.4 (NR)
(n= 21)
Significant group-by-time interaction for
inpatient hospital days; no significant
interaction found for outpatient clinic
visits
continued
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Contact with health-care services
Of the 11 studies57,68,75,77,83,89,90,98,104,109,119 reporting on some form of contact with health-care professionals
in a health-care setting, seven studies83,89,90,98,104,109,119 provided means and/or SDs that could be combined
in a forest plot (Figure 54). Golkaramnay et al.68 and Mosher et al.77 reported proportions of patients
accessing services. The meta-analysis results showed no significant differences (SMD –0.19, 95% CI –0.57
to 0.18). Willmott et al.104 reported on two outcomes relating to health-care contact: median number of
GP and hospital visits, which was higher in the control arm, and the mean number of cardiac rehabilitation
sessions attended, which was higher in the intervention group. Overall, the results suggest that TW has
little impact on health centre visits.
Use of medication
Three studies57,83,104 reported means and SDs for the impact of TW on use of medication, and
Golkaramnay et al.68 reported the proportion of participants receiving medication. Stark57 reported on the
number of units of pain and psychotropic medication per patient per month, finding lower levels of use in
the intervention group 10 weeks after baseline. Willmott et al.104 and Rosenberg et al.83 took a different
approach, looking at the number of medications participants report using at similar time spans post baseline
(5 and 6 months, respectively). In both cases, participants in the intervention group were identified as
using fewer medications, although in Willmott et al.104 this difference was not significant, and Rosenberg
et al.83 did not report on significance. Willmott et al.104 also noted a potential time effect – medication use
decreased in the intervention group but increased in the control group. The meta-analysis results (Figure 55)
suggested that fewer medications were taken after TW (SMD –0.28, 95% CI –0.54 to –0.02).
TABLE 69 Resource use results (continued )
First author,
year Resource use reported
Intervention:
mean (SD) or
percentages
Control:
mean (SD) or
percentages Comments
Wallander
2011109
Number of health-care
contacts
1.0 (2.36)
(n= 32)
2.36 (2.21)
(n= 24)
Authors report that 43% of
intervention group had no contact with
clinical services compared with 11% of
the control group
Willmott
2011104
Number of GP and
hospital visits
8.6 (3.7)
(n= 79)
10.3 (5.0)
(n= 77)
Patients in the intervention group
reported to make significantly fewer
visits to GPs or hospital clinics than
those in the control group. Although
the number of prescribed medicines
was lower in the intervention group,
the difference was not significant;
however, authors identified a significant
interaction between group and time,
suggesting that the number of
medications decreased over time for
the intervention group and increased
over time for the control group. For the
other two outcomes reported, the
control group was associated with
lower levels of resource usage. It was
not reported if the difference in the
number of attendances at cardiac
rehabilitation sessions was significant.
The difference in the number of weeks’
absence from work was not significant
Median number of GP
and hospital visits in the
5 months following
completion of treatment
(range)
8 (2–22) 10 (3–25)
Mean number of
prescribed medications
5 months following
completion of treatment
(SD)
4.8 (1.7) 5.3 (1.7)
Mean number of cardiac
rehabilitation sessions
attended (SD); p= 0.01
7.99 (5.26) 5.68 (5.85)
Mean number of weeks
absent from work (SD)
12.2 (7.4) 10.3 (6.9)
NR, not reported; NS, not statistically significant.
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Many of the costs associated with the use of medication are indirect, and not examined in these studies,
for example consultations with prescribers, and treatment for side effects. Although these add to the
uncertainty around impact of decreased medication use, it also raises the possibility that there are potentially
unacknowledged benefits associated with TW, which have not been explicitly accounted for here.
As with health-care contacts, this evidence base is not strong enough to draw conclusions about the likely
impact of TW interventions on patient use of medication.
Costs of therapeutic writing interventions
None of the identified studies presented estimates of the cost of TW or EW in the UK. Therefore, estimates
for a range of interventions in a NHS context were made, after discussion with practitioner experts.
The primary driver of costs is likely to be the staff costs associated with employing (or contracting) TW
practitioners. TW practitioners come from a wide range of professional backgrounds, and many are
self-employed, rather than NHS employees. However, for illustrative purposes, the costs for NHS
occupational therapists published by the Personal Social Services Research Unit (PSSRU)126 were adapted
(Table 70).
Costs were estimated for NHS staff at Agenda for Change pay bands 5, 6, 7 and 8a to reflect a range
of levels of qualifications and experience. The estimated total cost per hour ranged from £36 to £63
(at 2012–13 prices). For comparison, the PSSRU report126 estimated a cost of £36 per hour for a
hospital-based occupational therapist; £48 per hour for a counsellor in primary care; and £59 for
a clinical psychologist.
All of the above costs were inclusive of staff training, as well as salary on-costs (employer’s national
insurance plus 14% of salary for employer’s contribution to superannuation); management and
administration overheads, and capital overheads (annuitised over 60 years at a discount rate of 3.5%).
The capital cost included an allocation for patient care and non-patient care facilities within a NHS
hospital, and can therefore be assumed to include the cost of a room for delivery of the individual or
group TW sessions. There may be some other costs for materials, such as printed instructions, videos,
pens and paper, but these are difficult to estimate.
TABLE 70 Unit cost of practitioner time (adapted from PSSRU 2013126)
Cost item (£)
Salary gradea
5 6 7 8a
Salary 23,441 30,712 38,146 45,593
On-costs 5483 7184 8923 10,664
Qualifications 5531 5531 5531 5531
Overheads: staff 5585 7318 9089 10,863
Overheads: non-staff 12,139 15,905 19,755 23,611
Overheads: capitalb 4776 4776 4776 4776
Total cost 56,956 71,425 86,219 101,039
Cost per hourc 36 45 54 63
a Agenda for Change band for professions allied to medicine.
b Estimate for hospital occupational therapist (PSSRU 2013126).
c Assumes 42.7 weeks per year and 37.5 hours per week (PSSRU 2013126).
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The time required for a TW practitioner to prepare for a session was not quantified. The PSSRU report126
estimated the percentage of working time spent on face-to-face client contact: 77% for primary care
counsellors and 45% for clinical psychologists (no estimates were available for occupational therapists).
This implies that, for every hour of client contact, approximately 15–30 minutes will be spent on other
activities. For cost estimates, it was assumed that it takes 10 minutes for a TW practitioner to prepare for a
session with clients; this is not assumed to vary according to the length of the session or the number of
participants in the session.
The majority of studies included in the systematic review used self-administered unfacilitated form of
writing. This typically involves a brief initial consultation with the patient, either in person or over the
telephone. Following this initial discussion, the patient is left to continue with the intervention on their
own, writing unsupervised, often in their own home, for the prescribed time and on the prescribed topic.
There is minimal subsequent interaction with practitioners – in some cases, the TW is not returned to, or
read by, practitioners. Although this set of methods is used in the majority of studies – possibly due to its
relative ease of implementation – this form of writing is not representative of current clinical practice in the
UK. Practitioner experts advised that facilitated writing is much more common in a NHS setting: writing
sessions run by trained experts. These sessions may be individual or group, and patients may attend
multiple sessions.
The estimated costs for a range of TW interventions, with varying group sizes, numbers of sessions and
contact times per session, are outlined in Table 71.
The upper and lower limits of these ranges are based on interventions described in the included studies in
Chapter 3. Session length for facilitated TW ranged from 45 minutes in Lange et al.69 to 120 minutes in
Rickett et al.66 and Sloan et al.70 The length of the intervention varied from four sessions in Sloan et al.70 to
16 sessions in Hong and Choi.67 The number of participants in the interventions ranged from two to eight,
based on advice from a TW practitioner that sessions range from one to seven participants, with four
being the optimal number. It was assumed that the introductory session for unfacilitated writing would last
for 10–30 minutes. Even the more resource-intensive, facilitated versions of TW seem to be low cost in
relation to other health-care interventions. However, the range of estimated costs is wide: from £17 to
about £2200 per patient. The estimated cost per patient for unfacilitated EW here is less than the
US$130 estimated in Taylor et al.89 In that study89 the cost was largely based on the psychologist’s fee of
US$130 per hour, which is more than the £59 per hour for a UK clinical psychologist quoted above.
Without adequate evidence on the effects of TW on patients’ health and well-being, or its effect on other
health-care expenditure, it is difficult to draw conclusions about whether or not TW is a cost-effective use
of NHS resources.
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TABLE 71 Illustrative costs for a range of TW interventions
Type of TW
Number of
sessions
Preparation
time per session
(minutes)
Contact time
per session
(minutes)
Mean cost per participant (£),
by grade of practitionera
5 6 7 8a
£36 £45 £54 £63
Unfacilitated 1 10 10 12 15 18 21
1 10 30 24 30 36 42
Facilitated: eight patients
per session
4 10 45 17 21 25 29
4 10 60 21 26 32 37
4 10 120 39 49 59 68
10 10 45 41 52 62 72
10 10 60 53 66 79 92
10 10 120 98 122 146 171
16 10 45 66 83 99 116
16 10 60 84 105 126 147
16 10 120 156 195 234 273
Facilitated: four patients
per session
4 10 45 33 41 50 58
4 10 60 42 53 63 74
4 10 120 78 98 117 137
10 10 45 83 103 124 144
10 10 60 105 131 158 184
10 10 120 195 244 293 341
16 10 45 132 165 198 231
16 10 60 168 210 252 294
16 10 120 312 390 468 546
Facilitated: one to one 4 10 45 132 165 198 231
4 10 60 168 210 252 294
4 10 120 312 390 468 546
10 10 45 330 413 495 578
10 10 60 420 525 630 735
10 10 120 780 975 1170 1365
16 10 45 528 660 792 924
16 10 60 672 840 1008 1176
16 10 120 1248 1560 1872 2184
a Agenda for Change band for professions allied to medicine.
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Exploratory cost–consequence analyses
Methods
Studies included in the effectiveness review spanned a wide range of disease areas and populations,
making it difficult to identify where TW may have value. Three disease areas were examined in
more detail, bringing together effectiveness evidence alongside estimates of economic impacts
(cost–consequence analyses). The areas chosen for further analysis were PTSD, inflammatory arthritis and
breast cancer. These topics were chosen by the SGC before the results of the meta-analyses were known,
with the aim of reflecting a range of different conditions for which TW has been used. There was also a
pragmatic element to this choice – these topics contained a greater number of studies, including some of
the higher-quality ones. It was felt that they were likely to provide a stronger evidence base than some
other areas. It is important to note that these case studies are unlikely to be representative of the whole
evidence base for TW.
For each case study, a summary of effectiveness evidence was prepared, and presented alongside
estimates of costs and use of health-care resources. Where possible, costs were estimated using
information about the intensity of practitioner input in the related clinical studies.
Case study 1: post-traumatic stress disorder
In total, four studies69,70,98,121 reported on the use of TW in the treatment of people with PTSD. Gidron et al.98
and Smyth and Arigo121 tested unfacilitated TW to treat PTSD. Details of these studies are presented in
Chapter 3 (pp. 78–83). Lange et al.69 and Sloan et al.70 evaluated a facilitated TW intervention in a PTSD
population (see Chapter 3, F43: post-traumatic stress disorder).
Summary of study design and quality
Two studies69,70 evaluated individual forms of facilitated TW compared with waiting list controls
(see Table 5). Both recruited from the community: Lange et al.69 recruited online and screened for
post-traumatic stress and grief; those in the Sloan et al.70 study were recruited through local advertisement
and had a primary diagnosis of PTSD related to a MVA. Study quality was mixed (see Figure 4). The
Lange et al. study69 was at risk of bias because of non-reporting of randomisation, concealment of
allocation or blinding of outcome assessment. Sloan et al.70 was a randomised trial, but did not report on
blinding of participants or outcome collection.
The unfacilitated studies compared EW with factual or time-management writing as control in patients
with diagnosed PTSD (see Table 32). Smyth and Arigo121 was conducted in the USA, and Gidron et al.98
in Israel. Both studies had methodological and reporting flaws that left them susceptible to bias
(see Figure 26).
Estimated costs of intervention
The two studies69,70 of facilitated writing gave quite detailed information about the treatment protocol and
therapist input, which was used for costing. Lange et al.70 evaluated a 5-week internet programme
(Interapy), consisting of 10 45-minute writing sessions. Feedback on submitted writing was sent to each
patient by a therapist on seven occasions. The feedback consisted of about 450 words. The time taken by
the therapists to prepare this feedback was not reported but is unlikely to have been much less than
1 hour. The mean basic salary for qualified clinical psychologists is £46,280, similar to Agenda for Change
band 8a.126 However, the therapists employed in this study were graduate and postgraduate students in
clinical psychology (mean age 29 years), not yet fully qualified, but who had attended advanced courses
in behavioural cognitive psychotherapy and received special training in using writing assignments in PTSD.
For costing purposes we assumed a band 6 salary (£30,712), or £45 per hour including indirect costs and
overheads (see Table 70). The estimated cost per participant is therefore in the region of £315 (7 × £45).
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Sloan et al.70 evaluated a written exposure therapy (WET) intervention consisting of five weekly sessions
(one lasting 60 minutes and four lasting 40 minutes). Participants had individual contact with a clinician for
approximately 25 minutes during the first session, and for 10 minutes in each of the remaining sessions. In
addition, it was assumed that therapists would need some time to prepare for sessions: 10 minutes for the first
session and 5 minutes for each remaining sessions. Total therapist time per participant is therefore approximately
95 minutes. Therapists were clinicians with masters or doctoral level qualifications and prior experience of
treating PTSD with exposure-based therapies. Therefore, it was assumed that a band 8a salary, with a mean cost
per hour of £63, was reasonable. The estimated cost participant is in the region of £100 (95/60 × £63).
It is more difficult to estimate the cost of the unfacilitated writing interventions. Participants were asked to
write on three or four occasions, for 15–30 minutes per session. However, after an initial briefing, patients
wrote on their own, either at home or in a health-care environment. Neither study of unfacilitated TW in
PTSD reported who instructed participants on the writing tasks, or how long this took. A cost of between
£12 and £42 for unfacilitated writing interventions was assumed (see Table 71).
Summary of costs and consequences
Table 72 presents an overall summary of evidence relating to the clinical effectiveness and cost of TW for
people with PTSD. It can be seen that evidence for facilitated TW is sparse but promising: the included
studies reported significant benefits for the intervention group compared with control, for a range of
outcomes of importance to patients: PTSD symptoms, measures of emotion, anxiety, depression, sleep and
somatisation. The estimated cost of delivering these interventions in a NHS context is relatively modest: in
the region of £100–300. However, evidence about the impact of facilitated TW on patients’ overall QoL
and well-being, and on their use of other health-care services is lacking.
Evidence relating to unfacilitated forms of TW is sparse and inconsistent. Of the two included studies,98,107
one reported some positive effects on mood and a biomarker for stress (Smyth et al.107). However, the other
study98 reported negative effects on PTSD symptoms and somatisation and an increase in non-routine
health visits.
Case study 2: inflammatory arthropathy
Six studies107,113–117 reported on the use of TW in the treatment of people with inflammatory arthropathy
and five studies107,113–115,117 were used for this analysis (i.e. except Lumley et al.’s116 which was found in the
update searches). Details of the studies were presented Chapter 3.
Summary of study design and quality
All five studies107,113–115,117 evaluated an unfacilitated EW intervention compared with neutral writing
(time-management control). In addition, Broderick et al.113 included a second intervention group, who
were asked to write about the meaning of the trauma, and Lumley et al.’s115 included a second control
group, who were asked to write about a positive emotional event. All studies recruited patients with
diagnosed RA, except Hamilton-West and Quine114 which recruited participants with a diagnosis of AS.
Follow-up ranged from 13 to 43 weeks, and outcomes included measures of disease activity, pain,
function, mood depression and QoL. None of the studies reported on health-care use or costs. Wetherell
et al.117 and Hamilton-West and Quine114 were conducted in the UK, and the other four studies107,113,115,116
were conducted in the USA. The quality of the studies was mixed (see Figure 39). Three were classified as
true RCTs,107,114,115 but all had design or reporting flaws that left them susceptible to bias.
Estimated costs of intervention
As in PTSD, it is difficult to assess the cost of the interventions because papers did not generally report on
the grade or qualifications of the staff who gave patients instructions on the writing task, or specify how
long this took. The location of the writing intervention varied: in Smyth et al.107 participants wrote in a
private room in a laboratory; Broderick et al.,113 Wetherell et al.117 and Lumley et al.115 adapted the
intervention for participants to write in their home; Hamilton-West and Quine114 did not report the location
of the intervention.
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Broderick et al.113 produced a videotape to introduce the rationale for the writing task and to provide
detailed instructions for patients. They noted that this method was chosen as there is evidence that
patients respond well to video-based introductions, and because it was likely to be a cost-effective
approach that could be reproduced across large numbers of patients with minimum input from
professionals. However, Broderick et al.113 noted that some physician time would still be required to
introduce the idea of the intervention to participants, and to encourage them to participate. In addition,
a cost would be incurred for each patient given a video: including the cost of materials and reproduction;
and a proportion of the cost for the development and production of the video. The latter is very difficult to
estimate, as it is unknown how many patients would use the video.
In Wetherell et al.117 participants were contacted by telephone before and after each writing session.
Assuming 10 minutes’ preparation, 10 minutes for the introductory conversation and 5 minutes per
telephone call before and after each of four writing sessions, the total estimated practitioner time to
deliver the intervention is approximately 60 minutes, incurring a cost in the region of £36–63 per patient,
depending on the grade of the practitioner.
TABLE 72 Summary of evidence on TW costs and consequences of unfacilitated EW in PTSD
Cost/consequences
Facilitated EW Unfacilitated EW
Lange 200369 Sloan 201270 Gidron 199698 Smyth 2008107
Physical health
Somatisation ↑ SCL-90-S ↓ PILL
Sleep/fatigue ↑ SCL-90-Sl ∼ POMS-f
Biomarkers ↑ Cortisol
Psychological health
PTSD symptoms ↑ CAPS
Intrusion/avoidance ? IES ∼ IES ∼ PSS-I
Emotion ? SAM
Positive mood ? PANAS-p ∼ POMS-v
Negative mood ↓ PANAS-n ↑ POMS-t, POMS-a
Anxiety ↑ SCL-90-A
Depression ↑ SCL-90-D ? BDI ∼ POMS-d
QoL
Well-being ↑ PTGI
NHS resource use
Cost of intervention (£) 315 100 12–42 12–42
Health-care use ↑ Visits
↑, Statistically significant positive treatment effect; ↓, statistically significant negative treatment effect; ∼, no significant
treatment effect; ↑∼ or ↓∼, multiple tests for subscales and/or time points with some significant results (positive or
negative); ?, statistical significance test not reported; PANAS-n, Positive and Negative Affect Schedule, negative subscale;
PANAS-p, Positive and Negative Affect Schedule, positive subscale; POMS-A, Profile of Mood States anger subscale;
POMS-f, Profile of Mood States fatigue subscale; POMS-t, Profile of Mood States tension subscale; PSS-I, Post-Traumatic
Stress Disorder Symptom Scale Interview; PTGI, Post-Traumatic Growth Inventory; SAM, Self-Assessment Manikin;
SCL-90-A, Symptom Checklist-90, anxiety subscale; SCL-90-D, Symptom Checklist-90, depression subscale;
SCL-90-S, Symptom Checklist-90, somatisation subscale; SCL-90-SI, Symptom Checklist-90, sleeping problems subscale.
Shaded cells show the pattern of evidence.
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Summary of costs and consequences
Summary results for inflammatory arthropathy are presented in Table 73. In this case, the results look
rather more promising for unfacilitated EW. The meta-analysis of measures of disease activity in the four
RA studies107,114,115,117 found a significant benefit in the intervention group at short-term follow-up
(8–10 weeks). Three of these studies114,115,117 also reported significant positive effects for some outcomes
at some time points: measures of mood in Wetherell et al.117 pain in Lumley et al.115 and function in
Hamilton-West and Quine.114 However, no significant effects were found across a number of other
outcomes – including QoL – and Lumley et al.115 reported some negative effects on mood immediately
after writing.
Case study 3: breast cancer
Eight studies53,54,74–79 reported on the use of unfacilitated EW in participants with breast cancer;
see Chapter 3 for details.
Summary of study design and quality
The studies evaluated unfacilitated EW against a usual care comparator53,54,74,75,78 or against an un-EW
control74,76,77,79 (note that Craft et al.74 had two control groups). The participants were at various stages
of disease and treatment: Jensen-Johansen et al.,76 Gellaitry et al.75 and Craft et al.74 recruited women with
early-stage breast cancer who had recently completed treatment; Mosher et al.77 recruited women
with metastatic breast cancer who were in significant distress. The studies were all conducted in the
USA, with the exception of one Korean study78 and one Danish study.76 There were three randomised
studies,54,74,79 but all studies were subject to design or reporting bias (see Figure 9).
TABLE 73 Summary of evidence on TW costs and consequences of unfacilitated EW in inflammatory arthropathies
Costs/consequences
First author, year
Meta-analysis
SMD (95% CI)
Smyth
1999107
Broderick
2004113
Wetherell
2005117
Hamilton-
West 2007114
Lumley
2011115
Physical health
Disease activity ↑∼ DAS ∼ DAS ↑∼ DAS ∼ BASDAI ∼ VAS –0.49 (–0.83
to –0.14)
Biomarkers ∼ ESR, CRP ∼ ESR
Psychological health
Mood ↑∼POMS-SF ↓∼ PANAS-X
Depression ∼ HADS-D ∼ AIMS-as
Pain ↑∼ MPQ
Functioning ↑ BASFI ∼ AIMS
QoL ∼ SF-36 PCS ∼ BAS-G
NHS resource use
Cost of intervention (£) 12–42 Video 36–63 12–42 12–42
Health-care use Data absent
↑, Statistically significant positive treatment effect; ↓, statistically significant negative treatment effect; ∼, no significant
treatment effect; ?, statistical significance test not reported; ↑ or ↓, multiple tests for subscales and/or time points with
some significant results (positive or negative); AIMS, Arthritis Impact Measurement Scale; AIMS-as, affective dysfunction
subscale of the Arthritis Impact Measurement Scale-2; BAS-G, Bath Ankylosing Spondylitis Disease Global Score;
BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; MPQ, McGill Pain Questionnaire; PANAS-X, Positive and
Negative Affect Schedule–Expanded Form; VAS, visual analogue scale.
Shaded cells show the pattern of evidence.
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Estimated costs of intervention
Henry et al.53 sent written instructions to participants by post, asking them to write for 20 minutes, on one
occasion at home. The cost of this intervention would be minimal, say £5 for materials. Three studies74,75,79
reported a single face-to-face or telephone contact with participants, either before the first writing
session74,79 or after the final session.75 A cost of £12 for these three interventions74,75,79 was assumed.
Two studies76,77 reported a rather more resource-intensive approach, with telephone calls to the
participants before and after each writing session. Jensen-Johansen et al.76 first contacted women
participating in another study by mail. The intervention consisted of three 20-minute writing sessions at
home over a 3-week period. Participants were telephoned by a research assistant, trained by a clinical
psychologist, before and after each writing session. Assuming 10 minutes’ preparation, 10 minutes for the
initial telephone call and 5 minutes for each subsequent call, the total contact time would be 45 minutes:
costing £27 (at £36 per hour). Mosher et al.77 included women with advanced disease and high levels of
distress. Women were screened and recruited by telephone, and then sent written instructions, paper and
envelopes to return their writing. The intervention consisted of four writing sessions over 4/7 weeks, each
lasting from 20 to 40 minutes. The women were telephoned by a psychology research fellow before each
writing session, after 20 minutes, and, sometimes, again after an additional 20 minutes. The contact time
was therefore greater than in other unfacilitated writing interventions. Assuming that the initial telephone
call lasted for 20 minutes, and that each subsequent call lasted for an average of 5–10 minutes, the total
contact time would have been approximately 60–90 minutes. At £36 per hour, the total cost per patient
would be around £36–100.
Summary of costs and consequences
Summary results for breast cancer are presented in Table 74. The evidence base for unfacilitated EW in
breast cancer is rather larger than in the other case studies presented above, with eight comparative
studies,53,54,74–79 but the results are not encouraging. Although some studies did report some significant
effects, meta-analyses of measures of positive mood, negative mood and depression at short-term
follow-up failed to find a significant treatment effect.
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Chapter 5 Realist synthesis
Aims
The focus of the realist synthesis was to make sense of the outcomes observed in the studies included in
the effectiveness review, in effect addressing the objective: How is heterogeneity in results of empirical
studies accounted for in terms of patient and/or contextual factors, and what are the mechanisms and
moderators responsible for the success, failure or partial success of interventions (i.e. what works for
whom in what circumstances and why)?
Methods
The realist synthesis drew initially on the studies included in the original searches for the systematic review
(i.e. searches ending March 2013), as its intended purpose was to try to explain the outcome patterns
found within this review. The inclusion criteria for the realist synthesis were thus initially identical to that of
the systematic review. Additional searching was planned if it was deemed necessary as the programme
theory developed.
The central task of the realist synthesis was to develop and refine a realist programme theory of TW. In
order to do this, a series of steps – needed to achieve the final desired outcome from a TW intervention in
the form of a programme theory – was set out. For each step, a realist logic of analysis was applied, so as
to explain how the (intermediate) outcome for each step was achieved in realist terms [i.e. what interaction
between context and mechanism(s) led to that outcome]. The initial programme theory was iteratively
developed and refined in two ways:
1. Consulting with our practitioner experts Two meetings were held, at which the project team met with
external experts to discuss and develop the programme theory. In the first meeting – attended by
members of the project team and all the practitioner experts – the discussion was open-ended and
exploratory. The main goal of this meeting was to get an initial rough idea of what the various
mechanisms might be. Practitioner experts were asked how they thought TW worked and why. This
first meeting took place in March 2013 (month 3) of the 18-month project. Later on in the project
(month 14), we held a second meeting with the practitioner experts. On this occasion, a series of
questions was circulated prior to the meeting (see Appendix 2) to prime those attending on what the
focus of the meeting would be. Those unable to attend the meeting were invited to submit written
responses. During the latter meeting the comments provided by the experts were discussed and
attempts were made to organise the comments into an initial programme theory. Both meetings were
facilitated by GW, with GW and OPN taking contemporaneous notes. The contents of the notes
were used as data for programme theory development. By analysing (see point 2 on p.118) and
discussing the contents of these notes from the second meeting, we produced a draft programme
theory. This was circulated to the practitioner experts and project team, and, from their feedback, it
was revised (e.g. to include more details on the steps and mechanisms within specific TW methods).
A further draft was circulated in a steering group meeting and, from feedback received, refinements
made (e.g. the addition of potential harm as an intermediate outcome from TW). The draft programme
theory was revised in response to all feedback received.
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2. Interrogating the studies included in the effectiveness review A total of 59 studies were included in the
systematic review (original searches). All of these studies were potentially eligible for the realist synthesis.
Realist reviewers read all the papers included in the effectiveness review and data from the included
studies were used if they were relevant to the realist analysis – that is, could inform some aspect of the
programme theory (see Box 1). An assessment of rigour (how trustworthy were the data being used)
was also made.127 To illustrate how rigour was operationalised, if data had been generated using an
instrument then the trustworthiness of the data was considered to be greater if the instrument had been
previously tested, shown to be reliable and valid and had not been altered (or if alterations had been
made subsequent testing had been undertaken).
Theorising is an interpretive process, requiring immersion in the data and abductive reasoning (considering
what mechanisms might have been in play). The contents of all the included studies (except theses – as the
decision was made not to obtain these in full-text for the systematic review) were read and re-read by GW,
looking for data that informed the development and/or refinement of the programme theory. Relevant
sections of texts relating to contexts, mechanisms and/or their relationships to outcomes were extracted
into an Excel spreadsheet (see Appendix 4). The analytic and synthesis processes consisted of a series of
questions that the reviewer asked of the contents of included documents. These questions were all asked
sequentially of each section of text that was thought to be possibly relevant. Some section of text turned
out not to be relevant after these questions were asked. The questions asked were as follows:
1. Relevance:
i. Are the contents of a section of text within an included document referring to data that might be
relevant to programme theory development?
2. Interpretation of meaning:
i. If it is relevant, do the contents of a section of text provide data that may be interpreted as being
context, mechanism or outcome?
3. Judgements about context, mechanism, outcome and configurations (CMOCs):
i. What is the CMOC (partial or complete) for the data?
ii. Are these data to inform CMOCs contained within this document or other included documents?
iii. If so, which other documents?
iv. How does this CMOC relate to CMOCs than have already been developed?
4. Judgements about programme theory:
i. How does this (full or partial) CMOC relate to the programme theory?
ii. Within this same document are there data that inform how the CMOC relates to the
programme theory?
iii. If not, are these data in other documents? Which ones?
iv. In light of this CMOC, and any supporting data, does the programme theory need to be changed?
5. Rigour:
i. Are the data sufficiently trustworthy and rigorous to warrant making changes to the CMOC?
ii. Are the data sufficiently trustworthy and rigorous to warrant making changes to the
programme theory?
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The process of configuring the data into a programme theory took place through the use of a Microsoft
Word version 2010 (Microsoft Corporation, Redmund, WA, USA) document with text boxes and use
of arrows. As analysis and synthesis progressed, text boxes were created that contained a context,
mechanism or outcome. These were dragged around the Word document to construct (where possible)
complete context, mechanism, outcome configurations. The locations and relationships between the text
boxes were driven by the interpretations and judgements of the reviewer of the answers obtained to the
questions listed above. Where necessary, some text boxes were removed and others added as driven
by the data. The text boxes were also combined when it was judged to be indicated by the data. Lines
with arrows were added to show the relationships between and within context, mechanism and
outcome configurations.
As the programme theory was refined, included studies were re-read and rescrutinised to check if relevant
data had been missed out that might inform the revised programme theory (Box 2). Where necessary
(as directed by the programme theory), and within the resource constraints of the study, we reanalysed our
initial searches looking for additional studies that might contain relevant data. Realist programme theory
development and refinement occurred mainly between February and April 2014.
BOX 2 Illustrative examples of how the data to build and refine programme theory were used
Example 1
A suggestion was made during a steering group meeting that one of the possible outcomes for those
participating in TW was harm (e.g. increase in negative emotions immediately following writing) and that this
had been reported in the literature. This had not initially been included in the current version of the programme
theory. The included studies were re-read with the specific goal of looking for examples of some form of harm
(early or delayed). Six such examples were found.69,70,73,74,119,121 Therefore, it was considered reasonable to refine
the programme theory to include harm as a possible outcome.
Example 2
During the second programme theory development meeting, the practitioner experts told that in their TW
groups they put up very few barriers to attendance (i.e. participants could come and go as they pleased and
did not necessarily have to undertake any TW). This context was not accounted for in the current version of the
programme theory. As a response, an additional step to the programme theory was added, and sought data to
support, refute or refine this change. Supporting data were found in only two documents,128,129 both of which
were descriptions by practitioners of their experiences of running TW groups. The nature of these sources
raised questions about the trustworthiness of these data and hence cast doubt on the change made. However,
while on its own, the sources were of questionable trustworthiness, there was existing substantive theory that
supported the rationale behind allowing potential participants to just attend a group. This was the concept of
trialability from Diffusion of Innovations theory.130 This theory suggested that when something is new and has
not been used by a person before, the persons perceptions and feelings about it is influenced by being able
to try and see it. Thus it was inferred that, for those unfamiliar with TW, its uptake might be influenced by
individuals being allowed to try and see for themselves. The existence of substantive theory added coherence to
the change we made. This change is only partially supported, however, by data from published documents and
hence is less secure than other sections of the programme theory. It would benefit from refinement from
additional data.
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Results
Overview
The characteristics of the studies included in the effectiveness review and the document flow diagram
have already been outlined (see Chapter 3 and Figure 1, respectively). Most used (some with minor
modifications) the unfacilitated EW model. In this, there appeared to be a deliberate attempt to minimise
the degree of support provided to participants. In other words, TW was something that participants were
expected to undertake on their own with minimal input from anyone else. Five of the included studies
used a different approach – facilitated TW.
The TW intervention that was used in all but the five facilitated writing studies differed significantly from
the approach used by our practitioner expert. Within both the NHS and UK voluntary sector, when TW was
being used, it was rarely, if ever, used as a stand-alone intervention (i.e. in the form of unfacilitated EW).
Rather, different types of TW was used as one of the activities within a group setting, and facilitated by
a practitioner with expertise in both TW and running groups. Such approaches were thus more akin to
the activities and processes as described (e.g. in Rickett et al.66) than the stand-alone, minimal-support
approaches found with unfacilitated EW used in the majority of the studies included in the
systematic review.
In subsequent analyses, two different programme theories were developed to reflect this: first, to explain
how TW might work if introduced in a stand-alone context with minimal support (unfacilitated EW), and,
second, what was almost certainly an elaboration of the first programme theory to explain how it might
work when it was introduced with facilitation in a group setting (facilitated TW).
Discussions with the practitioner experts contributed to refinement of the programme theories. The initial
meeting (held before a definitive list of studies to include in the systematic review was established)
indicated that there was a great deal of uncertainty as to how TW was meant to work to achieved desired
outcomes. By the second expert meeting, it had become clear that there was a difference between current
NHS and UK voluntary sector use of TW. By this second meeting the studies that would be included in
the systematic review had been arrived at and thus a body of literature to use for programme theory
refinement was available.
Not all of the included studies were used in programme theory refinement. Six studies were PhD or MSc
theses54,57,87,91,94,131 that did not appear to have led to publications in the peer-reviewed academic literature.
One study was in Korean78 and a full translation was performed. Because the practitioner experts had
highlighted the widespread use of facilitated TW, studies that had not met the inclusion criteria for the
systematic review and thus had been excluded, were screened again (by GW and OPN) and 11 relevant
documents that specifically explored facilitated TW were identified.128,129,132–140 The reference lists within
each included study was also searched to look for information on whether or not there were any
additional studies (of any type) of the same intervention. One such study141 was retrieved.
What happens, how and why in unfacilitated emotional writing?
Analysis and interpretation of the data indicated that there are a number of processes that need to occur
for TW to be effective, and that a TW intervention takes place within a wider context. In the following
section, descriptions, explanations and evidence for the programme theory illustrated in Figure 56 are
provided. The intermediate outcomes that may result from engaging in TW, as perceived by the
participants, range from harm through to no benefit, and possible benefit to definite benefit, as illustrated,
as intermediate outcomes 1–4, in Figure 56. The benefit perceived by a participant in a TW intervention
can be broad, and, in particular, may go beyond the predefined outcomes that are measured in an
included study. Furthermore, perceived benefits are sometimes delayed and appear to vary from person to
person. It is of interest to note that none of the included studies had attempted to ask participants why
the decided to take part in the study in the first place or what they hoped to gain from taking part.
Supporting data below illustrate that (1) participants reported a range of different benefits from
REALIST SYNTHESIS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
172
M
ec
h
an
is
m
s:
• 
Fe
el
s 
‘s
af
e’
• 
Fe
el
s 
‘s
u
p
p
o
rt
ed
’
• 
Pe
rc
ep
ti
o
n
s 
o
f 
b
en
efi
ts
 o
f 
TW
 
M
ec
h
an
is
m
s:
Th
e 
th
er
ap
eu
ti
c 
w
ri
ti
n
g
‘b
la
ck
 b
o
x’
 
In
te
rm
ed
ia
te
o
u
tc
o
m
e 
Pa
rt
ic
ip
an
ts
 in
u
n
fa
ci
lit
at
ed
 E
W
In
te
rm
ed
ia
te
 o
u
tc
o
m
e
N
o
n
 o
r 
in
co
n
si
st
en
t 
en
g
ag
em
en
t
(b
u
t 
m
ay
 r
e-
en
g
ag
e 
la
te
r 
if
al
lo
w
ed
 t
o
)
In
te
rm
ed
ia
te
 o
u
tc
o
m
e 
1 
Su
b
je
ct
iv
e 
fe
el
in
g
 o
f 
H
A
R
M
fr
o
m
 u
n
fa
ci
lit
at
ed
 E
W
 
In
te
rm
ed
ia
te
 o
u
tc
o
m
e 
4 
Su
b
je
ct
iv
e 
fe
el
in
g
 o
f 
b
en
efi
t
fr
o
m
 u
n
fa
ci
lit
at
ed
 E
W
In
te
rm
ed
ia
te
 o
u
tc
o
m
e 
3
Su
b
je
ct
iv
e 
fe
el
in
g
 o
f 
PO
SS
IB
LE
b
en
efi
t 
fr
o
m
 u
n
fa
ci
lit
at
ed
 E
W
 
In
te
rm
ed
ia
te
 o
u
tc
o
m
e 
2
Su
b
je
ct
iv
e 
fe
el
in
g
 o
f 
N
O
b
en
efi
t 
fr
o
m
 u
n
fa
ci
lit
at
ed
 E
W
C
o
n
te
xt
 
Th
e 
fa
ci
lit
at
ed
 g
ro
u
p
 (
se
e 
Fi
g
u
re
 5
7
fo
r 
m
o
re
 d
et
ai
ls
)
C
o
n
te
xt
 
Pa
rt
ic
ip
an
t 
is
 o
ff
er
ed
u
n
fa
ci
lit
at
ed
 E
W
 
FI
G
U
R
E
56
Pu
ta
ti
ve
g
en
er
ic
su
b
p
ro
g
ra
m
m
e
th
eo
ry
fo
r
u
n
fa
ci
lit
at
ed
EW
.
Sh
ad
in
g
in
d
ic
at
es
m
ec
h
an
is
m
s
an
d
d
as
h
ed
lin
es
in
d
ic
at
e
w
h
er
e
m
ec
h
an
is
m
s
h
av
e
th
ei
r
in
fl
u
en
ce
s.
DOI: 10.3310/hta20270 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 27
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Nyssen et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
173
unfacilitated EW; (2) the benefits were not necessarily what the participants might have predicted they
would have received; and (3) these benefits were not necessarily those measured in the studies by
the researchers.
. . . this writing helped me get over, you know, my anger . . .50
To questioning about whether or not the study was helpful, several responses included:
Yes, [it] has made me see how well I am doing; Yes, [it] reduced some stress; and Yes, I got to write
about what I was feeling so I got it out and feel better afterwards not right after, but after.142
Six months after the EW [Expressive Writing] intervention, we conducted interviews with 24 (57%)
women about their experience of writing. Several women talked about the value of being able to
express feelings that they had not acknowledged to themselves or to others; women also talked about
the benefits of being able to process their experience of having breast cancer. Engaging in the EW
process impacted on some women’s relationships in that the writing made them more aware of how
much support they had had. We found that some women who had initially reported finding the
writing difficult were able to reflect that there were benefits to writing which had not been
immediately apparent. Several women expressed a sense of relief on the last day of writing indicating
that something had been dealt with.
Copyright © 2009 John Wiley & Sons, Ltd. Reproduced with permission from Gellaitry G, Peters K,
Bloomfield D, Horne R. Narrowing the gap: the effects of an expressive writing intervention on
perceptions of actual and ideal emotional support in women who have completed treatment for early
stage breast cancer. Psychooncology 2010;19:77–84.75
Participants appreciated the opportunity to work together on something that they found challenging.
They saw the poetry writing group as not simply a support mechanism, but a serious challenge to their
intellects and creativity.66
For the majority of the participants, disclosing their emotions resulted in perceived psychological benefits.
Some participants recognised that writing was a therapeutic process that helped to reduce the burden of
stressful events.
It was good for me to air these feelings, as they have been bottled up for a long time, I feel better
now I have written about them [P17, Intervention]. Although I ended up with lots of what may have
seemed negative stuff on the paper it has actually left me feeling quite strong, empowered,
understanding, focused, lighter, however.
P15, Intervention. Copyright © 2009 John Wiley & Sons, Ltd. Reproduced with permission from
Theadom A, Smith H, Horne R, Bowskill R, Apfelbacher CJ, Frew AJ. Participant experiences of a
written emotional disclosure intervention in asthma. Stress Health 2010;26:45–50.58
I found all the exercises to be very relaxing and helpful in clearing my mind of the day’s events.
P24, Control58
Difficult to say whether this [therapeutic writing] is helping my emotional or mental state – and what it
is doing to my asthma – if anything.
P15, Intervention58
Some women reported that the writing provided them with a forum for expressing emotions they felt
might be burdensome for family members or other confidants . . . Others indicated that writing helped
them to identify priorities or focus concerns more specifically . . . Several women commented on the
writing task itself, indicating that it was helpful or expressing surprised at the issues that came to mind
as they wrote.
Reproduced with permission from Walker BL, Nail LM, Croyle RT. Does emotional expression make a
difference in reactions to breast cancer? Oncol Nurs Forum 1999;26:1025–32.79
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Some studies revealed perceptions of harm (such as immediate negative feelings) or possible harm from
TW.69,70,73,74,119,121 Analysis indicates that when a person subjectively experienced harm or felt that they had
not benefited from unfacilitated EW, they were likely to take no further part or engage inconsistently.
Contrary to the hypothesized outcome . . . the group who wrote about a self-selected trauma did not
have a statistically significant benefit from the writing experience. This was true even though the
majority of them did write about their breast cancer. This was also the group with the highest dropout
rate. Having to make a choice about what to write about seemed to increase affective distress and
alter the benefit that focusing on ones self might offer, even if choosing to write about the personal
experience of breast cancer.
Copyright © 2012 Blackwell Publishing Ltd. Reproduced with permission from Craft MA, Davis GC,
Paulson RM. Expressive writing in early breast cancer survivors. J Adv Nurs 2013;69:305–15.74
. . . 13 persons (29.5%) dropped out because they experienced the writing about their stressful events
to be too much of a burden.69
One participant indicated that the reason she dropped out of WET [Written Exposure Therapy] (after
3 sessions) was because the treatment was making her think too much about her car accident, which
she found unpleasant. The other participant reported that he dropped out of WET (after 2 sessions)
because he was feeling better.70
One experimental participant self-selected out of the study after the first writing session for iatrogenic
reasons, indicating an unwillingness to continue writing due to distress.121
When participants believed that they were gaining some benefit from using unfacilitated EW, they
appeared to want to continue to engage with it. Within Figure 56, this has been illustrated by including a
feedback loop to the intermediate outcome of participants in unfacilitated EW.
Some group 1 members had elected to keep on meeting regularly after their program had ended.66
One participant started the course 2 years after being diagnosed with endometrial cancer:
One of the reasons I wanted to do this writing, I feel like I need to draw more strength from within . . .
The oncologists are wonderful at what they do . . . it’s about killing the cancer cells and that’s really
great, but there is also a place for having those other contacts for healing the illness.
Rickett C, Greive C, Gordon J. Something to hang my life on: the health benefits of writing poetry for
people with serious illnesses. Australas Psychiatry vol. 19. pp. 265–8, Copyright © 2016 by The Royal
Australian and New Zealand College of Psychiatrists. Reprinted by Permission of SAGE
Publications, Ltd.66
After the course, she said:
[It was] really enriching, because I’ve missed working and . . . it was really nice going to do something
and exercising your brain . . . Poetry has given me an outlet to try to untangle some of the
confusion within.66
Finally, taking part in a writing intervention may have motivated some participants to start writing on their
own. For example, one control participant said:
It kick-started me into entering some more things into my journal again, just got some feelings. But
you didn’t really ask for thoughts and feelings in the writing exercises. But it had that side benefit but I
didn’t write similar passages in my journal as I did for you.143
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Participants in both groups commented that they particularly appreciated having dedicated time to
themselves. Completing the writing exercise necessitated them creating protected time and generated
valuable time for reflection. It was a good time to reflect on how I feel about various issues [P25,
Intervention]. Having 20 minutes a day to myself was quite a miracle and something I hope to
continue in the future.
P20, Control. Copyright © 2009 John Wiley & Sons, Ltd. Reproduced with permission from Theadom A,
Smith H, Horne R, Bowskill R, Apfelbacher CJ, Frew AJ. Participant experiences of a written emotional
disclosure intervention in asthma. Stress Health 2010;26:45–50.58
There appears to be an element here of emergence. The perception of benefit is an intermediate outcome
from participating in unfacilitated EW, but appears to also act as a context to one of the mechanisms
identified that appears to cause continuing use of unfacilitated EW.
In Figure 56, the inferred mechanisms are illustrated by shaded boxes. As alluded to above, and
unsurprisingly, continuing use of unfacilitated EW occurs when participants perceive benefit from its use.
Repeated beneficial experiences reinforce continuing use. However, perceiving benefit in TW is not the
only mechanism that appears to be in operation. In order for participants to remain engaged, they also
have to feel that it is safe to write and that they are supported. These mechanisms of feeling safe,
supported and perceptions of benefits from TW seem to be important not only in encouraging participants
to continue with TW, but also in starting to use it in the first place. Different contextual influences trigger
the feeling safe and supported mechanisms and they are discussed in more detail in the next section
(see What happens, how and why in facilitated therapeutic writing?).
From the analysis of included studies it is not immediately apparent what the mechanisms are within
unfacilitated EW, as described by Pennebaker and Chung and in the various other models used in practice
(e.g. mindfulness writing, positive writing, memory evoking, literary, reflective writing and perspective
shifting writing).10,144 In Figure 56, the TW has been termed as black box. Those studies that have used the
approach to TW described by Pennebaker and Chung, or modifications of it, invariably cite one or more
explanations proposed by Pennebaker and Chung145 for how TW was meant to work. The possible
explanations for why expressive writing might work may be found in Box 3.
Pennebaker and Chung145 state:
If you are expecting a clean and simple explanation for the effectiveness of writing, we have some very
bad news: There is no single reason that explains it. Over the last two decades, a daunting number of
explanations have been put forward and many have been found to be partially correct. Ultimately,
there is no such thing as a single cause for a complex phenomenon. The reason is twofold. First, any
causal explanation can be dissected at multiple levels of analysis ranging from social explanations to
changes in neurotransmitter levels. Second, an event that takes weeks or even months to unfold will
necessarily have multiple determinants that can inhibit or facilitate the process over time.
Oxford Handbook of Health Psychology edited by Howard S. Friedman (2011): Extract of 115 words
(p. 426) from Chapter 18: ˝Expressive Writing: Connections to Physical and Mental Health˝ by
James W. Pennebaker and Cindy K. Chung (pp. 417–437). Reproduced with permission.145
The data reported within the included studies did not enable any coherent and plausible interpretations on
what the possible mechanisms for unfacilitated EW approaches might be. Few of the included studies
directly explored potential underlying mechanisms or provided data that would enable any inferences to be
made. The challenge here is one of the absence of data in included studies.
In summary, it is reasonable to infer that the realist programme theory for unfacilitated EW is as follows.
Participants are offered the option of undertaking unfacilitated EW. This forms the starting context.
When offered this resource, participants make a choice about whether to participate. The reasoning in
the participant in response to the resource offered is threefold: (1) an initial assessment as to whether or
not the individual felt or thought there was any value in participating (i.e. will he/she gain any benefit);
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BOX 3 Brief overview of possible explanations on why expressive writing works (from Pennebaker and Chung145)
Individual and social inhibition
When people are encouraged to talk or write about a previously inhibited event, health improvements would
be seen. Once people put their experience into words, they would no longer have the need to inhibit.
Emotions and emotional expression
The emotional response from writing fosters important cognitive changes.
Habituation to emotional stimuli
The benefits of writing accrue because individuals habituate to the aversive emotions associated with the
trauma that they are made to confront by writing.
Language and emotions: towards an A-to-D theory of emotional processing
When an emotional event is represented in a language format, such as during expressive writing,
verbal/conceptual processing becomes possible.
Use of emotion words in writing
Individuals who use very few emotional words or use a very high rate of them may be repressing their
emotions of being unable to express their emotions, leading to being or remaining unwell.
Beyond emotions: the construction of a story
Being able to structure emotions into a coherent story helps in the process of addressing the problem.
The components of a story: the analysis of cognitive words
The story created by the participant helps them to come to terms, explain and understand the behavioural
and/or mental problem associated with their experiences.
Writing as a way to change perspective
The writing produced by a participant may help them stand back and look at the experience from a
different perspective.
Expressive writing and social dynamics
After writing, participants continue to think about what they have written and this may lead to further
changes, such as to their day-to-day behaviour.
The big picture: life course correction
The change in perspective from writing may lead to participants re-examining how their life is progressing and
how they may need to change.
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(2) was this a safe environment in which to write; and (3) was there any support on offer to them? These
three responses form the most prominent mechanisms and their contextual triggers are discussed below.
In unfacilitated EW, generally no attempts are made (by those offering this resource) to create a safe
writing environment. Some studies did provide support should the participant require it (because they felt
distressed) either face to face75 or by telephone.113
Once a participant has decided to undertake unfacilitated EW, they are then in a position to experience for
themselves its effects, which may range from harms to benefits. No benefit or perceptions of harm appeared
to result in non-engagement or inconsistent engagement. When the individual perceives benefits, they
seemed to engage in further TW. This perceived benefit seems to accumulate with repeated engagement
and become a new contextual trigger for the mechanism related to perceptions of benefit.
What happens, how and why in facilitated therapeutic writing?
A consensus emerged from the programme theory planning meetings with practitioner experts. This was
that within the NHS and voluntary sector writing groups, TW was routinely used in a group setting. The
group formed part of the intervention in addition to the TW itself and this meant that the programme
theory described above and in Figure 56 needed to be refined and elaborated on.
The practitioner experts contributed their insights into three areas that needed to be incorporated into the
initial programme theory (as described above and illustrated in Figure 56). These were (1) the functions
and purpose of the group; (2) the range of TW approaches used with participants; and (3) the range of
outcomes that might be expected by participants. These are elaborated on below, and incorporated into
a refined programme theory of facilitated TW (Figure 57). The information provided by the expert
practitioners indicated that their groups had a range of similar characteristics. They were all voluntary, and,
in addition, individuals were welcome to come and go and stay as long or as short a time as they pleased.
Participation in TW was not always a compulsory condition for attending the group. There were rules for
the group but they were designed to be as inclusive as possible, for example those that attended were
expected not to disrupt the group. The groups existed in a context of tolerance. This meant that individuals
were given permission to come and go as they please to the groups for the length of time that they chose,
to as few or many group sessions, and to engage in TW or not.
The programme theory was refined to include steps that outline the processes involved with how and why
individuals may wish to participate in facilitated TW group (left-hand side of Figure 57). In the section
below, additional data from the 11 studies on facilitated TW128,129,132–140 found from additional purposive
searching is provided to support the changes made to the programme theory. These supplement the data
that were already presented to develop and refine the programme theory in Figure 56.
Individuals either would self-refer to TW groups or might be encouraged to do so by health-care
professionals or another person. The mechanism that seemed to cause attendance and re-attendance
might be termed trialability. This concept comes from work on the Diffusion of Innovations theory,130 and
suggests that any new innovation may be more likely to be adopted when the user has opportunities
to experiment with it. There are some data (from the studies included in the effectiveness review and from
further searching for the realist synthesis) to indicate that, for many potential participants, TW in groups
was not something in which they had engaged and participated in the past and so the opportunity to see
what it was all about was important.
Our workshop became a space, a sandbox, in which they could come to play.128
Patients who are generally withdrawn and reticent have found this [newsletter] a valuable means of
communication and now are rarely short of ideas for articles.135
Data from the practitioner experts indicated that attendance in TW groups in the real world was very fluid.
Individuals would come and go to the groups, sometimes only to talk to other group members or to make
use of other services being offered (e.g. the food provided). In some groups, individuals might be absent
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for some time, only to appear and attend more consistently later. Group attendance was thus a fluid affair,
as indicated in Figure 57, and participation was driven more by the individuals own perceptions and
feelings about what their needs were.
An important distinction has been made in the programme theory between group attendance and
participation with TW. Those who attend may not necessarily undertake any TW. There appears to be
complex interactions between contexts and mechanisms here when it comes to the intermediate outcome
of whether or not an individual participates in a TW activity.
Group attendance enables an individual to make decisions about whether to participate in TW. In effect it
exposes them to what TW is all about, and what benefits they might obtain from the TW activity itself and
being an active participant in the a group.
Data from included studies indicate that the degree of tolerance of the group, the level of support on offer
from the group, the range of therapeutic activities available, the voluntary nature of the group, interaction with
the group, listening and understanding are all context influences that may trigger perceptions of benefits of TW.
The informal and relaxed atmosphere of the group encourages patients to read their work aloud and
to welcome discussion, criticism and admiration.135
Participants told us that they enjoyed the technical challenges of writing poetry and the opportunity to meet
as a group to share their writing and get feedback. They were particularly proud to have the anthology of
their own writing, interspersed with poems by recognized Australian poets, as a tangible outcome.66
If I could think of any ideas of how the group can be improved, well, it’s to get more people. Like I
know a lot of people are very shy or afraid of coming out and forcing themselves out there, thinking
that they’re gonna be exposed, but it’s really an environmentally friendly place where we have the
group. So it could be improved if more people would join and say how they really feel about living
with HIV or AIDS [aquired immunodeficiency virus].
Reprinted from Arts Psychother, vol. 39, Fair CD, Connor L, Albright J, Wise E, Jones K. “I’m positive,
I have something to say”: assessing the impact of a creative writing group for adolescents living with
HIV. pp. 383–9. Copyright © 2012, with permission from Elsevier.134
Perceiving that TW (or the group itself) may have benefits does not necessarily mean an individual will
participate. Attendance at a group enables individuals to make subjective and/or objective judgements on
some of the context influences mentioned above – degree of tolerance, support, nature and type of the
interaction and so on. Another two mechanisms appear to be triggered if the context is right – individuals
can not only perceive benefits from participating in TW, but will also feel that it is safe to do so and they
will be supported. These mechanisms speak to the potential emotional costs of engaging in TW:
embarrassment, ridicule, feeling exposure, upset, and so on.
Allowing persons to safely share their thoughts and feelings about themselves reassures them that it is
okay to experience the feelings they have.74
The paper became that space where the students could meet themselves and their concerns
unimpeded by the predetermined expectations of others; the classroom became a safe place to read
the stories that could not be heard elsewhere.128
. . . many people were unable to write directly about significant, traumatic experiences without
re-experiencing overwhelming emotions. One woman, an experienced licensed counsellor, wrote copious
and beautiful poetry but became rigid and almost frantic when we worked with memoir. Interestingly, in
her poetry, deep issues and memories would surface. She was able as well to write a fictional, third
person story full of effective emotional content and events similar to her life. Yet to approach her past
directly frightened her. There was clearly no safe place for her to go to in her own history.
Baker S. Tell it slant: history, memory, and imagination in the healing writing workshop.
Traumatology vol. 15 pp. 15–23, 2009. Published by American Psychological Association
and reprinted with permission.128
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. . . in reading this piece to a group who had been with her the better part of 6 months, she was able
to reveal herself in a way that felt safe.128
The interaction with a group of HIV-positive peers provided them with a safe place to talk openly
about their experiences, which not only served to deepen their understanding of their illness, but also
resulted in increased support. A 15-year old male explained that group members knew Everybody
[in the group] was born with it [HIV], and we talked about how it was nobody’s fault.
Reprinted from Arts Psychother, vol. 39, Fair CD, Connor L, Albright J, Wise E, Jones K. “I’m positive,
I have something to say”: assessing the impact of a creative writing group for adolescents living with
HIV. pp. 383–9. Copyright © 2012, with permission from Elsevier.134
An example of the safety of the group is seen in the following quotation from a group leader:
And so really the group became a way for them to help one another, and the older kids sort of took
over in that regard, and kind of became peer counsellors in a way and were able to help them answer
some responses to people . . . there was one girl, the oldest girl in the class, just felt like everyone
should be out and open about it and perhaps that would release the stigma. So really a means for
them to figure things out on their own and figure out how they wanted to represent themselves and
HIV or if they wanted that to be a part of who they were.
Reprinted from Arts Psychother, vol. 39, Fair CD, Connor L, Albright J, Wise E, Jones K. “I’m positive,
I have something to say”: assessing the impact of a creative writing group for adolescents living with
HIV. pp. 383–9. Copyright © 2012, with permission from Elsevier.134
Working in a group creates an inner/outer dynamic that can help people to make sense of illness.66
Positive changes in the adolescent were attributed to the experience of meeting other young people living
with HIV.
One mother stated participation in the group lets them know that there are other young people out
there that are dealing with the same issues that they’re dealing with. Another mother agreed: more
than anything else, being able to be around someone as themselves and see someone just like them
and see that they’re doing things and going on with their lives and not having pity parties. I thought it
was good.
Reprinted from Arts Psychother, vol. 39, Fair CD, Connor L, Albright J, Wise E, Jones K. “I’m positive,
I have something to say”: assessing the impact of a creative writing group for adolescents living with
HIV. pp. 383–9. Copyright © 2012, with permission from Elsevier.134
Parents and guardians reported few concerns. Most had longstanding relationships with the social worker
who first introduced the idea of a creative writing group; their trust in her contributed to their confidence
that the group experience would be helpful.
One mother stated:
I knew she was in good hands it was going to be a good educational experience for her. I thought it
was great.134
In contrast, there are data to indicate that some potential participants in some context may find that the
private nature of unfacilitated TW may be more suitable to their needs.
The structured, private nature of the intervention was particularly helpful to people who were unable
to express emotion or who had ambivalent attitudes about expressing emotions to others.100
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As described above and illustrated in Figure 57, there are data to support the gradual accumulation of
perceived and real benefits of TW, of being in a group, and feelings of safety and support. To reflect this
reinforcing cycle – of engagement with TW, being in a group, accruing benefits, feeling safe and
supported – the shaded triangle and text in Figure 57 have been used. Within a group with the relevant
mix and balances of contexts, individuals move from an unsafe to a safe context at a pace that is under
their control.
As previously mentioned, the practitioner experts pointed out that within the NHS and voluntary sector a
broader range of TW techniques or activities were used (e.g. mindfulness writing, positive writing, memory
evoking, literary, reflective writing and perspective shifting writing). The practitioner experts provided
explanations on when these different techniques might be used and for what ends. An example of the
information provided can be seen in Appendix 2.
There were no data within the included studies to inform the relevance and/or importance of these
different TW techniques in the programme theory. Different TW techniques are used in the included
studies, but the paucity of the reported data does not enable any firm conclusions to be made. This is one
area of the programme theory that is thinnest and would benefit from the search for further relevant
studies and documents.
Finally, the practitioner experts reported that the benefits an individual gains from engaging in TW can
occur early and later as well as be broad and unpredictable. In the section above, data from the studies
included in the systematic review, which support their observations, have already been presented. Below
are data gleaned from studies on when TW was used in a group setting that provides further support.
My guiding principle is that the individuals healthy self will gravitate toward what it needs; that I as
the practitioner cannot know whether this is ahead of time and that my job is to listen to the
emerging self and allow it expression.128
In summary, it is reasonable to infer that the realist programme theory when TW intervention is used as
part of a group (facilitated TW) is as follows. Within the NHS and voluntary sector, TW is usually offered
as an activity within a group context. Potential participants either self-refer or are encouraged to attend.
These groups tend to operate in a context in which actual participation in TW is voluntary and
non-participation is tolerated. Such a context enables potential participants to try out (the mechanism
here being trialability) the group – seeing for themselves how it works and what goes on. A range of
group-related contexts appear to be important in influencing potential participants to participate in a TW
technique. With repeated attendance at the group, potential participants can subjectively and objectively
assess the (contextual influences of) degree of tolerance, support and guidance (from others and the
facilitator), the range of activities on offer, voluntariness, interactivity of the group, and so on. These
appear to trigger the mechanisms of perceptions of benefits, safety and support. Potential participants feel
that it is safe to take part in TW when they perceive that they are likely to receive support from the group
if potentially troubling emotions are surfaced. If they perceive subjective benefits, continuing participation
is more likely to occur.
Once a participant has decided to undertake TW, they are then in a position to experience for themselves
its effects – from harms to benefits. No benefit or perceptions of harm will likely result in non-engagement
or inconsistent engagement. When the individual perceives benefits, he/she is likely to engage in further
TW. This perceived benefit seems to accumulate with repeated engagement and become a new contextual
trigger for the mechanism related to perceptions of benefit. The range of benefits that a participant
obtains from TW appears to be individually specific; they may be immediate or delayed to some degree
and not necessarily predictable in advance or those that are measured by the researchers in the
included studies.
Within the realist synthesis, we were unable to clarify further the mechanisms of how different TW
techniques are meant to produce desired outcomes.
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Chapter 6 Discussion
This is the first comprehensive systematic review of TW interventions for people with LTCs. There aremany various forms of TW interventions that have been suggested as potential therapies for the
treatment of mental and physical illnesses. However, in this systematic review, unfacilitated EW such as
described in 1986 by Pennebaker and Beall1 was the most frequently used approach. As few as five
studies66–70 reported a facilitated type of TW intervention. However, even these five studies are not that
similar to the form of TW which has been described by TW practitioners as the most frequently used
writing therapy in both NHS and voluntary sectors in the UK.
Statement of main findings
Systematic review
Five studies66–70 were identified which examined the effect of facilitated TW on four different disease
areas (two studies in PTSD,69,70 and one each in dementia,67 psychiatric problems,68 and serious physical
problems – primarily cancer66). The actual TW interventions studied were extremely varied, two being
internet based. Three of the studies66,67,70 were very small, and across the studies quality was mostly
unclear. The studies measured different outcomes but all reported positive outcomes in favour of the
writing intervention, suggesting that facilitated TW may be beneficial but it requires much more
evaluation, which should be conducted rigorously.
Unfacilitated EW was evaluated in 59 studies.71–119 There was considerable heterogeneity in participants,
interventions (context, content, delivery mode), comparators (factual writing, time management, non-writing,
waiting list or SMC) and outcomes (type measured and length of follow-up). For measurement of outcomes,
172 instruments were used and more than 300 different measures were reported. All but four52,53,78,87 of the
studies were RCTs. Methodological quality was frequently unclear, but most studies were likely to have
introduced performance or detection biases that could have increased the likelihood of finding a positive result.
l Of the six heterogeneous studies50,55,56,71–73 in patients with HIV, five were very small50,55,71–73 and all
were of very unclear quality. Overall, there was no evidence of benefit in any of the outcomes
examined (disease markers and psychological instruments), nor did a meta-analysis show any evidence
of evidence of benefit on depressive symptoms.
l Eight studies53,54,74–79 examined EW in patients with breast cancer: one was very large,76 and their
quality ranged from unclear to poor (Hughes54). Most examined mood, depressive symptoms or QoL
but there was no convincing evidence of benefit from EW across the studies or on meta-analysis of
mood or depressive symptoms.
l Five studies80–84 examined genitourinary and gynaecological cancers, and, again, quality ranged from
unclear to poor. Across the wide variety of outcomes examined there was no consistent pattern of
benefit from TW. Two other studies85,86 of unfacilitated EW in patients with various cancers also failed
to identify any benefit from EW.
l Three studies90–92 explored substance misuse: two were very small and study quality was unclear or
poor; across a wide range of outcomes they found no evidence of benefit from EW.
l Five small studies93–97 of variable quality examined EW in patients with various psychiatric conditions;
there was little consistent evidence of benefit from TW across a variety of outcomes or on
meta-analysis of the effect on anxiety or depression in the short term.
l Two very small, low-/poor-quality studies9,98 looked at EW for PTSD; in the immediate or short term,
both report inconsistent beneficial results on mood or PTSD symptoms with unfacilitated EW.
l Three studies102–104 of variable quality found no consistent evidence of benefit in CVD.
l Four studies58,106–108 (of mixed quality) investigated unfacilitated EW in patients with asthma but no
evidence of benefit on a variety of outcomes was seen, and meta-analysis suggested that there was no
benefit on short-term FEV1.
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l Two low-quality studies52,109 of IBS reported mostly positive results.
l Three low-quality studies110–112 of psoriasis found little effect from the intervention.
l For inflammatory arthropathies (six studies107,113–117) there was a reduction in disease severity (n= 191,
SMD –0.61, 95% CI –0.96 to –0.26) in the short term on meta-analysis of four studies,107,114,115,117 with
a random-effects model and with non-significant heterogeneity, I2= 1%.
l Four low-quality studies51,57,118,119 in FM and chronic pain showed mostly positive results.
l Single studies looking at EW in sickle cell disease,87 diabetes mellitus,88 cystic fibrosis,89 BN,99
amyotrophic lateral sclerosis,100 migraine and tension headache,101 and chronic lung disease (COPD and
IPF)105 were nearly all of low or unclear quality and found no evidence of benefit from EW.
l The meta-analyses in the breast cancer studies53,54,74–79 showed no significant differences in depression
(among 562 participants), positive and negative mood at short term (among 618 participants each) for
the EW group compared with the control group. Likewise, the remaining meta-analyses on HIV
(depression at short term in 249 participants); asthma (lung function at short term in 281 participants);
mental and psychiatric disorders (anxiety at short term in 127 participants); inflammatory arthropathies
(disease activity at both immediate and short term in 146 participants); and FM and chronic pain (pain
severity at two different short term assessments in 216 participants) found no significant differences
between EW groups and control subjects.
l Twenty-four studies50,51,56–58,71,83,89,90,99,101,104–108,110–113,115–117,119 reported disease-based outcomes across
different LTCs, and only two studies104,110 found a significant beneficial effect for EW: on DBP, but not
SBP, in cardiovascular disease, and on the severity of psoriasis.
l For anxiety and depression, across different LTCs, none of the meta-analyses showed significant effects.
Economic considerations
The review of economic evidence did not identify any true economic evaluations, quantifying both the
monetary costs and health consequences of TW interventions. Only one of the studies89 included in the
systematic review attempted to quantify the cost of delivering the TW intervention itself and made an
estimate of cost savings. Some studies did report on the impact of TW on patients’ use of other health
services: there was a significant reduction in reported use of medications with TW, but no significant effect
on the use of other health services. Costs for delivering programmes of TW are likely to vary, depending
principally on the amount of paid practitioner time per participant. The estimated direct cost to the NHS
ranged from as little as £12 for unfacilitated interventions to > £2000 for a series of 16 one-to-one facilitated
TW sessions. There is insufficient evidence to estimate how much, if any, of this cost would be offset by
savings from reduced use of other NHS services. There is also insufficient evidence to estimate the overall
cost-effectiveness of TW to the NHS. Cost–consequence analysis suggested that there might possibly be a
favourable balance of participant benefits to NHS costs for selected interventions in selected LTC groups.
Realist synthesis
The realist synthesis was able to develop two programme theories that (to some extent) explained some of
the findings within the studies included in the systematic review. Uncertainty continues to exist over why
individuals with LTCs might wish to participate in TW (of any variety) and what, how, and in what way these
individuals hope to gain from TW. For unfacilitated EW, there remains uncertainty as to how and why it
generates any outcomes of interest, for whom, and in what circumstances. In facilitated TW the relative
importance of the different processes within it (i.e. what processes need to be used – how and why – to
generate desired outcomes) is unclear.
In unfacilitated EW, when participants were offered the option of undertaking EW, this formed the starting
context. When offered this resource, participants made a choice about whether or not to participate. The
participant reasoning in response to the resource offered might be threefold: (1) an initial assessment as to
whether or not the individual felt or thought there was any value in participating (i.e. will he/she gain any
benefit); (2) was this a safe environment in which to write; and (3) was there any support on offer to
them? These three responses formed the most prominent mechanisms and their contextual triggers are
discussed in more detail with reference to facilitated TW. Studies using unfacilitated EW generally did not
attempt to create a safe writing environment or provide support. Once a participant had decided to
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undertake unfacilitated EW, they were then in a position to experience for themselves its effects –
which may range from harms to benefits. No benefit or perceptions of harm appeared to result in
non-engagement or inconsistent engagement. When the individual perceived benefits, he/she seemed
to engage in further TW. This perceived benefit seemed to accumulate with repeated engagement and
became a new contextual trigger for the mechanism related to perceptions of benefit. The range of
benefits that a participant obtained from TW appeared to be individually specific; they may have been
immediate or delayed to some degree, and not necessarily predictable in advance or those that were
measured by the researchers in the included studies.
The programme theory for facilitated TW is an elaboration of that for unfacilitated EW. Within the NHS
and voluntary sector, TW is usually offered as an activity within a group context. Potential participants
either self-refer or are encouraged to attend. These groups tend to operate in a context in which actual
participation in TW is voluntary and non-participation tolerated. Such contexts enables potential
participants to try out (the mechanism here being trialability) the group – seeing for themselves how it
works and what goes on. A range of group related contexts appear to be important in influencing
potential participants to participate with a TW technique. With repeated attendance at the group,
potential participants can subjectively and objectively assess the (contextual influences of) degree of
tolerance, support and guidance (from others and the facilitator), the range of activities on offer,
voluntariness, interactivity of the group, and so on. These appear to trigger the mechanisms of perceptions
of benefits, safety and support. Potential participants feel safe to take part in TW, when they perceive that
they are likely to receive support from the group if potentially troubling emotions arise. If they perceive
subjective benefit, continuing participation is more likely to occur. The programme theory for facilitated
TW and unfacilitated EW are the same once a participant has decided to undertake TW. Within the realist
synthesis we were unable to clarify further the mechanisms of how different TW techniques are meant to
produce desired outcomes.
Strengths
Systematic review
The systematic reviews and realist synthesis were supported during all phases by the expert advice of four
TW professional practitioners. The systematic review has been undertaken following PRISMA criteria63 and
was registered with PROSPERO at the start of the project. Comprehensive database searches were adopted,
supplemented by checking citation lists, theses and grey literature and contacting experts in the field.
Selection criteria were developed to include only participants with documented diagnoses of LTCs and
the list of LTCs considered was generous, with careful consideration of whether or not specific medical
conditions could be considered long term (e.g. patients with bladder papilloma following resection).
No restrictions were applied regarding the intervention (i.e. all types of therapies falling within the TW
umbrella were considered). Included was any comparative study, not only RCTs, and careful consideration
of appropriate comparators was given; where the control intervention appeared to have an inadvertent
EW component, for example when patients with cancer were asked to write about the facts of their
treatment, these studies were not included.
The assessment was not restricted to stated primary outcomes only. Independent double data extraction
for all numerical data was used. The reporting of all results is very comprehensive and analyses were very
thorough. Study authors (32 out of 64 included studies) were contacted for missing numerical data and
14 responded. In the report results were categorised by ICD-10 code as a systematic way of dealing with
the very wide range of conditions in which TW had been investigated. Categorising by ICD-10 code is an
unusual way to present systematic review results, and can be used sensibly only when an intervention
can be applied to a wide range of conditions – in this case both psychiatric and physical conditions.
Meta-analyses were conducted both within and across conditions to fully explore any potential effects of
these interventions.
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Economic considerations
The review of published economic evidence was nested within a thorough systematic review, following
accepted methodological guidelines. An attempt was made to estimate the costs of TW from a NHS
perspective, based on information about the range of interventions provided in the included studies
and expert advice on how TW is used in practice. The cost–consequence summaries brought together
best-available evidence of effects on outcomes of importance to patients with simple estimates of NHS
costs for three illustrative case studies.
Realist synthesis
This realist synthesis has been undertaken following (where applicable) the RAMESES (Realist and
Meta-review Evidence Synthesis: Evolving Standards) quality standards for realist syntheses.146 Two
programme theories have been developed. Document selection and appraisal applied the principles of
relevance and rigour, and data extraction has focused on extracting data that are capable of supporting
programme theory refinement. Where possible, a realist logic of analysis has been applied to the data and
the synthesis has been reported following the RAMESES publication standards for realist syntheses.146
Reporting for the realist synthesis has been distributed across different sections of this report as some of
the processes used are similar to those of the systematic review. For example, the searching process of the
systematic review was used as the starting point of the realist synthesis. This also meant that the document
flow diagram is shared across both reviews. Additional searching (of a limited nature) was undertaken and
this has not been shown in the main document flow diagram (see Figure 1). Based on the focus of the
realist synthesis (to explain the outcome patterns found in the systematic review) no scoping of the
literature was undertaken. No changes were made to the initially planned review process other than a
much more limited additional searching due to time constraints. The RAMESES publication standards have
been followed and an overview of compliance may be found in Appendix 7.
Weaknesses
Systematic review
We were not able to identify a UK-based therapeutic practitioner of unfacilitated EW as an expert advisor.
We double checked only 10% of our retrieved titles and abstracts, so there is a risk that we missed relevant
studies; however, our 10% checks did show excellent agreement between reviewers. We did not exclude
studies in which the underlying condition was poorly described (e.g. patients with various cancers). The
facilitated/unfacilitated TW split was a post hoc decision based on the background literature21 and discussion
with the TW expert practitioners collaborating in the project. We tried to be consistent with our decisions
around selection of interventions and comparators, particularly in the meta-analyses, but not all interventions
and comparators were similar, introducing some heterogeneity. For example, when a study had two
interventions – one with positive writing and one with standard unfacilitated EW – the latter group was
selected. If a study had one intervention only, it would be included in the meta-analyses even if participants
were asked to write about positive aspects of their experience, particularly on the last day of writing.
A disadvantage of using ICD-10 codes to categorise studies meant we had a large number of categories,
often with relatively few studies in them, and this, in turn, constrained the sensitivity analyses that we
could conduct within these categories.
Studies not reporting any numerical data (raw scores or proportions for any one of the outcomes) were
excluded from the systematic review. Therefore, relevant studies might have been omitted. However,
strenuous efforts were made to contact study authors regarding missing data. Authors were not contacted
about study quality or when an explanation of a given instrument was not provided.
Many of the meta-analyses had high levels of statistical heterogeneity and should be interpreted with
caution. Additionally, meta-analyses are on small numbers only. A post hoc decision was made to conduct
overall meta-analyses across all LTCs for the outcomes of depression and anxiety. This decision was made
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before knowing the individual LTC meta-analyses results and was based on the large number of studies
reporting these outcomes, and their clinical usefulness as an exploratory analysis.
Regarding the study designs, both RCTs and non-RCTs were included but no sensitivity analyses of
randomisation compared with non-randomisation design were performed. This was because there were so
few studies within each ICD-10 code that further subdivision was thought to be unhelpful. We also did not
conduct any sensitivity analyses by study quality; we described study quality comprehensively but did not
use it further in our analyses.
We made a pragmatic decision not to investigate subgroup analyses within the included studies because
almost all appeared to be post hoc analyses, and the studies were not sufficiently powered for these
analyses. Therefore, we did not look for moderators, which was in the aims and objectives in our original
proposal. Regarding interventions, self-completion books were included as a TW intervention.
Economic considerations
The lack of evidence on cost and cost-effectiveness from published comparative studies was a major
challenge. Most studies did not report impact on health-care resource use, only 12 out of 64 studies
included such information.57,68,75,77,83,89,90,97,98,104,109,119 In addition, the reporting standards for resource use
in most papers were weak. It was also difficult to estimate the cost of the interventions in some studies,
owing to a lack of detail on the level of practitioner input. The diversity of the studied populations, the
inconsistent and sparse nature of the available effectiveness evidence, and, particularly, the lack of
evidence on QoL outcomes, made de novo decision modelling an unrealistic prospect.
Realist synthesis
Although searches were exhaustive, selection criteria for the realist synthesis could have been identified
earlier in order to conduct even more iterative searches. There was only one qualitative study147 identified
as being useful for the realist synthesis process. Additional searching would have been desirable as it
would have enabled more relevant data sources (especially those that contained potentially relevant
existing substantive theories) to have been identified. However, because of time constraints, only one
single round of additional searching specifically for the realist synthesis was undertaken. The absence of
these additional searches is likely to have impacted on the degree of the explanatory powers of the realist
synthesis. In addition, it was not possible to include the studies found in the updated search (to January
2015) in the realist synthesis.
The selection criteria for the realist review could have been more closely defined, or tailored earlier, in
order to capture more relevant literature. Studies investigating healthy students and non-comparative
studies were identified as a potentially useful tool for further programme theory development.
The development of the programme theory relied predominantly on the data contained within
randomised, non-randomised and case–control study data. Previous review teams have identified that the
data necessary for conducting a high-quality realist synthesis is often not found in RCTs. However, as the
included studies consisted of a broader range of study types and much larger numbers of studies than that
found in Dieleman et al.148 and Kane et al.149 it was anticipated during the project that sufficient data
would be available. To supplement the data within the studies included in the effectiveness review, two
additional searches were undertaken: one to look for studies on facilitated TW and the other for studies of
any type that reported on one or more of the included studies. Despite these two additional searches,
gaps in the data existed, which meant that it was not possible to fully elucidate and test a number of
aspects of the programme theories, such as:
l The mechanisms underlying the TW techniques encountered in this project. Additional searching for
data from different disciplines (e.g. humanities) might have been more informative. In addition, there
exists a large body of research on the use of unfacilitated EW in populations without LTCs and data
from this body of work might have been valuable in mechanism identification and elucidation.
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l The role of the group in facilitated TW requires greater elucidation. The realist synthesis identified a
number of contextual influences and mechanisms, but these are unlikely to be the only relevant ones.
A large body of work exists on groups in general and on therapeutic groups specifically. Further
searching in these areas would likely have provided further relevant data. The role and competencies of
the group facilitator also needs further elucidation and additional searching for data on this topic area
would have been helpful.
l The value placed by participants in TW on the presence of an audience was noted in some of the data.
This is another area with a large body of literature located within disciplines outside of health services
research that is worthy of further attention.
This is the first realist synthesis that has sought to develop a realist programme theory that attempts to
explain the outcome patterns for unfacilitated EW and facilitated TW when used for LTCs. In other words,
it is the first attempt that tries to unpack the black box of TW when used in a population with LTCs. The
programme theory provides potentially transferable knowledge about how these types of TW techniques
might fare under different contexts. However, an important caveat on this programme theory is that it
requires further development and refinement. This is because it includes only some of the relevant and
important mechanisms and related contextual triggers. The paucity of relevant data in the studies used to
develop and refine the programme theory has had an impact on both its detail and extent. In addition,
the strength of the inferences made has been affected by the rigour of the included studies. Many of the
outcomes reported within the included studies must be considered to be less trustworthy as a result of
the conduct of the studies. For example, all reported findings of benefits, harms, correlations and/or
associations were treated with caution when used in programme theory development. Findings that could
reasonably be considered to be more trustworthy were those that had not been as a result of statistical
manipulation and/or interpretation by the authors. Consideration was still given as to how such data were
generated, for example the interview method for qualitative data. The result is that many of the inferences
made in the development of the programme theory were often tentative. The implication is that further
testing and refinement of the programme theory is needed, through future secondary or primary research.
This project faced two significant methodological challenges in trying to undertake both a systematic
review and realist synthesis. The first related to the purpose of the realist synthesis and the other to human
resources required. The purpose of the realist synthesis was to explain the outcome patterns reported in
the studies included in the systematic review. Thus the realist synthesis was not able to proceed in earnest
until it had been clearly decided what the final set of included studies were for the systematic review.
This process for confirming the final set of included studies for the systematic review did not occur until
month 11/12 of the project. This meant that the realist synthesis could only begin in the last third of
the project. An additional related challenge that emerged from the focus of the realist synthesis was
around the nature of the included studies. About midway through the project, the expert advisors had
indicated that within the NHS and voluntary sector for LTCs, the main form of TW used was facilitated
TW. Only when the final set of included studies for the systematic review had been finalised and were
being analysed did it emerge that the vast majority of these related to the use of unfacilitated EW. This
unexpected finding meant that additional unanticipated work was needed in the realist synthesis, as it had
to develop one or more programme theories to make sense of both unfacilitated EW and facilitated TW.
In terms of human resource requirements, it must be kept in mind that both systematic reviews and realist
syntheses are labour intensive. Within this project the majority of the researchers time was devoted to the
systematic review. This meant that one of the two reviews had to be truncated – in this case the realist
synthesis. Once the included studies had been identified, data extraction, analysis and synthesis took place
in parallel for the systematic review and realist synthesis. As the project had only one full-time researcher
(OPN) and almost all of her time was devoted to the systematic review, less human resources allocation,
and time was available for the realist synthesis before the expected end date of the project. Within the
3-month time frame left to undertake the realist synthesis (especially in light of the additional work
needed, as explained above), it was not possible to undertake the additional searches that would be
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needed to more fully develop the programme theories for unfacilitated EW and facilitated TW. These
would have been especially important, as the studies included in the systematic review did not contain
sufficient relevant data. There was simply not the spare human resources capacity or time to do so.
The challenges mentioned above provide important lessons to review teams and funders who wish to
undertake both combined systematic reviews and realist syntheses.
(a) Sequencing If the purpose for undertaking a realist synthesis is to explain the outcome patterns of
studies included in a systematic review then additional time is likely to be needed to enable the
rigorous execution of the realist synthesis component. Identifying the included studies takes time and
the realist synthesis can pragmatically start only once it is clear what the included studies are. Its start
is thus delayed and it is likely that an additional minimum of 9 months (ideally 12–18 months) is
needed for a rigorous realist synthesis to take place. Review teams and funders need to expect that
such combined reviews are going to take longer to complete.
(b) Human resources Both systematic reviews and realist syntheses are labour intensive. Planning and
budgeting needs to reflect the need for additional researcher(s) time when a project gets to the stage
when data extraction, analysis and synthesis is taking place for both the systematic review and realist
synthesis. Otherwise, one or the other of the reviews is likely to suffer. Ideally, two different
individuals with sufficient funded time are needed with the necessary skill sets to undertake the
systematic review and realist synthesis separately.
Uncertainties
Systematic review
Most interventions evaluated were unfacilitated EW and did not mirror those currently used by professional
TW practitioners in clinical practice in the UK. The main uncertainty is the clinical effectiveness of TW as it
is practised by therapeutic practitioners, including within the NHS. It must be noted that the facilitated TW
interventions included in the systematic review do not mirror those used in current NHS practice. There is
insufficient clinically relevant evidence on facilitated TW as practised within these studies to know whether
or not it is beneficial. It is uncertain if unfacilitated EW might be harmful, particularly in psychotic patients,
but there was little evidence of harm in the studies evaluated.
Economic considerations
The economic case for the NHS to fund TW interventions for people with LTCs remains unproven.
Depending on the level of practitioner input, these interventions are likely to be relatively inexpensive, and
there is some evidence suggestive of possible cost savings related to reduced use of other health care,
although this evidence is sparse and inconsistent. The cost–consequence case studies also suggest that
there may be positive impacts on measures of health and well-being for some types of TW in some patient
groups but these are exploratory analyses. Until there is robust evidence of patient benefit, it is difficult to
conclude that TW would be a cost-effective use of NHS money.
Realist synthesis
Unfacilitated TW appears to have some effect in that the people who took part did notice some changes
to intermediate or more proximal outcomes. However, the outcome of interest was health functions of
some form, but TW does not seem to have much of an effect on this final desired outcome.
Within another realist synthesis, one could try to work out what outcomes (final desired and/or
intermediate/proximal) might be influenced by unfacilitated TW. This would be the programme theory
development aspect of a realist synthesis of unfacilitated TW. In this project we could touch on this only
because of insufficient relevant data. This further realist synthesis could try to build a more detailed realist
programme theory [i.e. one that further explains what has caused each outcome (final/intermediate) and
under what contexts], the causal force being the mechanism(s).
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We did not look at unfacilitated EW on healthy students but these studies may or may not inform what
outcomes (final/intermediate) might be possible with unfacilitated TW, under what contexts and what the
mechanisms might be. So there may be contexts within which it is reasonable to extrapolate what can be
learnt from the healthy students studies to those who are unhealthy – based on making (and if possible
testing) the assumption that the same mechanism(s) might be in operation under these different contexts.
The programme theory for unfacilitated EW and facilitated TW in LTCs highlights how complex these
interventions are. It cannot and should not be assumed that they will work as expected when applied in
differing contexts. The outcomes participants will get from TW are at present neither predictable nor
necessarily achieved. In addition, these outcomes are rarely the ones hoped for by the researchers who
have undertaken the primary studies included in the effectiveness reviews and realist synthesis. A number
of contexts appear to influence whether or not individuals will choose to participate and continue with
TW. In the real-world setting of clinical practice (such as in the NHS and voluntary sectors), due
consideration needs to be given to ensuring that these contexts exist (or can be made to) if there is to be
any hope that meaningful and continued participation in TW is to take place. Of note is that many of
these contextual influences are beyond the TW technique itself and sit in the wider world that surrounds
the individual and the TW technique. Despite the development of the programme theory, at present there
is too much uncertainty surrounding too many aspects of it to enable a firm recommendation to be made
about the benefits for the large-scale introduction of unfacilitated EW or facilitated TW into routine
clinical practice.
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Chapter 7 Conclusions
The systematic reviews and realist synthesis together with the economic considerations provided furtherand robust assessment of TW interventions across a broader range of chronic conditions than previously
published research.
The clinical utility of TW interventions must be questioned, particularly the unfacilitated type of EW
interventions frequently evaluated in different chronic conditions over almost two decades with no clear
benefit on physiological, physical, psychological or QoL outcomes. In the UK, professional TW practitioners
use other types of TW interventions, usually facilitated and with a variety of types of writing; however,
such interventions have not yet been formally trialled. In addition, there is little information on any adverse
effects of the evaluated TW and EW interventions, although increased negative mood immediately after
the unfacilitated EW exercise was reported in nearly all of the included studies that looked at this, and may
be worse among people with higher levels of baseline distress.
Further research
Realist synthesis
From the programme theory developed in the realist synthesis, it can be seen that further research might
fruitfully be conducted in a number of areas. The primary research to date where TW (facilitated or not) is
used to treat patients with LTCs appears to be highly under-theorised. Little is known about a number of
aspects of these interventions. Although it is possible that a further dedicated realist synthesis might be
able to make more sense of these intervention types, it is likely that greater mileage would be gained by
first conducting additional primary research, particularly in patients with LTCs. This is especially the case if
there is any intention to use unfacilitated EW for patients with LTCs. The existing studies demonstrate that
greater attention is needed on theorising why it might be that such an intervention type would even work
in the first place. In other words, in summary, better theorised TW interventions are first needed prior to
undertaking any further realist synthesis. To provide guidance the following three questions are probably
the most pressing areas to address with suitably designed primary research. This is because the answers to
the following questions are most likely to provide data that are relevant for further programme
theory refinement:
l Why do people with LTCs want, or not want, to participate in TW (of any type or form)?
l What do people with LTCs hope to get out of participating in TW (of any type or form)? How
and why?
l Which has a bigger influence on outcomes in facilitated TW, the group, the facilitator or the writing
technique? How and why?
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Unfacilitated emotional writing
l There are large numbers of RCTs of unfacilitated TW in a variety of LTCs. The results suggest that there
is no consistent and predictable benefit with this type of intervention. However, there may be some
conditions where further robustly designed research with adequate sample sizes, comparing TW
to usual care, might be useful, in particular, in people with substance misuse (because they may have
experienced considerable trauma), and in PTSD (because there is weak evidence of possible benefit
from the studies included in this review), or other areas in which people may have experienced
traumatic events and have difficulty expressing themselves. If further research in unfacilitated writing is
to be conducted, an explicit choice of patients and outcomes should be declared and CONSORT
(Consolidated Standards of Reporting Trials) guidelines should be followed.150 In view of the generally
poor quality of the evidence to date, attention to statistical power and the maintenance of study
quality are essential. Capturing any adverse events is important. Programme theory presented here
might be a useful starting point to help researchers conceptualise unfacilitated EW. For example, if
researchers are to investigate patients with COPD there needs to be a coherent and plausible reason as
to why they think that FEV1 might be affected by TW. It would be very useful if standard outcomes for
the different conditions were measured [COMET (Core Outcome Measures in Effectiveness Trials)]151 to
facilitate comparison with other interventions and length of follow-up should be considered.
l From the current research base, there are few data on patients understanding of, or expectations from,
unfacilitated EW. Most of the trials appear to be explanatory and, in many cases, the researchers were
at pains to withhold all information from participants about the possible nature of the intervention
before they were randomised. If further research on unfacilitated EW in a health context is conducted,
we recommend including qualitative studies to explore patients’ understanding of, and experience of
undergoing, EW interventions.
Facilitated therapeutic writing
l An audit of the types of TW currently being used in the NHS in both primary and secondary care would
be very useful.
l Further, robust research into the facilitated TW interventions that are used in clinical practice and the
voluntary sector is recommended. Developmental work on the role of the facilitator, TW and group
dynamics would be required. Some TW disciplines are very well developed but have not yet been
formally evaluated in clinical settings.16 Programme theory presented here might be a useful starting
point to help researchers conceptualise facilitated TW. Development work and feasibility or pilot studies
should probably be conducted prior to full evaluation. Cluster RCTs and studies of other appropriate
designs could be conducted on these interventions, evaluating patients with chronic physical or mental
ill health. The comparators could be standard practice without TW or other comparable therapeutic
interventions, such as relaxation CDs or reading bibliotherapy. Outcomes would be the standard clinical
outcomes for the patient’s medical condition, and patient satisfaction, HRQoL and costs. The sample
sizes would need to be large enough to find a potentially modest effect.
CONCLUSIONS
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Victoria Field’s perspective
A practitioner’s perspective: some snapshots
Types of writing
I concur with the list that Carol Ross provided – these are tried-and-tested writing suggestions that have
therapeutic potential.
Rather than techniques being necessarily applicable to certain diagnoses, my own model is more to do
with the level of wellness of the person or the group. The techniques are adapted according to the
following continuums:
1. Containing factors
These keep the process safe and accessible.
(a) Length of time For someone in distress, writing for a minute might be sufficient.
(b) Length of writing Sometimes, for someone withdrawn, one word might be the starting point.
(c) Amount of direction/structure Structured suggestions can help with inchoate material.
2. Complexity
Tolerance of complexity is a marker of mental health and I would use TW techniques that encourage
nuanced responses with a more well population or with a group that has been meeting for a while.
This determines the kinds of writing suggestions I make, such as:
(a) metaphor – narrative
(b) direct – elaborated
(c) first-person – second-person – third-person writing
(d) single perspective – multiple perspective.
3. Focus
(a) Self – others – wider world These dimensions are all important to understanding experience – as a
practitioner, I make judgements about when it is appropriate to encourage writing in a different direction.
(b) Pain/distress – positive aspects of life – as above There is evidence that it is important to acknowledge
a sense of victimhood before beginning to write a new story.
(c) Past – present – future Again all are important but for example, the very elderly often appreciate
writing that stays in the moment, especially nature writing.
Settings
My experience with TW includes the following health-care settings in which patients had LTCs, and we
worked in groups unless otherwise stated:
1. stroke rehabilitation unit – some group work and one-to-one at the bedside
2. Arts for Older People – in care homes
3. Age Concern day centre
4. day treatment centre for people with severe and enduring mental illness
5. primary care – a health centre attached to a GP practice
6. one-to-one with a dementia patient in her home (referred by an occupational therapist) and,
subsequently, on a psychogeriatric inpatient ward.
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I have also worked in the following community settings in which participants have often had mental health
issues, some severe and enduring, and other LTCs, but these were not the primary reason for attending.
For example, the library promotional literature said service users welcome but people were not required to
self-identify.
1. St Petroc’s Centre, offering services for street homeless people
2. open-access sessions in public libraries
3. Adult education Writing for Self-Discovery courses
4. Truro Cathedral (was writer-in-residence in 2006).
I also supervised a number of pilot projects in TW by other practitioners, which included the following
client groups as part of an Arts Council England-funded Arts in Health project:
1. prisoners at risk of self-harm
2. children in hospital long term
3. long-term unemployed
4. patients at a GP surgery with mild depression
5. women at a clinic for pelvic pain.
The model for my intervention is a psychosocial rather than medical one. However, the outcomes can be
measured in medical terms.
There follows a couple of examples that might exemplify some of approaches, justifications and outcomes:
l On the stroke unit, I was part of a multi-art form team offering afternoon sessions for a year as a way
of preventing boredom and depression, which, in turn, had an impact on motivation to get well,
which, in turn, impacts on length of stay. Elevated mood was seen as a way of making it more likely
patients would do the physiotherapy prescribed, for example.
The different art forms worked best with different patients but one characteristic of the writing was that it
enabled catharsis and safe expression of emotions, such as despair and hopelessness, which were not
permitted with medical staff or family: permission to be oneself is a characteristic of TW.
The average length of time on the unit was 96 days; to justify the intervention financially, this would need
to reduce by 4.4 days per patient. The full report is available from: www.artsforhealthcornwall.org.uk/
wp-content/uploads/2010/10/Arts-for-Stroke-Rehabilitation-Evaluation.pdf
l On the Arts for Older People project in care homes (also an Arts for Health Cornwall and Isles of Scilly
initiative), the improvements were mostly social and psychological – I feel all twinkly (care home
resident) – but there are benefits from just moving residents into a group setting that indirectly led to
more interaction and motivation to be more mobile, which, in turn, might help with constipation and
the other common problems of being sedentary (summarised as poetry makes you poo).
The work can also change perceptions and lead to better care. One participant, relatively young, a retired
headmaster, who had had a stroke and was severely depressed, was wheeled in to weekly care home
sessions and never spoke nor made eye contact until the sixth session when he contributed one word and
then smiled; subsequently, speech therapy was accessed and he made considerable progress.
Victoria Field, 9 May 2013
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Appendix 2 Realist synthesis: expert practitioners’
feedback
TABLE 76 Carol Ross: views on how TW was meant to work, for whom and why
INTERVENTION PROCESS/ASPECTS
OF THE INTERVENTION: What do
you do and why?
RECRUITMENT/SUITABILITY: Who is
it suitable for and why?
OUTCOMES IMPACT: What do
you hope to achieve and why?
Note on duration of writing: In my sessions in MH units, the writing done in the exercises listed below lasts from 2-minute
bursts to 15 minutes. Most often writing is 5–10 minutes in duration and 25–30 minutes in total for a 1-hour session
(very brief writing is the subject of this research article: Burton and King152)
Writing about positive experiences,
or positive aspects of situations
Why: People with MH problems can
become totally focused on their
problems and lose interest in their
normal life. I have been influenced by
the research of Laura King and
collaborators (e.g. Burton and King,153,154
Mackenzie et al.155)
Flexible enough to be used in PICU and
adult and older people’s MH units.
The technique is good for most MH
problems, but I do not use, or else use
with caution, when people are severely
depressed because they can turn even
positive writing around to be negative
Increased positivity and motivation
Lifted mood
Rediscovery of remembered
interests and pleasures
Focus on exceptions to their
problem-saturated life
Hope
Mindful writing about the world –
notice something in the world and
write to describe it in detail
Why: Mindfulness is recognised to be
useful in MH conditions and has been
incorporated into therapies such
as Dialectical Behaviour Therapy
(McKay et al.,156 chapter 3)
Very helpful in all of the MH units in
which I work, and something I
recommend as daily practice. I use an
adapted form frequently in PICU –
writing to describe large landscape
photographs. Especially useful when
someone is experiencing symptoms of
mania, psychosis, anxiety, agitation,
stress
Calming
Increased mental focus
Increased interest in the real world
Grounding
External perspective
Respite/distraction
Mindful expressive writing – how I
feel right now
In a ward situation I would say scan
body from toes to top of head writing
about how each part of the body feel,
and then move on to write about
thoughts and feelings right now
Why: Mindfulness is recognised to be
useful in MH conditions and has been
incorporated into therapies such
as Dialectical Behaviour Therapy
(McKay et al.,156 chapter 3). See also
Poon and Danoff-Burg157
Not something I use in PICU or, so far,
with older people but I do use it in the
general adult MH unit with people who
are well enough to manage to do it.
When these individuals are sufficiently
recovered, I recommend this, along
with mindful writing about the world,
as daily practice to people with MH
issues. Many people who find
meditation difficult are able to do
mindful writing instead
Calming
Shift of focus from past/present
worries to the here and now
Insight
Clarification of thoughts and
feelings
With regular practice can look
back at how things have changed
Creating a fictional character and
writing about them. I start with a
variety of prompts such as photographs
of (unknown) people, pieces of fabric, a
character questionnaire
Why: To raise awareness of others’ lives
and shift focus away from self. No
reference – I developed this one based
on my own observations of MH
inpatients
I find this useful in all of the MH units
in which I work. Especially useful where
someone is completely wrapped up in
themselves and their own problems.
I have found this useful in individuals
with MH problems from severe
depression to personality disorder to
paranoid schizophrenia
Perspective shift away from self
and own problems
External focus
Could help with emotional
connections and relationships
Respite/distraction
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TABLE 76 Carol Ross: views on how TW was meant to work, for whom and why (continued )
INTERVENTION PROCESS/ASPECTS
OF THE INTERVENTION: What do
you do and why?
RECRUITMENT/SUITABILITY: Who is
it suitable for and why?
OUTCOMES IMPACT: What do
you hope to achieve and why?
Neutral writing exercises that I expect
will elicit memories in many individuals,
e.g. older people writing about objects
they would have used in the past
Why: This is a low pressure way of
eliciting memories – rather than show
an object and asking people to write
about a memory evoked by the object,
I ask individuals to write about the
object and what it makes them think of
Suitable in all MH units as above but
particularly helpful with older people
and people with Alzheimer’s disease if
they are able to do it
Stimulation of memory
Enjoyment
Comfort
Social benefits – past experiences
the individual remembers can
then form topics of conversation
with family/visitors/other patients
and so help with emotional
connections and relationships
Second- and third-person writing
and unsent letters
This type of writing is very varied,
e.g. someone could write a letter from
a future version of him/her, who is well,
to a person who helped and inspired
them in their recovery, or someone
could write a third-person account of a
conversation from the other person’s
point of view
Why: To change perspective in some
way, e.g. externalising a problem.
Example reference: East et al.158
Very useful in MH settings. I do not use
often in PICU because the inpatients
tend to be too unwell to do this sort of
writing. I have found this type of
writing helpful with people with
different problems from personality
disorder to bereavement. Some voice-
hearing patients find it helpful to write
letters to their voice, for example
Insight
Externalisation of problem
Closure
Catharsis
Acceptance
Empathy
Hope
Perspective shift
Could help with emotional
connections and relationships
Visualisation writing, e.g. imagining
oneself into a landscape or building or
on a journey
I prompt the writing with a photograph
or a short piece of writing about
their favourite way of travelling, or
(occasionally) with a guided
visualisation
Why: Stimulating the imagination, a
positive flight of fancy, a visit to a world
outside the ward environment
I often use variations on this idea with
working age MH inpatients, and have
had some success even with someone
who was severely depressed
Stimulating interest in the world
Motivation
Respite/distraction
Writing in response to a fairly random
prompt such as single words, symbols,
shapes, colours
Often the writing is freewriting (writing
fast without stopping to think or
correct anything)
Why: Very flexible, minimal structure,
freeing up the writing and allowing the
individual to write whatever comes into
their mind
I use this in the adult MH unit mainly,
but also with some patients in PICU.
This type of writing, e.g. using symbols
and metaphor, can be especially useful
with people who have schizophrenia.
However, I would not use where
individuals are clearly manic, psychotic
or voice hearing at the time of the
session
It’s difficult to predict what the
effects will be with this sort of
exercise but it can bring out
unexpected/subconscious
thoughts and can spark an
interest in doing more writing –
which can be helpful
Could help with freeing up
mental blocks
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TABLE 76 Carol Ross: views on how TW was meant to work, for whom and why (continued )
INTERVENTION PROCESS/ASPECTS
OF THE INTERVENTION: What do
you do and why?
RECRUITMENT/SUITABILITY: Who is
it suitable for and why?
OUTCOMES IMPACT: What do
you hope to achieve and why?
Poetry therapy – writing in response
to selected published poems
Why: They can reflect common
experiences, clear or metaphorical. Also
thought provoking and stimulates
group discussion
Suitable for anyone in a MH unit who is
capable of doing the exercise
Recognition that others have
similar problems
Stimulating interest in the world
apart from self and problems
Self-expression
Insight
Hope
Positivity
Re-writing a memory – not to change
or block it but to express the memory
with a shift of perspective, e.g.
re-writing a memory to show how the
individuals strengths helped them get
through it
Why: To shift perspective about a
traumatic or difficult memory so that it
can become less dominant
I believe this could be very useful in
conditions such as PTSD and for
survivors of abuse (as many MH
patients are). This kind of idea,
although not written, is at the heart of
narrative therapy. I have suggested
this kind of writing to one or two
individuals as something they might try
for themselves, but have not as yet
used it in a group setting
Externalising and reducing the
emphasis on problems
Seeing the past from a more
helpful perspective
Seeing the future in a more
hopeful light
Structured journal techniques, e.g.
write one word every hour, for a whole
day, which sums up how you feel right
then, or write a daily journal containing
only positives
Suitable for anyone, I would think, as
long as the techniques are tailored for
the individual. Unstructured journals
can also be very helpful too – pouring
out one’s thoughts and feelings to an
impartial observer. I would worry about
people, who are of completely negative
thinking, writing an unstructured
journal, however, because writing
down negative thoughts repeatedly is
likely to reinforce them
Depends on technique used:
self-expression, positive thinking,
motivation, insight, catharsis,
clarification of thoughts and
feelings, coming to terms with
things
Creative writing in a group, e.g.
collaborative poems, each writing the
story depicted by a picture
Why: To give participants a
thought-provoking, surprising,
enjoyable group experience
This is a bit different. This kind of
exercise works best with a group in
which all participants are well enough,
and thinking clearly enough, to manage
it. Of all the exercises, this one is as
much about group members sharing
and relating to each other as about
what is actually written in the exercise
Lifted mood
Increased self-esteem and
confidence
Group bonding
External focus
Could help with emotional
connections and relationships
Respite/distraction
continued
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TABLE 76 Carol Ross: views on how TW was meant to work, for whom and why (continued )
INTERVENTION PROCESS/ASPECTS
OF THE INTERVENTION: What do
you do and why?
RECRUITMENT/SUITABILITY: Who is
it suitable for and why?
OUTCOMES IMPACT: What do
you hope to achieve and why?
Benefit finding about an illness or
problem, for example what are you
able to do, or do more of, since having
the illness that you couldn’t do
previously
Why: Change perception of illness to
help with acceptance. Example
references: King and Milner;159
Danoff-Burg and Mosher160
Not something I use with MH inpatients
but I can see it could be helpful with
some long-term physical conditions
Increased positivity and motivation
Improved acceptance of illness
Decreased focus on illness
Insight
Head chatter – writing everything that
comes into your head for a timed
period, say 5 minutes
Why: To clear the mind, for example
before going to bed or before doing a
writing session
I believe this to be a good daily journal
practice for many people, e.g. doing
this late evening every day could help
with sleep. However, I never use this in
MH units because it is too unstructured,
which means it is difficult for most
inpatients to do and could well give
opportunity for a voice or negative
thoughts to dominate the writing
Clearing the mind of a confused
jumble of thoughts
Calming
Increased mental focus
Can bring out unexpected/
subconscious thoughts and help
with freeing up mental blocks
Expressive writing about illness/
problem/trauma – write your deepest
thoughts about . . . along the lines of
Pennebaker and Beal1
Why: Expressing one’s deepest
thoughts and feelings in writing can be
easier than speaking them aloud
Not something I use in inpatient MH
units but I can see that it could be
helpful, e.g. in long-term physical
conditions and with undisclosed
trauma. In inpatient MH units, I believe
this kind of writing should be either at
the individual’s instigation or that of
his/her clinical psychologist/psychiatrist
and under that clinician’s guidance.
Some individuals write in this way
during sessions or in between group
sessions, but not at my direction. Some
individuals ask me to pass this type of
writing to their named nurse, or to
shred it, which I do
Insight
Catharsis
Getting to the point of being able
to talk to therapist
Improved self-expression
Clarification of thoughts and
feelings
Coming to terms with illness/
problem
Acceptance
MH, mental health; PICU, paediatric intensive care unit.
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TABLE 77 Victoria Field: views on how TW was meant to work, for whom and why
RECRUITMENT/SUITABILITY:
Who is it suitable for and
why?
INTERVENTION PROCESS/ASPECTS
OF THE INTERVENTION: What do
you do and why?
OUTCOMES IMPACT: What do you hope
to achieve and why?
General population with mild
anxiety and/or depression:
Can be due to ongoing
mental health problems, life
circumstances, such as
bereavement, divorce, or caring
responsibilities, or LTCs or
adjustment to disability or just
being at that difficult stage
between birth and death
Reflective writing – a whole variety
of writing prompts (including lists, free
writing, acrostics, dialogues, mind
maps, responding to images, music,
environment, realia, fictionalising) –
this writing may be kept private or
shared
l Using the reflective writing as a
means of processing, e.g. using
deeper prompts, questioning
the material that arises,
proprioreceptive writing. This
stage is important to prevent
someone writing themselves into
a dark place and where the
interactive aspect of the process
is crucial
l Using published poems as stimuli
for writing
l Doing all of the above in a group
Connection with self and inner processes
l Catharsis
l Emotional expression
l Ability to observe self from outside
l Reality orientation
l Encouraging mindfulness
l Encouraging clearer articulation
Reducing black-and-white thinking
l Introducing possibilities
l Establishing mastery over both writing
and self
l Promoting resilience
l Promoting a sense of agency
Isoprinciple, i.e. other people have similar
feelings, which offers solace
l Pleasure in responding to an artistic
artefact
l Containment of complex feelings
l Tolerance of ambiguity
l Developing AND-AND thinking –
especially useful with LTCs
l Exercise of imagination
l Ability to reflect on experience rather
than remain within it
l Ability to transform experience into art
Sense of connection – with self, great
literature, the human condition
l Sense of community endeavour
l Being heard, given equal status
l Validation of emotions – happy and sad
l Pleasure and surprise
l Sense of common humanity AND
individuality
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Appendix 3 Original systematic review searches
TABLE 78 Databases and time span of the searches
Database Time span of the search (mapping search) Provider (platform)
AMED From 1985 to March 2013 Ovid
ASSIA 1987–week 12 2013 ProQuest
CAB Abstracts From 1973 to week 11 2013 Ovid
The Campbell Collaboration Library of
Systematic Reviews
From 2005 to Issue #4, Volume 9 2013 The Campbell Library
CENTRAL From 1992 to Issue 1 of 12, January 2013 The Cochrane Library
CDSR From 1992 to Issue 2 of 12, February 2013 The Cochrane Library
CINAHL 1981–week 12 March 2013 EBSCOhost
DARE From 1994 to Issue 1 of 4, January 2013 The Cochrane Library
EMBASE From 1974 to 11 March 2013 Ovid
ERIC 1966–18 March 2013 ProQuest
HTA Database Issue 1 of 4, January 2013 The Cochrane Library
Linguistic and Language Behaviour
Abstracts (LLBA)
1973–18 March 2013 ProQuest
MEDLINE From 1946 to 11 March 2013 Ovid
NHS EED From 1995 to February 2013 The Cochrane Library
PEDro 1929–4 March 2013 Centre for Evidence-Based
Physiotherapy/University of
Sydney
Periodicals Index Online (PIO) 1665–95 ProQuest
PILOTS 1871–18 March 2013 ProQuest
PsycINFO From 1806 to March week 2 2013 Ovid
SSCI 1970–15 March 2013 Web of Knowledge
SCI 1970–15 March 2013 Web of Knowledge
Zetoc 1993–18 March 2013 Mimas
CAB Abstracts: the monitoring and search service for global research publications; NHS EED, NHS Economic
Evaluation Database.
Zetoc: the monitoring and search service for global research publications.
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Search strategy
TABLE 79 MEDLINE (via Ovid) searches
# Search term
1 chronic*.mp
2 ((persistent or (long* adj term) or ongoing or degenerative) adj3 (disease* or disab* or ill* or condition* or (health
adj condition*) or (medical adj condition*) or impairment)).tw.
3 LONG TERM CARE/
4 (long* adj term adj care).tw.
5 exp CARDIOVASCULAR DISEASE/
6 ((heart adj disease*) or (heart adj failure) or (myocardial adj ischemia) or (angina adj pectoris) or (coronary adj
disease*) or (coronary adj artery adj disease*) or (myocardial adj infarction) or hypertension or (high adj blood adj
pressure)).tw.
7 exp LUNG DISEASES OBSTRUCTIVE/
8 ((obstructive adj lung adj disease*) or (obstructive adj pulmonary adj disease*) or copd or asthma or bronchitis).tw.
9 exp EMPHYSEMA/
10 exp PULMONARY EMPHYSEMA/
11 emphysema.tw.
12 exp CEREBROVASCULAR DISORDERS/
13 ((cerebrovascular adj disease*) or (cerebrovascular adj disorder*) or (brain adj ischemia) or (cerebral adj infarction)
or (carotid adj artery adj disease*) or stroke or epilep*).tw.
14 exp NEURODEGENERATIVE DISEASES/
15 (neurodegenerative or (Huntington* adj disease) or (Parkinson* adj disease) or (amyotrophic adj lateral adj
sclerosis) or (motor adj neuron* adj disease)).tw.
16 exp MULTIPLE SCLEROSIS/
17 (multiple adj sclerosis).tw.
18 exp INFLAMMATORY BOWEL DISEASES/
19 IRRITABLE BOWEL SYNDROME/
20 ((inflammatory adj bowel) or (irritable adj bowel)).tw.
21 Kidney disease/
22 ((renal adj failure*) or (renal adj insufficienc*) or (kidney adj failure*) or (kidney adj insuffcienc*)).tw.
23 DIABETES MELLITUS/
24 (diabetes or diabetic*).tw.
25 exp ARTHRITIS/
26 exp RHEUMATIC DISEASE/
27 (arthritis or osteoarthritis or rheumati* or fibromyalgia).tw.
28 exp low back pain/
29 exp backache/
30 NECK PAIN/
31 ((back adj pain) or (neck adj pain)).tw.
32 exp OSTEOPOROSIS/
33 osteoporosis.tw.
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TABLE 79 MEDLINE (via Ovid) searches (continued )
# Search term
34 exp THYROID DISEASE/
35 exp NEOPLASMS/
36 (cancer* or oncolog* or neoplasm* or carcinom* or tumo?r* or malignan*).tw.
37 exp HIV INFECTIONS/
38 ((hiv adj infect*) or (hiv adj disease*)).tw.
39 ENDOMETRIOSIS/
40 endometriosis.tw.
41 exp MENTAL DISORDERS/
42 DEPRESSION/
43 ((mental* adj ill*) or (mental adj disorder*) or (mental adj disease*) or (mental adj distress*) or (mental adj disab*)
or (mental adj problem*) or (mental adj health*) or (mental adj patient*) or (mental adj treatment) or (psychiatr*
adj ill*) or (psychiatr* adj disorder*) or (psychiatr* adj disease*) or (psychiatr* adj distress*) or (psychiatr* adj
disab*) or (psychiatr* adj problem*) or (psychiatr* adj health*) or (psychiatr* adj patient*) or (psychiatr* adj
treatment) or (psychological* adj ill*) or (psychological*ADJ and disorder*) or (psychological* adj disease*) or
(psychological* adj distress*) or (psychological* adj disab*) or (psychological* adj problem*) or (psychological* adj
health*) or (psychological* adj patient*) or (psychological* adj treatment)).tw.
44 ((personality adj disorder*) or (mood adj disorder*) or (dysthymic adj disorder*) or (cognit* adj disorder*) or
(anxiety adj disorder*) or (stress adj disorder*) or (eating adj disorder*) or (adjustment adj disorder*) or (reactive
adj disorder*) or (somatoform adj disorder*) or (conversion adj disorder*) or (behavio* adj disorder*) or (percept*
adj disorder*) or (psycho* adj disorder*) or (impulse adj control adj disorder*) or (development* adj disorder*)).tw.
45 (psychos#s or psychotic* or paranoi* or schizo* or neuros#s or neurotic* or delusion* or depression or depressive
or bipolar or mania or manic or obsessi* or compulsi* or panic or phobic or phobia or anorexia or bulimia or
neurastheni* or dissociative or affective or borderline or narcissis* or suicid* or (self adj injur*) or (self adj harm) or
dementia or Alzheimer*).tw.
46 or/1-45
47 ((writ* adj therap*) or (therapeutic* adj writ*) or (writ* adj cure*) or (writ* adj heal*) or (self adj management adj
writ*) or (self adj help adj writ*) or (self adj conceal* adj writ*) or (self adj disclosure adj writ*) or (creative adj
writ*) or (expressi* adj writ*) or (emoti* adj writ*) or (EMO adj writ*) or (sensitiv* adj writ*) or (sensor* adj writ*)
or (reactive adj writ*) or (reflective adj writ*) or (descriptive adj writ*) or (biography* adj writ*) or (workshop adj
writ*) or (epistolar* adj writ*) or (fiction* adj writ*) or (paradigm adj writ*) or (group adj writ*) or (letter* adj
writ*) or (Pennebaker adj writ*) or (reminiscence adj review*) or (story adj writ*) or (stories adj writ*) or blog* or
forum* or (memoir* adj writ*) or (journal* adj writ*) or (narrative* adj writ*) or (hand adj writ*) or (poe* adj
writ*) or (health adj status adj writ*) or “program* writ*”).tw.
48 ((emoti* adj disclosure adj tip*) or (emoti* adj disclosure adj key*) or (emotional adj disclosure adj writ*) or
(emotio* adj disclosure) or catharsis).tw.
49 ((express* or creativ* or emoti* or sensitiv* or reflect* or therap* or disclos* or conceal* or manag* or
pennebaker or cathar* or “writing paradigm”) adj2 (writ* or “hand writ*” or blog or epistol* or letter* or story or
stories or memoir* or narrat* or diary or diaries or poem or poet* or reminisc* or “life review” or “life writing” or
journaling or “Journal Writing” or (“health status” adj2 writ*) or “program* writ*”)).tw.
50 46 and 49
51 47 and 48
52 Writing/
53 46 and 52
54 50 or 51 or 52
DOI: 10.3310/hta20270 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 27
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Nyssen et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
225
TABLE 80 EMBASE (via Ovid) searches
# Search term
1 chronic*.mp.
2 ((persistent or (long* adj term) or ongoing or degenerative) adj3 (disease* or disab* or ill* or condition* or (health
adj condition*) or (medical adj condition*) or impairment)).tw.
3 LONG TERM CARE/
4 (long* adj term adj care).tw.
5 exp CARDIOVASCULAR DISEASE/
6 ((heart adj disease*) or (heart adj failure) or (myocardial adj ischemia) or (angina adj pectoris) or (coronary adj
disease*) or (coronary adj artery adj disease*) or (myocardial adj infarction) or hypertension or (high adj blood adj
pressure)).tw.
7 exp LUNG DISEASES OBSTRUCTIVE/
8 ((obstructive adj lung adj disease*) or (obstructive adj pulmonary adj disease*) or copd or asthma or bronchitis).tw.
9 exp EMPHYSEMA/
10 exp PULMONARY EMPHYSEMA/
11 emphysema.tw.
12 exp CEREBROVASCULAR DISORDERS/
13 ((cerebrovascular adj disease*) or (cerebrovascular adj disorder*) or (brain adj ischemia) or (cerebral adj infarction)
or (carotid adj artery adj disease*) or stroke or epilep*).tw.
14 exp NEURODEGENERATIVE DISEASES/
15 (neurodegenerative or (Huntington* adj disease) or (Parkinson* adj disease) or (amyotrophic adj lateral adj
sclerosis) or (motor adj neuron* adj disease)).tw.
16 exp MULTIPLE SCLEROSIS/
17 (multiple adj sclerosis).tw.
18 exp INFLAMMATORY BOWEL DISEASES/
19 IRRITABLE BOWEL SYNDROME/
20 ((inflammatory adj bowel) or (irritable adj bowel)).tw.
21 Kidney disease/
22 ((renal adj failure*) or (renal adj insufficienc*) or (kidney adj failure*) or (kidney adj insuffcienc*)).tw.
23 DIABETES MELLITUS/
24 (diabetes or diabetic*).tw.
25 exp ARTHRITIS/
26 exp RHEUMATIC DISEASE/
27 (arthritis or osteoarthritis or rheumati* or fibromyalgia).tw.
28 exp low back pain/
29 exp backache/
30 NECK PAIN/
31 ((back adj pain) or (neck adj pain)).tw.
32 exp OSTEOPOROSIS/
33 osteoporosis.tw.
34 exp THYROID DISEASE/
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TABLE 80 EMBASE (via Ovid) searches (continued )
# Search term
35 exp NEOPLASMS/
36 (cancer* or oncolog* or neoplasm* or carcinom* or tumo?r* or malignan*).tw.
37 exp HIV INFECTIONS/
38 ((hiv adj infect*) or (hiv adj disease*)).tw.
39 ENDOMETRIOSIS/
40 endometriosis.tw.
41 exp MENTAL DISORDERS/
42 DEPRESSION/
43 ((mental* adj ill*) or (mental adj disorder*) or (mental adj disease*) or (mental adj distress*) or (mental adj disab*)
or (mental adj problem*) or (mental adj health*) or (mental adj patient*) or (mental adj treatment) or (psychiatr*
adj ill*) or (psychiatr* adj disorder*) or (psychiatr* adj disease*) or (psychiatr* adj distress*) or (psychiatr* adj
disab*) or (psychiatr* adj problem*) or (psychiatr* adj health*) or (psychiatr* adj patient*) or (psychiatr* adj
treatment) or (psychological* adj ill*) or (psychological*ADJ and disorder*) or (psychological* adj disease*) or
(psychological* adj distress*) or (psychological* adj disab*) or (psychological* adj problem*) or (psychological* adj
health*) or (psychological* adj patient*) or (psychological* adj treatment)).tw.
44 ((personality adj disorder*) or (mood adj disorder*) or (dysthymic adj disorder*) or (cognit* adj disorder*) or
(anxiety adj disorder*) or (stress adj disorder*) or (eating adj disorder*) or (adjustment adj disorder*) or (reactive
adj disorder*) or (somatoform adj disorder*) or (conversion adj disorder*) or (behavio* adj disorder*) or (percept*
adj disorder*) or (psycho* adj disorder*) or (impulse adj control adj disorder*) or (development* adj disorder*)).tw.
45 (psychos#s or psychotic* or paranoi* or schizo* or neuros#s or neurotic* or delusion* or depression or depressive
or bipolar or mania or manic or obsessi* or compulsi* or panic or phobic or phobia or anorexia or bulimia or
neurastheni* or dissociative or affective or borderline or narcissis* or suicid* or (self adj injur*) or (self adj harm) or
dementia or Alzheimer*).tw.
46 or/1-45
47 ((writ* adj therap*) or (therapeutic* adj writ*) or (writ* adj cure*) or (writ* adj heal*) or (self adj management adj
writ*) or (self adj help adj writ*) or (self adj conceal* adj writ*) or (self adj disclosure adj writ*) or (creative adj
writ*) or (expressi* adj writ*) or (emoti* adj writ*) or (EMO adj writ*) or (sensitiv* adj writ*) or (sensor* adj writ*)
or (reactive adj writ*) or (reflective adj writ*) or (descriptive adj writ*) or (biography* adj writ*) or (workshop adj
writ*) or (epistolar* adj writ*) or (fiction* adj writ*) or (paradigm adj writ*) or (group adj writ*) or (letter* adj
writ*) or (Pennebaker adj writ*) or (reminiscence adj review*) or (story adj writ*) or (stories adj writ*) or blog* or
forum* or (memoir* adj writ*) or (journal* adj writ*) or (narrative* adj writ*) or (hand adj writ*) or (poe* adj
writ*) or (health adj status adj writ*) or “program* writ*”).tw.
48 ((emoti* adj disclosure adj tip*) or (emoti* adj disclosure adj key*) or (emotional adj disclosure adj writ*) or
(emotio* adj disclosure) or catharsis).tw.
49 ((express* or creativ* or emoti* or sensitiv* or reflect* or therap* or disclos* or conceal* or manag* or
pennebaker or cathar* or “writing paradigm”) adj2 (writ* or “hand writ*” or blog or epistol* or letter* or story or
stories or memoir* or narrat* or diary or diaries or poem or poet* or reminisc* or “life review” or “life writing” or
journaling or “Journal Writing” or (“health status” adj2 writ*) or “program* writ*”)).tw.
50 46 and 49
51 47 and 48
52 Writing/
53 46 and 52
53 50 or 51 or 53
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TABLE 81 The Cochrane Library: CENTRAL, DARE and NHS EED searches
# Search term
1 chronic*
2 ((persistent or “long* term” or ongoing or degenerative) near/2 (disease* or disab* or ill* or condition* or “health
condition*” or “medical condition*” or impairment))
3 MeSH descriptor: [Long-Term Care] explode all trees
4 long* term care
5 MeSH descriptor: [Cardiovascular Diseases] explode all trees
6 “heart disease*” or “heart failure” or “myocardial ischemia” or “angina pectoris” or “coronary disease*” or
“coronary artery disease*” or “myocardial infarction*” or hypertension or “high blood pressure”
7 MeSH descriptor: [Lung Diseases, Obstructive] explode all trees
8 “obstructive lung disease*” or “obstructive pulmonary disease*” or copd or asthma or bronchitis
9 MeSH descriptor: [Emphysema] explode all trees
10 MeSH descriptor: [Pulmonary Emphysema] explode all trees
11 emphysema
12 MeSH descriptor: [Cerebrovascular Disorders] explode all trees
13 “cerebrovascular disease*” or “cerebrovascular disorder*” or “brain ischemia” or “cerebral infarction” or stroke
or epilep*
14 MeSH descriptor: [Neurodegenerative Diseases] explode all trees
15 neurodegenerative or “Huntington* disease” or “Parkinson* disease” or “amyotrophic lateral sclerosis” or “motor
neuron* disease”
16 MeSH descriptor: [Multiple Sclerosis] explode all trees
17 Multiple Sclerosis
18 MeSH descriptor: [Irritable Bowel Syndrome] explode all trees
19 MeSH descriptor: [Inflammatory Bowel Diseases] explode all trees
20 inflammatory bowel or “irritable bowel”
21 MeSH descriptor: [Kidney Diseases] explode all trees
22 MeSH descriptor: [Renal Insufficiency] explode all trees
23 “renal failure*” or “renal insufficienc*” or “kidney failure*” or “kidney insufficienc*”
24 MeSH descriptor: [Diabetes Mellitus] explode all trees
25 diabetes or diabetic*
26 MeSH descriptor: [Arthritis] explode all trees
27 MeSH descriptor: [Arthritis, Rheumatoid] explode all trees
28 arthritis or osteoarthritis or rheumati* or fibromyalgia
29 MeSH descriptor: [Back Pain] explode all trees
30 MeSH descriptor: [Neck Pain] explode all trees
31 “back pain” or “neck pain”
32 MeSH descriptor: [Osteoporosis] explode all trees
33 Osteoporosis
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TABLE 81 The Cochrane Library: CENTRAL, DARE and NHS EED searches (continued )
# Search term
34 MeSH descriptor: [Thyroid Diseases] explode all trees
35 MeSH descriptor: [Neoplasms] explode all trees
36 cancer* or oncolog* or neoplasm* or carcinom* or tumo?r* or malignan*
37 MeSH descriptor: [HIV] explode all trees
38 “hiv infect*” or “hiv disease*”
39 MeSH descriptor: [Endometriosis] explode all trees
40 endometriosis
41 MeSH descriptor: [Mental Disorders] explode all trees
42 MeSH descriptor: [Depression] explode all trees
43 “mental* ill*” or “mental disorder*” or “mental disease*” or “mental distress*” or “mental disab*” or “mental
problem*” or “mental health*” or “mental patient*” or “mental treatment” or “psych* ill*” or “psych*
disorder*” or “psych* disease*” or “psych* distress*” or “psych* disab*” or “psych* problem*” or “psych*
health*” or “psych* patient*” or “psych* treatment”
44 “personality disorder*” or “mood disorder*” or “dysthymic disorder*” or “cognit* disorder*” or “anxiety
disorder*” or “stress disorder*” or “eating disorder*” or “Nustment disorder*” or “reactive disorder*” or
“somatoform disorder*” or “conversion disorder*” or “behavio* disorder*” or “percept* disorder*” or “psycho*
disorder*” or “impulse control disorder*” or “development* disorder*”
45 psychos?s or psychotic* or paranoi* or schizo* or neuros?s or neurotic* or delusion* or depression or depressive
or bipolar or mania or manic or obsessi* or compulsi* or panic or phobic or phobia or anorexia or bulimia or
neurastheni* or dissociative or affective or borderline or narcissis* or suicid* or “self injur*” or “self harm” or
dementia or Alzheimer*
46 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or
#18 or #19 or #20 or #21 or #22 or #23 or #24 or #25 or #26 or #27 or #28 or #29 or #30 or #31 or #32 or #33
or #34 or #35 or #36 or #37 or #38 or #39 or #40 or #41 or #42 or #43 or #44 or #45
47 ((express* or creativ* or emoti* or sensitiv* or reflect* or therap* or disclos* or conceal* or manag* or
pennebaker or cathar* or “writing paradigm”) near/2 (writ* or “hand writ*” or blog or epistol* or letter* or story
or stories or memoir* or narrat* or diary or diaries or poem or poet* or reminisc* or “life review” or “life writing”
or journaling or “Journal Writing” or (“health status” adj2 writ*) or “program* writ*”))
48 MeSH descriptor: [Writing] this term only
49 #47 or #48
50 #46 and #49
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TABLE 82 PsycINFO (via Ovid) searches
# Search term
1 chronic*.mp.
2 ((persistent or (long* adj term) or ongoing or degenerative) adj3 (disease* or disab* or ill* or condition* or (health
adj condition*) or (medical adj condition*) or impairment)).tw.
3 LONG TERM CARE/
4 (long* adj term adj care).tw.
5 exp cardiovascular disorders/
6 ((heart adj disease*) or (heart adj failure) or (myocardial adj ischemia) or (angina adj pectoris) or (coronary adj
disease*) or (coronary adj artery adj disease*) or (myocardial adj infarction) or hypertension or (high adj blood adj
pressure)).tw.
7 exp lung disorders/
8 ((obstructive adj lung adj disease*) or (obstructive adj pulmonary adj disease*) or copd or asthma or bronchitis).tw.
9 exp EMPHYSEMA/
10 exp PULMONARY EMPHYSEMA/
11 emphysema.tw.
12 exp CEREBROVASCULAR DISORDERS/
13 ((cerebrovascular adj disease*) or (cerebrovascular adj disorder*) or (brain adj ischemia) or (cerebral adj infarction)
or (carotid adj artery adj disease*) or stroke or epilep*).tw.
14 exp NEURODEGENERATIVE DISEASES/
15 (neurodegenerative or (Huntington* adj disease) or (Parkinson* adj disease) or (amyotrophic adj lateral adj
sclerosis) or (motor adj neuron* adj disease)).tw.
16 exp MULTIPLE SCLEROSIS/
17 (multiple adj sclerosis).tw.
18 exp colon disorders/
19 IRRITABLE BOWEL SYNDROME/
20 ((inflammatory adj bowel) or (irritable adj bowel)).tw.
21 Kidney disease/
22 ((renal adj failure*) or (renal adj insufficienc*) or (kidney adj failure*) or (kidney adj insuffcienc*)).tw.
23 DIABETES MELLITUS/
24 (diabetes or diabetic*).tw.
25 exp ARTHRITIS/
26 exp rheumatoid arthritis/
27 exp joint disorders/
28 (arthritis or osteoarthritis or rheumati* or fibromyalgia).tw.
29 exp back pain/
30 chronic pain/
31 ((back adj pain) or (neck adj pain)).tw.
32 exp OSTEOPOROSIS/
33 osteoporosis.tw.
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TABLE 82 PsycINFO (via Ovid) searches (continued )
# Search term
34 exp thyroid disorders/
35 exp NEOPLASMS/
36 (cancer* or oncolog* or neoplasm* or carcinom* or tumo?r* or malignan*).tw.
38 ((hiv adj infect*) or (hiv adj disease*)).tw.
39 gynecological disorders/
40 endometriosis.tw.
41 exp MENTAL DISORDERS/
42 DEPRESSION/
43 ((mental* adj ill*) or (mental adj disorder*) or (mental adj disease*) or (mental adj distress*) or (mental adj disab*)
or (mental adj problem*) or (mental adj health*) or (mental adj patient*) or (mental adj treatment) or (psychiatr*
adj ill*) or (psychiatr* adj disorder*) or (psychiatr* adj disease*) or (psychiatr* adj distress*) or (psychiatr* adj
disab*) or (psychiatr* adj problem*) or (psychiatr* adj health*) or (psychiatr* adj patient*) or (psychiatr* adj
treatment) or (psychological* adj ill*) or (psychological*ADJ and disorder*) or (psychological* adj disease*) or
(psychological* adj distress*) or (psychological* adj disab*) or (psychological* adj problem*) or (psychological* adj
health*) or (psychological* adj patient*) or (psychological* adj treatment)).tw.
44 ((personality adj disorder*) or (mood adj disorder*) or (dysthymic adj disorder*) or (cognit* adj disorder*) or
(anxiety adj disorder*) or (stress adj disorder*) or (eating adj disorder*) or (adjustment adj disorder*) or (reactive
adj disorder*) or (somatoform adj disorder*) or (conversion adj disorder*) or (behavio* adj disorder*) or (percept*
adj disorder*) or (psycho* adj disorder*) or (impulse adj control adj disorder*) or (development* adj disorder*)).tw.
45 (psychos#s or psychotic* or paranoi* or schizo* or neuros#s or neurotic* or delusion* or depression or depressive
or bipolar or mania or manic or obsessi* or compulsi* or panic or phobic or phobia or anorexia or bulimia or
neurastheni* or dissociative or affective or borderline or narcissis* or suicid* or (self adj injur*) or (self adj harm) or
dementia or Alzheimer*).tw.
46 or/1-45
47 ((writ* adj therap*) or (therapeutic* adj writ*) or (writ* adj cure*) or (writ* adj heal*) or (self adj management adj
writ*) or (self adj help adj writ*) or (self adj conceal* adj writ*) or (self adj disclosure adj writ*) or (creative adj
writ*) or (expressi* adj writ*) or (emoti* adj writ*) or (EMO adj writ*) or (sensitiv* adj writ*) or (sensor* adj writ*)
or (reactive adj writ*) or (reflective adj writ*) or (descriptive adj writ*) or (biography* adj writ*) or (workshop adj
writ*) or (epistolar* adj writ*) or (fiction* adj writ*) or (paradigm adj writ*) or (group adj writ*) or (letter* adj
writ*) or (Pennebaker adj writ*) or (reminiscence adj review*) or (story adj writ*) or (stories adj writ*) or blog* or
forum* or (memoir* adj writ*) or (journal* adj writ*) or (narrative* adj writ*) or (hand adj writ*) or (poe* adj
writ*) or (health adj status adj writ*) or “program* writ*”).tw.
48 ((emoti* adj disclosure adj tip*) or (emoti* adj disclosure adj key*) or (emotional adj disclosure adj writ*) or
(emotio* adj disclosure) or catharsis).tw.
49 ((express* or creativ* or emoti* or sensitiv* or reflect* or therap* or disclos* or conceal* or manag* or
pennebaker or cathar* or “writing paradigm”) adj2 (writ* or “hand writ*” or blog or epistol* or letter* or story or
stories or memoir* or narrat* or diary or diaries or poem or poet* or reminisc* or “life review” or “life writing” or
journaling or “Journal Writing” or (“health status” adj2 writ*) or “program* writ*”)).tw.
50 46 AND 49
51 47 AND 48
52 exp Creative Writing/
53 exp Journal Writing/
54 46 and (52 OR 53)
55 50 or 51 or 54
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TABLE 83 Allied and Complementary Medicine Database (via Ovid) searches
# Search term
1 chronic*.mp.
2 ((persistent or (long* adj term) or ongoing or degenerative) adj3 (disease* or disab* or ill* or condition* or (health
adj condition*) or (medical adj condition*) or impairment)).tw.
3 LONG TERM CARE/
4 (long* adj term adj care).tw.
5 exp CARDIOVASCULAR DISEASE/
6 ((heart adj disease*) or (heart adj failure) or (myocardial adj ischemia) or (angina adj pectoris) or (coronary adj
disease*) or (coronary adj artery adj disease*) or (myocardial adj infarction) or hypertension or (high adj blood adj
pressure)).tw.
7 exp LUNG DISEASES OBSTRUCTIVE/
8 ((obstructive adj lung adj disease*) or (obstructive adj pulmonary adj disease*) or copd or asthma or bronchitis).tw.
9 exp EMPHYSEMA/
10 exp PULMONARY EMPHYSEMA/
11 emphysema.tw.
12 exp CEREBROVASCULAR DISORDERS/
13 ((cerebrovascular adj disease*) or (cerebrovascular adj disorder*) or (brain adj ischemia) or (cerebral adj infarction)
or (carotid adj artery adj disease*) or stroke or epilep*).tw.
14 exp nervous system disease/
15 (neurodegenerative or (Huntington* adj disease) or (Parkinson* adj disease) or (amyotrophic adj lateral adj
sclerosis) or (motor adj neuron* adj disease)).tw.
16 exp MULTIPLE SCLEROSIS/
17 (multiple adj sclerosis).tw.
18 exp INFLAMMATORY BOWEL DISEASE/
19 IRRITABLE BOWEL SYNDROME/
20 ((inflammatory adj bowel) or (irritable adj bowel)).tw.
21 Kidney disease/
22 ((renal adj failure*) or (renal adj insufficienc*) or (kidney adj failure*) or (kidney adj insuffcienc*)).tw.
23 DIABETES MELLITUS/
24 (diabetes or diabetic*).tw.
25 exp ARTHRITIS/
26 exp RHEUMATIC DISEASE/
27 (arthritis or osteoarthritis or rheumati* or fibromyalgia).tw.
28 exp low back pain/
29 exp backache/
30 NECK PAIN/
31 ((back adj pain) or (neck adj pain)).tw.
32 exp OSTEOPOROSIS/
33 osteoporosis.tw.
34 exp THYROID DISEASE/
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TABLE 83 Allied and Complementary Medicine Database (via Ovid) searches (continued )
# Search term
35 exp NEOPLASMS/
36 (cancer* or oncolog* or neoplasm* or carcinom* or tumo?r* or malignan*).tw.
37 exp HIV INFECTIONS/
38 ((hiv adj infect*) or (hiv adj disease*)).tw.
39 ENDOMETRIOSIS/
40 endometriosis.tw.
41 exp MENTAL DISORDERS/
42 DEPRESSION/
43 ((mental* adj ill*) or (mental adj disorder*) or (mental adj disease*) or (mental adj distress*) or (mental adj disab*)
or (mental adj problem*) or (mental adj health*) or (mental adj patient*) or (mental adj treatment) or (psychiatr*
adj ill*) or (psychiatr* adj disorder*) or (psychiatr* adj disease*) or (psychiatr* adj distress*) or (psychiatr* adj
disab*) or (psychiatr* adj problem*) or (psychiatr* adj health*) or (psychiatr* adj patient*) or (psychiatr* adj
treatment) or (psychological* adj ill*) or (psychological*ADJ and disorder*) or (psychological* adj disease*) or
(psychological* adj distress*) or (psychological* adj disab*) or (psychological* adj problem*) or (psychological* adj
health*) or (psychological* adj patient*) or (psychological* adj treatment)).tw.
44 ((personality adj disorder*) or (mood adj disorder*) or (dysthymic adj disorder*) or (cognit* adj disorder*) or
(anxiety adj disorder*) or (stress adj disorder*) or (eating adj disorder*) or (adjustment adj disorder*) or (reactive
adj disorder*) or (somatoform adj disorder*) or (conversion adj disorder*) or (behavio* adj disorder*) or (percept*
adj disorder*) or (psycho* adj disorder*) or (impulse adj control adj disorder*) or (development* adj disorder*)).tw.
45 (psychos#s or psychotic* or paranoi* or schizo* or neuros#s or neurotic* or delusion* or depression or depressive
or bipolar or mania or manic or obsessi* or compulsi* or panic or phobic or phobia or anorexia or bulimia or
neurastheni* or dissociative or affective or borderline or narcissis* or suicid* or (self adj injur*) or (self adj harm) or
dementia or Alzheimer*).tw.
46 or/1-45
47 ((writ* adj therap*) or (therapeutic* adj writ*) or (writ* adj cure*) or (writ* adj heal*) or (self adj management adj
writ*) or (self adj help adj writ*) or (self adj conceal* adj writ*) or (self adj disclosure adj writ*) or (creative adj
writ*) or (expressi* adj writ*) or (emoti* adj writ*) or (EMO adj writ*) or (sensitiv* adj writ*) or (sensor* adj writ*)
or (reactive adj writ*) or (reflective adj writ*) or (descriptive adj writ*) or (biography* adj writ*) or (workshop adj
writ*) or (epistolar* adj writ*) or (fiction* adj writ*) or (paradigm adj writ*) or (group adj writ*) or (letter* adj
writ*) or (Pennebaker adj writ*) or (reminiscence adj review*) or (story adj writ*) or (stories adj writ*) or blog* or
forum* or (memoir* adj writ*) or (journal* adj writ*) or (narrative* adj writ*) or (hand adj writ*) or (poe* adj
writ*) or (health adj status adj writ*) or “program* writ*”).tw.
48 ((emoti* adj disclosure adj tip*) or (emoti* adj disclosure adj key*) or (emotional adj disclosure adj writ*) or
(emotio* adj disclosure) or catharsis).tw.
49 ((express* or creativ* or emoti* or sensitiv* or reflect* or therap* or disclos* or conceal* or manag* or
pennebaker or cathar* or “writing paradigm”) adj2 (writ* or “hand writ*” or blog or epistol* or letter* or story or
stories or memoir* or narrat* or diary or diaries or poem or poet* or reminisc* or “life review” or “life writing” or
journaling or “Journal Writing” or (“health status” adj2 writ*) or “program* writ*”)).tw.
50 46 and 49
51 47 and 48
52 Writing/
53 46 and 52
54 50 or 51 or 52
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TABLE 84 Published International Literature on Traumatic Stress (via ProQuest) searches
# Search term
1 ((chronic*) OR (persistent) OR (long* term) OR (ongoing) OR (degenerative))
2 (catharsis AND (writ* OR typ* OR key*)) OR ((emoti* disclos* typ*) OR (emoti* disclos* key*) OR (emotion*
disclos* writ*))
3 ((writ* therap*) OR (therapeutic* writ*) OR (“writ* cure*”) OR (“writ* heal*”) OR (“self management writ*”) OR
(“self help writ*”) OR (“self conceal* writ*”) OR (“self disclosure writ*”) OR (“creative writ*”) OR (“expressi*
writ*”) OR (“emoti* writ*”) OR (“Emotion* writ*”) OR (“sensitiv* writ*”) OR (“sensor* writ*”) OR (“reactive
writ*”) OR (“reflective writ*”) OR (“descriptive writ*”) OR (“biography* writ*”) OR (“workshop writ*”) OR
(“epistolar* writ*”) OR (“fiction* writ*”) OR (“paradigm writ*”) OR (“group writ*”) OR (“letter* writ*”) OR
(Pennebaker writ*) OR (“reminiscence review*”) OR (writ* reminisc*) (“story writ*”) OR (“writ* stories”) OR
(blog*) OR (forum*) OR (memoir* writ*) OR (“journal* writ*”) OR (“narrative* writ*”) OR (“writ* narrative*”) OR
(“hand writ*”) OR (poe* writ*) OR (“health status writ*”) OR (“program* writ*”) OR (writ* diar*))
4 1 and (2 or 3)
TABLE 85 Education Resource Information Centre (via ProQuest) searches
# Search term
1 ((chronic*) OR (persistent) OR (long* term) OR (degenerative)) AND ((disease*) OR (disab*) OR (ill*) OR (condition*)
OR (“health condition*”) OR (“medical condition*”) OR (impairment))
2 (catharsis AND (writ* OR typ* OR key*)) OR ((emoti* disclos* typ*) OR (emoti* disclos* key*) OR (emotion*
disclos* writ*))
3 ((“writ* therap*”) OR (“therapeutic* writ*”) OR (“writ* cure*”) OR (“writ* heal*”) OR (“self management
writ*”) OR (“self help writ*”) OR (“self conceal* writ*”) OR (“self disclosure writ*”) OR (“creative writ*”) OR
(“expressi* writ*”) OR (“emoti* writ*”) OR (“Emotion* writ*”) OR (“sensitiv* writ*”) OR (“sensor* writ*”) OR
(“reactive writ*”) OR (“reflective writ*”) OR (“descriptive writ*”) OR (“biography* writ*”) OR (“workshop writ*”)
OR (“epistolar* writ*”) OR (“fiction* writ*”) OR (“paradigm writ*”) OR (“group writ*”) OR (“letter* writ*”) OR
(Pennebaker writ*) OR (“reminiscence review*”) OR (writ* reminisc*) (“story writ*”) OR (“writ* stories”) OR
(blog*) OR (forum*) OR (memoir* writ*) OR (“journal* writ*”) OR (“narrative* writ*”) OR (“writ* narrative*”) OR
(“hand writ*”) OR (poe* writ*) OR (“health status writ*”) OR (“program* writ*”) OR (writ* diar*))
4 1 AND (2 OR 3)
TABLE 86 Linguistic and Language Behaviour Abstracts (via ProQuest) searches
# Search term
1 ((chronic*) OR (persistent) OR (long* term) OR (degenerative)) AND ((disease*) OR (disab*) OR (ill*) OR (condition*)
OR (“health condition*”) OR (“medical condition*”))
2 (catharsis AND (writ* OR typ* OR key*)) OR ((emoti* disclos* typ*) OR (emoti* disclos* key*) OR (emotion*
disclos* writ*))
3 (“writ* therap*”) OR (“therapeutic* writ*”) OR (“writ* cure*”) OR (“writ* heal*”) OR (“self management writ*”)
OR (“self help writ*”) OR (“self conceal* writ*”) OR (“self disclosure writ*”) OR (“creative writ*”) OR (“expressi*
writ*”) OR (“emoti* writ*”) OR (“Emotion* writ*”) OR (“sensitiv* writ*”) OR (“sensor* writ*”) OR (“reactive
writ*”) OR (“reflective writ*”) OR (“descriptive writ*”) OR (“biography* writ*”) OR (“workshop writ*”) OR
(“epistolar* writ*”) OR (“fiction* writ*”) OR (“paradigm writ*”) OR (“group writ*”) OR (“letter* writ*”) OR
(Pennebaker writ*) OR (“reminiscence review*”) OR (writ* reminisc*) (“story writ*”) OR (“writ* stories”) OR
(blog*) OR (forum*) OR (memoir* writ*) OR (“journal* writ*”) OR (“narrative* writ*”) OR (“writ* narrative*”) OR
(“hand writ*”) OR (poe* writ*) OR (“health status writ*”) OR (“program* writ*”)
4 1 AND (2 OR 3)
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TABLE 87 The British Library’s Electronic Table of Contents (via Mimas) searches
# Search term
1 therap* writ*
2 written emotional disclosure
3 expressive writing
4 pennebaker writing
5 writing emotion
6 1 OR 2 OR 3 OR 4 OR 5 [NB: have to be collated separately, this function cannot be performed by Zetoc]
TABLE 88 The Campbell Collaboration Library of Systematic Reviews (The Campbell Collaboration) searches
# Search term
1 Therapeutic writing
2 Written emotional disclosure
3 Expressive writing
TABLE 89 CAB Abstracts, Periodicals Index Online, ASSIA, PEDro and CINAHL searches
# Search term
1 (writing or written or blog or story) and (disease or disorder) and (chronic or long-term)
DOI: 10.3310/hta20270 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 27
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Nyssen et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
235

Appendix 4 Data extraction form and quality
assessment methods used
Systematic review data extraction forms
Baseline data
TABLE 90 Data extraction form template: study overview
# (reference number in the citation manager)
Publication details Author(s)
Year
Title
Journal
Volume
Issue
Pages
Format of publication
Study overview Study name
Study objectives
Study overall conclusions
DID TW WORK?
Why does it work? Why not? Who do they think it works for?
Country/region of the study
Time span of the study
Number of sites
Funding Description of funding (public/private, etc.)
Funded? Yes/No
Study moderators and/or
mediators
Moderator(s) effect? Including: effect moderators (patients’ characteristics) interacting with
the intervention to change outcome – baseline variables that affect outcome but not interact
with intervention
Mediator(s) effect? Including: change-in-process factors impacting outcome with or without
interaction with intervention
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TABLE 91 Data extraction form template: intervention and participant’s characteristics
Study intervention: exposure and
comparator
Intervention type(s)
Definition
Site of the intervention(s)
Intervention(s) exposure episode and duration
Length of the intervention(s)
Comparator type
Comparator definition
Time of assessment
Concomitant therapies
Intervention fidelity
Intervention credibility or subjective essay evaluation or manipulation checks
Participant(s) type Target population LTC category
LTC type and diagnostic criteria
LTC category
ITT (and PP) sample size
ITT sample size by groups (treatment arms)
Participants selection criteria Main inclusion criteria
Main exclusion criteria
Participants baseline characteristics Baseline characteristics Age
Gender
Ethnicity
Disease status and severity
Comorbidities
Other characteristics
PP, per protocol.
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TABLE 92 Data extraction form template: primary studies’ participation and types of outcomes evaluated
Study flow diagram Study participation [based on Sohanpal
et al., www.systematicreviewsjournal.
com/content/1/1/66 (accessed June 2014)]
# participants ELIGIBLE to the study (and # of
non-participants)
# participants RECRUITED (# of study participants
willing to take part)
# study participants NON-ATTENDERS (recruited not
willing to attend intervention)
# study ATTENDERS (attending at least one session
of the intervention)
# study attenders DROPPING OUT (after one session
or more)
# programme COMPLETERS (# participants
completing all sessions of the intervention)
Study DROP-OUTs (# non-attenders or programme
dropouts or programme completers that drop out
also from the study)
Recruitment method(s)
Type(s) of outcome(s)
reported (by responding
Yes/No)
Outcomes assessed
Physical health Physiological
Haematological/immunological/hormonal
Disability/handicap
Pain
Non-physical health Psychological
Social health
Mental status
Behavioural
Performance
HRQoL
Costs/resource use
Safety
Compliance
Other
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Results section
TABLE 93 Data extraction form template: outcomes reported
Physiological outcomes Description Selected end point(s)
Definition(s) and type of outcome
Time of assessment(s) and overall outcome follow-up
Type of analysis
Results Values
Summary of the impact of intervention(s) on
patient-reported outcomes
Haematological/immunological
outcomes
Description Selected end point(s)
Definition(s)
Time of assessment(s) and overall outcome follow-up
Type of analysis
Results Values
Summary of the impact of intervention(s) on
patient-reported outcomes
Physical disability/handicap
assessment
Description Selected end point(s)
Definition(s)
Time of assessment(s) and overall outcome follow-up
Type of analysis
Results Values
Summary of the impact of the intervention
Pain measurement Description Selected end point(s)
Definition(s)
Time of assessment(s) and overall outcome follow-up
Type of analysis
Results Values
Summary of the impact of intervention(s) on
patient-reported outcomes
Psychological assessment Description Selected end point(s)
Definition(s)
Time of assessment(s) and overall outcome follow-up
Type of analysis
Results Values
Summary of the impact of intervention(s) on
patient-reported outcomes
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TABLE 93 Data extraction form template: outcomes reported (continued )
Social health assessment Description Selected end point(s)
Definition(s)
Time of assessment(s) and overall outcome follow-up
Type of analysis
Results Values
Summary of the impact of intervention(s) on
patient-reported outcomes
Mental status assessment Description Selected end point(s)
Definition(s)
Time of assessment(s) and overall outcome follow-up
Type of analysis
Results Values
Summary of the impact of intervention(s) on
patient-reported outcomes
Behavioural assessment Description Selected end point(s)
Definition(s)
Time of assessment(s) and overall outcome follow-up
Type of analysis
Results Values
Summary of the impact of intervention(s) on
patient-reported outcomes
Performance assessment Description Selected end point(s)
Definition(s)
Time of assessment(s) and overall outcome follow-up
Type of analysis
Results Values
Summary of the impact of intervention(s) on
patient-reported outcomes
General health status and quality
of life
Description Instrument(s) type
Definition
Time of assessment(s) and overall outcome follow-up
Type of analysis
Results Values
Summary of the impact of intervention(s) on
patient-reported outcomes
Assessment of adverse events
due to intervention (and not
related to concomitant therapy)
Description and
identification of AEs
Selected end point(s)
Definition(s)/reported categories of AEs
Time of assessment(s)
Type of analysis
Results
continued
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TABLE 93 Data extraction form template: outcomes reported (continued )
Assessment of compliance
(adherence)
Description Selected end point(s)
Definition(s)
Time of assessment
Results
Costs and levels of resource use
(related to specific intervention)
Resource use Type
Analysis
Levels of resource used
Summary of the impact of intervention(s) on resource used
Perspective
Currency Currency
Price year
If inflated, inflator
Time period to which costs relate
Unit cost
Total costs
Specific findings helping
programme theory
Theories or mechanisms postulated by study’s authors to explain the success of the
intervention
Process factors identified by study authors helping the successful theory
Theories or mechanisms postulated by study’s authors to explain the failure(s) of the
intervention
Process factors identified by study authors helping the failure of the theory
How study contributes to realist review
Summary of the impact of intervention(s) on patient-reported outcomes
Additional comments to the study (does the study support previous research?)
Correspondence required with authors for missing data?
References not captured by the review (cross-referencing)
Notes
AE, adverse event.
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Realist synthesis data extraction forms
TABLE 94 Tabular summary for data collection in realist synthesis
First author, date Data to support programme theory
included in the systematic review
Primary study author’s explanation for
how TW works
TABLE 95 Questions formulated for practitioner experts during programme theory development
Recruitment/suitability
Intervention process/aspects of the
intervention Outcomes impact
Who is it suitable for and why? What do you do and why? What do you hope to achieve and why?
Quality assessment tools
Clinical trials: Cochrane Handbook for Systematic Reviews of Interventions
TABLE 96 Data extraction form template: quality of the methods used in clinical trials
Study design Trial design
Study quality checklist (based on
the checklist in the Cochrane
Handbook)
Randomisation Sequence generation (selection bias)
Allocation concealment (selection bias)
Blinding Outcome
Performance
ITT analysis? (Yes/No)
Description of outcomes differences between groups (selective reporting)
Description of withdrawals (attrition bias)
Pre-specified criteria for eligibility of patients
Similarity of groups at baseline regarding prognostic factors
Statement supporting the quality of the methods used
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Observational studies: Newcastle–Ottawa checklist
TABLE 97 Data extraction form template: quality of the methods used in observational studies
Study quality
checklist
Case–control studies Selection Is the case definition adequate?
Representativeness of the cases
Selection of controls
Definition of controls
Comparability Comparability of cases and controls on the basis
of the design or analysis
Factor(s)
Exposure Ascertainment of exposure
Same method of ascertainment for cases and
controls
Non-response rate
Cohort (and cross-sectional)
studies
Selection Representativeness of the exposed cohort
Selection of the non-exposed cohort
Ascertainment of exposure
Demonstration that outcome of interest was not
present at start of study
Comparability Comparability of exposed and unexposed (design
or analysis)
Factor(s)
Outcome Assessment of outcome
Was follow-up long enough for outcome to
occur
Adequacy of follow-up
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Appendix 5 Characteristics of included studies
Study design
TABLE 98 Study design of included studies
First author, year Country Study design n of intervention groups n of control groups
Abel 200450 USA RCT 1 1
Arden-Close 201380 UK RCT 1 1
Averill 2013100 USA RCT 1 1
Bartasiuniene 2011102 Lithuania RCT 1 2
Bernard 200693 UK RCT 1 1
Broderick 2004113 USA RCT 2 1
Broderick 2005118 USA RCT 1 1
Canna 200694 USA RCT 2 2
Cepeda 200885 Colombia RCT 1 2
Craft 201374 USA RCT 2 2
Dennick 201488 UK RCT 1 1
D’Souza 2008101 USA RCT 1 1
Gellaitry 201075 UK RCT 1 1
Gidron 199698 Israel RCT 1 1
Gillis 2006119 USA RCT 1 1
Golkaramnay 200768 Germany Controlled cohort 1 1
Graf 200895 USA RCT 1 1
Graham 200851 USA RCT 1 1
Grasing 201090 USA RCT 1 1
Halpert 201052 USA Controlled cohort 1 1
Hamilton-West 2007114 UK RCT 1 1
Harris 2005106 USA RCT 2 1
Henry 201053 USA Case–control 1 1
Hevey 2012103 Ireland RCT 1 1
Hong 201167 Korea RCT 1 1
Hughes 200754 USA RCT 1 1
Ironson 201371 USA RCT 1 1
Jensen-Johansen 201376 Denmark RCT 1 1
Kraaij 201055 Netherlands RCT 1 1
Krpan 201396 USA RCT 1 1
Lange 200369 Netherlands RCT 1 1
Lumley 2011115 USA RCT 2 1
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TABLE 98 Study design of included studies (continued )
First author, year Country Study design n of intervention groups n of control groups
Lumley 2014116 USA RCT 2 2
Mann 200172 USA RCT 1 1
McElligott 200687 USA Non-RCT 1 1
Meshberg-Cohen 201091 USA RCT 1 1
Milbury 201481 USA RCT 1 1
Mosher 201277 USA RCT 1 1
Paradisi 2010110 Italy RCT 2 1
Park 201278 Korea Controlled cohort 1 1
Pauley 201182 USA RCT 2 1
Petrie 200456 New Zealand RCT 1 1
Richards 200097 USA RCT 1 2
Rickett 201166 Australia RCT 1 1
Rini 201486 USA RCT 3 1
Robinson 200899 UK RCT 1 1
Rosenberg 200283 USA RCT 1 1
Sharifabad 2010105 USA RCT 1 1
Sloan 201270 USA RCT 1 1
Smyth 1999107 USA RCT 1 1
Smyth 2008121 USA RCT 1 1
Stark 201057 USA RCT 3 1
Tabolli 2012111 Italy RCT 1 1
Taylor 200389 USA RCT 1 1
Theadom 201058 UK RCT 1 1
Van Dam 201392 Netherlands RCT 1 1
Vedhara 2007112 New Zealand RCT 1 1
Wagner 201073 USA RCT 1 1
Walker 199979 USA RCT 2 1
Wallander 2011109 USA RCT 1 1
Warner 2006108 USA RCT 1 1
Wetherell 2005117 UK RCT 1 1
Willmott 2011104 UK RCT 1 1
Zakowski 200484 USA RCT 1 1
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Participants’ conditions
TABLE 99 Long-term conditions, ICD-10 codes and diagnostic criteria used at study entry in included studies
First author,
year LTC ICD-10 code LTC: inclusion criteria/diagnostic tool(s)
Abel 200450 HIV B24 Taking ART for their diagnosis, able to report their
last VL of < 80 000–100,000 copies/ml, free of
major psychiatric problems (self-report)
Arden-Close
201380
Ovarian cancer C56 Disease stage from I to IV, with CA125 level
checked by oncologist and categorised above or
below 35U/ml for the prognosis of the cancer and
within 5 years of treatment
Averill 2013100 ALS G12 Definite or probable ALS using El Escorial criteria
at least 6 months prior to study entry (World
Federation of Neurology Research Group on
Neuromuscular Diseases, 1994); FVC in the 50th
percentile or higher
Bartasiuniene
2011102
CVD I51
Bernard 200693 PTSD F43 First episode of psychosis conforming to broad
ICD-10 criteria (F20, F22, F23, F25)
Broderick 2004113 RA M06 Formal diagnosis of RA
Broderick 2005118 FM M79 Formal diagnosis of FM by a physician
Canna 200694 Axis I anxiety or
mood disorder
F41 Individuals with axis I anxiety or mood disorder
primary diagnosis
Cepeda 200885 Cancer C80 Any type of cancer and reporting average pain
intensity levels of at least 5/10 on a 0–10 scale;
scored > 50% in the Karnofsky scale
Craft 201374 Breast cancer C50 Invasive or non-invasive early stage breast cancer,
definitive treatment (surgery, chemotherapy and/or
radiation therapy) completed, time from diagnosis
< 2 years
Dennick 201488 Type 2 diabetes
mellitus
E11
D’Souza 2008101 Tension/migraine
headaches
G43/G44 International Headache Society criteria for either
tension or migraine headaches
Gellaitry 201075 Breast cancer C50 Patients with early-stage breast cancer, attending
the last radiotherapy appointment at the outpatient
clinic and without a defined psychiatric disorder
Gidron 199698 PTSD F43 PTSD assessed with the Mississippi Scale for PTSD
Gillis 2006119 FM M79 Rehabilitation hospital patients with CVD
Golkaramnay
200768
Mental disorders F41–F60 Inpatient from hospital with mental health
conditions according to the ICD-10 criteria
Graf 200893 Psychiatric disorder F99 Participants from an university-based outpatients’
psychiatric clinic and student counselling centre
Graham 200851 Chronic pain Unclassifiable Patients had experience for at least 6 months and
were recruited during routine visits to a university
hospital-affiliated outpatient pain centre
Grasing 201090 Cocaine dependence F14 Meeting DSM-IV criteria for cocaine dependence at
the time of admission
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TABLE 99 Long-term conditions, ICD-10 codes and diagnostic criteria used at study entry in
included studies (continued )
First author,
year LTC ICD-10 code LTC: inclusion criteria/diagnostic tool(s)
Halpert 201052 IBS K58 Fulfilled the Rome III Criteria for IBS
Hamilton-West
2007114
AS M45 Inflammation of the joints in the pelvis; low back
pain and stiffness for > 3 months, which improves
with exercise but is not relieved by rest; limited
movement of the lower back and restricted chest
expansion
Harris 2005106 Asthma J45 Asthma was confirmed by a history of asthma
diagnosed by a physician and either evidence of
reduced expiratory volume and reversibility obtained
through medical records or evidence of reduced
expiratory volume evaluated by study staff
Henry 201053 Breast cancer C50 Female breast cancer survivors attending radiation
oncology clinics
Hevey 2012103 MI I21 Patients with confirmed MI, who received treatment
at a large teaching hospital
Hong 201167 Dementia
(Alzheimer’s disease/
vascular dementia/
Parkinson’s disease)
F03 (F00/F01/F02) Elderly people housed in a nursing home and
already medically diagnosed with dementia, and
scoring ≤ 19 on the MMSE-K
Hughes 200754 Breast cancer C50 Stage I, II or III breast cancer women receiving
curative radiation therapy for breast cancer
Ironson 201371 HIV (plus PTSD) B24 (plus F43) HIV-positive, falling into a CD4 range of 100–600.
Included were also those with one Category C
symptom (AIDS defining) but without C symptoms
1 year prior to study entry. The stress of HIV was
considered sufficient to enter the study and no
other trauma was required
Jensen-Johansen
201376
Breast cancer C50 Female Danish residents, able to read and write
Danish, aged 18–70 years, and treated surgically
within 3 weeks of their diagnosis (mastectomy or
lumpectomy) for invasive breast cancer, stages I
and II
Kraaij 201055 HIV B24 HIV-diagnosed patients. No restricted criteria
regarding the VL or the CD4+ count
Krpan 201396 Depression F41 According to SCID
Lange 200369 PTSD F43 Participants had to score below the cut-off scores of
the Depression subscale of the SCL-90 in the Dutch
norm, the SDQ-5, and the Dutch Screening Device
for Psychotic Disorder of the Dutch norm group
Lumley 2011115 RA M06 Patients with RA who met American College of
Rheumatology criteria for non-juvenile RA. Patients
had to report experience pain or disability due to
their RA in the preceding week
Lumley 2014116 RA M06 RA patients meeting American College of
Rheumatology criteria for non-juvenile RA. Patients
had to report experience pain or disability due to
their RA in the preceding week
Mann 200172 HIV B24 Women being treated for HIV or diagnosed with
AIDS
McElligott 200687 Sickle cell disease D57 Medically diagnosed with sickle cell disease
APPENDIX 5
NIHR Journals Library www.journalslibrary.nihr.ac.uk
248
TABLE 99 Long-term conditions, ICD-10 codes and diagnostic criteria used at study entry in
included studies (continued )
First author,
year LTC ICD-10 code LTC: inclusion criteria/diagnostic tool(s)
Meshberg-Cohen
201091
SUD F19 The Structured Clinical Interview for DSM-IV-TR –
Alcohol and Substance Use Disorders Module (SCID)
was used as the diagnostic interview assessing SUD
diagnosis, including alcohol and other drugs
Milbury 201481 RCC C64 Newly diagnosed with stage I–IV RCC and with a
Zubrod performance status of < 2
Mosher 201277 Breast cancer C50 Distressed women with stage IV breast cancer
Paradisi 2010110 Psoriasis L40 Plaque-type psoriasis involving > 10% of body area
Park 201278 Breast cancer C50 Stage II and III, breast cancer survivors, women. No
restriction to staging, surgery or drugs intake
Pauley 201182 Testicular cancer C62 Testicular cancer survivors, men. No restriction to
staging, surgery or drugs intake
Petrie 200456 HIV B24 Documented HIV infection and not had their
classified oral drug regimen changed in the previous
12 months
Richards 200097 Mental disorder F41–F60 Diagnosed with at least one mental disorder,
as classified with the DSM-III-R
Rickett 201166 Cancer C80 All diagnosed with cancer except for one participant
with a history of severe CVD, and one with an
autoimmune disorder
Rini 201486 Following stem cell
transplant
C80
Robinson 200899 BN F50 Diagnosis was made using information from the
QEDD using DSM-IV (American Psychiatric
Association, 1994) for definitions of disorders.
Included were those with a diagnosis of BN (purging
or non-purging)
Rosenberg 200283 Prostate cancer C61 Histological diagnosis of adenocarcinoma of the
prostate being followed with serial PSAs. Previously
local treatment (prostatectomy or radiation) within
the last 4 years
Sharifabad
2010105
COPD plus IPF J44 plus J84 Medically diagnosed with COPD or IPF
Sloan 201270 PTSD F43 Participants met DSM-IV PTSD Criterion A for a
traumatic stressor (American Psychiatric Association,
1994)
Smyth 1999107 Asthma/RA J45/M06 RA diagnosis was confirmed by board-certified
rheumatologists and all patients met American
College of Rheumatology criteria
Asthma was diagnosed by a history of asthma,
confirmed by a physician; patients were also
required to provide a documented reduction in
expiratory function (either in physician records or
when evaluated by study staff)
Smyth 2008121 PTSD F43 Based on PTSD diagnosis verification defined by the
DSM-IV
Stark 201057 FM plus facial pain M79 Diagnosis made by the referring physician
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TABLE 99 Long-term conditions, ICD-10 codes and diagnostic criteria used at study entry in
included studies (continued )
First author,
year LTC ICD-10 code LTC: inclusion criteria/diagnostic tool(s)
Tabolli 2012111 Psoriasis L40 Diagnosis by an experienced staff dermatologist,
according to established internationally accepted
criteria, with ≥ 10% of body surface affected
Taylor 200389 Cystic fibrosis E84 Medically diagnosed with cystic fibrosis
Theadom 201058 Asthma J45 Diagnosed with asthma and requiring regular
inhaled medication (British Thoracic Society step 2
or higher; British Thoracic Society and Scottish
Intercollegiate Guidelines Network, 2005)
Van Dam 201392 SUD F14 Diagnosed with SUD
Vedhara 2007112 Psoriasis L40 A clinically verified diagnosis of psoriasis for at least
6 months
Wagner 201073 HIV B24 Diagnosed with HIV only
Walker 199979 Breast cancer C50 Women completing radiation therapy for breast
cancer stage I or II with a Karnofsky performance
status of ≥ 70%
Wallander 2011109 GI RAP R10 Patients with GI RAP, who met Apley’s (1975)
criteria for functional RAP as determined by a
paediatric GI specialist
Warner 2006108 Asthma J45 Participants classified with mild, persistent asthma
(i.e. asthma symptom activity at least 2 days per
week and nocturnal symptoms at least twice
monthly)
Wetherell 2005117 RA M06 Diagnosed with RA
Willmott 2011104 MI I21 Participants were the first patients with MI who
were receiving treatment at two acute hospital
clinics
Zakowski 200484 Prostate plus
gynaecological cancer
C61 (prostate) plus
C55 (uterus), C56
(ovary), C53 (cervix)
Participants with a first-time diagnosis of prostate or
gynaecological cancer within the last 5 years
AIDS, acquired immunodeficiency virus; MMSE-K, Mini Mental State Examination Korean Version; PSA, prostate-specific
antigen; SCL-90, Symptom Checklist-90; SDQ-5, somatoform dissociation questionnaire-5.
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Included studies categorised by International Classification of
Diseases, Tenth Edition code by the reviewers
TABLE 100 Included studies by ICD-10 code
First author, year LTC ICD-10 code
Abel 200450 HIV B24
Kraaij 201055 HIV B24
Mann 200172 HIV B24
Petrie 200456 HIV B24
Wagner 201073 HIV B24
Ironson 201371 HIV (plus PTSD) B24
Craft 201374 Breast cancer C50
Gellaitry 201075 Breast cancer C50
Henry 201053 Breast cancer C50
Hughes 200754 Breast cancer C50
Jensen-Johansen 201376 Breast cancer C50
Mosher 201277 Breast cancer C50
Park 201278 Breast cancer C50
Walker 199979 Breast cancer C50
Arden-Close 201380 Gynaecological and genitourinary cancer C57 (ovarian)
Rosenberg 200283 Gynaecological and genitourinary cancer C61(prostate)
Zakowski 200484 Gynaecological and genitourinary cancer C61 (prostate) plus C55 (uterus),
C56 (ovary), C53 (cervix)
Pauley 201182 Gynaecological and genitourinary cancer C62 (testicular)
Milbury 201481 Gynaecological and genitourinary cancer C64
Cepeda 200885 Cancer from various sources C80
Rickett 201166 Cancer from various sources C80
Rini 201486 Cancer from various sources C80
McElligott 200687 Sickle cell disease D57
Taylor 200389 Cystic fibrosis E84
Hong 201167 Dementia (Alzheimer’s disease/vascular
dementia/Parkinson’s disease)
F03 (F00/F01/F02)
Grasing 201090 Cocaine dependence F14
Meshberg-Cohen 201091 SUD F19
Van Dam 201392 SUD F19
Bernard 200693 First episode psychosis F41–F60
Canna 200694 Mental disorder (Axis I anxiety or mood
disorder)
F41–F60
Golkaramnay 200768 Mental disorder F41–F60
Richards 200097 Mental disorder F41–F60
Graf 200895 Mental disorder (psychiatric disorder) F41–F60 (F99)
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TABLE 100 Included studies by ICD-10 code (continued )
First author, year LTC ICD-10 code
Krpan 201396 Depression F41
Gidron 199698 PTSD F43
Lange 200369 PTSD F43
Sloan 201270 PTSD F43
Smyth 2008121 PTSD F43
Robinson 200899 BN F50
Averill 2013100 ALS G12
D’Souza 2008101 Tension/migraine headaches G43/G44
Hevey 2012103 MI I21
Willmott 2011104 MI I21
Bartasiuniene 2011102 CVD I51
Sharifabad 2010105 COPD plus IPF J44 plus J84
Harris 2005106 Asthma J45
Theadom 201058 Asthma J45
Warner 2006108 Asthma J45
aSmyth 1999107 Asthma/RA J45/M06
Halpert 201052 IBS K58
Wallander 2011109 IBS (GI RAP) K58 (R10)
Paradisi 2010110 Psoriasis L40
Tabolli 2012111 Psoriasis L40
Vedhara 2007112 Psoriasis L40
Broderick 2004113 RA M06
Lumley 2011115 RA M06
Lumley 2014116 RA M06
Wetherell 2005117 RA M06
Hamilton-West 2007114 AS M45
Broderick 2005118 FM M79
Gillis 2006119 FM M79
Stark 201057 FM M79
Graham 200851 Chronic pain M79
a Smyth et al.107 has been reported twice under J45 and M06/M45 ICD-10 categories.
Note that this table includes the studies classified as assessing an unfacilitated TW intervention.
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Interventions assessed
Interventions assessed
TABLE 101 Intervention groups as described in included studies
First author,
year
Experimental condition Control condition
Intervention group 1 Intervention group 2 Control group 1
Control
group 2
Abel 200450 EW disclosure (unfacilitated
type of TW)
Daily activities writing
Arden-Close
201380
Written emotional disclosure
(unfacilitated type of TW)
Details of previous day
writing
Averill 2013100 Written or oral expressive
disclosure (unfacilitated type
of TW) plus completion of
study measures
Attentional control writing
(completion of study
measures)
Bartasiuniene
2011102
Expressive writing
(unfacilitated type of TW)
Daily events writing Non-writing
group (wrote
nothing)
Bernard 200693 Written emotional disclosure
(unfacilitated type of TW)
Non-EW (activities that day,
the room they were in, and
plans for the next week)
Broderick 2004113 Standard expressive writing
(unfacilitated type of TW)
Enhanced meaning
writing
Day-to-day activities in
relation to the time
invested
Educational
attention
control group
Broderick 2005118 Written emotional expression
with cognitive reappraisal
Day-to-day activities in
relation to the time
invested
Non-writing
(usual care)
Canna 200694 Expressive writing plus CBT CBT Inexpressive writing plus
CBT
Waiting list
Cepeda 200885 Narrative emotional disclosure Questionnaire writing Usual care
Craft 201374 Breast-cancer trauma writing
(unfacilitated type of TW)
Self-selected trauma
writing (unfacilitated
type of TW)
Breast cancer factual
writing (unfacilitated type
of TW)
Non-writing
Dennick 201488 Written emotional disclosure Previous day’s activities
D’Souza 2008101 Written emotional disclosure
(unfacilitated type of TW)
Time-management control
writing
Gellaitry 201075 Expressive writing
(unfacilitated type of TW)
Routine care
Gidron 199698 Written disclosure
(unfacilitated type of TW) plus
oral disclosure of most severe
event
Casual daily agenda writing
plus oral disclosure of daily
activity
Gillis 2006119 Written emotional disclosure
(unfacilitated type of TW)
Time-management writing
Golkaramnay
200768
Group therapy through
internet chat
No intervention
continued
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TABLE 101 Intervention groups as described in included studies (continued )
First author,
year
Experimental condition Control condition
Intervention group 1 Intervention group 2 Control group 1
Control
group 2
Graf 200895 Written emotional disclosure
(unfacilitated type of TW)
Plans for the rest of the
day writing
Graham 200851 Written anger expression
through letter-writing format
(Rusing and Nolen-Hoeksema
type of TW)
Goals writing through
letter-writing format
Grasing 201090 Written emotional expression
(Pennebaker type of TW)
Time-management writing
Halpert 201052 Expressive writing
(unfacilitated type of TW)
Non-writing
Hamilton-West
2007114
EW exercise (unfacilitated
type of TW not approved by
ethics committee – adapted
version used)
Time-management exercise
Harris 2005106 Stressful experiences writing Positive writing Neutral topic writing
Henry 201053 Positive expressive writing
(single episode unfacilitated
type of TW)
Usual care
Hevey 2012103 Expressive writing (single
episode unfacilitated type of
TW)
Daily activities writing in
the year prior to heart
attack
Hong 201167 Songwriting Waiting list
Hughes 200754 Expressive writing Usual care
Ironson 201371 Augmented trauma writing
(unfacilitated type of TW) plus
processing probes
Daily event writing
Jensen-Johansen
201376
Expressive writing
(unfacilitated type of TW)
Daily activities writing
Kraaij 201055 Structured writing
intervention (through website)
Cognitive–behavioural
self-help programme
Waiting list
Krpan 201396 Expressive writing (deepest
thoughts and feelings)
How they organised their
day
Lange 200369 Interapy Waiting list
Lumley 2011115 Written or oral emotional
disclosure
Positive writing (or
talking)
Neutral topic writing (or
talking)
Lumley 2014116 Expressive writing, coping
skills training
Neutral writing, coping
skills training
Mann 200172 Positive future writing Non-writing
McElligott 200687 Expressive writing
(unfacilitated type of TW)
Details of previous day
writing
Meshberg-Cohen
201091
Expressive writing
(unfacilitated type of TW)
Neutral topic writing
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TABLE 101 Intervention groups as described in included studies (continued )
First author,
year
Experimental condition Control condition
Intervention group 1 Intervention group 2 Control group 1
Control
group 2
Milbury 201481 Expressive writing
(unfacilitated type of TW)
Neutral topic writing
Mosher 201272 Expressive writing Neutral topic writing
Paradisi 2010110 Written emotional disclosure
(unfacilitated type of TW)
Positive future writing
(unfacilitated type of
positive TW)
Non-emotional disclosure
Park 201278 Expressive writing programme
(unfacilitated type of TW)
No intervention
Pauley 201182 Negative expressive writing
(unfacilitated type of TW)
Positive expressive
writing (unfacilitated
type of TW)
Innocuous writing
Petrie 200456 Written emotional expression
(unfacilitated type of TW)
Time-management writing
Richards 200097 Trauma writing (unfacilitated
type of TW)
Trivial writing Usual routine
Rickett 201166 Poetry writing programme/
workshop
Waiting list
Rini 201486 Expressive writing Peer helping,
expressive helping
Neutral writing
Robinson 200899 eBT Unsupported SDW
(unfacilitated type of
TW)
Waiting list
Rosenberg 200283 Expressive writing
(unfacilitated type of TW)
Non-disclosure
Sharifabad
2010105
Written emotional disclosure
(unfacilitated type of TW)
Neutral topic writing
Sloan 201270 WET Waiting list
Smyth 1999107 Disclosure exercise
(unfacilitated type of TW)
Neutral topic writing
Smyth 2008121 Expressive writing
(unfacilitated type of TW)
Daily plans writing
Stark 201057 Trauma writing (unfacilitated
type of TW) plus Change
Theory (King type of TW)
Time management (factual
writing)
Tabolli 2012111 Writing exercise (unfacilitated
type of TW)
Non-writing
Taylor 200389 Written self-disclosure
intervention (unfacilitated
type of TW)
SMC
Theadom 201058 Written emotional disclosure
(unfacilitated type of TW)
Details of previous day
writing
Van Dam 201392 Expressive writing
(unfacilitated type of TW)
Treatment as usual
continued
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TABLE 101 Intervention groups as described in included studies (continued )
First author,
year
Experimental condition Control condition
Intervention group 1 Intervention group 2 Control group 1
Control
group 2
Vedhara 2007112 Written emotional disclosure
(unfacilitated type of TW)
Details of previous day
writing
Wagner 201073 Expressive writing
(unfacilitated type of TW)
Trivial writing
Walker 199979 Single-episode written
emotional expression
(unfacilitated type of TW)
Three-episode written
emotional expression
(unfacilitated type
of TW)
Attentional control
(standard care)
Wallander
2011109
WSD (unfacilitated type of
TW)
SMC
Warner 2006108 Written emotional disclosure
(unfacilitated type of TW)
Time management
Wetherell 2005117 Emotional disclosure (writing
or talking) (unfacilitated type
of TW)
Time-management writing
Willmott 2011104 Written emotional expression –
positive and negative
(unfacilitated type of TW)
Details of previous day’s
prior to heart attack
Zakowski 200484 Written emotional disclosure
(unfacilitated type of TW)
Details of daily activity
writing
WSD, written self-disclosure.
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Interventions as evaluated by the reviewers
TABLE 103 Facilitated and non-facilitated intervention names in included studies
First author, year
Experimental condition Control condition
Intervention
group 1
Intervention
group 2 Control group 1
Control
group 2
Facilitated
intervention?
Yes/No
Abel 200450 Unfacilitated EW Factual writing No
Arden-Close 201380 Unfacilitated EW Time-management
writing
No
Averill 2013100 Unfacilitated EW Non-writing No
Bartasiuniene 2011102 Unfacilitated EW Factual writing Non-writing No
Bernard 200693 Unfacilitated EW Factual and time-
management writing
No
Broderick 2004113 Unfacilitated EW Unfacilitated
EW
Time-management
writing
Attention
controla
No
Broderick 2005118 Unfacilitated EW Time-management
writing
SMC No
Canna 200694 Unfacilitated EW Factual writing ?
Cepeda 200885 Unfacilitated EW Attention controla SMC No
Craft 201374 Unfacilitated EW Unfacilitated
EW
Factual writing Non-writing No
Dennick 201488 Unfacilitated EW Factual writing No
D’Souza 2008101 Unfacilitated EW Time-management
writing
No
Gellaitry 201075 Unfacilitated EW SMC No
Gidron 199698 Unfacilitated EW Factual writing No
Gillis 2006119 Unfacilitated EW Time-management
writing
No
Golkaramnay 200768 Internet chat
room
No intervention Yes
Graf 200895 Unfacilitated EW Time-management
writing
No
Graham 200851 Questionnaire
plus unfacilitated
EW
Factual goal writing No
Grasing 201090 Unfacilitated EW Time-management
writing
No
Halpert 201052 Unfacilitated EW Non-writing No
Hamilton-West
2007114
Unfacilitated EW Time-management
writing
No
Harris 2005106 Unfacilitated EW Positive writing Factual writing No
Henry 201053 Positive writing SMC No
Hevey 2012103 Unfacilitated EW Factual writing No
Hong 201167 Songwriting Waiting list Yes
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TABLE 103 Facilitated and non-facilitated intervention names in included studies (continued )
First author, year
Experimental condition Control condition
Intervention
group 1
Intervention
group 2 Control group 1
Control
group 2
Facilitated
intervention?
Yes/No
Hughes 200754 Unfacilitated EW SMC No
Ironson 201371 Unfacilitated EW Factual writing No
Jensen-Johansen
201376
Unfacilitated EW Time-management
writing
No
Kraaij 201055 Website
structured writing
Waiting list No
Krpan 201396 Unfacilitated EW Time management
writing
No
Lange 200369 Website Interapy Waiting list Yes
Lumley 2011115 Unfacilitated EW Positive writing Time-management
writing
No
Lumley 2014116 Unfacilitated EW Time-management
writing
No
Mann 200172 Positive writing Non-writing No
McElligott 200687 Unfacilitated EW Factual writing No
Meshberg-Cohen
201091
Unfacilitated EW Factual writing No
Milbury 201481 Unfacilitated EW Factual writing No
Mosher 201277 Unfacilitated EW Factual writing No
Paradisi 2010110 Unfacilitated EW Positive writing Non-EW No
Park 201278 Unfacilitated EW No intervention No
Pauley 201182 Unfacilitated EW Positive writing Factual writing No
Petrie 200456 Unfacilitated EW Time-management
writing
No
Richards 200097 Unfacilitated EW Time-management
writing
SMC No
Rickett 201166 Poetry writing Waiting list Yes
Rini 201486 Unfacilitated EW Factual writing No
Robinson 200899 Unfacilitated EW Waiting list No
Rosenberg 200283 Unfacilitated EW Non-writing No
Sharifabad 2010105 Unfacilitated EW Factual writing No
Sloan 201270 Written exposure
therapy
Waiting list Yes
Smyth 1999107 Unfacilitated EW Time-management
writing
No
Smyth 2008121 Unfacilitated EW Time-management
writing
No
Stark 201057 Unfacilitated EW
(mixed writing)
Non-writing ?
continued
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TABLE 103 Facilitated and non-facilitated intervention names in included studies (continued )
First author, year
Experimental condition Control condition
Intervention
group 1
Intervention
group 2 Control group 1
Control
group 2
Facilitated
intervention?
Yes/No
Tabolli 2012111 Unfacilitated EW Non-writing No
Taylor 200389 Unfacilitated EW SMC No
Theadom 201058 Unfacilitated EW Factual writing No
Van Dam 201392 Unfacilitated EW Treatment as usual No
Vedhara 2007112 Unfacilitated EW Factual writing No
Wagner 201073 Unfacilitated EW Factual and time-
management writing
No
Walker 199979 Unfacilitated EW Positive writing SMC No
Wallander 2011109 Unfacilitated EW SMC No
Warner 2006108 Unfacilitated EW Time-management
writing
No
Wetherell 2005117 Unfacilitated EW Time-management
writing
No
Willmott 2011104 Unfacilitated EW Factual writing No
Zakowski 200484 Unfacilitated EW Factual writing No
Unfacilitated EW, unfacilitated type of TW or an adaptation of it.
a This attention control group has not been considered for analysis in current systematic review given it was considered to
have an active component and therefore not suitable for comparison. It would have been taken into account in the
situation where the two other intervention groups had undertaken the same educational activity on top of the
writing exercise.
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Outcomes measures definitions
TABLE 106 Outcome measures from included studies: acronyms and definitions
Acronym
Definitions given in the primary
studies Scale and scoring Meaning
6MWD Changes in 6 Minutes’ Walk
Distance (6MWD) over the study
period
Values are given in metres The longer the distance in the
6MWD, the higher the
performance
ABP The Asthma Bother Profile (ABP)
is a 23-item self-administered
questionnaire (Hyland et al.162)
designed to measure level of
distress caused by asthma. It covers
two domains: distress and asthma
management measured with a
unidimensional scale
6-point Likert scale with 0
(no) and 5 (yes); with use
of 0–5 scale. All scores are
added up with a maximum of
75 and minimum of 0
Higher scores indicate higher
distress caused by asthma
ABS The Affects Balance Scale (ABS;
Bradburn163) is a self-reported
measure, which rates the degree to
which participants experienced 20
positive and 20 negative emotions
during the past week through two
subscales: Positive Affect Scale
(PAS) and Negative Affect Scale
(NAS). It is a 10-item outcome
measure: it contains five statements
reflecting positive feelings and five
statements reflecting negative
feelings
An affect balance score is
calculated based on the
difference between the
number of yes responses to
positive-feeling questions
minus the number of yes
responses to negative-feeling
questions
The greater the score
difference, the higher the
affect unbalance
Abdominal pain
frequency
Stomach pain frequency was rated
when it was sufficiently bad not to
pursue with normal activity
From 0 to 5
With 0 (not at all), 1 (once),
2 (once a week), 3 (about two
or three times a week),
4 (about every other day),
5 (every day)
Higher scores indicate more
frequency of abdominal pain
ACT The Asthma Control Test (ACT), a
five-question survey (with 4-week
recall) on symptoms and
daily functioning, which is
self-administered by the patient
to measure asthma control in
individuals of ≥ 12 years. The
survey measures the elements of
asthma control as defined by the
National Heart, Lung, and Blood
Institute: frequency of shortness
of breath and general asthma
symptoms, use of rescue
medications, the effect of asthma
on daily functioning, and overall
self-assessment of asthma control.
ACT is clinically validated by
specialist assessment and
spirometry (www.thoracic.org/
assemblies/srn/questionaires/
act.php)
5-point scale for symptoms
and activities from 1 (all the
time) to 5 (not at all); for
asthma control rating from 1
(not controlled at all) to 5
(completely controlled). The
scores range from 5 (poor
control of asthma) to 25
(complete control of asthma)
Higher scores reflecting
greater asthma control.
An ACT score of > 19
indicates well-controlled
asthma
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TABLE 106 Outcome measures from included studies: acronyms and definitions (continued )
Acronym
Definitions given in the primary
studies Scale and scoring Meaning
Adherence Self-reported adherence in the study
by Mann72 was measured using the
general measure of adherence from
the RAND Medical Outcomes Study.
It consists of five items
6-point Likert scale ranging
from 1 (none of the time) to 6
(all of the time)
NA
ADSEI An adult version (Ryden164) of the
Coopersmith Self-Esteem Inventory
(SEI; Coopersmith165): test–retest
reliability and social desirability
The Coopersmith Self-Esteem
Inventory (SEI): 58 short statements
that are answered by checking the
box like me or unlike me. These
items consist of 50 self-esteem
items and eight items that compose
a lie scale, anxiety, depression,
behavioural problems and physical
well-being
The test has a built-in lie scale
that helps to determine if the
participant is trying too hard
to appear to have high
self-esteem
The higher the number of
like me, the greater the
participant’s self-reports are
markedly influenced by the
social desirability factor
AEE The Ambivalence Emotional
Expression (AEE; King and Emmons166)
Questionnaire is a 28-item
questionnaire used to assess the
extent to which participants feel
uncomfortable or regret expressing
their emotions (e.g. I’d like to talk
about my problems with others but at
times I just cannot, I feel guilty after I
have expressed anger to someone)
The test predicts more benefit
from disclosure
NA
AIMS2 The Arthritis Impact Measurement
Scale-2 (AIMS2) is a 28-item scale
that surveys the effects of arthritis
on multiple domains of functioning
during the previous month. It uses
six subscales: mobility level (e.g.
you were in bed or chair for most
of the day), walking and bending
(e.g. you had trouble either
bending, lifting, or stooping), hand
and finger function, arm function,
self-care tasks, and household
tasks. In the study by Lumley
et al.115 they analyse two scales:
(1) physical dysfunction, which
assesses dysfunction in mobility,
walking/bending, hand and finger
function, arm functioning, ability to
perform household tasks, and self-
care; and (2) affective disturbance,
which assesses both anxious and
depressive symptoms
5-point scale with respect to
the frequency (number of
days in a week) that a
particular behaviour or
symptom was experienced
from 1 (all days) to 5 (no
days). Ratings are averaged
Higher scores indicate greater
dysfunction
AIMS2: lack of
social support
subscale
The 4-item subscale from the
AIMS2 assesses one’s perceptions
that family and friends are available
if needed, are sensitive to needs,
interested in helping, and
understand the effects of the FM.
Items were rated regarding how
frequently support is available
From 1 (all days) to 5
(no days) and averaged
Higher values indicate less
social support
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TABLE 106 Outcome measures from included studies: acronyms and definitions (continued )
Acronym
Definitions given in the primary
studies Scale and scoring Meaning
AIMS2: pain
subscale
The 5-item pain subscale from the
AIMS2, a widely-used instrument
that measures health status in
rheumatic diseases during the past
month. Items were worded for FM
rather than arthritis (e.g. you had
severe pain from your FM)
5-point scale from 1
(all days) to 5 (no days),
reverse scored and averaged
Higher values indicate more
pain
AIMS2 for
physical
dysfunction
The AIMS2 was used and assessed
28 items from six subscales:
mobility level (you were in bed or
chair for most of the day), walking
and bending (you had trouble
either bending, lifting, or stooping),
hand and finger function, arm
function, self-care tasks and
household tasks
5-point scale from 1
(all days) to 5 (no days) and
scored
Higher scores indicate greater
physical dysfunction
ARS-20 The Assertiveness/Responsiveness
scale (ARS-20; Richmond and
McCroskey167) is a 20-item scale
consisting of two subscales, one for
each trait, with 10 items each
Both scales ask respondents
to rate how much they
identify with a list of
representative behaviours.
Behaviours for the
Assertiveness scale include
items like defend own beliefs
and have strong personality,
whereas items from the
Responsiveness scale include
items such as sympathetic and
sensitive to the needs of
others
Higher scores indicate greater
levels
ASS The Asthma Sum Scale (ASS) is a
9-item scale used to report both
asthma and nasal or allergy
symptoms during the past 2 weeks
5-point scale from 0 (none) to
4 (severe)
Higher scores indicate greater
symptoms
BA use Beta-agonist use, measured as
puffs per day
Numbers of puffs per day
were summed up
Higher number of puffs
indicated greater symptoms
BAI The Beck Anxiety Inventory
(BAI; Beck and Steer168) is a
21-item self-report measure that
uses a 4-point Likert scale with
ratings from not at all to severely to
measure physical and cognitive
symptoms of anxiety
Each BAI item is rated on a
4-point scale: 0 (not at all) to
3 (severely, I could barely
stand it)
Higher total scores indicate
more severe anxiety
symptoms
BAS-G The Bath Ankylosing Spondylitis
Disease Global Score (BAS-G;
Jones et al.169) requires patients to
respond to two questions regarding
the effect of their disease on their
health: over the past week, and
over the past 6 months. Responses
to these scales are indicated by
marking a line on a 100-mm VAS
Scale 0–10 VAS, best 10
Total score range from
0 to 10
Higher scores indicate greater
effect of AS on the patient’s
life
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TABLE 106 Outcome measures from included studies: acronyms and definitions (continued )
Acronym
Definitions given in the primary
studies Scale and scoring Meaning
BASDAI The Bath Ankylosing Spondylitis
Disease Activity Index (BASDAI)
comprises six questions relating to
individual domains of fatigue,
spinal pain, joint pain and
symptoms, together with
perception of pain relating to bony
areas of the body and to morning
stiffness
BASFI comprises 10 questions
regarding function in AS and ability
to meet the physical demands of
everyday life. Responses to these
scales are indicated by marking a
line on a 100-mm VAS
Scale 0–10 VAS, best 10
Total score ranges from
0 to 10
Higher scores indicate higher
levels of disease activity
BASFI The Bath Ankylosing Spondylitis
Disease Functional Index (BASFI;
Calin et al.170). Responses to these
scales are indicated by marking a
line on a 100-mm VAS
Scale 0–10 VAS, best 10
Total score range from
0 to 10
Higher scores indicate to
greater limitation of function
BDI The Beck Depression Inventory (BDI;
Beck et al.171). The full BDI has
21 items, which stress cognitive
symptoms of depression, each with
four Guttman-type responses
choices in the form of statements,
ranked in order of severity. In
some categories, two alternative
statements are assigned the same
score
Scale 0–3, reflecting severity
Total scores range from
0 to 63
Higher total scores indicate
more severe depressive
symptoms
BDI-II The revised Beck Depression
Inventory (BDI-II; Beck et al.172)
is a 21-item self-report measure
incorporating cognitive, affective
and somatic aspects of depressed
mood. In this revised version, there
is one alternative score for each
level (so no statement is assigned
the same weight)
Four alternatives for the 21
items ranging from 0 (low) to
3 (high). Total scores range
from 0 to 63
Higher total scores indicate
more severe depressive
symptoms
BDI-SF The short 13-item version of Beck
Depression Inventory (BDI-SF; Beck
et al.173 and Furlanetto et al.174)
measures depressive symptoms
during the last 7 days
NA Higher total scores indicate
more severe depressive
symptoms
BFI The Brief Fatigue Inventory (BFI;
Mendoza et al.175) is a 10-item
questionnaire asking participants to
rate the severity of their fatigue
and the degree to which it
interferes with their lives. BFI has
been specifically developed for
cancer patient populations
Response to the first question,
‘Are you usually tired?’ is
either yes or no. The
remaining nine items are
measured on a 11-point
Likert scale ranging from 0
(no fatigue) to 10 (worst that
you can even imagine).
Individual scores are added up
in a total score
Higher scores indicate worse
fatigue, and a score of > 3
indicates clinically significant
fatigue
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TABLE 106 Outcome measures from included studies: acronyms and definitions (continued )
Acronym
Definitions given in the primary
studies Scale and scoring Meaning
BITE The Bulimia Investigatory Test
Edinburgh (BITE; Henderson and
Freeman176). This 33-item scale
provides a rating of symptoms of
BN and BED, and has a symptom
and severity subscale. BITE was
used to measure symptoms over
the past month, as a response to
treatment. The symptom scale
comprised 27 items and the
severity scale comprised three items
l Items 1, 13, 21, 23 and
31 in the symptom scale
scored one point for a no
response and the
remaining 25 items
scored one point for a yes
response. The maximum
possible score is 30
l Items 6, 7 and 27
constitute the severity
scale. The total score is
the sum of the numbers
corresponding to the
circled responses
Scorers on this scale can be
subdivided into three main
groups: high scorers with a
score of ≥ 20, medium scorers
with a score of 10–19,
and low scorers with a
score of < 10
l A symptom score of > 20
indicates a highly
disordered eating pattern
and the presence of
binge eating
l A symptom score in the
medium range (10–19)
suggests an unusual
eating pattern but not
meeting criteria for a
diagnosis of bulimia
l A symptom score in the
15–19 range may well
reflect a subclinical group
of binge-eaters, either in
the initial stages of the
disorder or a recovered
bulimic
l A symptom score in the
low range (0–10) falls
within normal limits
l A severity score of > 5 is
clinically significant
l A severity score of > 10
indicates high degree
of severity
BMI In the study by Taylor et al.,89
the body mass index (BMI) was
recorded as kg body weight
(kg)/height (m2)
NA A reduction in the BMI
indicated disease progression
and/or exacerbation
BPI The Brief Pain Inventory (BPI), short
form, is a 11-item self-report rating
scale using simple numeric rating
scales to assess the severity of pain
(four questions) and impact of
pain (seven questions)
From 0 to 10 Higher scores indicate greater
pain
Brief COPE The Brief COPE is a 28-item
measure of 14 coping responses
(Carver177). The responses can be
categorised as adaptive coping
(e.g. active coping, planning,
use of emotional support) and
maladaptive coping (e.g. denial,
self-blame and behavioural
disengagement)
5-point Likert scale ranging
from 1 (I haven’t been doing
this at all) to 5 (I have been
doing this a lot)
Items are calculated into 14
separate indices
Higher scores indicate greater
active coping
Brief POMS The Brief Profile of Mood States
(Brief POMS) provides a summary
measure of distress or mood. The
original 65-item POMS has been
widely used with cancer patients
5-point Likert scale ranging
from 0 (not at all); 1 (a little);
2 (moderately); 3 (quite a bit);
4 (extremely)
Higher scores indicate higher
distress
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TABLE 106 Outcome measures from included studies: acronyms and definitions (continued )
Acronym
Definitions given in the primary
studies Scale and scoring Meaning
BSCS The Brief Substance Craving Scale
(BSCS) is a 12-item self-report
instrument assessing intensity,
frequency and length of craving
over a 24-hour period for
substances of abuse. Each of the
three items is related to the
intensity, frequency and length of
craving during the prior 24 hours.
In Grasing et al.,90 the reductions in
craving intensity were measured
and those are calculated by
subtracting baseline measures
recorded during screening from
results obtained at the initial
outpatient visit
5-point Likert scale ranging
from 0 (not at all) to 4
(extremely). The total score
ranges from 0 to 12
Higher scores indicate higher
craving
BSI The Brief Symptom Inventory
(BSI; Derogatis and Melisaratos178)
is a 53-item scale, a shortened
version of the SCL-90 (Symptom
Checklist-90) that assesses nine
symptoms of distress and provides
three global distress indices. The
BSI measures symptoms associated
with distress on nine symptom
dimensions (including somatisation,
obsessive–compulsive, interpersonal
sensitivity, depression, anxiety,
hostility, phobic anxiety, paranoid
ideation and psychoticism).
Participants report the extent to
which they experienced each of the
symptoms in the past week
including today. The scale also
includes a global index of distress,
the Global Severity Index (GSI) used
in both studies by Zakowski et al.
published in 200484 and 2011161
Likert-type scale ranging from
0 (not at all) to 4 (extremely)
Higher scores indicate higher
symptoms
C-QoL Cancer Quality of Life (C-QoL;
Lee179) is a cancer-specific type of
QoL measurement tool developed
in Korea to better reflect the
cultural characteristics of the
country. The C-QoL was used in
Park and Yi78 and consists of
21 items with specific questions:
physical conditions (n= 6),
emotional states (n= 6), social role
(n= 3), social status (n= 3) and
coping ability (n= 4)
5-point scale (0= not at all,
1= a little yes, 2=moderate,
3= quite a lot and 4= very
much so)
Range from 0 to 84
Higher scores indicate greater
QoL
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TABLE 106 Outcome measures from included studies: acronyms and definitions (continued )
Acronym
Definitions given in the primary
studies Scale and scoring Meaning
CAPS The Clinician-Administered PTSD
Scale (CAPS; Weathers et al.180)
used to assess PTSD symptom
severity. CAPS rates the frequency
and intensity of each symptom
along 5-point ordinal scales, the
impact of symptoms on the
patient’s social and occupational
functioning, the overall severity of
the symptom complex, and the
global validity of ratings obtained.
There is a total score for the CAPS
PTSD ratings (frequency and
intensity). The CAPS yields both
dichotomous (i.e. present or
absent) and continuous (i.e.
severity) scores for each symptom
and for the disorder as a whole
5-point scale ranging from
0 to 136
Higher scores indicate greater
severity of PTSD symptoms
CBCL The Child Behavior Checklist (CBCL)
and by youth on the Youth
Self-Report of the CBCL
(Achenbach181) consists of 113
questions used to detect emotional
and behavioural problems in
children and adolescents
3-point Likert scale ranging
from 0 (absent), 1 (occurs
sometimes), 2 (occurs often)
Higher scores indicate more
emotional and behavioural
problems
CD4+ count CD4+ lymphocyte count was
determined by flow cytometry. A
square root transformation was
used on the CD4+ counts to give
an approximately normal
distribution. Data were analysed as
a multivariate hierarchical model
using the hierarchical linear
modelling programme HLM 5.04. In
Ironson et al.,71 flow cytometry was
performed in one laboratory to
enumerate CD3+/CD4+
lymphocytes with fluorochrome
conjugated monoclonal antibodies
in a four-colour system
Threshold used in the study
was not reported but used as
a predictor of disease
progression
Higher count in CD4+ cells
when associated with
improved immune status and
better health
CDI The Children Depression Inventory
(CDI) contains 27 items that
represent a range of depressive
symptoms including disturbed
mood, hedonic capacity, vegetative
functions, self-evaluation and
interpersonal problems. The child is
asked to choose the item that best
describes him or her for the past
2 weeks. The five factors for the CDI
are negative mood, interpersonal
problems, ineffectiveness, anhedonia
and negative self-esteem
Each item consists of three
statements that are keyed
0, 1 or 2
Higher scores indicating
increased severity
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TABLE 106 Outcome measures from included studies: acronyms and definitions (continued )
Acronym
Definitions given in the primary
studies Scale and scoring Meaning
CES-D The Centre for Epidemiological
Studies Depression Scale (CES-D;
Radloff182) is a 20-item scale;
participants rated the intensity and
frequency of depressive symptoms
they had experienced in the past
week. The CES-D has been used to
measure clinical and subclinical
levels of depression in medical
populations and effectively
identifies depression among
patients with chronic pain
(Geisser et al.183). It includes
four factors: dysphoria, positive
affect, a somatic factor, and an
interpersonal factor. In Henry
et al.,53 four subscales were
calculated from the CES-D:
depressed mood (seven items,
α= 0.83–0.92), (lack of) positive
affect (four items, α= 0.71–0.9),
somatisation or retarded activity
(seven items, α= 0.5–0.9), and
(lack of) interpersonal relations
(two items)
4-point Likert-type scale from
0 (rarely or none of the time)
to 3 (most or all of the time)
Higher scores indicates the
greatest frequency of
depressed mood over the
past week
CG-FBD The functional bowel disease-
related cognition consisted of
CG-FBD Q16 My bowel symptoms
make me feel out of control and
CG-FBD Q31 Nothing seems to
help my bowel symptoms
Scale 0–7, worse cognition 7 Higher scores indicate worse
adaptive cognition
CLINHAQ Three items from the Clinical
Health Assessment Questionnaire
(CLINHAQ; Wolfe184) were used in
Broderick et al.118 to assess GI,
headache and fatigue symptoms.
The CLINHAQ contains self-reports
for the Health Assessment
Questionnaire (HAQ; Fries185)
disability index, Arthritis Impact
Measurement Scale (AIMS) anxiety
and depression index (Hawley and
Wolfe186), VAS pain, VAS global
severity, VAS GI symptoms, VAS
sleep problems, VAS fatigue,
satisfaction with health, and patient
estimate of health status. In 1996,
the helplessness subscale of the
RAI was added to the CLINHAQ
(deVellis et al.187). The variables
contained in this questionnaire
consider factors that are thought to
be of major importance in FM
(Burckhardt et al.188)
On a 100-point VAS Higher scales indicate greater
symptoms
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TABLE 106 Outcome measures from included studies: acronyms and definitions (continued )
Acronym
Definitions given in the primary
studies Scale and scoring Meaning
Cortisol Cortisol reactivity was assessed in
Smyth et al.9 by asking participants
to collect saliva by placing a sterile
cotton wad in their mouth for a
few minutes and then sealing the
cotton in a salivette, a test tube-like
container (Sartstedt, Rommelsdorf,
Germany). Samples were kept
frozen until shipped for assay at a
clinical laboratory
Cortisol levels were assessed
in response to imagery-based
trauma re-exposure
Lower levels indicate greater
health improvement
CRP The C-reactive protein (CRP), which
is another serum measure of
inflammation, was measured in
Wetherell et al.117 CRP is an acute
phase protein, levels of which
fluctuate over a shorter time period
than ESR (Kushner189). CRP
therefore provides an objective
marker of disease activity in
addition to the components of the
DAS
CRP is a measure of
inflammation and provide
markers for clinical status in
rheumatic disease. CRP is
sensitive and is only raised
during periods of acute
inflammation
Higher CRP levels indicate
greater transitory acute
inflammation
CRQ The Chronic Respiratory Disease
Questionnaire (CRQ) is an
interviewer-administered
questionnaire measuring both
physical and emotional aspects of
chronic respiratory disease. It has
20 questions in four categories:
dyspnoea, fatigue, emotional
function and mastery
7-point scale, with 7
indicating no health
impairment. A change of 0.5
for each is considered the
minimal clinically significant
change
Higher scores indicate better
HRQoL
CS use Corticosteroid use, measured as
puffs per day
CS use is an indicator of
disease status
The higher the use of CS,
the worst the disease course
CSAQ The Cognitive-Somatic Anxiety
Questionnaire (CSAQ; Schwartz190)
a trait anxiety inventory, is a
14-item self-report inventory that is
divided into two 7-item scales
(cognitive and somatic) that appear
to reflect cognitive or somatic
anxiety. Participants are asked to
rate the degree to which they are
generally or typically experiencing
symptoms of anxiety by circling a
number from 1 through to 5
5-point Likert scale ranging
from 1 (not at all) to 5 (very
much so). The sums of the
circled rating are separately
computed for the cognitive
and somatic items, and
constituted the main
dependent measures
Higher total scores indicate
higher symptoms
CSI The Children’s Somatisation
Inventory (CSI) includes 36
symptoms from the criteria for
Somatisation Disorder and the
Somatisation factor of the Hopkins
Symptom Checklist. Ratings are
obtained on the severity with which
the youth have experienced each
symptom (e.g. headaches, pains in
the heart, muscle aches) in the past
2 weeks
5-point scale from 0 (not at
all) to 4 (a whole lot). A total
score was calculated in the
standard fashion to measure
severity of general
somatisation symptoms
Higher scores indicate higher
severity of symptoms
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TABLE 106 Outcome measures from included studies: acronyms and definitions (continued )
Acronym
Definitions given in the primary
studies Scale and scoring Meaning
CT3 Catastrophising (maladaptive
coping)
Scale 0–36; worse
catastrophising, 36
Higher scores indicate worse
catastrophising
DAS The Disease Activity Score (DAS)
involves measurement of four
variables: counts of the number of
swollen and tender joints (assessed
by physical examination); a patient
self-report measure (All things
considered, how are you feeling?),
measured using a 100-mm VAS;
and a serum measure of
inflammation, i.e. ESR. ESR is
an indirect measure of acute
phase reactions and provides a
standardised and validated clinical
index for assessing disease activity
in RA (Fuchs191). A total score can
be computed or individual
components of the DAS can be
used
The DAS ranges from 2 to 10 Scores of < 2.6 indicate
disease remission and scores
of > 5.1 indicate high disease
activity
DASS The Depression Anxiety Stress
Scales (DASS) is a 42-item
self-report measure used to
assess depression, anxiety and
stress in clinical samples over the
previous week
4-point Likert scale from 0
(did not apply to me at all) to
3 (applied to me very much,
or most of the time)
Higher scores indicate greater
symptoms
Davidson PTSD
scale
The Davidson PTSD scale (PTSDTOT;
Davidson et al.,192 Zlotnick et al.193)
is a 17-item, interview-administered
measure based on the PTSD
symptom clusters defined by
DSM-IV. Respondents are asked to
rate each of the 17 items referring
to a particular traumatic event, or
series of events, according to level
of distress based on their ratings
of symptoms that have occurred
during the past week. Both
frequency and severity are rated for
each item. If the respondent has
experienced multiple traumatic
episodes, multiple copies of the
scale may be administered
From 0 to 4 for both
frequency and severity during
the past week
Items are summed for a total
score, and subscales measure
re-experiencing, avoidance
and arousal
Higher scores indicate greater
symptoms
DBP Diastolic blood pressure (DBP),
measured in mmHg
BP is indicative of chronic
complications post MI, such
as cardiac arrhythmias and
left ventricular failure
Higher DBP indicated greater
post-MI complications
DIS The Perception of Disclosure Scale
(DIS) measures the perception of
the extent to which participants
had already expressed their deepest
thoughts and feelings about their
cancer experience through writing
or discussion with others
Scale ranges from 0 (not all)
to 10 (complete disclosure)
Higher scores indicate more
complete disclosure
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TABLE 106 Outcome measures from included studies: acronyms and definitions (continued )
Acronym
Definitions given in the primary
studies Scale and scoring Meaning
Disease Activity
Rating Scale
The Disease Activity Rating Scale is
a scale used by physicians to
indicate the current status of the
patient’s RA. Factors that physicians
would take into account in making
this rating include number of
tender and swollen joints, and
degree of inflammation and pain
5-point rating scale ranging
from 0 (asymptomatic) to
4 (very severe)
A 1-point change is
considered clinically significant
Higher scores indicate greater
disease activity
DLQI The Dermatology Life Quality Index
(DLQI; Finlay and Khan194) is
used widely in patients with
dermatological conditions,
including psoriasis. It examines
respondents views on the
functional consequences of their
skin condition on their lives in the
previous week. It correlates well
with clinical measures of disease
severity and boasts of good
reliability statistics. It measures how
much the skin problem has
affected your life. It is designed for
young people aged > 16 years and
for adults
4-point Likert scale ranging
from very much to not at all
The scoring is:
l Very much scored 3
l A lot scored 2
l A little scored 1
l Not at all scored 0
l Not relevant scored 0
l Question 7, prevented
work or studying scored 3
The DLQI is calculated by
summing the score of each
question, resulting in a
maximum of 30 and a
minimum of 0
The higher the score, the
more QoL is impaired
DS-14 The DS-14 is a 14-item measure of
negative affectivity (seven items) and
social inhibition (seven items)
(Denollet195)
The DS-14 has good psychometric
properties and is widely used with
cardiac populations (e.g. Denollet
et al.196)
5-point Likert scale from
0 to 4
A score of ≥ 10 on both the
negative affectivity and social
inhibition scales indicates
Type D personality
DT The Distress Thermometer (DT;
Roth et al.197) assessed general
distress
11-point Likert scale from 0
(no distress) to 10 (extreme
distress)
Higher scores indicate greater
distress
Emotional
approach coping
In Averill et al.,100 the emotional
approach coping (Stanton et al.198)
was measured to assess emotional
processing (four items: e.g. I take
time to figure out what I am really
feeling; α= 0.76) and emotional
expression (four items; e.g. I feel
free to express my emotions;
α= 0.89). Because the two
subscales were correlated only
0.61, they were used separately in
analysis
8-item scale Lower emotional approach
copying are related to lower
psychological well-being
EQ-5D QoL measured by utility and VAS. A
measure of perceived health status
Utility: 0–1, where 0 is death
and 1 is perfect perceived
health
VAS: 0–100, where 0 is death
and 100 is perfect perceived
health
Higher scores indicate better
health
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TABLE 106 Outcome measures from included studies: acronyms and definitions (continued )
Acronym
Definitions given in the primary
studies Scale and scoring Meaning
ESR The erythrocyte sedimentation rate
(ESR)
ESR is an indicator of
inflammation and disease
activity
Values of >20mm/hour
indicate elevated inflammation
and disease activity
Expressed anger In Graham et al.,51 the degree of
express anger was uniquely
accounted for intervention effects
and meaning making mediated
effects on depressed mood
From 0 (none) to 4 (very much)
A code of 4 was given when
the letter included an explicit
statement indicating that the
participant was, for instance,
very angry or furious or if the
participant had used many
examples that sounded
frustrating and/or used
underlining, exclamation
points, or other techniques for
emphasis
A code 0 was given when the
participant neither identified at
all with an anger-related
emotion (including frustration)
nor gave any examples that
seemed frustrating
Higher scores indicate higher
expression of anger
FACIT-F The Functional Assessment of
Chronic Illness Therapy Fatigue
subscale version 4 (FACIT-F;
Yellen199) assessed fatigue during
the past 7 days. It measures
physical well-being, social/family
well-being, emotional well-being,
functional well-being and
additional concerns
All items are measured on a
5-point Likert scale ranging
from 0 (not at all) to 4
(very much)
Higher scores indicate greater
fatigue
FACIT-Sp The meaning/peace subscale of the
Functional Assessment of Chronic
Illness Therapy–Spiritual Well-Being
scale (FACIT-Sp; Peterman et al.200)
A 12-item self-report measure
comprises two subscales: one
measuring a sense of meaning and
peace and the other assessing the
role of faith in illness
A total score for spiritual well-being
is produced. In Mosher et al.,77 the
FACIT-Sp is used to measure
existential well-being by assessing
participant’s degree of purpose in
life and inner peace
Scale ranging from 0 to 48
Two subscales:
l Meaning/peace
(items 1–8)
l Faith (items 9–12)
Higher scores signifying
greater spiritual well-being
FACT-General The Functional Assessment of Cancer
Therapy (FACT; Basen-Engquist
et al.201) questionnaire is a 34-item
general cancer QoL measure for
evaluating patients receiving cancer
treatment. It covers five general
cancer-related domains (physical
well-being, social family well-being,
relationship with health-care
provider, emotional well-being, and
functional well-being) and one
disease/site-specific domain
5-point scale from 0
(not at all) to 4 (very much)
Higher scores indicate better
QoL
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TABLE 106 Outcome measures from included studies: acronyms and definitions (continued )
Acronym
Definitions given in the primary
studies Scale and scoring Meaning
FACT-B The Functional Assessment of
Cancer Therapy-Breast Cancer
Version (FACT-B) is a 37-item
self-report instrument, with known
validity and reliability, containing
27 general items (from the FACT-
General) plus 10 breast cancer-
specific items (Brady et al.202)
Subscales include physical well-
being (seven items), social/family
well-being (seven items),
emotional well-being (six items) and
functional well-being (seven items)
The 10 additional items address
physical and psychological concerns
related to breast cancer
Respondents are asked to rate how
true each statement had been for
them over the past 7 days
5-point Likert-type scale from
0 (not at all) to 4 (very much).
All 37 items can be combined
for a total QoL score, and
subscale scores may be
computed as well
Higher scores indicate higher
QoL
FDI The Functional Disability Inventory
(FDI; Walker and Greene203) is a
15-item assessing difficulty
performing various routine
behaviours during the last few
weeks
Items range from 0 (no
trouble) to 4 (impossible) and
totalled
Higher scores indicate greater
disability
FEV1 The forced expiratory volume in
1 second (FEV1)
FEV1 is one of the primary
indicators of health status and
disease progression for cystic
fibrosis or patients with
asthma, for instance
A decrease in FEV1 indicates
disease exacerbation and/or
reduction of lung functioning
FIQ The Fibromyalgia Impact
Questionnaire (FIQ) evaluates the
global health status using a 10-item
survey assessing those components
of health that are most affected by
FM (physical functioning, work
status, depression, anxiety, sleep,
pain, stiffness, fatigue and
well-being) during the prior week
FIQ is an adaptation of the HAQ
and the AIMS
In Broderick et al.,118 items
assessing physical functioning and
stiffness were used
Scores range from 0 to 100 Higher scores indicate poorer
health or functioning
FLZ The Fragebogen zur Erfassung des
Lebenszufriendenheit (FLZ) is a Life
Satisfaction Scale used to measure
life satisfaction
The FLZ uses eight items assessing
patient’s satisfaction with different
areas of their life (e.g. social
contacts, partnership, financial
situation)
7-point Likert scale from 1
(very satisfied) to 7 (very
unsatisfied)
The sum score indicates
overall life satisfaction
Higher scores indicate less life
satisfaction
continued
DOI: 10.3310/hta20270 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 27
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Nyssen et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
309
TABLE 106 Outcome measures from included studies: acronyms and definitions (continued )
Acronym
Definitions given in the primary
studies Scale and scoring Meaning
FSS The 9-item Fatigue Severity Scale
(FSS) assesses the frequency and
severity of fatigues interference
with physical functioning
Items were rated on a 1–7
scale and averaged
Higher scores indicate greater
fatigue
FVC The forced vital capacity (FVC) FVC is one of the primary
indicators of health status and
disease progression for cystic
fibrosis or patients with
asthma, for instance
A decrease in FVC indicates
disease exacerbation and/or
reduction of lung functioning
GBB The Giessener Beschwerdebogen
(GBB) is a 24-item scale assessing
various symptomatic complaints
The sum score measures subjective
physical well-being
5-point Likert scale ranging
from 0 (not applicable) to
4 (strongly)
The total score ranges from
0 to 12
Higher scores indicate greater
symptoms, decreased
subjective physical health
GDS The Geriatric Depression Scale
(GDS; Yesavage et al.204) is a
30-item scale that is more
appropriate for use with people
with ALS than other depression
instruments that include somatic
symptoms regularly experienced in
ALS
l A score of > 5 points is
suggestive of depression
l A score of ≥ 10 points is
almost always indicative
of depression
l A score of > 5 points
should warrant a
follow-up comprehensive
assessment
Higher scores indicate higher
symptoms of depression
GHQ-12 The General Health Questionnaire
(GHQ-12; Goldberg et al.205) was
used as an indicator of overall
mental health in hundreds of
studies that assessed both clinical
and non-clinical populations
Items from the GHQ-12 included:
Have you recently been able to
concentrate on what you are
doing? Have you been able to face
up to your normal problems?
Owing to the various thresholds of
the GHQ-12, the mean GHQ score
for a population of respondents
was suggested as a rough indicator
for the best cut-off point (Goldberg
et al.206). Therefore, based on the
mean GHQ score for this sample,
the cut-off point is used to
determine the respondent’s level of
psychological well-being
4-point Likert scale
The scores are summed up by
adding all the items on the
scale ranging from 0 to 12
NA
GSI The Global Severity Index (GSI) is a
widely used index of stress and is
highly correlated with the BSI
subscales. Individuals report the
extent to which they experienced
each of the symptoms in the past
week including today
5-point Likert scale
Ranges from 0 (not at all) to 4
(extremely)
Higher scores indicate greater
severity
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TABLE 106 Outcome measures from included studies: acronyms and definitions (continued )
Acronym
Definitions given in the primary
studies Scale and scoring Meaning
HADS The Hospital Anxiety and
Depression Scale (HADS; Zigmond
and Snaith207), which contains 14
items (seven anxiety items and
seven depression items)
This scale requires participants to
indicate how they have been
feeling during the past week.
In Wallander et al.,109 participants
with a HADS total score of 15 were
classified as being clinically
distressed
4-point scale ranging from 0
(not at all) to 3 (most of the
time)
Total score ranges from
0 to 21
Higher scores indicate higher
anxiety/depression
HADS-A The anxiety subscale of the Hospital
Anxiety and Depression Scale
(HADS-A; Zigmond and Snaith207)
A score of 0–7 is considered
to be normal
Scores of ≥ 20 indicate
moderate, severe or very
severe anxiety
Higher scores on each
individual scale or the entire
scale indicate greater anxiety
or mood disorder
HADS-D The depression subscale of the
Hospital Anxiety and Depression
Scale (HADS-A; Zigmond and
Snaith207)
A score of 0–7 is considered
to be normal
Scores of ≥ 20 indicate
moderate, severe or very
severe depression
Higher scores on each
individual scale or the entire
scale indicate greater
depression or mood disorder
HAM–D The Hamilton Depression Scale
(HAM–D; Hamilton208) is a
17-item, interview-based measure,
considered the gold standard for
assessing severity of depression
A score of 0–7 is considered
to be normal
Scores of ≥ 20 indicate
moderate, severe, or very
severe depression
Higher scores indicate more
depression or mood disorder
Headache
frequency
Number of days in the last month
with a headache
NA The higher the frequency the
worst the health status
HIV symptom
checklist
In Ironson et al.,71 experimenters
assessed symptoms relevant to HIV
(based on the Centre for Disease
Control and Prevention criteria for
Category B symptoms) by interview
using a HIV symptom checklist
Symptoms were assessed for the
previous month at baseline and the
1-month visit, and for the previous
6 months, at the 6- and 12-month
visits; thus, symptoms were
assessed during the complete
follow-up period
Examples of symptoms are
herpes zoster (shingles), oral
thrush, cervical dysplasia,
pelvic inflammatory disease,
low platelet count (50,000),
peripheral neuropathy,
chronic unexplained fever and
chronic unexplained diarrhoea
More symptoms indicate a
worse health
HIV VL HIV VL was determined using a
quantitative reverse-transcriptase
PCR assay (Amplicor HIV-1 Monitor,
Roche Diagnostic Systems), which
measures down to 400 copies of
HIV RNA in plasma
Threshold not reported A reduction in VL indicates
better health
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TABLE 106 Outcome measures from included studies: acronyms and definitions (continued )
Acronym
Definitions given in the primary
studies Scale and scoring Meaning
HIV-OS The HIV-Specific Optimism Scale
(HIV-OS) is a self-report measure of
optimistic beliefs related to HIV
issues
Seven items were adapted from the
LOT (Scheier and Carver209)
specifically for Wagner et al.73
Sample HIV-OS items include ‘I am
not counting on things going my
way in the course of my HIV
infection’ and ‘Although the future
course of my HIV infection is
uncertain, I expect the best’
6-point Likert scale ranging
from strongly disagree to
strongly agree
Higher scores indicate higher
levels of optimism related to
HIV issues
IBS-QoL The Irritable Bowel Syndrome QoL Scale 0–100, best= 100 Higher scores indicate better
QoL
IBSSS The irritable bowel severity (IBS)
scale/scoring system (IBSSS;
Francis et al.210) is a 9-item survey
designed to enable clinicians to
record and monitor the severity of
IBS
Participants have to answer the
questions based on how they feel
currently (i.e. over the last 10 days
or so)
A total IBS severity score is given
l Mild severity: 75–175
l Moderate severity:
175–300
l Severe severity: > 300
The maximum score is 500
Higher scores indicate
increase in IBS severity
IES The Impact of Event Scale
(IES; Horowitz et al.211) assesses
frequency of intrusive thoughts and
avoidance over the past week
including today. Participants are
asked to specifically refer to their
cancer experience when answering
the questions
Responses for each item are
0 (not at all); 1 (rarely);
3 (sometimes); 5 (often)
Possible score ranges from 0
to 40
Higher scores indicate the
greater extent to which
participants have experienced
each item, in the preceding
7 days
IES-R The Impact of Event Scale-Revised
(IES-R; Weiss and Marmar212), which
contains 22 items that measure
avoidance, intrusive re-experiences
and arousal associated with a
traumatic event
5-point scale ranging from
0 (not at all) to 4 (extremely)
Higher scores indicate greater
extent to which participants
have experienced each item in
the preceding 7 days in
relation to their psychotic
experiences and treatment
IS The 8-item Insight Scale
(IS; Birchwood et al.213), which
measures three dimensions of
insight: perceived need for
treatment, awareness of illness
and relabelling of symptoms as
pathological
Response to each item
reported as agree, disagree or
unsure
NA
K-10 The Kessler Psychological Distress
Scale (K-10) detects non-specific
emotional distress and has been
used in a number of population
health surveys in Australia. It
contains 10 statements covering
the preceding 4 weeks
5-point Likert scale from
1 (none of the time) to 5
(all the time)
Possible scores range from
10 (no distress) to 50
(maximal distress)
Higher scores indicate higher
distress
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TABLE 106 Outcome measures from included studies: acronyms and definitions (continued )
Acronym
Definitions given in the primary
studies Scale and scoring Meaning
LIFE The Longitudinal Interval Follow-Up
Evaluation (LIFE; Keller et al.214) is a
semistructured interview for
assessing the longitudinal course of
psychiatric disorders
It consists of a semistructured
interview, an Instruction booklet, a
coding sheet, and a set of training
materials. An interviewer uses the
LIFE to collect detailed psychosocial,
psychopathological, and treatment
information for a 6-month
follow-up interval
The weekly psychopathology
measures (psychiatric status ratings)
are ordinal symptom-based scales
with categories defined to match
the levels of symptoms used in the
Research Diagnostic Criteria
The ratings provide a separate,
concurrent record of the course of
each disorder initially diagnosed in
patients or developing during the
follow-up
Any DSM-III or Research Diagnostic
Criteria disorder can be rated with
the LIFE, and any length or number
of follow-up intervals can be
accommodated. The psychosocial
and treatment information is
recorded so that these data can be
linked temporally to the psychiatric
status ratings
NA NA
LIWC The Linguistic Inquiry and Word
Count (LIWC) is a text analysis
software program designed
by Pennebaker et al.19
LIWC calculates the degree to
which people use different
categories of words across a wide
array of texts, including e-mails,
speeches, poems, or transcribed
daily speech. With a click of a
button, you can determine the
degree any text uses positive or
negative emotions, self-references,
causal words, and 70 other
language dimensions
(www.liwc.net/)
NA NA
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TABLE 106 Outcome measures from included studies: acronyms and definitions (continued )
Acronym
Definitions given in the primary
studies Scale and scoring Meaning
LOT The Life Orientation Test (LOT)
assesses generalised positive
outcome experiences measures
optimism on eight items to indicate
the extent to which they agree with
each statement
5-point Likert scales ranging
from 1 (strongly agree) to
5 (strongly disagree)
The items are summed to
create a score ranging from
8 to 40
Higher numbers indicate more
optimism
Mac New
HRQOL
The Mac New Health Related
Quality Of Life (Mac New HRQOL)
scale is a 27-item measure of
physical, emotional and social QoL
(Valenti et al.215)
In addition to separate physical,
emotional and social QoL subscales,
an overall index of QoL is provided.
It has been extensively used in
cardiac populations, and based on
data from over 1000 cardiac
patients
7-point Likert scale. A change
of 0.5 units reflects a minimal
clinically important difference
(Dixon et al.216)
Higher scores indicate better
health
Marks The Marks Asthma Quality of Life
Questionnaire (Marks; Marks
et al.217) is a self-administered
questionnaire intended for use with
adults
Respondents are asked to describe
how troubling particular items have
been over the past 4 weeks. Covers
both physical and emotional impact
Should not be confused with the
Asthma Quality of Life Questionnaire
(AQLQ; Juniper et al.218)
Scaling of items from 1 to 5 NA
McGill Pain Q-SF The McGill Pain Questionnaire-
Short Form (McGill Pain Q-SF;
Melzack219) assesses these two
dimensions of pain, as currently
experienced by the patient. It
contains 11 items assessing several
domains of pain experience:
intensity, sensory and affective
Scale from 0 (none) to
3 (severe) scale
Ratings were averaged
Higher scores indicate greater
severity
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TABLE 106 Outcome measures from included studies: acronyms and definitions (continued )
Acronym
Definitions given in the primary
studies Scale and scoring Meaning
McGill QOL In Averill et al.,100 psychological and
existential QoL were measured with
the McGill QOL questionnaire to
assess the subjective QoL of
patients with terminal illness.
Psychological QoL reflects the
extent to which patients have
experienced symptoms of
depression, anxiety, sadness and
hopelessness. There were six
measures of psychological well-
being that were highly correlated
with each other: positive affect,
negative affect, depression,
psychological QoL, existential QoL
and spirituality
Existential QoL reflects patients’
ratings of the worth and meaning
of their life, their progress towards
their goals, their control over their
life and the value of each day
11-point Likert scale ranging
from 0 to 10
Scores are summed up into a
total score
Lower scores indicate better
health
MDASI The MD Anderson Symptom
Inventory (MDASI; Cleeland
et al.220) is used to assess multiple
symptoms experienced by cancer
patients and the interference with
daily living caused by these
symptoms. Participants rate the
severity of 13 core symptoms (in
the last 24 hours) common across
all cancer diagnoses and treatments
and the extent to which these
symptoms interfere with daily
activities
In Park and Yi78 a Korean version
(Yun et al.221) was adapted
From 0 (symptom has not
been present) to 10 (the
symptom was as bad as you
can imagine it could be)
Higher scores indicate greater
severity and interference
MIDAS The Migraine Disability Assessment
Scale (MIDAS) is a 5-item inventory
that assesses the number of days in
the past month when the
respondents functioning was
reduced or impaired because of
headaches (behavioural disability
from headaches) including days of
work (including housework), school
or other activities missed, as well as
the number of days for which
productivity was reduced by half
A total of five items are calculated
and analysed
The number of days is added
up, totalling a final number of
days from questions 1–5
MIDAS scores thresholds are
as follows:
l 0–5: no disability
l 6–10: mild disability
l 11–20: moderate
disability
l > 21: severe disability
Higher scores indicate greater
migraine disability
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TABLE 106 Outcome measures from included studies: acronyms and definitions (continued )
Acronym
Definitions given in the primary
studies Scale and scoring Meaning
Mississippi Scale
for PTSD
The Mississippi Scale for combat-
related PTSD (Hebrew version) is a
35-item self-reported questionnaire
describing participant’s feeling on
each of the items
Items 2, 6, 11, 17, 19, 22, 24, 27,
30 and 34 are scored in reverse
order
The cut-off score for PTSD is set at
107, a score that correctly classifies
90% of all subjects as PTSD or
non-PTSD
Means for the three validation
groups are as follows: PTSD 130
(SD= 18); psychiatric 86 (SD= 26);
well adjusted 76 (SD= 18)
Each item receives a score of
1–5
Add all items to obtain the
total score
A total score of > 107
indicates a diagnosis of PTSD
MMSE-Korean The Mini Mental State Examination
(MMSE) is often taken to rate
cognitive functioning difficulties in
a relatively short time: in the
present study, the Korean version
of MMSE, named MMSE-K, was
used in the included study by
Hong and Choi67
The MMSE-K has 30 questions for
rating and each question is counted
as one point. The full score of
MMSE-K is 30 points. It consists of
seven subitems. The standard
MMSE-K was slightly modified,
combining time orientation and
space orientation into orientation
to which 10 points were allocated,
and also unifying memory
registration and memory recall to
memory to which six points were
allocated
Diagnostic criteria of dementia in
terms of the MMSE-K score are
given as follows: a total score of
> 23 points is classified as normal,
20–23 points as doubted as
dementia and < 20 points as
dementia
The score of each item is
allocated as follows:
(1) 5 points for time
orientation, (2) 5 points for
space orientation, (3) 3 points
for memory registration,
(4) 3 points for memory recall,
(5) 5 points for attention and
calculation, (6) 7 points for
language, and (7) 2 points
for comprehension and
judgement
A total score of < 20 indicates
dementia
Modified MRC
dyspnoea scale
The Modified Medical Research
Council dyspnoea scale (MMRC)
is an instrument to document
subjective feeling of shortness
of breath
From 0 (shortness of breath
only with strenuous activity)
to 4 (shortness of breath with
minimal activity, even dressing
or undressing)
Higher scores indicate higher
subjective feeling of shortness
of breath
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TABLE 106 Outcome measures from included studies: acronyms and definitions (continued )
Acronym
Definitions given in the primary
studies Scale and scoring Meaning
MOS-HIV The Medical Outcomes Study HIV
Health Survey, a brief,
multidimensional and
comprehensive measure of HRQoL
used extensively in HIV/AIDS
research (MOS-HIV; Wu et al.222)
It measured the physical
functioning, pain, and mental
health using three subscales:
l The 6-item physical functioning
subscale is a
self-report measure of how
long one’s health has been
limited in vigorous physical
activities (such as lifting),
moderate physical activities
(such as carrying groceries) and
other activities of daily living
l The pain subscale consists of
two items: amount of bodily
pain and the extent to which
pain interfered with normal
work activities
l The mental health subscale
consists of five items: nervous,
calm and peaceful,
downhearted and blue, happy,
and down in the dumps
l 3-point scale: limited for
more than 3 months;
limited for the last
3 months and not at
all limited
l Amount of bodily pain
from none to severe, and
the extent to which pain
interfered with normal
work activities from not
at all to extremely
l Mental health subscale
ranges from 1 (all of the
time) to 6 (none of
the time)
l Higher scores indicate
better physical functioning
l The higher the scores on
the pain subscale, the
lower the pain
l Higher mental health
subscale scores indicate
better mental health
MPI The Multidimensional Pain
Inventory (MPI; Kerns223) is a
48-item self-reported questionnaire,
divided in three sections
In the first section, the participant
responds about their pain, and how
it affects their lives
In the second section, the
participant responds about how
his/her spouse or significant others
respond to them in that particular
way when they are in pain
In the third section, the participant
responds to how often they do
different daily tasks (such as
washing dishes, going to the
cinema, take a trip, or engage in
sexual activities)
Participants can also list any other
pain-related problem
Section 1: 7-point Likert scale
ranging from 0 (not at all) to
6 (extremely)
Section 2: range from never
to often
Section 3: range from never
to often
The scoring procedure
produces a mean score for
each scale
Higher scores indicate greater
pain
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TABLE 106 Outcome measures from included studies: acronyms and definitions (continued )
Acronym
Definitions given in the primary
studies Scale and scoring Meaning
MSPSS The Multidimensional Scale of
Perceived Social Support (MSPSS;
Zimet et al.224) is a 12-item self-
report measure used to measure
perceived social support
7-point Likert scale from
1 (very strongly disagree) to
7 (very strongly agree)
Higher scores indicate higher
perceived social support
NMCUES The National Medical Care
Utilisation Expenditure Survey
(NMCUES; National Centre for
Health Statistics225)
It assesses multiple forms
of health-care utilisation
and behaviours over a
period (3 months in
Rosenberg et al.83)
Questions addressed health-care
utilisation patterns, current use of
medicines and health-related
behaviours (e.g. smoking,
substance use)
NA NA
OQ-45.2 The Outcome Questionnaire
(OQ-45.2; Lambert et al.226)
is a 45-item self-report measure
intended for weekly assessment of
client progress through the course
of psychotherapy
The OQ-45.2 produces a total score
and three subscale scores (symptom
distress, interpersonal relations and
social role)
The total score is calculated
by summing the patient’s
ratings across all 45 items
(range 0–180)
Higher scores indicate greater
clinical improvement
PAID Problem Areas In Diabetes scale
(PAID; Polonsky et al.227), otherwise
not described
NA NA
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TABLE 106 Outcome measures from included studies: acronyms and definitions (continued )
Acronym
Definitions given in the primary
studies Scale and scoring Meaning
Pain behaviour In both included studies by
Lumley et al.115 and Macklem,131
a structured observation system228
which was designed for RA
patients, assessed overt pain
behaviour
At each evaluation, patients were
videotaped in the examination
room for 10 minutes by a camera
in the doorway while they engaged
in four standardised manoeuvres
(walking, sitting, standing and
reclining), which were presented in
a random order. The research
assistant operated the camera and
refrained from interacting with the
patient other than to give directions
for the next behaviour
Raters were trained to code these
videotapes by the developer of
the system (Francis J Keefe) and
achieved high inter-rater reliability
during training. Next, these raters,
blind to experimental condition,
reviewed study videotapes for the
presence of seven pain behaviours:
guarding, bracing, grimacing,
sighing, rigidity, passive rubbing
and active rubbing
The 10-minute tapes were divided
into 20 30-second epochs; the
presence or absence of each pain
behaviour during each epoch was
recorded, and a total score of all
behaviours across all epochs was
calculated
NA NA
Pain intensity In the included study by Cepeda
et al.,85 patients rated their average
pain intensity using a verbal
numerical rating scale
In the included study by
Macklem,131 pain intensity was
measured using a 100-mm VAS
Verbal numerical rating scale
from 0 (no pain) to 10
(the worst pain imaginable)
100-mm VAS ranges from
0 (no pain) to 100 (pain as
bad it can be)
Higher scores indicate more
pain intensity
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TABLE 106 Outcome measures from included studies: acronyms and definitions (continued )
Acronym
Definitions given in the primary
studies Scale and scoring Meaning
PANAS-X(a) The Positive and Negative Affect
Schedule (PANAS; Watson et al.229)
which contains 16 items (eight
positive items and eight negative
items)
In Wagner et al.73 the same scale is
reported as PANAS and defined as
a 20-item scale with the same
5-point response options. Words
that describe feelings and
emotions, such as interested,
distressed, and proud load on
either the positive or negative
affect factor (10 items each). In this
study, participants were asked to
rate their feelings during the past
week, including today
5-point scale ranging from
1 (very slightly or not at all) to
5 (extremely)
Higher scores indicate greater
mood change
PANAS-X(b) The Positive and Negative Affect
Schedule–Expanded Form
(PANAS-X, Watson and Clark230)
was applied to assess emotional
states of patients: 60-item scale,
which was created to assess not
only general dimensions of
emotional experience, but specific
emotional states too
It included the original PANAS
assessing short-term mood
fluctuations, with consistent
psychometric results in varying
populations and over various time
frames: this measure consists of
two 10-item scales for positive and
negative affect
In addition to the two original
higher order scales, the PANAS-X
measures 11 specific affects:
joviality, self-assurance,
attentiveness, fear, sadness, guilt,
hostility, shyness, fatigue, serenity,
surprise
5-point scale ranging from
1 (very slightly or not at all) to
5 (extremely)
Higher scores indicate greater
mood change
PANAS-X(c) The Positive and Negative Affect
Schedule for Children [PANAS-X(c);
Laurent et al.231] is a 30-item scale,
through which items are rated for
affect during the past few weeks
and averaged separately for positive
affect (PA) and negative affect (NA)
measures
6-point scale from 0 (very
slightly or not at all) to
5 (extremely)
Higher scores indicate greater
mood change
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TABLE 106 Outcome measures from included studies: acronyms and definitions (continued )
Acronym
Definitions given in the primary
studies Scale and scoring Meaning
PANAS-X(d) The Positive and Negative Affect
Schedule–Abbreviated version of
the expanded version [PANAS-X(d),
Watson and Clark232] was
used in the included study by
D’Souza et al.101
The four negative moods were
highly correlated (e.g. alpha for
session 1 was 0.75 for tension and
0.73 for migraine samples), so the
four ratings were averaged into
one negative mood score and
analysed it separately from
calmness
Items rated from 1 (not at all)
to 7 (a great deal) for four
negative moods (anger, guilt,
sadness, fear) and for
calmness
Higher scores indicate greater
mood change
PANAS-X NA
subscale
The 10-item negative affect
subscale from the 60-item
PANAS-X rated the frequency
that they experienced each item
during the prior 2 weeks
5-point Likert scale ranging
from 1 (not at all) to 5
(extremely)
Higher scores indicate greater
mood change
PASI The Psoriasis Area and Severity
Index (PASI; Feldman et al.233)
is an internationally accepted,
clinician-rated, psoriasis-specific
score, based on the body
surface area involved and on
semi-quantitative estimation of
erythema, infiltration and scaling; it
is by far the most common tool in
clinical studies and in daily practice.
The head, trunk, and upper and
lower extremities are assessed
Scores range from 0 (no
psoriasis) to 72 (extremely
severe psoriasis)
Higher scores indicate greater
psoriasis severity
PDS The Posttraumatic Stress Diagnostic
Scale (PDS; Foa et al.234), a 49-item
self-reported measure, aids in PTSD
diagnosis and symptom severity,
with items that parallel DSM-IV
criteria
A diagnosis of PTSD is made only
when DSM-IV criteria A–F are met
The PDS includes a symptom
severity score. Respondents rate
17 items representing the cardinal
symptoms of PTSD experienced
in the past 30 days. Finally,
respondents rate the level of
impairment caused by their
symptoms across nine areas of life
functioning
4-point scale
Scores range from 0 to 51,
and this is obtained by adding
up the individuals responses
of selected items
The cut-off points for
symptom severity rating are:
l 0: no rating
l 1–10: mild
l 11–20: moderate
l 21–35: moderate
to severe
l ≥ 36: severe
Higher scores indicate higher
PTSD symptoms
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TABLE 106 Outcome measures from included studies: acronyms and definitions (continued )
Acronym
Definitions given in the primary
studies Scale and scoring Meaning
PedsQL The Paediatric Quality of Life
(PedsQL) is a 23-item well-validated
scale with excellent internal
consistency – how much of a
problem various physical activities,
feelings, social situations, and
school activities have been in the
past month
QoL domains were restricted to
(a) physical (eight items) and
(b) psychosocial (15 items)
5-point scale from 0 (never a
problem) to 4 (almost always
a problem)
Lower scores indicate better
health
PSA spec –
CD4+/8+
Peripheral blood T-cell proliferation
to specified antigens
This technique was assessed by the
cell census proliferation assay
method. It involves the use of a
fluorescent membrane dye that
partitions between daughter cells at
division, in conjunction with flow
cytometry to measure the
proliferation of cells
With mathematical deconvolution of
the fluorescence histograms, the
precursor frequency of cells in the
original population that responded
to a specific stimulus can be derived
By using a second tagged fluorescent
antibody to stain for lymphocyte
subsets, the proliferation of specific
phenotypes (CD4+/CD8+) of
responding cells can be examined
NA NA
PHQ The Patient Health Questionnaire
(PHQ; Spitzer et al.235,236) is
designed as a screening instrument
for use with health-care seeking
populations
It provides information on perceived
symptoms of (a) depression,
(b) anxiety, (c) somatic complaints,
and (d) psychological distress
The two subscales that measure
symptoms of depression (nine items)
and anxiety (15 items) employ
DSM-IV criteria to screen for the
presence of these psychiatric illnesses
For each item:
l Depression scale range:
from 0 to 3
l Anxiety scale range: from
1 to 4
Depression severity:
l 0–4: none
l 5–9: mild
l 10–14: moderate
l 15–19: moderately severe
l 20–27: severe
Physician’s
global rating of
disease activity
In Lumley et al.,115 the evaluating
physician-rated patient’s overall
disease activity with a
100-mm VAS
In Macklem,131 scoring was done
on a 5-point Likert scale
From 0 to 100 VAS, with
anchors of 0 (no activity) to
100 (most activity)
Range from 0 (asymptomatic),
1 (mild), 2 (moderate),
3 (severe) to 4 (very severe)
Higher scores indicate higher
activity
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TABLE 106 Outcome measures from included studies: acronyms and definitions (continued )
Acronym
Definitions given in the primary
studies Scale and scoring Meaning
PILL The Pennebaker Inventory of Limbic
Languidness (PILL), a self-report
questionnaire that assess the
frequency of each of the most
54 physical symptoms
The PILL can be scored by summing
up the total number of items on
which individuals score C, D or E
(every month or so or higher)
With this strategy, the mean score
is 17.9 (SD= 4.5) based on a
sample of 939 college students.
You can also simply sum up the
54 items resulting in a mean
score of 112.7 (SD= 24.7)
(http://homepage.psy.utexas.edu/
HomePage/Faculty/Pennebaker/
Questionnaires/PILL.pdf)
From 0 to 216:
l 0 to 21: below
normal range
l 22 to 66: well within
normal range
l 67 to 84: slightly above
average, within normal
range
l ≥ 85: top 25%
Higher scores indicate
participants are more nervous,
distressed and unhappy
POMS The Profile of Mood States (POMS)
(McNair et al.237) consists of 34
items aimed at assessing global
negative and positive affect
Participants indicate how often they
experienced a particular feeling
(e.g. liveliness, forgetfulness,
unhappiness) since their cancer
diagnosis or their last survey
(for subsequent waves)
In the included study by Henry
et al.,53 mood disturbance was
calculated by summing the negative
affect subscales (e.g. anger,
depression, tension, fatigue,
confusion) and then subtracting
the positive affect subscale score
(e.g. vigour)
In the included study by Smyth
et al.,9 the POMS assessed current
mood states using subscales
for depression–dejection,
tension–anxiety, fatigue–inertia,
vigour–activity, anger–hostility and
confusion–bewilderment
Scale from 0 (not at all) to
4 (extremely often)
Higher scores indicate greater
mood disturbance
POMS-n The negative affect subscale of the
Profile of Mood States (POMS;
Zevon and Auke238) was measured
in Jensen-Johansen et al.76 with a
37-item version validated for use
with patients with breast cancer
(Di Lorenzo and Williamson239)
Scale from 0 (not at all) to
4 (extremely often)
Higher scores indicate greater
negative affect
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TABLE 106 Outcome measures from included studies: acronyms and definitions (continued )
Acronym
Definitions given in the primary
studies Scale and scoring Meaning
POMS-SF The Short Form of the Profile of
Mood States (POMS-SF; Shacham240)
is a 37-item questionnaire
that comprises six subscales
measuring transient states of
six moods: tension–anxiety,
depression–dejection, anger–hostility,
vigour–activity, fatigue–inertia and
confusion–bewilderment
Total mood disturbance is assessed
as the sum of the scores for these six
moods
5-point Likert scale, ranging
from 0 (not at all) to
4 (extremely)
Higher scores representing
greater mood disturbance,
except for vigour/activity,
where higher scores indicate
lesser mood disturbance and
the score of this subscale is
subtracted from the sum of
the rest to provide the total
mood disturbance
Poor sleep
quality
The poor sleep quality scale used
a 4-item scale designed to evaluate
the previous night’s sleep regarding
sleep quality, degree to which sleep
was restorative, waking daytime
level of alertness, and ability to
concentrate
1–7 scale and averaged Higher values indicate poorer
sleep
Post mTBI
Symptom
Checklist
The Post Mild Traumatic Brain
Injury (mTBI) Symptom Checklist
comprised 30 items, describing
symptoms that are commonly
experienced in the following days
or weeks after a mTBI
The list comprises questions about
physical changes, changes in
thinking, changes in emotions or
behaviours
NA The higher number of items
ticked, the greater post-mTBI
symptoms
PPMS A Passive Positive Mood Scale
(PPMS) was developed for the study
by Jensen-Johansen et al.,76 using
words reflecting non-active positive
mood to supplement the active
positive mood items of the POMS
vigour subscale
The PPMS consists of items
reflecting passive positive mood in
the past 7 days (positive/bright,
balanced, glad, peaceful, relaxed,
at ease, calm, contented)
NA Higher scores indicate better
passive positive mood
PSC The Paediatric Symptom Checklist
(PSC) is a 35-item psychosocial
screen designed to facilitate the
recognition of cognitive, emotional
and behavioural problems
The PSC is the parent-completed
version, as opposite to the Paediatric
Symptom Checklist-Youth Report
form (PSC-Y), which is the children-
completed version (see p. 317)
Items are rated as never,
sometimes or often present
and scored 0, 1 and 2,
respectively
The total score is calculated
by adding together the score
for each of the 35 items
A positive score on the PSC
indicates need of further
evaluation by a qualified
health or mental health
professional
Both false positive and false
negative can occur and this
should be interpreted by the
appropriate professional
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TABLE 106 Outcome measures from included studies: acronyms and definitions (continued )
Acronym
Definitions given in the primary
studies Scale and scoring Meaning
PSC-Y The Paediatric Symptom Checklist-
Youth Report form (PSC-Y; Little
et al.241) contains 35 items to
obtain a child’s report of their
emotional and behavioural
problems
The items describe specific emotions
and behaviours, and the respondent
is asked to indicate how often the
items apply to them by checking
always, sometimes or never
l For children aged 4 and
5 years, the PSC cut-off
score is ≥ 24
l For children and
adolescents aged
6–16 years, a cut-off
score of ≥ 28 indicates
psychological impairment
l The cut-off score for the
PSC-Y is ≥ 30
Items left blank are ignored.
If more than four items are
left blank, the questionnaire
is considered invalid
A positive score on the PSC-Y
indicates need of further
evaluation by a qualified
health or mental health
professional. Both false
positive and false negative
can occur and this should be
interpreted by the appropriate
professional
PSQI The Pittsburgh Sleep Quality Index
(PSQI; Buysse et al.242) evaluated
habitual sleep disturbances over a
1-month period
It differentiates poor from good
sleep quality by measuring seven
areas (components): subjective
sleep quality, sleep latency, sleep
duration, habitual sleep efficiency,
sleep disturbances, use of sleeping
medications, and daytime
dysfunction over the last month
Responses for each item are:
0 (very good); 1 (fairly good);
2 (fairly bad); 3 (very bad)
The total score sums the
seven item scores together
A total score of ≥ 5 is
indicative of poor sleep
quality
PSS The 14-item Perceived Stress Scale
(PSS) measure was used to assess
the degree to which participants
found their daily lives over the
period of the past 4 weeks to be
unpredictable, uncontrollable and
overloading
The questionnaire is designed to
quantify non-specific appraised
stress over the previous month
From 1 (never) to
5 (very often)
Higher scores indicate higher
levels of appraised stress
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TABLE 106 Outcome measures from included studies: acronyms and definitions (continued )
Acronym
Definitions given in the primary
studies Scale and scoring Meaning
PSS-I The Post-Traumatic Stress Disorder
Symptom Scale Interview (PSS-I;
Foa et al.243)
The PSS-I was used to generate
three PTSD subscale scores for
re-experiencing, avoidance, and
arousal symptoms
The PSS-I is a 17-item
semistructured interview that
assesses the presence and severity
of DSM-IV PTSD symptoms related
to a single identified traumatic
event in individuals with a known
trauma history. Each item is
assessed with a brief, single
question. There are no probes or
follow-up questions. Interviewees
are asked about symptoms they
have experienced in the past
2 weeks
For each item, the interviewer
assigns a rating to reflect a
combination of frequency and
severity from 0 (not at all) to
3 (five or more times per
week/very much)
Higher scores indicate greater
symptoms
PTGI The Post-Traumatic Growth
Inventory (PTGI; Tedeschi and
Calhoun244) measures the degree of
positive changes reported after
experiencing a traumatic event
The PTGI measures growth in five
domains: new possibilities, relating
to others, appreciation of life,
personal strength, and spiritual
changes
PTGI is a 21-item self-report
inventory. In addition to an overall
scale score, the PTGI comprises five
factors:
l relating to others
l new possibilities
l personal strength
l spiritual change
l appreciation for life
6-point Likert type scale,
ranging from 0 (I did not
experience this change as a
result of my crisis) to 5 (a very
great degree as a result of my
crisis)
Higher scores indicate greater
positive changes
QEDD The diagnosis of eating disorder on
the Questionnaire for Eating
Disorder Diagnosis (QEDD; Mintz
et al.245) is a 50-item diagnostic
instrument based on DSM-I criteria
NA NA
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TABLE 106 Outcome measures from included studies: acronyms and definitions (continued )
Acronym
Definitions given in the primary
studies Scale and scoring Meaning
QOL The Quality of Life Scale (QOL;
Burckhardt et al.246), used in
Broderick et al.,118 is a 16-item
instrument (rather than the 15-item
one found in the Flanagan version)
designed to measure QoL across a
broad array of life domains in
patients with chronic illness
Independence, doing for yourself
was added after a qualitative study
indicated that the instrument had
content validity in chronic illness
groups but that it needed an item
that reflected the importance to
these people of remaining
independent and able to care for
themselves
7-point Likert scale ranging
from 1 (terrible) to 7
(delighted)
The instrument is scored by
summing the items to make a
total score
Higher scores indicate better
QoL
RCMAS The Revised Children’s Manifest
Anxiety Scale (RCMAS; Reynolds
and Richmond247) is subtitled What
I Think and Feel, and contains 37
written statements describing
feelings or behaviours that the
individual is asked to respond to by
circling yes or no
This measure assesses the level and
nature of children’s anxiety. The yes
responses are counted to determine
a total anxiety score. There a four
subscales (for which scores can be
calculated separately): physiological
anxiety; worry/oversensitivity; social
concerns/concentration; lie
NA l High scores on the
physiological factor (items
1, 5, 9, 13, 17, 19, 21,
25, 29, 33) can indicate
physiological signs of
anxiety (e.g. sweaty
hands, stomach aches)
l High scores on the worry/
oversensitivity factor (items
2, 6, 7, 10, 14, 18, 22, 26,
30, 34, 37) would suggest
that the child internalises
their experiences of
anxiety and that he/she
may feel overwhelmed
and withdraw
l High scores on the
concentration anxiety
factor (items 3, 11, 15,
23, 27, 31, 35) would
suggest that the child is
likely to feel that he/she is
unable to meet the
expectations of other
important people,
inadequate and unable to
concentrate on tasks
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TABLE 106 Outcome measures from included studies: acronyms and definitions (continued )
Acronym
Definitions given in the primary
studies Scale and scoring Meaning
RSQ The Recovery Style Questionnaire
(RSQ; Drayton et al.248) is a
39-item self-report measure with
the categories developed by
McGlashan et al.249 integration vs.
sealing over styles of adaptation to
psychotic illness
The RSQ includes 13 aspects of
recovery style, each of which is
assessed by three items
Using a formula (Drayton
1998), the scores on each of
these aspects are combined
into the six following
classifications along one
dimension:
l Integration
l Towards integrating
l A mixed picture in which
integration dominates
l A mixed picture in which
sealing over dominates
l Towards sealing over
l Sealing over
l Scores were summed
across the items to
provide a total score
Higher scores indicate greater
recovery style
Rumination
Scale
The Rumination Scale (McIntosh
et al.,250) consists of a 10-item
report that assesses people’s
tendency to engage in ruminative
thinking
NA NA
SAM The paper-and-pencil version of the
Self-Assessment Manikin (SAM;
Bradley and Lang251) obtains
participant’s ratings of valence
(pleasantness) and arousal in
response to each session
(self-reported emotion)
9-point Likert-type scale:
l Valence: from 1
(very pleasant to 9
(very unpleasant)
l Arousal: from 1 (very
calm) to 9 (very aroused)
Higher scores indicate greater
pleasantness
SAPASI The Self-Administered Psoriasis
Area and Severity Index (SAPASI;
Sampogna et al.252), a patient-
rated, psoriasis-specific outcome
measure, is a widely validated
instrument that provides an
objective measure of disease
severity, and has been effectively
used in previous studies
Participants rate the colour,
induration, and scaliness of an
average psoriatic lesion using three
modified VASs. As in the original
PASI, the SAPASI weights the
involvement of the head (H), upper
extremities (U), trunk (T) and legs
(L) as 10%, 20%, 30%, and 40%
of the total body area, respectively
SAPASI= (0,1 ×AH)+
(0,2 ×AU)+ (0,3 ×AT)+
(0,4 ×AL)
Higher scores indicate greater
severity
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Acronym
Definitions given in the primary
studies Scale and scoring Meaning
SCL-90-R The Symptom Checklist-90-Revised
(SCL-90-R) is a 90-item, self-report
measure of current psychological
symptomatology, including global
psychological distress
It is a multidimensional complaint
list based on a self-assessment
covering an important part of the
compliant that can be seen in the
psychiatric inpatient clinic
5-point Likert scale ranging
from 0 (not at all) to
4 (extremely)
Items are summed for a total
score
Higher scores indicate greater
distress and psychological
symptoms
SCS The Social Constraints Scale (SCS;
Lepore and Ituarte253) is a
15-item scale assessing perceived
inadequacy of social support
resulting in reluctance among
individuals to express thoughts and
feelings about a specific stressor, in
this case their cancer experience
Example items include: How often
did they avoid you? How often did
they minimise your problems? How
often did they tell you to try not to
think about your cancer? and How
often did they make you feel as
though you had to keep feelings
about your cancer to yourself,
because they made him/her feel
uncomfortable?
In Zakowski et al.,84 two forms of
the SCS were used: one asking
about constraints from patient’s
spouse or partner and one asking
about constraints from people in
their lives other than their spouse
or partner (e.g. friends or family
members)
The mean of the two constraint
scores in all analyses (among the
19 patients who had no current
spouse or partner, the constraints
from others score was used, in that
we considered this score to be
reflective of their average constraint
level) were used in the
aforementioned study
Scores range from 15 (low
constraints) to 60 (high
constraints)
Higher scores indicate higher
social constraints
SDSCA Summary of Diabetes Self-Care
Activities scale (revised) (SDSCA;
Toobert et al.254)
Splits into general diet, specific diet,
exercise, blood glucose testing and
foot care subscales
NA NA
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TABLE 106 Outcome measures from included studies: acronyms and definitions (continued )
Acronym
Definitions given in the primary
studies Scale and scoring Meaning
Self-rated health
status (a)
Compared with the person in
excellent health, how would you
rate your health at the present
time?
7-point scale from 1 (terrible)
to 7 (excellent)
Higher scores indicate better
health
Self-rated health
status (b)
How you rate your health overall? From 1 (very bad) to
5 (very good)
Higher scores indicate better
health
Serum cytokine
levels of TNF-α,
IL-4 and IL-10
Levels were determined using a
high sensitivity ELISA sandwich
essay
In this method, the concentration
of the selected cytokine in the
serum is calculated from the linear
portion of a standard curve of
purified cytokine at known
concentrations
The detection limits of the
assay were < 0.25 pg/ml
The detectable range for
TNF-α was 0.5–32 pg/ml and
for IL-10 0.8–50 pg/ml
Sexual health
and performance
In the included study by
Pauley et al.,82 sexual health and
performance was assessed by a
designed 6-item measure created
by the authors
The scale was intended to work as
two separate subscales: one
measuring performance and the
other measuring sexual desire
NA Higher scores indicate greater
levels
SF-12 The Short Form questionnaire-12
items (SF-12; Ware et al.255) is a
widely used, brief generic measure
of self-reported health status
derived from the larger SF-36
survey
Self-ratings are made of severity
and frequency of 12 physical and
mental health problems, as well as
of their impact on the patient’s
overall perceived health status
This modified version of the SF-36
has consistently been shown to
have good reliability and validity
It yields both physical health
and mental health summary
scores, which are reported
as standard scores
Slower scores indicated
positive psychological and
physical health
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TABLE 106 Outcome measures from included studies: acronyms and definitions (continued )
Acronym
Definitions given in the primary
studies Scale and scoring Meaning
SF-36 The Medical Outcomes Short Form
questionnaire-36 items (SF-36;
Ware and Sherbourne256) is used to
evaluate psychological (SF mental),
physical health (SF physical) and
general health
The eight subscales include
(a) limitations in physical activities
because of health problems;
(b) limitations in social activities
because of physical or emotional
problems; (c) limitations in usual
role activities because of physical
health problems; (d) bodily pain;
(e) general mental health
(psychological distress and
well-being); (f) limitations in usual
role activities because of emotional
problems; (g) vitality (energy and
fatigue); and (h) general health
perceptions
A physical health composite score
embodies concepts (a), (c), (e) and
(g) and a mental health composite
score embodies concepts (b), (d),
(e) and (f)
This instrument has been also used
a measure of HRQoL
In the included study by Broderick
et al.,118 four additional subscales
from the MOS-SF-36 General
Health Survey were selected: overall
health, social functioning, health
distress, and cognitive dysfunction.
Three additional items assessing
tiredness on awakening, tiredness
during the day, and quality of sleep
were rated over the past week on
4-point scales
6-point Likert scale from
1 (excellent) to 5 (worst)
Lower scores indicated
positive psychological and
physical health
continued
DOI: 10.3310/hta20270 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 27
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Nyssen et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
331
TABLE 106 Outcome measures from included studies: acronyms and definitions (continued )
Acronym
Definitions given in the primary
studies Scale and scoring Meaning
SF-36v2 Health
Survey
The SF-36v2 Health Survey (Ware257)
is a 36-item inventory that yields
eight scale scores and two summary
scores for physical and mental
health
The 1998 US norm-based scoring
in version 2 allows for ready
interpretation of scores relative to
general population norms
The eight scaled scores are the
weighted sums of the questions in
their section. Each scale is directly
transformed into a 0–100 scale. The
eight sections are vitality, physical
functioning, bodily pain, general
health perceptions, physical role
functioning, emotional role
functioning, social role functioning
and mental health
In the included study by Broderick
et al.,118 the Pain Catastrophising
Scale served as a primary outcome,
because it measures the physical
health status of the patient. The
Mental Component Summary
(MCS) was also examined to
determine whether a psychological
impact of the intervention was
observed
Total score in each
component ranges from
0 to 100
The higher the score the less
disability
SGRQ The St George’s Respiratory
Questionnaire (SGRQ) is a
disease-specific instrument
designed to measure impact
on overall health, daily life and
perceived well-being, to be used
in patients with fixed and reversible
airway obstruction
It has 76 questions in three
sections: symptoms (frequency
and severity), activity (activities
that cause or are limited by
breathlessness) and impacts (social
functioning and psychological
disturbances resulting from airways
disease)
Total score ranges from
0 to 100
Higher scores indicate poor
health
SIP The Sickness Impact Profile
(SIP; de Bruin et al.258) used in the
included study by Hughes54
is 136 items
The SIP contains three items: the
physical functioning scale, mobility
subscale (SIP-m), and the recreation
and pastimes subscale (SIP-r&p-t)
The SIP describes activities of daily
living divided in 12 categories
Numerical scale Higher scores indicate greater
dysfunction
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TABLE 106 Outcome measures from included studies: acronyms and definitions (continued )
Acronym
Definitions given in the primary
studies Scale and scoring Meaning
Skindex-29 The Skindex-29 (Chren et al.259) has
been shown to be a valuable tool
for measuring HRQoL (QoL) in
dermatological patients, as
reported in the included study by
Paradisi et al.110
Its Italian version was developed
following guidelines for the
cross-cultural adaptation of
HRQoL measures and validated
in a previous survey260
VAS scale from 0 (no pain)
to 10 (worst possible)
Higher scores indicate poorer
QoL
SOC The Sense of Coherence Scale
(SOC) is a 13-item self-report
instrument (Antonovsky261) based
on the following underlying
constructs: comprehensibility,
manageability and meaningfulness
The SOC items are scored along
the 7-point scale
7-point scale with two
anchoring phrases: ‘until now
life has had no clear goals or
purpose at all’ and ‘until now
life has had very clear goals
and purpose’
Higher scores indicate a
strong sense of coherence
Social Constraints
Scale
The Social Constraints Scale (Lepore
et al.262) is a 15-item scale assessing
perceived inadequacy of social
support resulting in reluctance to
express thoughts and feelings
about a specific stressor,
in this case, experience with
amyotrophic lateral sclerosis
(e.g. How often did they tell you
not to think about amyotrophic
lateral sclerosis?)
All items referred to respondent’s
experiences over the prior week
5-point scale ranging from
1 (almost never) to 5 (almost
always)
Higher scores indicate greater
social constraint
Somatisation
Scale
The Somatisation Scale (13 items)
includes 13 common physical
complaints (e.g. stomach pain, back
pain, headaches), from which a
severity score can be calculated
Range 0–4 NR
SOPA The control subscale of the
Survey of Pain Attitudes (SOPA;
Jensen et al.263) is a questionnaire to
measure feelings of personal control
over pain
The SOPA is the most widely used
measure of pain-related attitudes
(De Good and Tait;264 Jensen et al.263)
5-point scale from 0 (this is
very untrue for me) to
4 (this is very true for me)
After reversing responses on
the four absence of control
items, responses are summed
to create a total score
Higher scores indicate greater
control over pain
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TABLE 106 Outcome measures from included studies: acronyms and definitions (continued )
Acronym
Definitions given in the primary
studies Scale and scoring Meaning
SOS The Significant Others Scale (SOS)
measured how much practical and
emotional support that individual
provided responding to two
questions for each item:
Emotional support answered by:
l (1) Can you trust, talk frankly
and share your feelings with
this person?
l (2) Can you lean on and turn
to this person in times of
difficulty?
Practical support:
l (1) Does he/she give you
practical help?
l (2) Can you spend time with
this person socially? Responses
were rated on
From 1 (never) to 7 (always)
scale
Higher scores indicate greater
emotional support
SSQ Asthma The Wasserfallen Symptom Score
Questionnaire (SSQ): asthma
subscale
NA NA
SSQ Awakenings The Wasserfallen Symptom Score
Questionnaire (SSQ): awakenings
subscale
NA NA
STAI-S The State/Trait Anxiety Scale
(STAI-S) is a 20-item, self-report
instrument that assesses the
subjective feelings of apprehension,
nervousness and anxiety at the
moment
4-point Likert scale ranging
from not at all, somewhat,
moderately so, to very much so
Higher scores indicate greater
state anxiety
Stigma Scale The Stigma Scale, designed for
individuals diagnosed with
HIV/AIDS, consisted of 13 items
that evaluated fear, avoidance,
and perceived negative responses
related to HIV status
1–4 ordinal scale reported as
strongly, not at all, rarely,
sometimes, often
Total scores ranging from a
low of 13 to a high of 52
Higher scores equating to
greater stigma
Survey–18
physical
symptoms items
The Survey–18 physical symptoms
items includes items derived
from other reports for their
appropriateness for the sample in
the included study by Henry et al.53
(Anderson and Tewfik;265
Ganz and Coscarelli;266
Whelan et al.267)
Example symptoms included
fatigue, nausea, appetite loss,
breast pain, hair loss, weight gain,
hot flashes, itchiness or discomfort
of the skin, decreased arm mobility
and swelling of the arm
A 7-point scale was used,
ranging from 1 (not at all) to
7 (severe)
Higher scores indicate greater
physical symptoms
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TABLE 106 Outcome measures from included studies: acronyms and definitions (continued )
Acronym
Definitions given in the primary
studies Scale and scoring Meaning
SUS The Social Undermining Scale (SUS;
Vinokur and van Ryn268) assesses
the extent to which each of the
four most important people in
participant’s lives caused them
distress by acting in an unpleasant
or angry manner towards them,
criticising them or making their life
difficult
5-point scale
Swollen joint
count
Joint swelling reflects local
inflammation and limited motion
in affected areas. The patient’s
rheumatologist, blind to the
patient’s experimental condition,
evaluated 16 joints bilaterally (five
interphalangeal and five metacarpal
phalangeal joints in addition to
shoulder, elbow, wrist, knee ankle
and metatarsals, for a total of 32
joints) and the presence or absence
of swelling was recorded for each
joint
Symptom and
Emotion Self-
report Survey
Participants rated the degree to
which they were currently
experiencing physical symptoms
and emotions. The symptom items
were averaged to yield a symptom
score, and emotion items were
averaged to form positive and
negative emotion scores
5-point scale from 1 (not at
all) to 5 (a great deal) and
scored
Symptom
Checklist-90-
Revised
Physical symptoms are reported on
a 12-item somatisation subscale of
the Symptom Checklist-90-Revised
(SCL-90-R)
In the included study by D’Souza
et al.101 symptoms were rated
regarding the past month, and
ratings were totalled
Rated from 0 (not at all) to
4 (extremely)
SLESQ The Stressful Life Events Screening
Questionnaire (SLESQ) (10 items)
includes 10 psychosocial complaints
common among health-care
seeking populations (e.g. difficulties
with family support, problems with
significant others, and financial
concerns)
Range 1–4 NR
The Ways of
Coping-Cancer
Version
The Ways of Coping-Cancer
Version is a self-report checklist of
coping responses to cancer-related
stressors
It assesses the frequency of
problem-focused and
emotion-focused coping efforts
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TABLE 106 Outcome measures from included studies: acronyms and definitions (continued )
Acronym
Definitions given in the primary
studies Scale and scoring Meaning
TLEQ The Trauma Life Experience
Questionnaire (TLEQ; Kubany
et al.269) is a 23-item self-report
measure of 22 types of potentially
traumatic events including natural
disasters, exposure to warfare,
robbery involving a weapon,
physical abuse and being stalked
TLEQ measures type and frequency
of trauma event exposures, and
responses to these exposures
The TLEQ has strong psychometric
properties (Kubany et al.269) and
was completed at the baseline
assessment
Trauma exposure was scored only if
the person indicated exposure to
the traumatic event and a response
to the event that was consistent
with DSM-IV PTSD criterion A2
For each event, respondents
are asked to provide the
number of times it occurred,
ranging from never to more
than five times, and whether
fear, helplessness or horror
was present: yes/no
Higher scores indicate greater
trauma
TLFB abstinence Timeline Followback Method (TLFB)
of assessing number of abstinent
days
Larger number means longer
abstinence
UCLA-Charles The UCLA-Charles R Drew
University Women and Family
Project (Wyatt and Chin270) was
adapted to assess changes in
meaning and perceived benefits
Participants were asked how, if at
all, being HIV positive changed the
way they think about themselves,
changed them as a person,
changed the way they are with
other people, and changed their
priorities
Different categories were
developed, based on the literature
and on an initial analysis of
14 patients
Ten categories of positive
changes, six categories of
negative changes and three
categories of mixed or neutral
changes, as well as codes for
uncategorised positive and
negative changes
The number of changes
falling into the positive
categories and negative
categories was computed for
each participant
Higher scores indicate greater
changes?
VSQ-9 The Visit Specific Satisfaction
Questionnaire (VSQ; Ware and
Hays271), a self-report measure
administered to participants and
providers at the conclusion of the
3-month follow-up period
To score the VSQ-9, the
responses from each
individual should be
transformed linearly to a
0–100 scale, with 100
corresponding to excellent
and 0 corresponding to poor
Responses to the nine VSQ
items should then be
averaged together to create a
VSQ-9 score for each person
Higher scores indicate greater
satisfaction related to the
visits
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TABLE 106 Outcome measures from included studies: acronyms and definitions (continued )
Acronym
Definitions given in the primary
studies Scale and scoring Meaning
Walking speed
and grip
strength
In the included study by Lumley
et al.,115 patients were instructed to
walk as quickly as possible, but
safely down a 50-foot corridor, and
recorded the time to do so in
seconds
In addition, patient’s grip strength
was assessed by having them
squeeze, as firmly as possible, a
sphygmomanometer bulb, and the
pressure generated was recorded
from two trials with each hand;
all four values were averaged to a
single score
NA Walking speed: higher values
mean slower walking
Grip strength: higher values
indicate better functioning
Well-being In the included study by Cepeda
et al.85 each patient’s sense of
general well-being was rated
7-point Likert scale from
awful to excellent
Higher scores indicate better
well-being
WHYMPI –pain
subscale
The Pain Severity subscale of the
West Haven-Yale Multidimensional
Pain Inventory (WHYMPI; Kerns
et al.272) is a 61-item self-report
inventory across three domains
The WHYMPI is for use in chronic
pain populations. It generates 13
empirically derived scale scores,
including pain severity, perception
of how pain interferes with daily
life activities, appraisals of the
support received from significant
others, and perception of how
significant others respond to their
displays of pain
From 0 to 6 Higher scores indicate more
extreme pain
AIDS, acquired immunodeficiency syndrome; CD3+, Cluster of differentiation antigen 3-positive lymphocyte;
ELISA, enzyme-linked immunosorbent assay; FIQ, Fibromyalgia Impact Questionnaire; HAQ, Health Assessment
Questionnaire; IL-4, interleukin 4; IL-10, interleukin 10; NA, not available; NR, not reported; PCR, polymerase chain
reaction; RAI, Rheumatology Attitudes Index; RNA, ribonucleic acid; VAS, visual analogue scale.
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TABLE 108 Quality assessment summary
Number of studies Quality assessment items
53 Studies were truly randomised (a valid method of randomisation was reported)
24 Studies were reported as randomised but the method of randomisation was not given
18 Studies were reported as having concealed the allocation of the sequence randomisation
6 Studies preserved blinding for outcome assessment
11 Studies preserved blinding during performance
25 Studies analysed the outcomes using the ITT approach
44 Studies reported outcomes differences between groups
44 Studies provided a description of withdrawals
44 Studies reported the prespecified criteria for eligibility of patients
33 Studies reported assessing similar groups at baseline
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Appendix 6 Excluded studies
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Appendix 7 List of items required when reporting
a realist synthesis (RAMESES checklist)
Reporting item Description of item Reported on page(s)
Title
1 In the title, identify the document as a realist synthesis or
review
i
Abstract
2 While acknowledging publication requirements and house
style, abstracts should ideally contain brief details of: the
study’s background, review question or objectives; search
strategy; methods of selection, appraisal, analysis and
synthesis of sources; main results; and implications for
practice
vii and viii
Introduction
3 Rationale for review Explain why the review is needed and what it is likely to
contribute to existing understanding of the topic area
6 and 7
4 Objectives and focus of
review
State the objective(s) of the review and/or the review
question(s). Define and provide a rationale for the focus of
the review
169–71
Methods
5 Changes in the review
process
Any changes made to the review process that was initially
planned should be briefly described and justified
169–71
6 Rationale for using realist
synthesis
Explain why realist synthesis was considered the most
appropriate method to use
169–71
7 Scoping the literature Describe and justify the initial process of exploratory scoping
of the literature
Not undertaken
8 Searching processes While considering specific requirements of the journal or
other publication outlet, state and provide a rationale for
how the iterative searching was done. Provide details on all
of the sources accessed for information in the review.
Where searching in electronic databases has taken place,
the details should include, for example, name of database,
search terms, dates of coverage and date last searched. If
individuals familiar with the relevant literature and/or topic
area were contacted, indicate how they were identified and
selected
169–71
9 Selection and appraisal of
documents
Explain how judgements were made about including and
excluding data from documents, and justify these
169–71
10 Data extraction Describe and explain which data or information were
extracted from the included documents and justify this
selection
169–71
11 Analysis and synthesis
processes
Describe the analysis and synthesis processes in detail.
This section should include information on the constructs
analysed and describe the analytic process
169–71
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Reporting item Description of item Reported on page(s)
Results
12 Document flow diagram Provide details on the number of documents assessed for
eligibility and included in the review, with reasons for
exclusion at each stage, as well as an indication of their
source of origin (e.g. from searching databases, reference
lists and so on). You may consider using the example
templates (which are likely to need modification to suit the
data) that are provided
172–82
13 Document characteristics Provide information on the characteristics of the documents
included in the review
172–82
14 Main findings Present the key findings with a specific focus on theory
building and testing
172–82
Discussion
15 Summary of findings Summarise the main findings, taking into account the
reviews objective(s), research question(s), focus and intended
audience(s)
183–90
16 Strengths, limitations and
future research directions
Discuss both the strengths of the review and its limitations.
These should include (but need not be restricted to)
(a) consideration of all the steps in the review process and
(b) comment on the overall strength of evidence supporting
the explanatory insights which emerged
The limitations identified may point to areas where further
work is needed
183–90
183–90
17 Comparison with existing
literature
Where applicable, compare and contrast the reviews
findings with the existing literature (e.g. other reviews)
on the same topic
183–90
18 Conclusion and
recommendations
List the main implications of the findings and place these in
the context of other relevant literature. If appropriate, offer
recommendations for policy and practice
183–90
19 Funding Provide details of funding source (if any) for the review, the
role played by the funder (if any) and any conflicts of
interests of the reviewers
xxxvii
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